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ABSTRACT 
 
CD4 “helper” T cells are central players in the regulation of immune responses. 
These T cells affect the magnitude and phenotype of immune responses, and indeed, 
affect whether or not the host responds, at all, to a given antigen. Thus, knowledge of the 
cellular and molecular requirements for the activation, differentiation, and survival of 
CD4 T cells is critical for understanding immune responses in general; this understanding 
may lead to advances in rational vaccine design and effective immunotherapy.  
Evidence supports a role for CD4 T cells in the activation and acquisition of 
effector function of other CD4 T cells. In this thesis I set out to develop experimental 
systems to directly observe, and explore the mechanisms involved in, cooperative 
interactions between CD4 T cells, “CD4 T cell cooperation”.  
I developed two major experimental systems wherein cooperative effects in the 
activation and differentiation of CD4 T cells were observed. Firstly, we show that 
simultaneous administration, in incomplete Freund’s adjuvant, of multiple peptides, but 
not single peptides, known to bind host class-two major histocompatability antigens 
(MHCII) and to stimulate endogenous naive CD4 T cells, results in the cooperative 
generation of cytokine-producing effector CD4 T cells, in vivo, as assessed by cytokine 
ELISpot assay. We demonstrate that these cooperative interactions depend on the 
presence of CD4 T cells with specificity for the administered peptides in the context of 
host MHCII. In the second experimental system, syngeneic, splenic antigen-presenting 
cells (APC), loaded in vitro with exogenous peptides, that bind the distinct MHCII 
molecules, I-A and I-E, mediate cooperation between peptide-specific CD4 T cell 
populations, in vivo, upon adoptive transfer.  Furthermore, we find that, in order for 
cooperative interactions to occur, these peptides must be simultaneously presented by the 
same APC. In addition it appears that B cells, and not splenic dendritic cells, efficiently 
mediate this cooperation. We demonstrate that cooperation between CD4 T cell 
populations depends on OX40L, as blocking this molecule abrogates cooperative effects. 
Enhanced primary effector CD4 T cell generation, influenced by cooperation, results in 
enhanced secondary effector CD4 T cell responses, indicating that cooperation between 
CD4 T cells plays a role in the establishment of immunological memory. 
 iii 
A third experimental system allowed us to address the role of CD4 T cell 
cooperation in immunological self-tolerance. We find that, in general, activated CD4 
cells are susceptible to inactivation by systemically administered peptides. However, 
under conditions that normally result in inactivation of effector CD4 T cells, the systemic 
ligation of CD40 or OX40 by agonistic antibodies, but not the administration of isotype-
matched control antibodies, rescues cytokine production by these cells. Given the role of 
these molecules in CD4 T cell cooperation, our findings lead us to propose that 
cooperation between autoreactive CD4 T cells may, occasionally, result in sustained 
autoimmune responses.  
The findings presented in this thesis allow us to make comprehensive models of 
the role of CD4 T cell cooperation in the activation, differentiation and, the maintenance 
of self-tolerance in CD4 T cells. Our findings have advanced our understanding 
sufficiently to allow for further experimentation in models of disease or immunological 
misregulation.  
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PREFACE 
 
In writing this thesis, I hoped that I could paint a picture of the study of CD4 T 
cell biology that would emphasize what I feel are important issues. Therefore, while the 
following chapters do not give a fully comprehensive view of the field, I hope that the 
reader will still be left satisfied that the remaining issues could be fitted into the models 
presented. 
I have decided to write the experimental chapters in, what I have been told, is a 
somewhat unconventional way. I have given a description of how the experimental 
systems described were developed. Often this description depends, as did the research 
itself, on pilot experimentation. I have included this preliminary type of data in my thesis. 
I believe that it not only makes the experimental chapters more easily comprehensible, 
but also honestly reflects how the science was originally undertaken. Too often, 
published works are so highly polished that it is difficult to see how anyone could have 
conceived of the experiments as presented.  
I hope that the reader can derive even a fraction of the pleasure from these 
experiments that I did.  
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1.0 CHAPTER 1 – INTRODUCTION 
 
1.1 General Introduction to Immunology 
 
The beginning of scientific study of the immune system dates to roughly the mid 
1700s. However, long before this, one of the major hallmarks of the adaptive immune 
system, immunity, was recognized. Observations of Greek historians, amongst others, 
suggest that ancient folk knowledge held that those who suffered sickness, associated 
with a given plague, and recovered, were free to tend to the sick, without fear of further 
infection (Silverstein 1989; Silverstein 1999). This essential feature of the vertebrate 
immune system, specific immunological memory, and how it is induced, remains one of 
the most studied phenomena in immunology.  
The cellular and molecular mechanisms surrounding how immunity is achieved 
were the subject of heated debate for decades in the 1800s. One of the first mediators of 
adaptive immunity identified was antibody, a substance present in the serum of immune 
animals that was found to specifically bind antigen and mediate its destruction or removal 
from solution. Some believed that antibody was the sole mediator of antigen clearance. 
Others, like Metchnikoff, argued that phagocytic cells were the main effectors of 
immunity. 
 The beginnings of modern immunology can be traced back to the theories of Paul 
Ehrlich who advanced a particularly interesting theory for the formation of antibody 
(Silverstein 2005). Ehrlich believed that antibody was a manifestation of increased 
production of receptors present on the surface of a cell. To Ehrlich, these receptors were 
nutrient receptors that would be blocked by a toxin. Thus, when a toxin bound to a given 
receptor, the cell would respond to this toxin by producing excess receptor, including 
secreted forms, which neutralized the toxin. While it was subsequently demonstrated that 
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Ehrlich’s theory could not be generally true, the essential features of his model bear a 
close resemblance to modern models for antibody production. In this model antigen 
selects the antibody from a pre-existing repertoire. 
 Those immunologists who believed that antibody was the sole effector 
mechanism mediating immunity eventually became dominant. Immunological 
researchers in the early 1900s were consumed by biochemical analysis of antibody-
antigen interactions and the functional consequences of this. However, in 1946 Merrill 
Chase demonstrated that a particular form of immune reaction, delayed type 
hypersensitivity (DTH), could be transferred between mice, not with serum from 
sensitized animals, but with leukocytes (Chase 1946). Cellular immunology was again 
brought into the consciousness of immunologists. In the following years, the cells 
responsible for antibody production, the bursa of fabricius-derived or, B cells, were 
identified in chickens due to the work of Bruce Glick (Ribatti, Crivellato et al. 2006). 
Subsequently, similar cells were identified in mammals. Investigations on the 
requirements for antibody production led to the identification of thymus-derived cells, T 
cells, as “helpers” for antibody production, and as the cells that mediate DTH (Claman, 
Chaperon et al. 1966; Miller and Mitchell 1968; Mitchell and Miller 1968; Mitchell and 
Miller 1968). 
The mechanistic requirements for antibody production remained poorly 
understood throughout the early 1900s. Many believed that antigens instructed the 
formation of complimentary antibody. Jerne suggested that the existence of “natural 
antibodies”, which pre-exist antigen exposure in unmanipulated animals, was evidence 
that antigens selected antibodies for production (Jerne 1955). In some ways this idea was 
rather similar to Ehrlich’s theory. Talmage extended this idea, suggesting that antigen 
selected a cell, bearing antibody, for multiplication leading to increased antibody 
production by multiple clones (Talmage 1957). Talmage’s ideas were borrowed by 
Burnet (Burnet 1957) and their “clonal selection theory”  was subsequently summarized 
and modified to accommodate accumulating evidence on the role of DNA in protein 
synthesis by Lederberg (Lederberg 1959). 
The clonal selection theory has become a pillar of immunology. The basic tenets 
of the theory, paraphrased from a modern review by Silverstein (Silverstein 2002) are: 1) 
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the entire immunological repertoire (antibody molecules) is generated in the host (i.e. it is 
not germline encoded), 2) each antibody is uniquely expressed by a single cell, 3) when 
these antibodies interact with antigen, the antibody-bearing cells proliferate and 
differentiate, and 4) some of these expanded clones produce antibody while others 
become “memory” cells.  These basic principles were demonstrated to be generally true. 
Both B cells and T cells express single antigen receptors that are encoded by somatically 
re-arranged genes. The need for an extensive immune repertoire means that clones are 
particularly rare and therefore selection of these cells as the multiplying unit, leading to 
effector functions in immunity, is essential.  
The idea that immune cells develop their repertoire somatically poses a potential 
problem. If this repertoire is randomly generated, as is more or less true, then often cells 
will be produced that bear antigen receptors specific for self-components. Burnet was 
particularly aware of this problem, and as early as 1949 proposed that a mechanism for 
removing reactivity to self, or for maintaining “self-tolerance” must exist (Burnet and 
Fenner 1949; Silverstein 2002). As I will describe below, intricate mechanisms have 
evolved to ensure that the immune system has the capacity to respond to virtually any 
pathogen, while at the same time remaining tolerant to the host’s antigens. 
  
1.2 Activation and Inactivation of CD4 T cells and the Maintenance of Self-
Tolerance 
 
1.2.1 Introduction 
 
 It has long been known that the immune system has the capacity to recognize self-
components. In order to avoid pathology it is important that checkpoints exist to control 
the activation of the powerful effector mechanisms of the immune response against the 
host. Paul Ehrlich’s famous coining of the term horror autotoxicus, translated as “the 
horror of autotoxicity”, to describe the body’s tendency to avoid producing antibodies 
that react to self, exemplifies this (Silverstein 1989). Some of the originators of the clonal 
selection theory also bore this idea in mind and they later proposed various models for 
how autoreactive lymphocyte clones could be removed during development. While 
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autoimmunity does exist, it is a rare phenomenon. In cases where control mechanisms 
fail, autoimmunity ensues. As I will describe, much that is encapsulated in the ideas of 
early immunologists has been demonstrated, while some findings, that would be 
surprising to them, demonstrate the sophisticated mechanisms that have evolved to limit 
autoimmunity.    
 The prolific Joshua Lederberg realized that naive precursors to antibody-
producing cells, that had specificity for self-components, should be removed to avoid the 
production of autoantibody (Lederberg 1959). Implicit in this idea was his proposition 
that the genes that encoded antibody molecules were capable of encoding autoreactive 
molecules as a result of the random mutations in the chromosomal DNA that lead to 
antibodies of more-or-less random specificity. Having previously reported that the cells 
that produce antibody are monospecific (Nossal and Lederberg 1958), he proposed that 
immature precursor cells, upon detection of antigen, for which their single receptor has 
affinity, are eliminated. Thus, it is both the specificity and the maturity of the precursor 
cell that determined whether it was sensitive to removal/inactivation, or induction to 
produce secreted antibody. According to this model, mature precursor cells, upon 
interaction with antigen, can only be induced. As I will describe below, this proposition 
was found to be inconsistent with experimental observation. Nevertheless, much of what 
is found in Lederberg’s elegant theoretical paper, Genes and Antibodies (1959), proved to 
be true, including his description of how small numbers of precursor cells divide upon 
antigen exposure, enhancing the number of cells that are available to produce the massive 
quantities of antibody seen upon immunization, and his description of how persistence of 
these “clones” leads to enhanced secondary immune responses. 
 Talmage and Pearlman offered their own model by which autoreactive antibody 
(autoantibody) production could be limited. According to their hypothesis, the binding of 
antigen alone, to antibody on the cell surface, would be insufficient to result in significant 
antibody production. However, a distinct stimulus could be delivered to the precursor cell 
by the degree of antigen aggregation when bound to the cell; appropriate delivery of the 
second stimulus results in antibody production (Talmage and Pearlman 1963). 
Supposedly, self-antigens would not be present in the appropriate concentration, or in a 
certain physical state, to cause appropriate aggregation of the antibody receptor. While 
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this model supposed, erroneously, that inactivation of autoreactive cells is not a major 
mechanism by which self-tolerance is maintained, the assertion that more than the simple 
binding of antigen to the antibody receptor, borne by a precursor cell, was needed to 
result in antibody production was prophetic. 
 
1.2.2 The Two Signal Model for Lymphocyte Activation 
 
 By the end of the 1960’s it became increasingly clear that binding of antigen 
alone to an antibody-bearing precursor cell was insufficient to result in the production of 
antibody. The two-signal model for lymphocyte activation, first put forward by Bretscher 
and Cohn, attempts to reconcile difficulties of a minimal model for antibody induction, 
the binding of antigen alone, and a number of experimental observations regarding the 
requirements for induction and inactivation of antibody producing lymphocytes 
(Bretscher and Cohn 1968; Bretscher and Cohn 1970; Bretscher 1972). According to the 
more polished 1970 version, interaction of a lymphocyte with antigen through the antigen 
receptor (signal 1) results in death of the cell unless it also receives another signal (signal 
2), that is provided by a T cell. This model was the first to give an essential role to the T 
cell (or T cell dependent factors), in the activation of the B cell, beyond simply an 
accessory function in facilitating the binding of antigen to B cells.  
Three major types of observation are cited in the original papers describing the 
two-signal model for the primary activation of lymphocytes that are consistent with that 
model, but inconsistent with a simple antigen-binding model, for how antibody 
production is induced.  
Macromolecular haptens, such as poly-L-lysine (PLL), were employed by some to 
demonstrate that the mere presence of a substance that can bind antibody is often 
insufficient to result in antibody production (McDevitt and Benacerraf 1969). Individuals 
of certain strains of guinea pig do not respond to PLL alone, by producing anti-PLL-
antibody. However, the same guinea pigs have the immunological capacity to produce 
antibody towards PLL as, upon immunization with PLL coupled to bovine serum 
albumin (BSA), but not when PLL is coupled to guinea pig serum albumin, anti-PLL 
antibody is made (Benacerraf, Green et al. 1967). Thus PLL perfectly fits the definition 
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of a hapten in certain strains of guinea pig; it binds antibody but is not itself 
immunogenic. The finding that coupling a foreign protein to PLL, but not a homologous 
serum protein, results in antibody production, suggests that simultaneous recognition of 
this foreign protein is required for anti-PLL antibody to be produced, a proposition that is 
inconsistent with the idea that the simple binding of PLL, by an antibody-bearing cell, 
should induce antibody production. 
 Secondly, observations were made on the role of carrier proteins in generation of 
secondary anti-hapten antibody responses, which suggested that these responses involve 
simultaneous recognition of more than one foreign determinant. For example, it was 
found in rabbits that in order for a secondary anti-hapten antibody response to occur, the 
rabbits must be previously immunized with both the hapten and the carrier (Rajewsky, 
Schirrmacher et al. 1969). The suggestion that antibodies may bind both the hapten and 
part of the carrier protein together, leading to efficient responses, was shown to be 
unlikely by the results of experiments of the following type: rabbits immunized with a 
hapten (h)-X (where X is a carrier protein like human gamma globulin), will respond 
with secondary-type antibody production when challenged with h-X, but not when 
challenged with h-Y, where Y is an unrelated, non-crossreacting carrier. However, if 
these rabbits are primed with h-X and Y, secondary antibody production is observed 
whether they are challenged with h-X or h-Y. Rajewsky makes reference to similar 
results that were originally reported by Mitchison in mice (Mitchison 1969). This 
“carrier-effect” was eventually seen as evidence supporting cellular collaboration 
(Mitchison 1971). Clearly, the results of experiments of this type, including others made 
with isozymes of lactate dehydrogenase (Rajewsky, Rottlander et al. 1967) are at odds 
with an antigen-binding model of antibody production. Simultaneous recognition of both 
hapten and carrier is needed to result in enhanced secondary immune responses.  
 Finally, studies on the breaking of the unresponsive state, by immunization with 
cross-reacting proteins, in rabbits given heterologous serum proteins at birth, were cited 
as evidence that simple binding of antigen, to cell-bound receptors, was insufficient to 
induce antibody production. Classical studies had shown that rabbits could be made 
immunologically unresponsive to certain proteins if given around the time of birth 
(Hanan and Oyama 1954).  The tolerance was fairly stable. Rabbits given BSA, HSA, or 
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human gamma globulin (HGG) remained unable to immunologically clear these antigens 
for months after the initial induction of unresponsiveness (Humphrey 1964).  Even upon 
challenge with the same protein with the adjuvant ALUM, most rabbits fail to make 
robust antibody responses (Humphrey 1964). Thus, the results of experiments reported by 
Weigle are somewhat surprising (Weigle 1964). Rabbits made unresponsive to BSA by 
administration of high doses of the protein, shortly after birth, remain tolerant upon 
challenge with BSA. However, when the cross-reacting protein HSA, containing some 
epitopes that are common to BSA and HSA and some epitopes unique to HSA, was 
employed as a challenge, previously tolerant rabbits responded by making antibody that 
reacted with both HSA and BSA. Thus, immunization with an antigen containing both 
epitopes to which the rabbits were supposed to be tolerant of, and epitopes that were 
“foreign”, allowed antibody production against both types of epitope. These results could 
not be readily understood under the simple antigen-binding model. 
In all cases above, the precursor cells that can produce antibody, upon appropriate 
immunization, are present in the experimental animals but are not induced to produce 
antibody. That is, the simple presence of the hapten, or antigen, does not induce antibody 
production. In all cases, it appears that the recognition of other antigenic determinants is 
required to result in antibody production. This observed requirement led to Bretscher and 
Cohn’s suggestion that cooperation between multiple cells bearing antibody (or the 
antibodies themselves) is required for antibody production. 
Citing the experimental evidence above, in the formulation of the two-signal 
model for lymphocyte activation, Bretscher and Cohn make the following general 
predictions for the generation of immune responses. Firstly, induction of antibody 
production requires a second signal; this signal comes from the presence of “associative” 
antibodies (or cells bearing these antibodies) specific for the carrier protein. In 
contemporary terms, B cells require the presence of T cells, which recognize physically 
linked determinants of the same antigen, to produce antibody. Secondly, if no second 
signal, deriving from the recognition of other parts of the antigen, is received, paralysis, 
or inactivation, of the precursor antibody-bearing cell ensues. The authors also suggest 
that the induction of carrier-specific antibody, or the cells that produce it, follows the 
above two-signal rules. Given the fairly recent discovery of collaboration between bone 
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marrow-derived and thymus-derived cells in the induction of antibody responses 
(Claman, Chaperon et al. 1966; Miller and Mitchell 1968; Mitchell and Miller 1968; 
Mitchell and Miller 1968; Nossal, Cunningham et al. 1968), it was suggested that carrier-
specific antibody is produced by T cells, while the true hapten-binding antibody is 
derived from bone marrow cells. Since recognition of the carrier is required for antibody 
production, under this model, all antibody responses should be thymus dependent. 
Finally, tolerance to self-components results from inactivation of both B cells and T cells, 
that react to self antigens (signal 1), but do not collaborate with other autoreactive cells 
(signal 2), as these cells should be eliminated, one by one, as they are generated. 
Lymphocytes specific for foreign antigens may accumulate in the absence of these 
antigens and, upon antigen impingement, may collaborate, resulting in antibody 
production.  
 The two-signal model for lymphocyte activation accounted for many 
experimental observations better that a simple antigen binding model. However, this 
model failed to stimulate much experimentation until nearly two-decades after its initial 
proposal. It seems that a conceptual block had occurred, possibly due to the ambiguity of 
the nature of antigen recognition by T cells, that limited immunologists’ ability to 
critically test this model. However, when people began to test some of the predictions of 
this model, many of its essential features were found to be correct. In general, as we will 
see below, signal one, delivered to lymphocytes by their interaction with antigen, results 
in inactivation, while a second signal is required for their activation to enable them to 
give rise to descendants that provide effector functions. 
   
1.2.3 Activation of CD4 T cells 
 
 The main cellular effectors of the adaptive immune response are B cells, which 
produce antibody, and cytotoxic CD8+ T cells which kill self-cells under appropriate 
circumstances. Most antibody responses require the presence of thymus-derived cells, 
called CD4+ helper T cells (Claman, Chaperon et al. 1966; Miller and Mitchell 1968). 
Keene and Foreman found that the activation of CD8-bearing T cells, specific for the 
murine MHCI-like antigen Qa1, required help from CD4 T cells specific for a linked 
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antigenic determinant (Keene and Forman 1982). Extending these findings Guerder and 
Matzinger showed that, in the absence of CD4 T cell help, exposure to antigen can 
inactivate CD8 T cells (Guerder and Matzinger 1992). Thus, all the major effector cell 
populations of the adaptive immune system abide by the rules of the two-signal model. 
However, in the early 1970s, the issue of how T lymphocytes are activated remained 
unresolved. The issue was complicated by the unknown nature of the antigen receptor of 
T cells (later known as the T cell receptor; TCR), and also by findings, discussed below, 
on the role of MHC in antigen recognition by T cells.  
 In the late 1960s Hugh McDevitt made a remarkable discovery, the ability of an 
animal to respond to a given antigen can be genetically controlled. The ability to respond 
to synthetic polypeptide antigens, by the production of potent antibody responses, 
depended on the existence of certain “immune response” (Ir) genes in mice (McDevitt 
and Sela 1965). The Ir locus mapped to the same segment of the germline DNA as H-2, 
the mouse major histocompatability gene complex (MHC) (McDevitt and Tyan 1968; 
McDevitt and Chinitz 1969). Interactions between the helper T cell, bearing the CD4 
surface antigen, (CD4 T cell) and antigen-specific B cells, resulting in antibody 
production, were found to require compatibility at the H-2 “locus” (Kindred and Shreffler 
1972; Kindred and Weiler 1972). Furthermore, it appeared that the proliferation in culture 
of previously primed T cells, in response to antigen in culture, depended on the presence 
of syngeneic “peritoneal exudate macrophages” and that proliferation could by blocked 
by antisera to H-2 encoded antigens (Shevach, Paul et al. 1972; Rosenthal and Shevach 
1973; Shevach and Rosenthal 1973). Taken together, these studies led to the suggestion 
that the germline DNA-encoded MHC antigens played an essential role in the initiation 
of T cell-dependent immune responses.  
The surprising finding of Zinkernagel and Doherty (Zinkernagel and Doherty 
1974), leading to their Nobel Prize, that cytotoxic T cells kill virally infected target cells 
only when they share identity at the MHC, tied the above observations together. T cells, it 
appeared, recognize antigen only in association with MHC-encoded cell surface 
molecules, which, according to Zinkernagel and Doherty, were altered by the presence of 
foreign antigen. CD8+ CTL were found to recognize antigen in an MHC class I (MHCI) 
restricted fashion, requiring identity at only the H-2K or H-2D loci (Zinkernagel and 
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Doherty 1974). This finding was independently confirmed by Shearer who showed that 
CTL-mediated lysis of trinitrophenyl- (TNP-) modified splenocytes is restricted by the 
presence of the appropriate H-2K or H-2D allele on these target cells (Shearer, Rehn et 
al. 1975). Miller demonstrated that CD4+ T cells, the helper cell for antibody production, 
and the cell responsible for delayed-type hypersensitivity, respond to antigen in 
association with Ir gene/MHCII encoded I-A and I-E gene products (Miller, Vadas et al. 
1975). Thus, MHC controls the activation and effector function of T cells.  
 The discovery of the MHC restriction of T cell antigen recognition had a dramatic 
impact on the field of immunology. At first, it was unclear what the implications of these 
findings were for the generation of T cell responses. For example, it was unclear whether 
antigen was recognized in complex with MHC or whether the MHC and antigen were 
detected as separate molecules bound on the surface of antigen-presenting cells (APC) 
that were recognized separately by different T cell receptors. However, in the absence of 
a clear description of the TCR, these possibilities could not be resolved. 
 While some immunologists made progress on the nature of the T cell-antigen 
interaction, some remained interested in the mechanistic rules governing the activation of 
T cells. In 1975, Lafferty and Cunningham published a half theoretical, half experimental 
paper in which they proposed a new two-signal model for the activation of alloreactive T 
cells (Lafferty and Cunningham 1975). The authors noted that in mixed lymphocyte 
reaction (MLR) cultures, only certain cell types were able to effectively stimulate T cells. 
The cells were called stimulator cells and thus possessed a positive stimulatory (S+) 
phenotype. The authors drew heavily on the proposals of Bretscher and Cohn, but placed 
the responsibility for delivering signal 2 to T cells on the shoulders of S+ cells. Thus, S- 
cells deliver only signal one to T cells, resulting in their inactivation, while antigen-
presenting cells that have, or acquire, the S+ phenotype, deliver both signal one and 
signal two, resulting in activation of T cells.  
Subsequent studies supported the propositions of Lafferty and Cunningham. 
Yano, Schwartz, and Paul confirmed the findings of Shevach (1973), originally made in a 
guinea pig-based system, that the proliferation of previously activated T cells required 
macrophages of the same H-2 haplotype; moreover, the authors showed that these 
macrophages must be viable to induce proliferation (Yano, Schwartz et al. 1977). 
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Presumably these macrophages provided additional signals to induce T cell proliferation. 
Work by others, employing the mitogenic lectin, concanavalin A (conA) as an analog of 
antigen stimulation, lent further weight to the notion that macrophages, or “accessory 
cells”, provided essential second signals for the activation of T cells. Habu and Raff 
showed that conA stimulation of highly purified T cells was insufficient to induce 
proliferation (Habu and Raff 1977). However, the proliferation of T cells, by conA, could 
be induced by also supplementing these cultures with spleen-derived plastic-adherent 
accessory cells, presumably macrophage-like cells. Larsson took this system further, 
confirming the requirement for accessory cells, but also showed that conA stimulation 
alone made T cells receptive to stimulation by growth factors present in the supernatant 
of culture of truly activated T cells (Larsson and Coutinho 1979). The presence of such T 
cell growth factors in the supernatants of conA-stimulated T cells had been demonstrated 
a few years previously (Paetkau, Mills et al. 1976). From a modern standpoint, these 
growth factors are likely to be cytokines such as interleukin-2 (IL-2). Thus, antigen-
mediated signals alone appear to be insufficient for T cell activation, but do affect these 
cells, making them receptive to second signals.   
Studies involving the culture of T cells with macrophage-like accessory cells 
provided another great insight into how activation of T cells is achieved. Following the 
lead of others who showed that processing of antigen may be involved in presentation to 
T cells (Weinberger, Herrmann et al. 1981; Ziegler and Unanue 1982), Scala and 
Oppenheim demonstrated that catabolism by human macrophages was essential for the 
priming of antigen specific T cells, but not alloreactive T cells, in culture (Scala and 
Oppenheim 1983). Moreover, inhibition of antigen processing by chemical fixation did 
not have any effect if done longer than two hours after the initial addition of antigen to 
culture, suggesting that processing of antigen occurs prior to presentation. Later that year, 
Shimonkevitz et al. demonstrated that a T cell clone specific for ovalbumin (OVA) would 
release IL-2 when fragments of artificially “digested” OVA were added exogenously to 
cultures of this clone and fixed APC (Shimonkevitz, Kappler et al. 1983). The authors 
concluded that digestion of antigen is both necessary and sufficient to enable antigen 
presentation to T cell clones in association with MHC molecules.  
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The isolation of the T cell receptor protein complex by Haskins et al. (Haskins, 
Kubo et al. 1983), and the elegant identification of the genes encoding of the TCR by 
Hedrick, Cohen and Davis in 1983 (Hedrick, Cohen et al. 1984), revealed that T cells 
recognize antigens via a single antigen receptor. Conceptually, this posed a problem for 
immunologists. How could a single receptor be responsible for both antigen recognition 
and MHC restriction? The solution was provided by Babbitt et al. working with Emil 
Unanue and confirmed and extended by Buus et al. in the laboratory of Howard Grey 
(Babbitt, Allen et al. 1985; Buus, Colon et al. 1986; Buus, Sette et al. 1987). Peptides, 
derived from digested protein antigens, bind hydrophobic clefts in MHC molecules. The 
antigenic peptides are presented to T cells as a single complex with the MHC-encoded 
surface molecules. Antonio Lanzavecchia demonstrated that antigens, presented by B 
cells to CD4 T cells, resulting in antibody production, must also be processed and 
presented in fragments via MHCII molecules. Thus, the role that the MHC gene products 
play, in the activation of all the major T cell effector functions, was resolved. 
These major discoveries in immunology revealed nature’s beautiful mechanism 
for ensuring antigen recognition by T cells is restricted by the highly polymorphic MHC. 
They further opened up the field, for the investigation of the biology of T cells, by 
removing the conceptual block surrounding the nature of T cell recognition of antigen. As 
we will discuss below, progress on the rules for T cell activation and inactivation was 
made rapidly in the following years.  
 
1.2.4 Dendritic Cells, the True S+ cell? 
 
 Throughout the time that the above studies were undertaken, the biology of 
dendritic cells (DCs) was being worked out. At the time of the initial identification of the 
DC, Steinman could not have known how big the field of DC biology would become 
(Steinman and Cohn 1973; Steinman 2003). DCs were characterized as a distinct 
population of cells, present within the population of adherent lymphoid cells, based on 
morphological and cell-surface-antigen phenotypes. These were shown to be non-B, non-
T, and non-macrophage cells with a branching morphology, as reviewed by Steinman and 
Nussenzweig (Steinman and Nussenzweig 1980). 
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The first evidence of a functional role for DCs came from MLRs carried out with 
various APC populations, or purified DCs, as stimulators (Steinman and Witmer 1978). It 
was demonstrated that the ability of various lymphoid populations, including splenocytes, 
to stimulate allogeneic T cells in MLR cultures, correlated with the numbers of DCs that 
were present in these populations. The authors concluded that DCs are at least 100-fold 
more potent in stimulating T cells in culture than are B cells or macrophages. Moreover, 
purified macrophages were very poor stimulators after thorough depletion of DCs. The 
finding that B cells, macrophages, and DCs express the I-A (MHCII) antigen at similar 
levels, led Steinman to suggest that molecules other than antigen alone are recognized, in 
association with DCs, in order for maximal proliferation to occur. It was suggested that 
the discrepancy between this finding and those of others, like Rosenthal and Shevach 
(1973), that macrophages are potent stimulators in MLR cultures, might be due to 
contamination of macrophages cultures with DCs. The importance of DCs as APC in the 
MLR was underscored by a later study wherein DCs were selectively depleted from 
allogeneic stimulator populations. Depletion of DCs by provision of the 33D1 antibody 
and complement, removed between 75 and 90% of the stimulatory capacity of allogeneic 
spleen (Steinman, Gutchinov et al. 1983). Thus, DC appeared to be very potent APC. 
Another functional role of the DC was demonstrated by Nussenzweig when he 
showed that DC are able to stimulate syngeneic T cells to divide in culture (Nussenzweig 
and Steinman 1980). This capacity was not due to the antigen specificity of T cells and 
required T cell-DC contact. Thus, DCs constitutively induce T cell proliferation in 
culture. It is possible that this proliferation is driven by the presentation of antigens 
“carried over” by DCs from the animals from which they are isolated. However, the 
possibility that this proliferation was influenced by the presentation of heterologous 
serum proteins, present in the culture medium, was excluded by employing only 
isologous serum in the DC preparation and culture procedures. Allogeneic stimulation by 
DCs was still found to be at least ten-fold more potent than syngeneic stimulation, and 
syngeneic cultures did not yield CTL, whereas allogeneic cultures did. DCs are also able 
to generate CTL specific for TNP-modified self cells, a common antigen-specific target 
(Nussenzweig, Steinman et al. 1980). However, the syngeneic MLR, as it was termed, 
appeared to have a functional role in inducing antibody responses. Inaba et al. 
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demonstrated that DC-T cell association allows for the production of “helper factors” for 
antibody production by B cells. Helper factors are presumably cytokines such as IL-4. 
According to Inaba, DCs activate the T cells to produce IL-2, which in turn stimulates the 
production of helper factors by these T cells. The culture supernatants from syngeneic 
MLR have the ability to stimulate antibody production when supplied to cultures of B 
cells and xenogeneic erythrocytes. While no antigen-specificity was found in syngeneic 
MLRs, the production of B cell helper factors was found to be dependent on MHC gene 
products, as antibodies to these blocked the ability of DC-T cell culture supernatants to 
stimulate antibody production (Inaba, Granelli-Piperno et al. 1983). The syngeneic MLR 
is a curious phenomenon that is no longer discussed in DC biology. Later studies 
demonstrated a potent, antigen-dependent APC role for the DC. 
 Through the 1980s great strides were made in uncovering the biology of T cells. 
The discovery of MHC-restriction and the isolation of the TCR resolved long-standing 
questions about how T cells “see” antigen. All the known major functions of T cells 
could finally be understood in the context of MHC restriction. Proliferation to allogeneic 
MHC, transfer of DTH, and help for the production of antibody and in the generation of 
CTL, were now understood as requiring recognition of peptide antigens, in association 
with the MHC gene products, by CD4 T cells. Significantly, DC have been shown to be 
involved in all of these phenomena. Though it took many years for the consequences of 
the work of Steinman and his colleagues to be thoroughly appreciated, these have become 
central to current immunological paradigms. The awarding of the 2011 Nobel Prize in 
Physiology and Medicine to Ralph Steinman makes this point.  
 
1.2.5 Shaping of the CD4 T cell Repertoire in the Thymus 
 
 Thymus derived cells are known to be essential for the development of antibody 
responses. It turns out that the thymus organ itself, is essential for the development of 
thymus-derived cells, as evidenced by classical studies on neonatal thymectomy. 
However, how the thymus is involved in the generation of T cells, and what its role is in 
shaping the repertoire of these cells, was not well established until well after the 
discovery of MHC restriction. Today it is known that the thymus plays an essential role 
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in ensuring that maturing T cells can recognize peptides in the context of self-MHC 
molecules while affecting elimination of those thymocytes whose T cell receptors (TCRs) 
react strongly with self peptide-MHC complexes. These processes have been called 
positive and negative thymic selection, respectively. 
 The thymus positively shapes the T cell repertoire, ensuring that T cells have 
affinity for self-MHC. Some of the first evidence that demonstrated a specific function of 
the thymus in positively determining the specificity of T cells came from Michael 
Bevan’s work with irradiation bone marrow chimeras (Bevan 1977). Irradiated parental 
strain mice were engrafted with bone marrow from F1 offspring derived from a cross 
between the parental strain and an H-2 disparate strain. Mature F1 T cells from chimeric 
mice, having developed in the presence of only one H-2 haplotype, efficiently killed 
virally infected target cells possessing the MHC molecules of the host, but not the other 
parent. Thus, the specificity of developing T cells is determined by the H-2 haplotype of 
the host. Zinkernagel confirmed this finding a year later employing a very similar 
experimental system. CTL of F1 into parental mouse bone marrow chimeras only lysed 
vaccinia infected target cells of the parental strain in which they developed (Zinkernagel, 
Althage et al. 1978). Studies like these led to the notion that thymocytes, that develop a 
TCR that interacts with self-MHC molecules, are given survival signals, the “kiss of life”, 
whereas those that do not are left to undergo “death by neglect”. Thus the thymus 
positively selects the affinity of the TCR. 
Later experiments confirmed a role for the thymus in positive selection and 
extended our knowledge of how this process occurs. Kisielow et al. took advantage of 
transgenic mouse technology to formally address this issue. In radiation chimera 
experiments, MHC congenic mice were engrafted with bone marrow from mice bearing a 
transgene-encoded TCR with affinity for a peptide of the male specific antigen, H-Y, in 
the context of H-2Db. Host mice that expressed H-2Db supported the generation of high 
numbers of mature CD8+ single positive thymocytes bearing the transgenic TCR, whereas 
no cells bearing the transgene-encoded TCR could be found in the thymus or periphery of 
host mice lacking H-2Db. However, the less mature CD4+CD8+ “double positive” 
thymocytes did show evidence of transgene-encoded TCR expression, suggesting that 
positive selection depends exquisitely on the presence of the correct restricting element 
! 16 
during the maturation of thymocytes from the double positive stage to the CD8 (or CD4) 
single positive stage (Kisielow, Teh et al. 1988). More recently, Chmielowski et al. have 
shown that a normal repertoire of TCRs is expressed in mice that express only a single 
peptide-MHC complex in the thymus (Chmielowski, Muranski et al. 1999). CD4 T cells 
from these mice respond well to peptides that are not related to the positively selecting 
peptide and there is no evidence that these cells have enhanced reactivity towards the 
positively selecting peptide, or derivatives thereof. These results reinforce the ideas that 
positive selection functions mainly to ensure that T cells bear TCRs with affinity for self-
MHC, and that positive selection is not dependent on the peptides that are presented. 
 At the time that thymic positive selection was being investigated, the first findings 
that the thymus had a role to play in maintenance of T cell self-tolerance were emerging. 
Shimon Sakaguchi made important discoveries on the role of the thymus in generating 
regulatory T cells that help maintain tolerance to self in a dominant fashion. However, the 
implications of these findings were not fully appreciated until much later, as will be 
discussed below. Rammensee and Bevan, and independently, Matzinger and Waldman, 
showed, by the use of sophisticated experimental systems, that tolerance to self-antigens 
is restricted by the host MHC (Matzinger, Zamoyska et al. 1984; Rammensee and Bevan 
1984). Both groups show that in the T cell repertoire of normal animals, precursor CTL 
exist that have affinity for self-antigens (minor histocompatability antigens) when 
presented in the context of foreign MHC. The system of Rammensee and Bevan was 
quite elegant. Mixed lymphocyte cultures were set up in the classical way, however 
directly alloreactive T cells were caused to undergo apoptosis by labeling with 
bromodeoxyuridine and exposure to UV light. This protocol resulted in a population of 
CTL, from strain A, that could not kill strain B targets. The few remaining cells, 
following multiple rounds of selection by this protocol, were re-stimulated with irradiated 
A.B cells (from MHC congenic mice expressing the B MHC molecules). A population of 
CTL were expanded that could lyse A.B targets, but neither A targets nor B targets. 
Presumably these CTL recognized self- (A) minor histocompatability antigens in the 
context of B MHC. This presumption was shown to be true by the finding that these CTL 
lysed AxB F1 cells. Thus, tolerance to self-antigens is achieved in an MHC-restricted 
fashion.  
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 Kappler et al. were the first to directly demonstrate negative selection in the 
thymus (Kappler, Roehm et al. 1987). Thymocytes that express V!17a-encoded TCR 
segments, which imparts affinity for I-E to many of the TCRs, exist in a normal 
proportion in I-E deficient mice. However, in I-E expressing mice, the single positive 
thymocytes and peripheral T cells expressing V!17a are drastically reduced. Importantly, 
immature double positive thymocytes contain normal populations of V!17a+ cells 
suggesting that negative selection occurs at the single positive stage. T cells that express 
TCRs that bind strongly to self-components are removed, or negatively selected in the 
thymus. 
Additional evidence suggested that distinct areas of the thymus fulfill distinct 
functions in positive and negative selection. The epithelial cells in the thymic cortex are 
thought to be mainly responsible for positive selection. Restriction of I-A expression to 
the thymic cortex results in positive selection without corresponding negative selection, 
leading to I-A reactive cells accumulating in the periphery (Laufer, DeKoning et al. 
1996). The epithelial cells of the thymic medulla express self-antigens promiscuously 
because they are under the control of non-specific promoters such as AutoImmune 
REgulator  (AIRE) (Anderson, Venanzi et al. 2002). These cells were once thought to be 
the main mediators of negative selection (Petrie 2002). However, recent evidence 
suggests that thymic resident dendritic cells acquire antigens from medullary epithelial 
cells, and mediate deletion of T cells that react with self peptide-MHC complexes 
(Brocker, Riedinger et al. 1997; Gallegos and Bevan 2004). The major role of the thymic 
medullary epithelial cell appears to be in inducing regulatory T cells (Aschenbrenner, 
D'Cruz et al. 2007), as I will discuss further below. As maturing thymocytes pass through 
distinct areas of the thymus, they are subject to distinct selection stimuli. 
Given the evidence above, it is clear that the thymus plays a major role in 
determining the repertoire of T cells. This is carried out by thymic  selection for 
thymocytes that have some affinity for self-MHC molecules, but by facilitating the 
elimination of maturing thymocytes with high affinity for self-antigens. Even in the face 
of heavy negative selection in the thymus, autoreactive T cells do emigrate to the 
periphery, particularly when the antigens for which they are specific are not well 
expressed in the thymus (Pircher, Burki et al. 1989). Thus, a mechanism for inducing 
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tolerance in T cells in the periphery should exist to limit autoimmunity. Evidence for 
such a mechanism of peripheral inactivation is outlined below. 
 
1.2.6 Peripheral Inactivation of CD4 T cells 
 
 The activation of T cells was found to require more than simply antigenic 
stimulation. While the nature of this second-signal or “co-stimulation” was unclear in the 
mid-1980’s, several groups turned to investigating the minimal requirements for the 
activation of T lymphocytes. However, both the models of Bretscher and Cohn and of 
Lafferty and Cunningham suggested that, when a lymphocyte receives a signal 1 from 
binding antigen in the absence of a second signal, it will be inactivated. In contrast to 
Lederberg’s idea that lymphocytes pass through a unique developmental stage, during 
which they are susceptible to deletion by self-antigen, two-signal models predict that 
inactivation, under the correct circumstances, may occur at any time. The shaping of the 
T cell repertoire in the thymus, and indeed the inactivation of self-reactive B cells in the 
bone marrow, are processes more reminiscent of the Lederberg model. A critical question 
for investigators was whether inactivation of lymphocytes, by signal 1 alone, can occur 
efficiently in the periphery. As will be discussed below, evidence supports the idea that 
tolerance to self- and experimental- antigens can be induced in mature peripheral 
lymphocytes.  
The predictions of the two-signal models were investigated in both B and T 
lymphocytes concurrently, and definitive evidence for the role of signal 1, in inducing 
inactivation of these cells, was obtained at roughly the same time. Extensive similarity in 
the rules governing the activation and inactivation B and T lymphocytes exists, as 
originally proposed by Bretscher and Cohn, and so it is informative to review evidence 
from the investigations of both of these cell types.  
 Nossal and Pike were the first to directly demonstrate that the interaction of B 
cells with antigen, in the absence of appropriate “help”, resulted in inactivation (Nossal 
and Pike 1975). When murine bone marrow was incubated in the presence of haptenated 
2,4 dinitrophenyl- (DNP-) HGG or HGG alone, and subsequently adoptively transferred 
into lethally irradiated hosts. Upon challenge with DNP conjugated to a protein 
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component of flagellin, mice that received bone marrow that was previously exposed to 
DNP were specifically unresponsive, in terms of antibody production, to the hapten. 
Metcalf and Klinman showed that B cells, particularly those immature cells in the bone 
marrow, were susceptible to inactivation upon exposure to antigen (Metcalf and Klinman 
1977). Thus, signal 1, received through interaction of the BCR with antigen inactivates B 
cells.  
Transgenic mouse technology greatly aided investigations into B cell tolerance 
induction and led to experiments that confirmed that mature B cells can be inactivated by 
signal 1. In 1988 Christopher Goodnow, employing a dual transgenic mouse system in 
which a strain of mice that ectopically expressed hen egg lysozyme (HEL) were crossed 
with a strain of mice that expressed a transgene-encoded BCR (immunoglobulin; Ig), that 
had affinity for the HEL protein. The resulting offspring, though functionally tolerant of 
HEL, still contained B cells that expressed the transgenic Ig (Goodnow, Crosbie et al. 
1988). The state of these B cells, not apoptotic but unresponsive to antigen stimulation, 
was called anergy. This initial study seemed to be at odds with the idea that inactivation 
of lymphocytes by signal 1 generally resulted in their death. In a subsequent study, 
Nemazee and Burki did not observe B cell anergy. They employed a similar transgenic 
system, wherein B cells expressed a transgene encoding a BCR with affinity for an 
MHCI molecule, of a given haplotype, not present in the host animal. When these 
transgenic mice were bred with mice of the H-2 haplotype, for which the transgene-
encoded BCR had affinity, there was a severe defect in the generation of mature B cells, 
both in the bone marrow and periphery (Nemazee and Burki 1989). The difference 
between Goodnow’s model and Nemazee’s model was sorted out a few years later. When 
mice transgenic for a membrane bound form of HEL were employed in crosses with BCR 
transgenic mice, transgene-expressing B cell development was impaired (Hartley, Cooke 
et al. 1993). B cells with affinity for self-antigens, particularly those antigens that are 
readily accessible by virtue of existing on the cell surface, are deleted as they are 
generated after experiencing signal 1 alone. 
Recently, Nemazee’s group has shown that polyclonal B cells that bind self-
antigens only in the peripheral tissues are subject to deletion. Employing an elegant 
experimental system that allowed them to avoid the complications that transgenic B cell 
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receptors may introduce, the authors show that an engineered superantigen, that binds 
kappa-encoded light chains of the BCR, expressed solely in the liver, induces deletion of 
kappa-bearing polyclonal B cells (Ota, Ota et al. year). These results, taken together, 
support the idea that B cells in the periphery, when exposed to antigen alone, signal 1, are 
removed via apoptosis, resulting in functional tolerance to these antigens. Thus the rules 
governing the activation and inactivation of B lymphocytes appear to be consistent with 
the original two-signal hypothesis. 
The identification and characterization of both the TCR and MHC gene products 
greatly facilitated the study of T cell biology. Once the nature of the interaction of T cells 
and the antigens for which they have specificity was known, investigators were able to 
address, in more reductionist and clearly defined ways, the mechanisms governing the 
activation and inactivation of these lymphocytes.  
Some of the first, and certainly some of the most influential studies, showing that 
T cells can be inactivated by the antigen-mediated signal 1 alone, came from Jenkins and 
Schwartz. These authors demonstrate that the pre-incubation of rested CD4 T cell clones 
with chemically “fixed” antigen presenting cells, from the spleen of normal mice, loaded 
with peptide antigen in culture, results in specific unresponsiveness of the CD4 T cell 
clones to further stimulation with the peptide. Similarly, unresponsiveness towards 
peptide antigens could also be achieved in vivo by the administration of fixed  peptide-
loaded APC (Jenkins and Schwartz 1987). Thus, signal 1, delivered by fixed splenocytes, 
resulted in the inactivation of CD4 T cells.  
Jenkins also investigated the molecular mechanisms involved in the inactivation 
of T cells using his experimental protocol. During the process of CD4 T cell inactivation 
by interation with antigen alone the IL-2 receptor was upregulated, but the cells fail to 
produce IL-2. This suggested that the clones require second signals for IL-2 production 
and, thus the lack of IL-2 stimulation may explain the inactivation of these clones 
(Jenkins, Pardoll et al. 1987). Importantly, the signals delivered to T cells required 
extracellular Ca2+, since cultures containing EGTA, a chemical that strongly chelates 
Ca2+, did not allow for antigen to inactivate the CD4 T cell clones. Moreover, the calcium 
ionophore, ionomycin, which artificially raises intracellular Ca2+ levels, could inactivate 
clones on its own. The authors also report a relative deficiency in protein kinase c (PKC) 
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activation and inositol triphosphate (IP3) accumulation in inactived clones compared to 
activated clones. They suggest that tolerance, mediated by the receipt of signal 1 alone, 
results in an imbalance between signals mediated by intracellular Ca2+ levels and those 
mediated by PKC.  
In a third paper, the authors show that the inactivation of CD4 T cell clones, by 
fixed APC, can be prevented by supplementing the cultures with unfixed allogeneic 
spleen cells (Jenkins, Ashwell et al. 1988). Presumably, the cells were S+ in phenotype, 
providing critical second signals that rescued CD4 T cell clones from inactivation. The 
second signals could not be replaced by IL-1 in culture, but were partially replaced by the 
phorbol ester PMA, which aggregates many cell surface receptors. Thus, signaling 
through these surface receptors, and not through soluble cytokine, is critical in preventing 
inactivation. Moreover, the induction of tolerance by fixed APC could be prevented by 
provision of Cyclosporine A (CsA). CsA functions by inhibiting the action of the Ca2+ 
dependent phosphatase calcineurin, thus confirming that Ca2+ is an important mediator of 
signal one, and leading to the suggestion that its major effect is mediated through the 
activity of calcineurin. 
 Working in the same laboratory, Quill et al. demonstrated, in a more reductionist 
way, that signal one alone resulted in death of CD4 T cell clones. Employing a system, 
previously used to show that antigen presentation to CD4 T cells required only peptide 
MHC complexes (Watts, Brian et al. 1984), Quill stimulated CD4 T cell clones with I-E 
molecules, loaded with the antigenic peptide, supported on an artificial planar lipid 
membrane (Quill and Schwartz 1987). Upon ligation of antigen, in this system, the clones 
were initially activated, as demonstrated by an increase in cell size, but became 
unresponsive to normal activation by antigen-pulsed splenocytes within 16-24 hours. The 
provision of PMA partially rescued clones from tolerance induction, but in this system, 
provision of IL-2 did not. The authors also demonstrated that a down-regulation of the 
TCR is not responsible for the inability of inactivated clones to be stimulated by antigen, 
suggesting that intracellular mechanisms are likely to be involved in specific inactivation 
of CD4 T cell clones in this manner. On receipt of signal one alone, CD4 T cells undergo 
apoptosis. 
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 Taken together, the finding of Jenkins, Quill, and Schwartz are striking. These 
findings brought two-signal hypotheses back into the consciousness of immunologists 
with regards to CD4 T cell activation. In clearly defined systems, and with insight into 
signaling events, the authors were the first to definitively demonstrate that the antigen-
mediated signal 1 was tolerogenic in CD4 T cell clones. However, this laboratory was not 
the only one to publish evidence that CD4 T cells are inactivated upon receiving signal 
one alone. Lamb, employing cultures of human CD4 T cell clones, demonstrated that 
incubation with the peptide of influenza HA, for which these cells had affinity, resulted in 
unresponsiveness (Lamb and Feldmann 1984). Critically, the induction of 
unresponsiveness in this system required MHC, as a blocking antibody could prevent 
inactivation. Human CD4 T cells express MHCII, and so in this system, act as both the 
stimulated cell and the APC. This finding was confirmed and extended, showing that 
inactivation of the cells in these cultures was long-lived, as was the case in the Jenkins 
system (Lamb, Zanders et al. 1987). The finding of Burkly et al. provided evidence that 
the inactivation of CD4 T cells occurs exrathymically in vivo (Burkly, Lo et al. 1989). 
Employing a similar methodology to Kappler (Kappler, Roehm et al. 1987), she showed 
that when I-E expression is restricted to pancreatic !-cells, inactivation, but not 
immediate deletion of V!17a+ T cells occurs. Thus, T cells can be “paralyzed” by 
antigen alone, a finding that is reminiscent of the anergy induced in B cells in Goodnow’s 
(Goodnow, Crosbie et al. 1988) BCR transgenic mice.   
 Although the findings of antigen-induced inactivation of CD4 T cell clones in 
culture were clear, questions about whether similar mechanisms could inactivate normal 
precursor T cells, in vivo, remained. As with the study of B cell tolerance, the study of the 
activation/inactivation decision of CD4 T cells was greatly aided by transgenic mouse 
technology. Development of a TCR-transgenic mouse, in which the T cells expressed the 
genes encoding rearranged " and ! chains from the DO11.10 CD4+ T cell clone that 
recognizes a peptide of OVA spanning residues 323-339 (OVA323-339), was pivotal. 
Murphy et al. demonstrated that the administration of large amounts of the OVA323-339 
peptide to DO11.10 TCR transgenic mice resulted in apoptosis of mature thymocytes 
expressing the TCR (Murphy, Heimberger et al. 1990). These transgenic T cells, it 
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appeared, are regulated in a similar manner to normal T cells; they are susceptible to 
negative selection in the thymus.  
Are mature TCR transgenic CD4 T cells also susceptible to inactivation in the 
periphery? Kearney, working with Jenkins, addressed this question directly (Kearney, 
Pape et al. 1994). After finding that administration of 300µg of OVA323-339 resulted in 
peptide-specific unresponsiveness in normal mice, she seeded mice with 2.5 x 106 
DO11.10 TCR transgenic cells, so that they could be easily followed by flow-cytometry. 
Upon administration of 300µg OVA323-339 intravenously or intraperitoneally, these cells 
were found to divide rapidly, implying that they were initially activated. DO11.10 TCR-
bearing cells rapidly underwent apoptosis and disappeared from all lymphoid tissues 
examined. Liblau et al. reported confirmatory results, in a different TCR transgenic 
mouse system (Liblau, Tisch et al. 1996), and Aichele et al. showed that endogenous 
CD8 T cells can be inactivated in a similar manner (Aichele, Brduscha-Riem et al. 1995). 
These results, which closely resemble those of Quill (Quill, Carlson et al. 1987), indicate 
that mature, but naive, peripheral CD4 T cells are highly susceptible to inactivation, by 
the provision of peptide alone, in the periphery. 
  The finding that administration of soluble peptide, via systemic routes, results in 
inactivation of the corresponding CD4 T cells implies that the cells that present this 
peptide do so in a manner that is primarily tolerogenic. According to the two-signal 
model of Lafferty and Cunningham, it is likely that these cells do not possess the S+ 
phenotype, or express what became known as co-stimulatory activity. The major 
populations of MHCII-bearing cells that could possibly present injected peptide are B 
cells, macrophage and DCs. As I will describe in section 1.4, resting and antigen-
presenting B cells are often found to be tolerogenic in culture with T cells (Chesnut, 
Endres et al. 1980; Kakiuchi, Chesnut et al. 1983; Croft, Joseph et al. 1997). Evidence 
also supports the idea that without activation by certain inflammatory stimuli, DC are 
tolerogenic (Hawiger, Inaba et al. 2001; Steinman, Hawiger et al. 2003). Thus, the results 
of Kearney, Liblau, and others imply that under normal conditions the majority of 
MHCII-bearing cells in the mouse are resting and unable to offer appropriate co-
stimulation to CD4 T cells for their activation. In addition, some extrathymic, MHCII-
bearing, stromal cells have recently been identified in the peripheral tissues. These cells 
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appear to function in a similar manner to the thymic medullary epithelial cells and 
express AIRE (Gardner, Devoss et al. 2008).  It is possible that these cells also play a role 
in presenting peptides to induce CD4 T cell tolerance, particularly since these cells do not 
express the major co-stimulatory molecules. Systemic administration of peptide antigen 
leads to presentation by primarily resting APC that lack co-stimulatory activity. We now 
turn, briefly, to investigations concerning the nature of co-stimulation.  
 
1.2.7 The Molecular Nature of Signal 2 for T cells 
 
 The activation of CD4 T cells in culture with “macrophages” and antigen is a 
classical system for the study of antigen-specific T cell biology. However, once the 
nature of antigen recognition by T cells became clear in the 1980s, some groups began to 
investigate the activation of T cells in more reductionist systems. Many people employed 
antibodies to the CD3 antigen, a component of the TCR signaling complex, to stimulate T 
cells (Geppert and Lipsky 1987). However, it rapidly became clear that signaling through 
the TCR alone was insufficient to activate naive T cells, resulting in acquisition of 
effector function. Another study employing different antigen presenting cell populations, 
illustrates this point. Upon culture of peptide-specific CD4 T cells with either IFN!-
stimulated fibroblasts (that express MHCII) or macrophages, pulsed with peptide, T cell 
proliferation was observed only in macrophage-containing cultures, indicating that 
presentation of antigen, through peptide-MHCII alone, is insufficient to result in 
proliferation of antigen-specific T cells (Geppert and Lipsky 1987). Clearly fibroblasts do 
not possess an essential co-stimulatory activity that “macrophages” do.  
 An antigen expressed almost universally on the surface of T cells was identified 
as having stimulatory activity complementary to TCR signaling. CD28, a member of the 
immunoglobulin superfamily of cell surface receptors, is found on virtually all peripheral 
T cells and stimulation via antibody crosslinking was shown to stabilize the messenger 
RNA for IL-2 (Lindstein, June et al. 1989). This finding was interesting in light of the 
earlier observations of Larsson (Larsson and Coutinho 1979) and Jenkins (Jenkins, 
Pardoll et al. 1987) that T cells, stimulated with antigen alone, fail to produce IL-2, 
preceding their inactivation, which can be prevented by provision of exogenous IL-2. 
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Thus it seemed that a regulatory loop had been closed: TCR stimulation results in up-
regulation of the IL-2 receptor, but not IL-2 production, co-stimulation through CD28 
leads to IL-2 production, and subsequent proliferation, and activation of the T cell. CD28 
stimulation enhances Ca2+ mobilization but does not increase IP3 or phosporylated 
protein tyrosine kinase (PTK) levels, which are normally a result of TCR ligation, thus 
these two signals are distinct (Ledbetter, Imboden et al. 1990).  
The natural ligand for CD28 was identified as the B cell activation-associated 
molecule, B7, which turned out to have at least two separate isoforms, B7.1 and B7.2 
(CD80 and CD86). These molecules also bind very strongly to another T cell surface 
receptor CTLA-4, which has different downstream effects than CD28 ligation. Blocking 
studies, in vitro, demonstrated that B7 was essential for proliferation of highly purified T 
cells in response to allogeneic B cells (Koulova, Clark et al. 1991). Confirmation of this 
finding, in live animals, was reported by Linsley et al. Administration of a soluble, 
recombinant CTLA-4 fusion protein completely blocks T cell dependent immune 
responses (Linsley, Wallace et al. 1992). The rapidly emerging findings regarding the 
molecular nature of the co-stimulatory signal were summarized by Schwartz at the time 
(Schwartz 1992) in a tidy minireview. In a number of experimental systems, the blocking 
of CD28 co-stimulation, during antigenic stimulation, was shown to result in anergy 
induction in T cells. The molecular nature of the Lafferty and Cunningham S+ phenotype 
had finally been resolved. However, the above description is altogether too simplistic.  
Only a few short years following the discovery of the B7 molecules as potent co-
stimulators of T cells, Ding and Shevach described a B7/CD28 independent co-
stimulatory activity of B cells (Ding and Shevach 1996). As it turns out, there are a great 
number of different molecules, expressed differentially on APC, that signal T cells in a 
co-stimulatory fashion. These fall broadly into two categories, the Ig superfamily and the 
tumor necrosis factor superfamily (TNFSF) (Peggs and Allison 2005). TNFSF members 
are generally homotrimeric surface-bound molecules with primary sequence similarity to 
the secreted cytokine TNF. These molecules, particularly OX40L and its corresponding 
receptor OX40, play an important role in inducing the effector function and survival of 
CD4 T cells.   
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There have been dozens of APC surface molecules identified that have some form 
of co-stimulatory activity in terms of the activation of T cells. The sheer numbers of  
molecules leads to the suggestion that some level of redundancy exists. It is generally 
believed that the regulation of these molecules stems from circumstances surrounding the 
acquisition of antigen by APC and thus, T cells receive distinct co-stimulation upon 
interaction with differentially activated APC (Manicassamy and Pulendran 2009). 
However, the details are not well understood at this time.  
 
1.2.8 Control of Survival and Apoptosis by Signal 2 
  
 As has been outlined above, experimental evidence demonstrates that T cells that 
experience signal 1 alone undergo apoptosis. The simultaneous provision of signal 2, to 
these cells, results in activation and prevents apoptosis. The findings of Jenkins, Quill, 
and Schwartz led to the suggestion that activation of the calcium dependent phosphatase, 
calcineurin, through the influx of Ca2+ to the T cell cytoplasm, is a critical event in signal 
1-mediated apoptosis. TCR signaling results in rapid Ca2+ influx, which eventually leads 
to cellular apoptosis if not prevented by factors generated when signal 2 is delivered to T 
cells. Molecular studies lend support to this basic two-signal tenet.  
 Apoptosis can regulate the growth of all cells. Unrestrained growth, or neoplasia, 
can result in cancer; cancers of immune cells are common. However, unrestrained growth 
and activation of autoreactive lymphocytes has another danger, the potential to induce 
autoimmunity. Therefore complex regulatory mechanisms have evolved to prevent 
autoimmunity by harnessing the normal apoptotic machinery present in all cells. The 
cellular mechanisms of this regulation are outlined above. The intracellular molecular 
signaling events that lead to apoptosis in lymphocytes that receive signal 1 alone are less 
well defined. However, over the past two decades, much about the molecular mechanism 
governing apoptosis has been learned. I will present a very oversimplified view of how 
the two-signal hypothesis for the activation of lymphocytes integrates with our current 
understanding of cellular death mechanisms. 
 All cells constitutively express proteins that are both pro- and anti-apoptotic. 
These proteins antagonize one another, resulting in a molecular stalemate, allowing 
! 27 
survival of the cell. Thus, tipping of the balance in either direction supports either 
enhanced survival or results in rapid apoptosis. The first enzymes that were shown to be 
associated with apoptosis, caspases, cleave one another in a cascade of reactions, 
resulting in degradation of the cellular DNA and eventually apoptosis. Lymphocytes are 
sensitive to death induced by this pathway. Kishimoto and Sprent demonstrate that TCR 
ligation in the absence of co-stimulation results in high-sensitivity to Fas-mediated 
apoptosis. Fas is a cell surface receptor with an ability to initiate caspase-dependent 
apoptosis. Thus, upon the receipt of signal 1 alone, T cells become very sensitive to 
ligation of Fas. The ligand for Fas, FasL, is expressed on the same activated T cells in 
this system. This leads to signal-1-activated T cells interacting with one another, inducing 
death amongst them - T cell fratricide (Kishimoto and Sprent 1999). Presumably, the 
provision of FasL by other cells would result in death of the TCR-stimulated T cells as 
well. The Fas pathway, it seems, is not as important, in the regulation of T cell survival, 
as a second pathway, the Fas-independent mechanism for apoptosis. 
 The Fas-independent apoptosis pathway consists of a highly complex network of 
signaling intermediates that integrate pro- and anti-apoptotic signals; the balance of these 
signals ultimately determines whether the T cell survives or undergoes apoptosis (Song, 
Ouyang et al. 2005). The signals that are integrated come from ligation of cell surface 
receptors like the TCR and CD28 as well as cytokine receptors, and other molecules 
(Salmond, Filby et al. 2009). Many of the ultimate effectors in this Fas-independent 
pathway share sequence homology to BCL-2, a protein originally isolated from B cell 
lymphomas. BCL-2 and its related family members exert potent anti-apoptotic activity. 
Current models hold that the function of these proteins is to sequester (and keep in an 
inactive form) other structurally related proteins, like Bax and Bak. Free (or appropriately 
activated) Bax and Bak molecules form oligomers in the mitochondrial membrane, which 
releases the mitochondrial stores of cytochrome C, initiating apoptosis. Bax and Bak 
associate with BCL-2 and other anti-apoptotic family members through their third BCL-2 
homology (BH3) domain. Other proteins, homologous to BCL-2 in only the BH3 domain 
(BH3-only proteins), are thought to displace (and activate) Bax and Bak from BCL-2. 
Thus, apoptosis can be initiated by the binding of BH3-only proteins such as BAD to 
BCL-2 (Lomonosova and Chinnadurai 2008). The ability of BAD to bind BCL-2 is 
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regulated by two factors, Akt/PKB and calcineurin. Phosphorylated BAD does not bind 
BCL-2; Akt phosphorylates BAD (Zhou, Liu et al. 2000) and calcineurin 
dephosphorylates BAD (Wang, Pathan et al. 1999). Thus, an excess of calcineurin 
activation or a deficiency of Akt-pathway activation should result in apoptosis. In T cells, 
calcineurin activation is induced by TCR-mediated calcium flux, and Akt-pathway 
stimulation is associated with co-stimulation and growth-factor (like IL-2) receptor 
ligation (Koyasu 2003). It appears therefore, that BAD activation acts as a fulcrum in the 
seesaw that balances apoptosis in the Fas independent apoptosis pathway. 
Given this highly simplified description, it is clear that signal 1 alone should 
normally result in the apoptosis of T cells. However, the pathways are more complex than 
outlined and there is considerable overlap in the induction and activation of the signal 1- 
and signal 2-associated pathways mentioned above. Moreover, other pathways may share 
intermediates, further complicating interpretation. Recent evidence suggests that both 
Fas-dependent and Fas-independent pathways are essential in maintenance of tolerance to 
self-antigens (Hughes, Belz et al. 2008). Induction of a state of anergy, in T cells, in the 
absence of apoptosis, is sufficient in some cases to prevent autoimmunity (Barron, 
Knoechel et al. 2008). Overall molecular studies appear to back up findings from cellular 
immunology regarding the roles of signal 1 and signal 2 in the activation/inactivation 
decision for lymphocytes.  
 
1.2.9 New Two-Signal Models for the Activation of CD4 T Cells 
 
Charles Janeway Jr. proposed a new model for the initiation of immune responses. 
First, at a Cold Spring Harbor symposium, and later in Immunology Today, taking into 
account emerging evidence that the expression of second-signal mediators appeared to be 
regulated, rather than constitutively present, he proposed that the mammalian immune 
system evolved from a primitive system that had the capacity to recognize conserved 
molecular patterns often associated with pathogens (Janeway 1992). Janeway 
hypothesized that, upon recognition of these pathogen-associated molecular patterns, or 
PAMPS, the innate APC, the macrophage and the DC, would be induced to express 
critical second signal molecules that would allow for the activation of T cells. Thus, the 
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decision criteria, for whether the host responds to an antigen or not, is whether or not this 
antigen is presented by APC that are activated in the presence of a PAMP (in addition to 
the availability of lymphocytes with antigen receptors that can recognize this antigen). 
Janeway then all but predicts the course of immunological study over the next decade by 
placing the importance of DC and germline encoded receptors as central controllers of 
immune responses. Many of Janeway’s ideas proved to be true and his rational and well-
reasoned arguments formed the basis for the next, and current paradigm for the initiation 
of the immune response.  
Matzinger extended Janeway’s idea in proposing that the activation of innate APC 
could be achieved by “danger signals” (Matzinger 1994). According to Matzinger, these 
danger signals could include conserved microbial products, but also cell stress molecules 
like heat-shock proteins, or interferons. This proposition was seen as an improvement, at 
the time, of Janeway’s model, as it explains why harmless organisms, for example 
commensal bacteria, are not normally subject to immune clearance. That is, commensal 
bacteria do not initiate immunity because they do not damage tissues. Matzinger also 
makes a point to reiterate the classical idea that signal 1 alone should result in tolerance 
of a lymphocyte. Since experimental evidence for this abounds (see above), the 
proposition is far from novel. However, in the context of a Matzinger’s model for the 
activation of lymphocytes, one would predict that inactivation of autoreactive cells would 
occur, one by one, as they are generated and interact with APC bearing self-antigens but 
not activated by the presence of danger signals.  
 A major conceptual problem arises from the models of Janeway and Matzinger 
(Bretscher 1999). These models, like that of Lafferty and Cunningham before, are 
principally concerned with the activation of T cells, and in particular, the CD4+ helper 
subset. Because these cells are seen as central to the induction of most antibody 
responses, and some CTL responses, help from CD4 T cells is often the limiting factor in 
the generation of immunity. Assuming that autoreactive CD4 T cells escape selection and 
emigrate to the periphery, and that APC present self-antigens, one can envisage how 
autoreactive CD4 T cells would readily be activated during the course of infection by a 
pathogen. Specifically, DCs bearing both pathogen-derived and self-antigens, but 
activated by PAMPS, would have the capacity to activate autoreactive T cells. If this 
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happens, the activated T cells, which depend less on signal two for their continued 
activation than naive cells (Dubey, Croft et al. 1996; Curtsinger, Lins et al. 1998), may 
initiate a cascade of autoimmune activation, leading to pathology. Thus, it would seem 
that the activation of autoreactive CD4 T cells should be stringently controlled, more 
stringently perhaps than is achievable under the models of Janeway and Matzinger.  
 
Bretscher proposed that while activated innate APC may initiate priming and 
expansion of CD4 T cells, their full activation and acquisition of effector function 
requires an antigen-mediated collaboration between CD4 T cells and B cells (Bretscher 
1999). Since both populations of lymphocytes are negatively selected for autoreactivity, 
the chance that autoreactive cells could achieve this type of collaboration was thought to 
be exceedingly rare. Thus, this model, called the “two-step, two-signal” model for the 
primary activation of CD4 T cells, takes into account observations concerning the role of 
inflammatory stimuli in activating innate APC, but remains consistent with the original 
two-signal model. As I will discuss later in this introduction, and demonstrate 
experimentally in this thesis, some of the implications of this model, particularly, the role 
of antigen-mediated CD4 T cell and B cell collaboration and CD4 T cell-CD4 T cell 
cooperation, may have important roles during the development of the immune response. 
However, experimental evidence does not appear to support the requirement for this type 
of lymphocyte interaction for the full activation of CD4 T cells as envisaged by Bretscher 
(1999).  
 Since the proposals of Janeway and Matzinger, much evidence has been reported 
that appears to support their hypotheses. The biology of DC, central to their theories, and 
shown to be an extremely potent APC in the induction of CD4 T cells was heavily 
investigated. DCs were shown to express B7.1 and B7.2 (CD80/86) which allows them to 
stimulate T cells in culture (Inaba, Witmer-Pack et al. 1994). The expression of CD86 
was found to be inducible on DCs, by the innate cytokine GM-CSF, which also caused 
their “maturation” as APC (Larsen, Ritchie et al. 1994). These findings led to the idea 
that DCs can be induced to express B7 molecules in response to inflammatory stimuli.  
The link between the maturation of DCs to express potent co-stimulatory 
molecules, and the detection of PAMPS was made by Medzhitov, working with Janeway. 
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The Toll protein was shown to be involved in resistance to fungal infection in Drosophila 
(Lemaitre, Nicolas et al. 1996). Toll was previously described as having sequence 
homology to the human IL-1 receptor suggesting a role in innate immune activity. 
Employing a homology search of the National Center for Biotechnology Information 
(NCBI) sequence bank, Medzhitov was able to identify and clone a human homologue of 
Toll. He expressed a constitutively active form of this human Toll in leukocyte cell lines 
and demonstrated that this leads to stimulation of the nuclear factor kappa-B (NF-!B) 
pathway and upregulation of IL-1, IL-8, IL-6 and B7.1-encoding mRNA (Medzhitov, 
Preston-Hurlburt et al. 1997). Subsequently, another protein homologous to Toll, encoded 
by the previously named Toll-like receptor gene, Tlr4, was shown to be critical in 
responses to bacterial lipopolysaccharide (LPS) (Poltorak, He et al. 1998). Toll-like 
receptor 4 (TLR-4) was identified as a receptor for a known PAMP, which induced the 
expression of co-stimulatory proteins, strongly supporting the hypotheses of Janeway. 
Serving to underscore the importance of these findings to the study of basic immunology 
is the fact that the 2011 Nobel Prize in physiology or medicine was awarded to the 
principle investigators of the work describing the discovery of the function of Toll in 
drosophila, Jules Hoffman, and the discovery of the function of TLR-4, Bruce Beutler. 
Ralph Steinman, for his discovery of DC, was also awarded the prize. Presumably, had he 
been alive at the time, Charles Janeway Jr. would have shared in this prize. 
New members of the TLR family were identified, and subsequent studies 
identified ligands for these receptors (Pasare and Medzhitov 2004; O'Neill 2006; 
Manicassamy and Pulendran 2009). TLR ligands include hypomethylated CpG sequences 
of bacterial DNA, and double-stranded RNA products found in some viruses. Most TLR 
ligands are derived from microbial pathogens and some respond to endogenous “danger 
signals” like heat-shock proteins. These TLR adaptor proteins signal via a variety 
intermediates, eventually leading to the transcription and protein expression of various 
co-stimulatory molecules, inflammatory cytokines, and homing molecules in DC that 
allow trafficking of these cells from peripheral tissues, where they reside, to the lymph 
nodes, as reviewed in: (Moynagh 2005; O'Neill 2006; Manicassamy and Pulendran 
2009). DC, it appears, are able to fully prime CD4 T cells, in an antigen and danger-
signal-dependent manner, upon migration to the lymph nodes. Experimental evidence 
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also suggests that both surface molecules borne by TLR-activated DC and the innate 
cytokines that they produce are critical for T cell activation (Pasare and Medzhitov 2004).  
Elizabeth Ingulli was one of the first to employ imaging to observe the interaction 
of DC with CD4 T cells in situ (Ingulli, Mondino et al. 1997). In the paracortical region 
of lymph nodes, draining areas where DCs were seeded, interactions between antigen-
specific CD4 T cells and peptide-loaded DC were observed whereas unloaded DC did not 
form many T cell contacts. Interestingly, peptide-loaded DCs, but not un-loaded DCs, 
disappear from the lymph node at 48 hours after the initial injection, suggesting that 
loaded cells are actively removed by some antigen-dependent mechanism. Subsequent 
dynamic imaging studies demonstrated the interaction of CD4 T cells and DCs in great 
detail (Stoll, Delon et al. 2002; Miller, Safrina et al. 2004). Thus interactions between DC 
and CD4 T cells have been visualized, underscoring the role of this interaction in the 
generation of immunity.  
Further evidence supports the idea that Toll-like receptor stimulation enables the 
selective formation of peptide-MHC complexes from ingested antigens (Inaba, Turley et 
al. 2000; Blander and Medzhitov 2006; Yarovinsky, Kanzler et al. 2006). DCs may 
preferentially avoid the presentation of self-antigens when exposed to inflammatory 
stimuli. This mechanism presumably serves to limit the activation of autoreactive T cells.  
These findings, taken together, illustrate the major role of DCs, activated by 
inflammatory stimuli, in the primary induction of CD4 T cell effector function. 
Comprehensive reviews are available on this subject (Banchereau and Steinman 1998; 
Villadangos and Schnorrer 2007; Segura and Villadangos 2009). However, DCs are not 
necessary for the induction of immune responses, as B cells can be sufficient to prime 
CD4 T cells in some cases (Constant, Schweitzer et al. 1995), and DC deficient mice 
generate CD4 T cell responses to DNA vaccines (Castiglioni, Lu et al. 2003). Moreover, 
danger signals are not absolutely required for immunity to sterile xenogeneic red-blood 
cells or to allografts (Bingaman, Ha et al. 2000), and signaling by TLRs is not required 
for immune responses to many conventional adjuvants (Gavin, Hoebe et al. 2006), 
despite the continual re-assertion of Janeway’s statement that the microbial components 
in adjuvants are immunologists’ “dirty little secret”. Overall, it appears that DCs facilitate 
CD4 T cell activation, often so greatly that it is seen as essential to developing effective 
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immunity, and this requires activation of the DCs by inflammatory stimuli. The role of 
DC in the primary activation of CD4 T cells is thus one of the most important factors in 
the generation of immunity. As it turns out, DCs are also efficient in aiding the 
maintenance of self-tolerance, the evidence for which will now be discussed. 
 
1.2.10 Maintenance of Self-Tolerance by DC 
 
Thymic DCs are able to negatively select mature thymocytes by presenting self-
antigens. However, if the models for activation of CD4 T cells of Janeway and Matzinger 
are correct, then inactivation of autoreactive CD4 T cells, by DC presenting self-antigens 
in the periphery, should also occur. Naturally, Ralph Steinman’s group was amongst the 
first to demonstrate that resting DCs can inactivate CD4 T cells in the periphery. Hawiger 
and colleagues devised an experimental system to target antigen uptake to immature DC. 
They constructed fusion protein antigens by joining a peptide derived from the primary 
sequence of hen-egg lysozyme (HEL) to an antibody molecule with affinity to DEC205 
(!DEC-HEL), a lectin receptor constitutively expressed on the surface of DC. Mice that 
were given !DEC-HEL, systemically, over a number of days, became tolerant to the 
HEL peptide as assessed by their failure to mount a T cell response to this peptide upon 
subsequent challenge. Interestingly, the effect of tolerance induction by immature DC 
targeted with !DEC-HEL could by prevented by the co-administration of FGK45 
antibody, an agonist to CD40, which systemically activates APC, including DC 
(Hawiger, Inaba et al. 2001). Thus, antigen presented by resting DC inactivates CD4 T 
cells.  
It has been shown that under non-inflammatory conditions immature DCs sample 
self-antigens for presentation to T cells, leading to their inactivation. Normally, DCs 
continually sample antigen in the periphery through endocytosis, mediated by surface 
receptors, like DEC205 or DCSIGN. The antigens that are taken up, self-proteins, are 
processed and loaded onto MHC molecules. These DCs also normally leave the 
peripheral tissues and traffic to the lymph nodes where they are free to interact with T 
cells. Because these cells have not been activated by exposure to PAMPS or other 
inflammatory stimuli, most DCs in this state express relatively low levels of MHC and 
! 34 
co-stimulatory molecules (Mahnke, Schmitt et al. 2002). DCs continually sample 
antigens from the periphery, where naive T cells do not normally have access to them, 
and bring them to lymph nodes where they are presented in a fashion that inactivates, 
rather than activates, T cells. This phenomenon was directly demonstrated by Liu et al. 
They administered dying, chicken ovalbumin- (OVA-) expressing, but antigen-
presentation incompetent, cells to normal mice. This protocol resulted in systemic 
unresponsiveness to OVA. However, if the OVA-expressing dying cells were given at the 
same time anti-CD40 agonistic antibody, in the fashion of Hawiger, OVA-specific T cell 
responses were observed (Liu, Iyoda et al. 2002). Thus, T cell tolerance to self-antigens is 
achieved, by immature DCs in the periphery, under what Ralph Steinman called the 
“steady state” (Steinman, Hawiger et al. 2003).  
 Raymond Steptoe’s group has addressed the role of steady-state DCs in tolerance 
induction in a more technologically advanced way. They make use of a transgenic mouse 
model wherein the DCs express ovalbumin under the control of the DC-specific promoter 
for CD11c. Because, in this system, immature DCs constitutively express OVA and 
cross-present OVA peptides on MHCII molecules, it was hypothesized that these 
transgenic mice would become tolerant of OVA at the T cell level. In a series of papers 
the authors have shown that, by virtue of this expression under normal conditions, DC 
can induce OVA-specific tolerance in naive CD4 and CD8 T cells (Steptoe, Ritchie et al. 
2007; Doan, McNally et al. 2009). The authors employ adoptive transfer experiments to 
ensure that inactivation occurred only in the periphery. Given this evidence, it is clear 
that steady state DCs play a major role in the induction of T cell tolerance in the 
periphery at many time points along their lifecycle.  
 The terms activated and inactivated DCs are somewhat inaccurate, as Caetano 
Reis e Sousa points out (Reis e Sousa 2006). This is because, in some cases, DCs that are 
activated and express higher levels of MHC and co-stimulatory molecules still lead to 
inactivation of T cells when they present antigen. For example, Perona-Wright et al. 
determined that DCs, activated by LPS in the presence of interleukin-10 (IL-10), though 
phenotypically indistinguishable in surface marker expression from LPS-alone-activated 
DCs, failed to elicit robust T cell responses in culture and in vivo. Mice that were treated 
with these IL-10-matured DCs became tolerant of peptides that the DCs were loaded 
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with. Whereas DCs matured with LPS alone generated robust T cell responses. The 
authors extended these observations to a model of experimental allergic 
encephalomyelitis (EAE) and found that IL-10 matured DCs pulsed with a myelin 
oligodendracyte glycoprotein (MOG) peptide could protect against EAE when given 
before MOG immunization (Perona-Wright, Anderton et al. 2007). Dendritic cells that 
reside in the lungs also, it appears, have a tendency to elicit tolerance in T cells. Akbari et 
al. found that lung DCs, by virtue of their production of IL-10, tolerized T cells when 
they presented antigen. However, lung DC from IL-10 knockout mice primed T cell 
responses (Akbari, DeKruyff et al. 2001). Thus, even some “activated” dendritic cells 
play a role in maintenance of T cell self-tolerance. 
 In general, it appears that DCs are highly efficient at inactivating T cells in both 
the thymus and the periphery. Findings, such as those outlined above support the 
Janeway/Matzinger/Steinman-type two-signal model for the activation/ inactivation of 
CD4 T cells. However, B cells are also highly efficient at inactivating CD4 T cells, under 
appropriate conditions, and the large numbers of resting B cells, that exist in the lymph 
nodes and spleen, lead one to suggest that B cells are more likely to interact with 
autoantigen-specific CD4 T cells, leading to inactivation, provided that these B cell 
express the self-antigen endogenously. Some experimental evidence supports this 
proposition (Dalai, Mirshahidi et al. 2008). Thus, DCs and B cells likely act in concert to 
maintain self-tolerance.  
Regardless of what cell type is mainly concerned with deleting autoreactive T 
cells in the periphery, the fact that autoimmunity arises, suggests that the removal of 
autoreactive T cells, sometimes fails. Fortunately, as I will outline below, the immune 
system has evolved at least two additional mechanisms to deal with activated autoreactive 
T cells in the peripheral tissues. 
 
1.2.11 Inactivation of Effector CD4 T cells 
 
 Two-signal models for the activation of T cells, are also concerned with the 
maintenance of self-tolerance. Signal 1 alone has been shown to result in the inactivation 
and death of T cells. It is clear that, under appropriate conditions, two signals, delivered 
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together, result in activation of CD4 T cells. The prevention of the activation of 
autoreactive cells was once thought to be critical for the maintenance of self-tolerance. 
This belief stemmed, in part, from the recognition that activated T cells appear less 
dependent on signal 2 for their continued activation than naive cells (Dubey, Croft et al. 
1996; Curtsinger, Lins et al. 1998). Thus, it seemed critical that autoreactive T cells are 
never activated, lest they proliferate and cause pathology. However as Adler reviews, 
experimental evidence suggests that both effector and memory T cells are susceptible to 
inactivation in the periphery by the same mechanisms that inactivate naive T cells (Adler 
2005). That is, signal 1 alone, presented by resting APC, inactivates T cells at virtually 
any stage in their life cycle.  
 Some of the first evidence that effector CD4 T cells can be inactivated came from 
studies in the EAE model of autoimmunity in mice and rats. Critchfield et al. 
demonstrated that administration of large quantities of a soluble MHCII-binding peptide, 
derived from the primary sequence of myelin oligodendracyte protein (MOG), to mice 
during the course of symptomatic EAE, resulted in attenuation of the normally self-
limiting disease (Critchfield, Racke et al. 1994). This finding was independently 
confirmed (Brocke, Gijbels et al. 1996) and recently has been extended to a different 
murine model of multiple sclerosis (Verbeek, van der Mark et al. 2007). Our own 
observations bear on this issue, as discussed in Chapter 5 of this thesis. Encephalitogenic 
T cells appear to be inactivated upon the administration of high doses of soluble peptide 
for which they have affinity.  
Does the administration of high doses of peptide reflect the natural biology of 
tolerance induction by resting APC? In order to test whether endogenous expression of 
experimental antigens in peripheral cells leads to tolerance in T cells, antigen-transgenic 
mouse models have been established.  The results obtained in these systems support the 
idea that steady-state DCs inactivate naive T cells in an antigen-specific manner. 
Recently, the question of whether effector and memory T cells can also be inactivated by 
antigen-presenting cells expressing experimental antigens, but not activated by 
inflammatory stimuli, has been addressed. Influenza HA-specific effector CD4 T cells are 
inactivated within days of their adoptive transfer into HA-transgenic mice that express 
this antigen ubiquitously (Higgins, Mihalyo et al. 2002). Recent evidence suggests that 
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the majority of this inactivation is due to B cells presenting the experimental antigen 
(Dalai, Mirshahidi et al. 2008). However, when expression of the experimental “self” 
antigen is restricted to the CD11c-expressing cells (conventional DCs), similar results are 
obtained; effector and memory CD4 T cells are efficiently inactivated by steady-state 
DCs that bear antigens for which these T cells have affinity (Nasreen, Waldie et al. 
2010). Similarly, memory CD8 T cells (Kreuwel, Aung et al. 2002; Kenna, Thomas et al. 
2008) and even effector CTL (Kenna, Waldie et al. 2010) are readily inactivated in mice 
where APC express the antigen for which they are specific. The bulk of experimental 
evidence, therefore, supports the idea that signal 1 alone inactivates all types of 
conventional !" TCR-bearing T cells, at virtually any stage during their development or 
during the effector phase. The results obtained employing antigen-transgenic mice are 
strikingly similar to those obtained upon injection of soluble peptide. Thus, it would 
appear that administration of high doses of soluble peptide is a valid protocol for the 
study of T cell tolerance. 
These findings may be surprising to immunologists familiar with the original 
rationale behind the development of two-signal models. Based on these results, one can 
envisage how autoimmunity is avoided: In the event that a microbial pathogen subverts 
the primary barriers and innate defenses, it is picked up by a DC. The DC is activated to 
express co-stimulatory molecules, inflammatory cytokines, and lymph node homing 
molecules, by TLR signaling following binding of the PAMPs associated with this 
microbe. Many of these DCs migrate to the lymph nodes draining the infected area where 
they present both the pathogen-derived peptides and some self-peptides along with potent 
signal 2 mediators. The T cells that recognize these peptides are activated. While the 
majority of these T cells are specific for the pathogen, some may be autoreactive. Upon 
emigration from the lymph node where they are activated, these T cells circulate to the 
inflamed peripheral tissues and through other lymph nodes. While pathogen-specific T 
cells are continually activated by relatively rare DCs (and other APC) presenting 
pathogen-derived peptides, always in association with co-stimulation, the auto-peptide-
specific effector cells are inactivated by the vast majority of APC that are resting, having 
never been activated by a PAMP. In cases where the majority of APC are activated, as 
may occur during disseminated infections, activation of autoreactive T cells may be 
! 38 
supported. However, if the individual recovers, clearing the pathogen, the majority of 
APC will return to a resting state and continue to inactivate the autoreactive cells. Thus, 
frank autoimmunity will only occur in special cases, which I will speculate upon later in 
this thesis.  
With the evidence given above, one would expect that clinical applications for 
therapy of autoimmune disease would be achievable. Indeed, the use of synthetic peptides 
is currently being explored in human models of allergy (Campbell, Buckland et al. 2009). 
While it is generally thought that administration of peptides, to allergy patients, results in 
the induction of regulatory T cells (discussed below) the possibility that some allergen-
specific T cells are inactivated and deleted remains (Larche and Wraith 2005). However, 
due to the great polymorphism in the human MHC, the peptides that are recognized by 
allergy mediating or autoreactive T cells are likely to be different in different individuals. 
To circumvent this problem, therapeutic strategies employing anti-CD3 (a signaling 
component of the TCR) have been developed. These therapies, currently in clinical trials 
for the treatment of various forms of autoimmunity, rely on the idea that anti-CD3 
antibodies stimulate T cells in a manner analogous to signal 1 alone, thus causing their 
inactivation (Chatenoud and Bluestone 2007). 
The finding that even activated T cells can be readily inactivated, under the 
appropriate conditions, has interesting implications for the mechanism by which 
autoimmunity arises. It would appear that, due to the continual inactivation of 
autoreactive T cells, outlined above, that autoimmunity would likely never occur. 
However, experientially, we know this is not the case. Even in the face of heavy selection 
against autoreactivity in T cells, at all stages of their development, autoimmunity does 
arise. The mammalian immune system has therefore evolved another mechanism that 
exerts dominant control over auto reactive cells. It turns out that this mechanism involves 
T cells that are able to actively suppress the activation of other T cells, the regulatory T 
cell subset.  
 
1.2.12 Dominant Self-tolerance  
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The importance of thymus derived cells in the generation of immune responses 
has been known since the early 1960’s (Miller 1961); but, by the end of that decade, the 
first clues that thymic emigrants were involved in the active suppression of autoimmunity 
were emerging in the literature. A curious study by Nishizuka and Sakakura, working 
with a murine models of cancer, demonstrated that thymectomy leads to autoimmune 
oophoritis and wasting in mice (Nishizuka and Sakakura 1969). The results of this 
experiment could not be interpreted at the time, given that the study of thymus-derived 
cells was still in its infancy - so these results were nearly forgotten. However, when he 
began working with a similar neonatal thymectomy protocol decades later, Sakaguchi 
observed the development of an equivalent wasting syndrome. This observation led to the 
identification of thymus dependent cells (T cells) that were essential suppressors of 
autoimmunity in mice (Sakaguchi, Takahashi et al. 1982; Sakaguchi, Fukuma et al. 
1985). Thymectomy after day ten of life often did not result in serious autoimmunity, 
indicating that the suppressive cells emigrate from the thymus by day ten. The thymus 
facilitates the generation of T cells that are able to dominantly suppress autoimmunity. 
By the early 1990s, observations regarding this suppressive T cell subset were 
accumulating. Powrie and Mason found that the subset of CD4+ T cells that express low 
levels of CD45RB, can regulate autoimmunity mediated by the CD45RB high-expressing 
population (Powrie and Mason 1990). Subsequently, this regulation was found to be a 
dominant process (Modigliani, Pereira et al. 1995), meaning that the suppression of 
autoimmunity, mediated by CD45RB low-expressers, was an active process that could be 
transferred to recipient mice through administration of T cells. CD4 T cells with 
suppressive capacity were shown to constitutively express the high-affinity IL-2 receptor 
!-chain, CD25 (Sakaguchi, Sakaguchi et al. 1995). In order to distinguish this 
suppressive subset from other types of suppressor cells, the term regulatory T cell or 
Treg, was coined. In 2003, a Treg lineage-specific transcription factor, foxp3, was 
identified (Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003). The proportion of 
foxp3+ cells of CD25+ CD4 T cells was estimated at around 95%, and enforced, ectopic 
expression of foxp3 is sufficient to cause naive CD4 T cells to acquire a regulatory 
phenotype. Foxp3, also known as scurfin, was identified earlier as a gene that was 
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involved in autoimmunity. Scurfy mice, with a natural mutation of the scurfin protein, 
succumb to a fatal lymphoproliferative disorder (Godfrey, Wilkinson et al. 1991).  
The TCRs of Tregs are very heterogeneous. It has been shown that in a naïve 
animal, variable (V) region usage in the TCRs of CD25- and CD25+ cells is not 
significantly different (Takahashi, Kuniyasu et al. 1998). This fact implies that Treg and 
naïve T cells are equally diverse. However, Hsieh et al. found the complementarity 
determining region 3 (CDR3) sequences (known to be a major specificity determining 
factor for the TCR) of CD25- and CD25+ CD4 T cells only overlap by around 25% in 
clones found frequently in either population (Hsieh, Liang et al. 2004). CD25+ derived 
TCRs appear to be dramatically more self-reactive than their CD25- derived counterparts. 
Following this finding, Hsieh et al. have shown that thymically derived Tregs are similar 
to their counterparts in the periphery, which may indicate that the Treg lineage is 
established mainly in the thymus and is stable upon emigration (Hsieh, Zheng et al. 
2006). The heterogeneity of the TCRs of Treg cells indicates that they are randomly 
generated, as are conventional CD4 T cells, and may derive from the same population of 
thymocytes. 
Pacholczyk et al. have demonstrated that in the periphery, the TCR diversity of 
the CD25+ population is in fact greater than that of the CD25- fraction (Pacholczyk, 
Ignatowicz et al. 2006). In contrast to the findings of Hsieh, this group finds that, in 
general, the specificity of Tregs and naïve T cells in the periphery is not significantly 
different (Pacholczyk, Kern et al. 2007). Seddon and Mason found that Tregs with a 
specificity for a peripheral autoantigen were only induced in mice where that antigen was 
present (Seddon and Mason 1999).  Furthermore, it has been well established that antigen 
specific Tregs can be generated in the periphery (Belkaid, Piccirillo et al. 2002; Graca, 
Cobbold et al. 2002; Apostolou and von Boehmer 2004; Dahlberg, Schartner et al. 2007; 
Sun, Hall et al. 2007). 
In 2003 Bluestone and Abbas proposed that a distinction be drawn between Tregs 
generated in the thymus and those generated in the periphery (Bluestone and Abbas 
2003). This separation of regulatory T cells into two populations called natural Tregs 
(nTregs) or inducible (iTregs), is currently considered to be valid. As mentioned above, 
some have found differences in the repertoire between the subsets. Natural, thymus 
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derived Tregs, appear to be self-reactive. This finding is entirely consistent with the 
classical thymectomy experiments, which suggested that the thymic suppressors were 
responsible for regulating autoreactive cells.  More recently, decisive experiments have 
demonstrated that the Tregs that are generated in the thymus and can be selected for by 
the presence of their cognate antigen there. By crossing TCR transgenic mice with 
transgenic mice expressing the antigen for which the cloned TCR is specific, Jordan et al. 
have shown that antigen-specific Tregs are produced in the thymus. The authors also 
show that the relative expression level of the antigen is critical for this induction. Only at 
intermediate levels of expression were significant numbers of Tregs generated. High 
expression resulted in deletion of TCR transgenic cells, while low expression levels were 
insufficient to cause Treg conversion of thymocytes (Jordan, Boesteanu et al. 2001). It is 
thought that Tregs undergo the normal selection processes experienced by other naïve T 
cells. Both positive and negative selection occur. After these, the process that is 
responsible for Treg conversion takes place (Takahama 2006). As Aschenbrenner et al. 
have elegantly shown, negative selection is mediated by haemopoetic cells (such as 
thymic DC), while the AIRE+ medullary thymic epithelial cells seem to play a critical 
role in the induction of Treg function (Aschenbrenner, D'Cruz et al. 2007).  
 Inducible Tregs can be produced from thymic emigrants in the periphery under 
conditions known to be non-immunogenic, or ex vivo by the provision of exogenous 
cytokine. In antigen specific systems, these cells can be produced at a very high ratio. In 
TCR transgenic RAG knockout mice, this ‘sub-immunogenic’ condition is achieved by 
the administration of the antigenic peptide in saline (Apostolou and von Boehmer 2004; 
Dahlberg, Schartner et al. 2007). In TCR transgenic mice that normally do not develop 
Tregs, this protocol can induce around 50% of the antigen-specific cells to become foxp3.  
Antigen-specific T cells can also be induced to express foxp3 in vivo by the oral feeding 
of the cognate antigen (Sun, Hall et al. 2007). This conversion has been attributed to the 
microenvironment of the lamina propria (LP) created by the resident dendritic cells 
(DC). Retinoic acid (RA), a vitamin A derivative expressed by various cells in gut 
lymphoid tissues, seems to be key for the induction of Tregs there. Additionally, TGF-! 
has been identified as a factor that is essential for foxp3 induction both in vivo and in 
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vitro (Chen, Jin et al. 2003). With TGF-! stimulation, other cytokines may synergize to 
produce optimal signaling for foxp3 induction (Namba, Kitaichi et al. 2002).  
Classically, CD4+CD25+ Tregs were known to be refractory to stimulation in 
vitro. Though this was shown not to be the case in vivo, the question arose as to the 
nature of the APC that is able to expand Tregs. To address this question Sayuri Yamazaki 
et al. purified CD4+ CD25+ T cells from DO11.10 (OVA323-339-specific) T cell receptor 
transgenic mice. They were able to show that bulk populations of splenocytes as APC 
were able to stimulate the division of Treg cells very poorly in vitro. However, it was 
found that conventional CD11c-expressing DCs purified from the spleen of these mice 
were able to expand DO11.10 Tregs very efficiently when they were loaded with the 
appropriate OVA323-339 peptide (Yamazaki, Iyoda et al. 2003). Thus, it appears that DCs 
play a role in the expansion of Tregs.  
 A perhaps more important role for DCs in the promotion of Tregs has been 
described – their ability to generate, de novo, Tregs from naive precursors. Cheng-Ming 
Sun, working with Yasmine Belkaid, demonstrated that a certain population of DCs that 
reside in the LP of the small intestine of mice preferentially induce CD4 T cells to 
become Treg when presenting antigen. The authors find that in the presence of TGF-!, 
which is constitutively produced in the LP, resident DCs, but not spleen DCs, were able 
to generate high numbers of Tregs from naive precursors. Further fractionation revealed 
that the CD103+ LP DCs are responsible for this effect. Purified CD103+ LP DCs, 
without exogenously supplied TGF-!, are capable of inducing Tregs in culture due to 
their production of RA (Sun, Hall et al. 2007). The production of RA appears to be 
crucial for the de novo generation of Tregs by tolerogenic DCs. By employing a 
sophisticated cell-sorting scheme, Martin Guilliams et al. were able to identify RA-
producing DCs in the dermis. Interestingly these cells do not express CD103, which 
implies that the presence of this surface marker does not exclusively identify tolerogenic 
DCs. These CD103-, RA producing DCs were able to generate Tregs in culture 
(Guilliams, Crozat et al. 2010). DCs are able to promote the generation of antigen-
specific Tregs under certain circumstances. 
 It has become clear that de novo Treg generation is a common function of DCs. 
The microenvironment in which the DCs reside plays an extremely important role. As 
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mentioned above, mucosal tissues constitutively express factors that aid in Treg 
differentiation. It has become appreciated that part of the role of these factors is to 
condition the resident DCs. Aside from what we might call constitutively tolerogenic 
DCs (RA-producers mentioned above), tolerogenic DCs may also be induced from 
immature precursors. There is evidence that tolerogenic DCs can be induced by certain 
pathogens (D'Ambrosio, Colucci et al. 2008) and in the tumor microenvironment 
(Gabrilovich 2004) which leads to regulation of protective immune responses. Moreover, 
Tregs themselves may induce a tolerogenic phenotype in DCs, promoting further Treg 
generation, a phenomenon known as “infectious tolerance” (Andersson, Tran et al. 2008). 
A key question in the field of Treg biology remains: What is the mechanism of 
the suppressor function of these cells? Though much effort has been expended in trying 
to answer this question, no general mechanism has been demonstrated for Tregs. This 
may suggest that under different conditions Tregs may function, or appear to function, in 
different ways. Tregs have been shown to exert their suppressive function by a number of 
mechanisms. The first in vitro assays used to detect suppressive function indicated that 
inhibition of IL-2 synthesis was a major mechanism of Treg suppression (Thornton and 
Shevach 1998). In this system, it was found that T cell-T cell contact was essential and 
that APC were not necessary to ‘bridge’ this interaction (Thornton and Shevach 2000). 
Subsequently, inhibitory roles for the cytokines IL-10 and TGF-!, produced by Tregs, 
have been defined in vivo (Nakamura, Kitani et al. 2001; Zhang, Koldzic et al. 2004). In 
addition, cell contact dependent mechanisms such as CD80/86 ligation by CTLA-4 on 
suppressive cells have been described (Paust, Lu et al. 2004). These contact dependent 
mechanisms may result in direct signaling from T cell to T cell or through antigen 
presenting cells (von Boehmer 2005). Tregs may exert their suppressive function through 
any or all of these mechanisms.  
Whatever the specific molecules involved in this suppression are, the effects of 
Tregs appear to be exerted at both the inductive and effector stages of T cell responses. 
Klein et al. have demonstrated that in vivo, the once-thought-to-be anergic Treg cells are 
able not only to proliferate upon antigen stimulation but to suppress the proliferation of 
naïve antigen specific cells as well (Klein, Khazaie et al. 2003). Additionally, the 
development of effector function by naïve cells was drastically limited, as assessed by 
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cytokine secretion. In tumor models, the removal of CD25+ cells results in tumor 
regression (Onizuka, Tawara et al. 1999; Shimizu, Yamazaki et al. 1999; Yu, Lee et al. 
2005). It is unclear whether the removal of these cells results in a switch to a protective 
class of immunity, or if Tregs (and therefore suppression) are specifically being removed. 
If the later is true, it is evidence that Tregs actively inhibit functional effector cells at a 
late effector stage. There is also evidence that Tregs specifically inhibit memory T cell 
responses but not primary responses (Kursar, Bonhagen et al. 2002). Taken together, this 
evidence suggests that Tregs function at virtually all stages of a T cell mediated response.  
The presence of Tregs has been shown in many disease models of chronic 
infections and tumors (Belkaid, Piccirillo et al. 2002; MacDonald, Duffy et al. 2002; 
Chen, Zhou et al. 2007; Kakinuma, Nadiminti et al. 2007). These cells are often found to 
be specific to pathogen derived antigens (MacDonald, Duffy et al. 2002; Suffia, Reckling 
et al. 2006). This line of evidence suggests that these cells are derived from peripheral 
naïve cells sometimes even in inflammatory conditions. This suggestion is paradoxical in 
light of the current paradigms. However, it has been suggested that pathogen-specific 
Treg cells act to limit the complete clearance of pathogens, leading to enhanced memory 
(Pepper and Jenkins).  
 Taken together, the experimental evidence concerning the existence, functional 
properties, and importance in limiting autoimmunity, of Tregs, suggests that the 
inactivation of autoreactive T cells by the conventional provision of signal 1 alone is 
insufficient to prevent damaging autoimmunity. The existence of many, somewhat 
redundant, pathways for the avoidance of autoimmunity also suggests that autoimmunity 
was a major selective pressure in the evolution of the immune system. This suggestion 
serves to validate the concerns of Ehrlich, Burnet, Lederberg, Talmage and Pearlman, 
Bretscher and Cohn, Lafferty and Cunnigham, Janeway, and Matzinger.  
 
1.2.13 Summary 
  
 Even at the very outset of the study of immunology it was recognized that the 
immune system had the potential to damage the host. As I have reviewed, several 
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mechanisms exist to limit autoimmunity; this underscores the potential that our immune 
system has to cause us harm.  
 The originators of the clonal selection theory for the generation of antibody 
attempted to integrate control mechanisms into their models for how lymphocytes could 
be activated. However, these models could not account for accumulating experimental 
evidence, and in the 1970s the two signal Models of Bretscher and Cohn, and 
subsequently Lafferty and Cunningham were put forward. Both models held that the 
signal mediated by antigen binding to the antigen receptor, signal 1, was tolerogenic, 
leading to the inactivation of a lymphocyte in the absence of an additional stimulus, 
signal 2. It took until the mid 1980s for experimental evidence for these models to 
accumulate to the point where many immunologists could begin to address predictions of 
them. The nature of the antigen receptor of T cells was determined and the MHC 
restriction of immune responses was integrated into the contemporary models for T cell 
activation.  
 The molecular nature of signal 2 was elucidated in the late 1980s and early 1990s 
and these discoveries led to new suggestions about how signal 2 could be regulated. 
Janeway proposed that the detection of infectious microbes, by innate antigen-presenting 
cells of the immune system would be critical to the induction of immunity. The dendritic 
cell, first identified by Steinman, emerged as a likely candidate for the initiation of T cell 
activation. The discovery of Toll-like receptors, that bind conserved microbial patterns, 
leading to enhanced presentation of antigen, particularly by dendritic cells, confirmed this 
suspicion. However, it is quite clear that DC can also efficiently maintain T cell self-
tolerance.  
 Recently, it has become clear that T cells can be inactivated at many stages along 
their life cycle. However, the existence of a subset of CD4 T cells that actively suppress 
the generation of autoreactive T cells serves to prove that negative selection processes are 
insufficient to prevent autoimmunity.  
   
1.3 CD4 T Cell Cooperation 
 
1.3.1 Introduction 
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 Cooperative interactions amongst cells of the adaptive immune system are well 
described. Indeed, cooperation between lymphocytes is essential for the induction of 
most immune responses. CD4 T cells provide help to B cells that present antigens in the 
context of MHCII molecules, endocytosed after binding the BCR (Claman, Chaperon et 
al. 1966; Miller and Mitchell 1968; Lanzavecchia 1985). CD8 T cells are aided in their 
transition to CTL effectors by CD4 T cell help (Keene and Forman 1982; Guerder and 
Matzinger 1992). In the case of B cell- T cell interaction, this cooperative interaction is 
achieved by direct cell-to-cell contact; B cells are both effector cells and antigen-
presenting cells. However, in the case of CD4 T cell help for CTL generation, this help 
proceeds via an APC intermediate (Shevach and Rosenthal 1973; Ridge, Di Rosa et al. 
1998; Schoenberger, Toes et al. 1998). Activation of DCs via the ligation of CD40, on 
their surface, by CD40L, present on the surface of activated CD4 T cells, serves to 
“license” these DCs to allow them to potently activate and maintain CTL responses 
(Shevach and Rosenthal 1973; Ridge, Di Rosa et al. 1998; Schoenberger, Toes et al. 
1998; Bachmann, Hunziker et al. 2004). Experimental evidence also suggests that 
activation of B cells, via ligation of CD40, makes these lymphocytes, normally 
tolerogenic in the resting state, potent APC for generating CD4 T effector cells (Jaiswal 
and Croft 1997; Evans, Munks et al. 2000). Given that CD40L is normally provided by 
activated CD4 T cells, it would seem likely that B cells, following antigen-mediated 
interaction with an activated CD4 T cell would then be able to potently activate other 
CD4 T cells. This type of phenomenon has been called CD4 T cell cooperation 
(Bretscher 1999), and is reminiscent of the phenomenon of epitope spreading, as I will 
discuss below. 
 
1.3.2 CD4 T Cell Cooperation 
 
 At the time of the first proposal of the two-signal hypothesis (Bretscher and Cohn 
1968; Bretscher and Cohn 1970), Bretscher was aware of the quantitative implications of 
one of the most contentious parts of the model. The assertion that T cells require help 
from other T cells, for their induction, became a conceptual problem for other 
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immunologists. However, this “help-for-help” also allowed for a mechanism by which 
the class of immune response could be controlled.   
 A classical observation, made by Salvin, demonstrated that the dose of antigen, 
given in an immunization, affects the class of immunity generated (Salvin 1958).  He 
observed that DTH generally precedes antibody production, and that the administration of 
very low doses of antigen tended to result in DTH that does not evolve into antibody 
production. Moreover, increased amounts of antigen result in a rapid transition from DTH 
to antibody production. Later, Pearson and Raffel linked a number of older observations 
together in proposing that the degree of foreignness of an antigen had a similar impact on 
the nature of the immune response generated upon immunization (Pearson and Raffel 
1971). They summarize that minimally foreign antigens, either very small molecules, or 
minimally foreign proteins, are capable of inducing only DTH, upon injection. Taking 
these observations together, it appears that the fewer CD4 T cells that are stimulated (or 
the less well they are stimulated), the more prone these cells are to becoming mediators 
of DTH; enhanced foreignness, or higher doses of antigen, generally favor the induction 
of antibody. Considering this evidence, in light of the findings of Parish, that DTH and 
antibody responses are often exclusive, one suppressing the induction of the other (Parish 
1971; Parish 1971; Parish and Liew 1972), it can be suggested that CD4 T cells play a 
major role in determining the class of immunity generated upon immunization. 
Bretscher put forward a model of immune class regulation that was consistent 
with the two-signal hypothesis (Bretscher 1974). According to this hypothesis, the 
number of inductive cellular interactions that occur in a population of responding 
lymphocytes, during the course of the development of an immune response, determines 
whether this population will express DTH or antibody. Thus, the cellular interaction 
involved in the generation of immune responses, as originally envisaged, may also be 
responsible for the determination of the class of an immune response. This hypothesis, 
extended to its natural ends, would then predict that 1) the absence of cellular 
collaboration results in inactivation of lymphocytes (by signal 1 alone), 2) small amounts 
of cellular collaboration results in DTH, and 3) increased interactions between 
lymphocytes result in antibody responses. These basic principles have been tested, in 
various experimental models, over the last four decades, and appear to be generally true. 
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 Initial experimental evidence that T cells provide help for the induction of DTH-
mediating T cells was provided by the experiments of Tucker and Bretscher (Tucker and 
Bretscher 1982). In order to determine the cellular requirements for the generation of 
DTH-mediating cells, the authors developed a culture system in which burro erythrocyte 
(BRBC)-specific DTH-mediating cells could be induced. After establishing that 
culturing, with BRBC, of a specific density of spleen cells was required to produce DTH-
mediating T cells, the number of spleen cells was reduced to a level where DTH-
mediating T cells were no longer induced. Only antigen-specific T cells, supplemented 
back into these cultures, resulted in restoration of the induction of DTH-mediating T 
cells. Furthermore, T cells specific for fowl gamma globulin (FGG) could aid in the 
induction of BRBC-specific DTH if FGG was physically linked to BRBC in culture. 
These results suggest that the density of T cells in the tissue culture dish had a great 
influence on the generation of DTH-mediating T cells.  
An interpretation of this finding is that density influences the number of antigen-
mediated interactions that occur in the dish over time. Bretscher published further 
evidence supporting this interpretation, showing that while low density cultures of 
splenocytes, with antigen, did not induce antigen-specific responses, medium densities of 
cells yielded DTH-mediating T cells and high-density cultures led to the production of 
antibody (Bretscher 1983). Further observations showed that activated CD4 T cells were 
responsible for the “help” in inducing DTH-mediating T cells in vitro (Bretscher 1986), 
and that culturing splenocytes from humorally immune mice, in medium densities, with 
antigen, resulted in a reversion to DTH, suggesting that the phenotype of immune 
responses can be modulated over time by cooperative interactions between lymphocytes 
(LeClercq and Bretscher 1987). These results have been confirmed in vivo, by the 
adoptive transfer of different numbers of syngeneic lymphocytes (Bretscher 1983; Ismail 
and Bretscher 2001; Ismail, Basten et al. 2005), and in vitro, by culturing different 
numbers of antigen-specific CD4 T cells with constant numbers of T cell depleted APC 
(Rudulier, Kroeger et al. 2012). In each case, it appears that increased interactions 
amongst lymphocytes enable the evolution of DTH to antibody. In modern terms, 
infrequent interactions between antigen-specific CD4 T cells results in the Th1 cells, as 
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assessed by the production of IFN! and frequent interactions between these CD4 T cells 
results in their evolution to IL-4-producing Th2-like cells.  
Conceptually, this idea is very simple. However, the cellular and molecular 
mechanisms that enable the interaction of CD4 T cells were, and are, not well 
understood. A major part of this thesis deals with my investigations into the mechanisms 
governing CD4 T cell cooperation. 
More recently, other groups have shown that cooperative interactions amongst 
CD4 T cells can serve to enhance their activation. Gerloni et al. demonstrated that mice 
immunized with a DNA vector encoding a polypeptide derived from the primary 
sequence of the tumor-associated antigen MUC.1 generate a greater CD4 T cell response 
if the vector also encodes an immunodominant peptide from a protozoan parasite 
(Gerloni, Xiong et al. 2000). Interestingly, the expression of proteins from this DNA 
vector was restricted to B cells, suggesting that B cells are sufficient to mediate the 
cooperative interaction between CD4 T cells. They subsequently showed that priming of 
CD4 T cells, following similar immunization, could also occur in mice made genetically 
deficient in the generation of DCs, indicating that DCs are not essential for cooperative 
responses in their system (Castiglioni, Lu et al. 2003). Taking their findings a step 
further, Gerloni demonstrated that cooperation between CD4 T cell populations, mediated 
by adoptively transferred, vector-transfected B cells, resulted in enhanced immunity to 
MUC.1 and tumor resistance in MUC.1 transgenic mice (Gerloni, Castiglioni et al. 2005). 
Creusot et al. have also reported that cooperation between two TCR-transgenic CD4 T 
cell populations can occur in response to in vivo vaccination with a DNA vector encoding 
proteins that give rise to peptides recognized by the transgenic CD4 T cells (Creusot, 
Thomsen et al. 2003). The cooperation observed was most efficient when two vectors, 
encoding each protein, were delivered on a single gold particle to the same cell, implying 
that cooperation occurs most efficiently by a linked mechanism.  
Another recent publication, from our own laboratory, has demonstrated 
cooperation between endogenous CD4 T cells in the primary generation of protein-
specific immune responses. Evidence was obtained in experiments in BALB/c mice made 
tolerant to HEL105-120. Critically, these mice fail to respond to HEL105-120 and all other HEL 
peptides upon immunization with HEL protein on ALUM. The generation of CD4 
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effector T cells specific for the other HEL peptides could be rescued by immunizing with 
HEL coupled to OVA, thus replacing the HEL105-120-specific cooperating CD4 T cells 
with an OVA-specific CD4 T cell population (Peters, Kroeger et al. 2009). Thus, it 
appears that in some cases CD4 T cells are required for the optimal generation of effector 
CD4 T cells even in the face of stimulation with potent adjuvants.  
  
1.3.3 The Role of the B Cell in CD4 T Cell Cooperation  
 
The results of the studies, cited above, are supportive of a role for cooperation 
between CD4 T cells in their optimal generation of effector cells and in determining their 
Th1/Th2 phenotype. Some of these results also suggest, and directly demonstrate, that 
CD4 T cell cooperation can be mediated by B cells acting as APC. Theoretically, the B 
cell seems to be the only APC that could achieve CD4 T cell cooperation, in a manner 
that would be consistent with observations of the past. The antigen-specific collaboration 
between CD4 T cells has been shown to be achieved by a linked mechanism (Tucker and 
Bretscher 1982; Creusot, Thomsen et al. 2003; Ismail, Basten et al. 2005). That is, 
presentation of epitopes to both the helper CD4 T cell, and to the CD4 T cell being 
helped, must be accomplished by the same APC. Given the B cell’s role as an antigen-
specific APC, that samples and presents antigen by virtue of its binding to the BCR, the B 
cell is ideally suited to mediate “linked” cooperative effects. If DCs and other APC, that 
endocytose antigen via germline-encoded receptors, normally mediate CD4 T cell 
cooperation, then no requirement for linked recognition would be seen; unlinked antigens 
could be taken up and presented together. In fact, upon simultaneous immunization with 
two antigens, one at a dose that normally induces Th1 responses, and the other at a dose 
that normally induces Th2 cells, results in independent generation of the appropriate 
phenotype, even if these antigens are presented in the same lymphoid organ (Ismail and 
Bretscher 1999). Thus, based on this experimental evidence, one would propose that B 
cells must be the APC that normally mediates CD4 T cell cooperation, as Bretscher did in 
his two-step, two-signal hypothesis for the primary activation of CD4 T cells (Bretscher 
1999).  
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1.3.4 Epitope Spreading 
 
1.3.4.1 The Phenomenon of Epitope Spreading and Autoimmunity 
 
 Epitope spreading, in immunity, is a process whereby the number of B cell- and T 
cell-recognized antigenic determinants that are responded to accumulate over the course 
of the immune response. In other words, while initially antibody and T cell recognition of 
antigen may be restricted to one, or a few, epitopes, during the evolution of the immune 
response, more antigenic determinants are incorporated into the repertoire of activated 
lymphocytes. This phenomenon has been observed in response to infection (van der 
Most, Sette et al. 1996), and experimental immunization, but is most commonly 
discussed in terms of the development of autoimmunity. However, as Mamula points out 
in a 1998 review, 
 
 It must first be understood that epitope spreading is a fundamental 
mechanism of the immune system that has evolved for the survival of 
organisms, not for the development of autoimmunity. It seems obvious that 
the most effective means by which to clear an infectious agent or tumor 
challenge is to attack as many target epitopes as possible. (Mamula 1998) 
 
Thus, epitope spreading appears to be a common mechanism for potentiating efficient 
immunity.  
 In cases where autoimmunity arises, spreading in the autoantigenic determinants 
that are recognized by T cells may result in chronic disease. An example of epitope 
spreading, in the commonly employed mouse model of multiple sclerosis, experimental 
autoimmune encephalomyelitis (EAE), was reported by Lehmann et al. who showed that 
primary immunization with myelin oligodendracyte glycoprotein (MOG) results in 
generation of effector CD4 T cells that recognize only the peptide consisting of amino 
acid residues 1-11. However, as the course of clinical disease progresses, CD4 T cells 
that respond to other peptides of MOG can be found. Eventually, CD4 T cells that 
recognize at least four different epitopes of MOG are generated (Lehmann, Forsthuber et 
al. 1992). Thus, while initially, these additional MOG epitopes are not responded to, 
following immunization with MOG in CFA, they become part of the CD4 T cell 
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repertoire through epitope spreading. Others have confirmed (Jansson, Diener et al. 1995) 
and extended this work in EAE and have even suggested that administration of high-dose 
peptide, which inactivates CD4 T cells, may be effective clinical therapy for MS (Yu, 
Johnson et al. 1996). Similar findings have been reported in murine models of lupus 
(Bockenstedt, Gee et al. 1995) and autoimmune diabetes (Kaufman, Clare-Salzler et al. 
1993). Epitope spreading appears to be a common mechanism by which the repertoire of 
lymphocytes is expanded during autoimmune responses, prolonging the clinical course of 
the disease.  
 Accepting that epitope spreading in CD4 T cells occurs, one is led to question the 
cellular and molecular mechanisms that underlie the phenomenon. Mamula (Mamula 
1998) outlines a two stage cellular model for epitope spreading in the context of 
autoimmunity. In stage one, the initial priming of autoreactive CD4 T cells is achieved by 
the activation of these cells by DC. The activated CD4 effector T cells, specific for a 
single peptide of the autoantigen then break B cell tolerance by activating an autoreactive 
B cell that presents the autoantigen following uptake via the BCR. The second stage of 
epitope spreading involves the expansion of B cells that bind, take up, and present 
autoantigen to T cells. Diversification of the T cell repertoire is achieved by activation of 
CD4 T cells, specific for linked determinants, taken up in physical association with the 
initial autoantigen by the activated and expanded pool of autoreactive B cells. A cascade 
of such reactions ensues leading to further diversification of the B cell and T cell 
repertoire. This mechanism is strikingly similar to the two-step two-signal model for the 
activation of CD4 T cells (Bretscher 1999). As I will outline in section 1.4, B cells are 
efficient APC for CD4 T cells. The presence of un-inactivated autoreactive B cells, in the 
periphery, is sufficient to allow for the loss of CD4 T cell self-tolerance (Lin, Mamula et 
al. 1991). The evidence that B cells, as antigen presenting cells, play a major role in the 
development of many autoimmunities supports this hypothesis. 
 
1.3.4.2 The B Cell as APC in the Induction of Autoimmunity 
 
 In order for autoreactive B cells to activate autoreactive CD4 T cells, leading to 
epitope spreading, they must avoid negative selection and persist in the periphery. Here, I 
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outline the evidence supporting the hypothesis that autoreactive B cells can survive in the 
peripheral tissues, and have the ability to initiate autoimmunity. Further evidence for the 
role of B cells in the activation and generation of CD4 effector T cells is discussed in 
section 1.4. 
Two model systems, discussed in section 1.2.5 above, lent not only to our 
understanding of central tolerance in B cells, but to how some autoreactive B cells persist 
in host animals.  
Some B cells with autoreactive BCRs may persist following dilution in avidity for 
self-antigens following a secondary immunoglobulin rearrangement. Nemazee noticed 
that a few B cells persisted in the offspring of BCR transgenic mice mated with mice 
transgenic for the antigen recognized by that BCR. They had somehow managed to alter 
their receptor immunoglobulin (Ig) to a form that was not self-reactive (Tiegs, Russell et 
al. 1993). This phenomenon became known as “receptor editing”. It appears that B cells 
that rearrange an immunoglobulin light chain (IgL) that confers autoreactivity, may 
reinitiate recombination of the IgL genes. The B cell has a second chance to generate a 
functional Ig molecule that does not bind self-antigens. More often than not, these 
secondary rearrangements fail to rescue the B cell, and upon further stimulation, the cell 
is deleted after binding of the autoreactive BCR to antigens in the bone marrow stroma. 
However, a small proportion of non-autoreactive, re-rearranged IgL abrogate the self-
affinity of the prior Ig molecule. In some cases, the new arrangement destroys the old IgL 
locus, but occasionally, a new locus is rearranged, resulting in B cells of dual specificity. 
Dilution of the autoreactive Ig with the new non-autoreactive Ig lowers the avidity of 
interaction with self-components and can allow these dual-specific B cells to escape 
deletion and emigrate to the periphery. This is a phenomenon that has been called allelic 
inclusion. Liu and colleagues demonstrated this phenomenon, in a system similar to 
Nemazee’s, and found that persisting dual specific B cells could be stimulated to produce 
autoantibody under certain circumstances (Liu, Velez et al. 2005). In some cases, B cells 
with dual BCRs, one specific for self, may persist in the periphery. 
 Chris Goodnow’s original dual transgenic system revealed another way that B 
cells may escape negative selection, anergy. In these mice HEL-specific B cells did 
emigrate to the peripheral tissues, though they remained unable to respond to Ig 
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stimulation. Even though anergic cells are found to be mostly unresponsive to antigenic 
stimulation, their reactivity can be recovered when antigen is removed, suggesting that 
anergic cells can recover their ability to respond to antigen (Goodnow, Crosbie et al. 
1988). Thus, anergic B cells, specific for self-antigens may persist in the periphery, and 
these cells can be activated under certain circumstances. 
 A third way that autoreactive B cells can persist in the periphery is as normal 
follicular B cells ignorant of their self-reactive potential. This “clonal ignorance” was 
observed by Mark Shlomchik, working in Martin Weigert’s lab, when he made mice 
transgenic for an Ig that had affinity for self-IgG molecules. In secreted form, these 
antibodies make up what is known as rheumatoid factor (RF). The B cells in these 
transgenic mice not only persist in the periphery, but enter the follicles and seem to be 
undisturbed by their reaction to self (Shlomchik, Zharhary et al. 1993).  
 How are autoreactive B cells activated under pathologic conditions to give rise to 
autoimmunity? A classical example of B cell mediated autoimmunity is rheumatic fever 
following group-A streptococcal infection. The highly immunogenic M polysaccharide 
antigen is thought to cross-react with protein components of the valves of the heart. Upon 
infection anti-M antibodies are induced which can subsequently bind the heart valves 
causing a type II hypersensitivity reaction in the heart which results in congestion and, in 
extreme cases, death (Mims, Nash et al. 2001). Clearly there are B cells specific for this 
cross-reacting antigen in the body prior to infection. Possibly these cells persist being 
ignorant of their affinity for the heart-valve tissue. The autoreactive B cells are activated 
via cognate interaction with CD4 T cells specific for peptides derived from streptococcal 
antigens. Thus, in some cases, activation of autoreactive B cells can occur via the 
conventional route.  
In the case of rheumatic fever, there is an abundance of CD4 T cell help for the 
autoreactive B cell. However, normally both the B cell compartment and T cell 
compartment are heavily biased against self-reactivity making this interaction very 
unlikely. There are at least two other ways in which autoreactive B cells may be activated 
in the periphery.  
 Despite the variable nature of systemic lupus erythramatosis (SLE), the antibodies 
that are generated are towards a limited number of targets. These antigens are often 
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normally hidden from Ig interaction by virtue of their location within cells. Major 
examples are DNA and Smith’s complex (Sm), a complex of RNA and associated 
proteins. It is easy to speculate that B cells that are specific for these antigens are often 
clonally ignorant and therefore need only to be induced. In special cases, B cells can 
produce antibody without cognate interaction with CD4 T cells. These cases involve 
strong stimulation through the interaction of the B cell with conserved microbial 
products. For example, the provision of LPS to anergic B cells can partially rescue 
antibody responses (Goodnow, Crosbie et al. 1988). A common thread between many 
lupus antigens is that they often provide such stimulation. Both DNA and RNA have the 
potential to stimulate toll-like receptors. The aggregation of Fc portions of antibodies 
causes complement deposition, which is highly inflammatory, and may be important in 
the generation of RF. Lupus prone mice that are deficient in toll-like receptor signaling 
have defects in the production of anti-DNA and anti-Sm autoantibodies (Shlomchik 
2008). Moreover, the ability of immune complexes and complement components to cause 
antibody production by anergic B cells has been directly demonstrated (Nemazee 1985; 
Lyubchenko, Dal Porto et al. 2007). Certain antigens, it seems, are able to provide both 
signal 1 and a second signal that allows for antibody production. 
 Defects in the normal signaling pathways in B cells may result in the third 
potential way that auto-reactive B cells can be induced (Shlomchik 2008). In general, 
defects in BCR signaling components, for example, may result in altered tolerance 
induction. Moreover, defects in molecular mediators of apoptosis may allow autoreactive 
B cells to survive negative selection processes, increasing the likelihood that one of the 
two previously mentioned mechanisms will take over. The complex genetic component to 
B cell mediated autoimmunities, was revealed by back crossing BCR transgenic strains 
with mice of the MRL.Fas SLE prone strain. Thus, in some cases, genetic abnormalities 
may predispose individuals to autoimmunity by altering the normal tolerance pathways. 
 Autoreactive B cells can persist in the periphery, but how do they mediate 
autoimmunity? Firstly, and most obviously, is the production of autoantibody, which 
leads to tissue destruction and inflammation, as in the case of rheumatic fever above. 
However, there are many reports of the critical role that B cells play in supporting T cell 
mediated autoimmunities (Lin, Mamula et al. 1991; Lyons, San et al. 1999; Matsushita, 
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Yanaba et al. 2008), and even in supporting SLE beyond antibody production (Chan, 
Hannum et al. 1999; Chan, Madaio et al. 1999). Treatment of a broad variety of primarily 
T cell mediated autoimmunities, by systemic depletion of CD20+ bearing B cells, is 
effective in treating these diseases (Lund and Randall 2010). Moreover, given the 
capacity of B cells to stimulate T cells, resulting in epitope spreading of the T cell 
repertoire, B cells are likely to be critical to the development of many different 
autoimmune diseases. It is likely then, that the major role for B cells in T cell 
autoimmunity is to present antigen. The role of B cells as antigen-presenting cell for T 
cells will be further discussed in section 1.4. 
 
1.3.5 Summary 
 
 Cooperative interactions amongst lymphocytes are essential for the generation of 
immunity. Experimental evidence, obtained in our laboratory and others, over the past 
three decades, has led to the conclusion that CD4 T cells cooperate with one another in 
the generation of optimal CD4 T cell responses. Moreover, it appears that the degree of 
the cooperative interactions involving CD4 T cells can have a role in determining the 
Th1/Th2 nature of the immune response generated. Due to the observation that CD4 T 
cell cooperation requires physical linkage of the T cell epitopes, both in culture and in 
vivo, B cells are thought to be the APC mediators of this interaction. 
 Another well-described phenomenon, from the literature regarding autoimmunity, 
is epitope spreading. As an immune response develops, the number of epitope-specific 
clones that react with the antigen increases. In normal immune responses, this 
phenomenon appears to ensure efficient clearance of the pathogen and the development 
of robust memory. In autoimmune disease, epitope spreading serves to prolong the course 
and to leads to immunopathogy. In some cases B cells, acting as APC, have been shown 
to be critical for the induction of T cell autoimmunity. Moreover, it appears that B cells 
mediate epitope spreading.  
Because of the high degree of similarity between the phenomena of CD4 T cell 
cooperation and epitope spreading, it can be suggested that these processes are 
manifestations of the same basic mechanism. As I will outline in the next section, much 
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evidence supports the hypothesis that B cells acting as APC can potentiate and mediate 
the evolution of Th1 to Th2 responses during the course of responses to experimental 
antigens and to infections. This evidence serves to further underscore the importance of 
CD4 T cell cooperation in the development of immunity. 
 
1.4. The Role of B cells as Antigen Presenting Cells in CD4 T Cell Activation  
 
1.4.1 Introduction 
 
 While T cells fulfill their effector function in eliminating infection by provision of 
cytokine, of by directly killing infected self-cells, B cells differentiate to produce 
antibody molecules, which bind antigen and harness a variety of potent secondary 
effector mechanisms to clear invading organisms. During infection, the fates of antigen-
specific B and T cells are intimately linked. B cell differentiation into antibody producing 
plasma cells depends on help from activated CD4 T cells. Whether this interaction is also 
essential for the optimal generation of effector CD4 T cells is the subject of a debate that 
has been ongoing for four decades.  
 In Chapter 4, I present evidence that cooperative interactions between CD4 T 
cells can be mediated by B cells. In light of this finding, the role of B cells as APC for 
CD4 T cells becomes more important to the study of their biology. Here, I attempt to 
explore, in an unbiased way, the literature surrounding the APC function of B cells. In 
bringing together diverse, and sometimes contradictory, observations on the role of B 
cells in the activation of CD4 T cells, I hope to reconcile these into a comprehensive 
model for B cell involvement in CD4 T cell responses. 
 
1.4.2 Do B Cells Present Antigen to T cells? 
 
Classical studies clearly defined a role for T cells in the activation of B cells 
leading to antibody production (Claman, Chaperon et al. 1966; Miller and Mitchell 1968; 
Mitchell and Miller 1968; Nossal, Cunningham et al. 1968). From this early perspective, 
the major role of T cells, in particular the CD4+ subset, is to provide “help” to the antigen 
! 58 
receptor-bearing B cells to allow for optimal antibody production. Though this interaction 
is often envisaged as a “one-way street”, with signals coming mainly from CD4 T cells 
and delivered to the B cell, a large amount of literature describes a role for the B cell in 
CD4 T cell activation. Many early studies were aimed at determining whether B cells 
were even capable of presenting antigen to CD4 T cells. Findings that B cells are capable 
of antigen presentation naturally led to the question of the functional significance of this 
interaction, beyond the induction of antibody production, a question to which we will 
return later.  
 By the early 1980s, technological advances led to the development of assays that 
allowed detection of immune responses ex vivo. The tritiated-thymidine incorporation 
assay, that allowed T cell-specific proliferation to be measured, was developed. Detection 
of the incorporation of radiolabeled nucleotides into the nascent DNA of dividing T cells, 
enabled the study of antigen presentation in a dish. These experiments involved mixing 
different combinations of antigen-primed T cells with different antigen-presenting cell 
populations and different antigens and then assessing the proliferation of the T cells. To 
ensure that the proliferation measured was due only to T cell incorporation of tritiated 
thymidine, the APC populations were most often heavily irradiated. Employing purified 
leukocyte populations allowed for direct assessment of APC capability. This basic assay, 
together with careful experimental design, yielded significant information regarding the 
role of B cells in presenting antigen to CD4 T cells.  
Chesnut and Grey demonstrated that splenic B cells, thoroughly depleted of 
macrophage-like cells, could induce antigen-specific proliferation of T cells. This 
presentation could occur provided that the B cells took up this antigen by way of 
interaction with the BCR and that the B cells and T cells were MHC compatible 
(Chesnut, Endres et al. 1980). Other groups extended these observations and 
demonstrated that B cell lymphoma cells could also present antigen to CD4 T cells 
(McKean, Infante et al. 1981; Glimcher, Hamano et al. 1982; Glimcher, Kim et al. 1982). 
Presentation occurred at a range of antigen concentrations similar to those that allowed 
presentation by macrophages. B cells, it appears, are efficient APC for CD4 T cells. 
Since B cells are subject to activation by interaction with antigen or with CD4 T 
cells, it was of interest to determine whether the activation status of the B cell had any 
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effect on antigen presentation to T cells. Following-up their earlier work, Grey and 
colleagues showed that small, dense, resting B cells, are inefficient APC for CD4 T cells, 
whereas less dense, presumably activated B cells, are highly efficient APC. Activation of 
resting B cells by culturing with LPS, or through stimulation with rat anti-mouse IgG, 
which aggregates the BCR providing an analog of antigen binding, resulted in efficient 
antigen-presentation to T cells (Kakiuchi, Chesnut et al. 1983). Making use of the A20 B 
cell lymphoma line, they also demonstrated that antigen processing, a phenomenon 
originally observed in presentation of antigen to T cells by macrophages, was required for 
antigen presentation by B cells (Shimonkevitz, Kappler et al. 1983). Malynn and Wortis 
demonstrated that antigen-specific B cells from the lymph nodes of immunized mice 
could present antigen to T cells in vitro provided that both the B cell and T cell epitopes 
were present and physically linked (Malynn and Wortis 1984), confirming long-
recognized rules for B cell-T cell interaction in vivo. Moreover, antigen-specific 
presentation by B cells is highly efficient, requiring only very low antigen concentrations. 
Ashwell et al. re-visited the question of whether the activation status of B cells was 
important in their antigen-presenting role. They found resting B cells could productively 
present antigen to T cells provided this presentation led to T cell-dependent B cell 
activation and proliferation. (Ashwell, DeFranco et al. 1984).  Thus the presentation 
function of resting B cells was radiosensitive. This finding explained why, in previous T 
cell proliferation type experiments, irradiated resting B cells were found to be inefficient 
APC. Therefore, B cells can present antigen to CD4 T cells if 1) they were activated in 
some way, often by way of BCR ligation, 2) they took up the polypeptide that gave rise 
to the T cell epitope and 3) the B and T cells were MHC compatible.  
The work of Antonio Lanzavecchia tied together these observations leading to a 
model of how B cells present antigen to CD4 T cells (Lanzavecchia 1985). He observed 
that presentation by antigen-specific B cells required a 104 to 105 fold lower antigen 
concentration than presentation of Ag by polyclonal B cells. This indicated that B cells 
specifically acquired antigens for presentation via the BCR. In his experimental system, 
B cells bound, internalized, and proteolytically digested antigen to enable presentation to 
CD4 T cells. The B cells and T cells had to be MHC compatible for presentation to occur. 
Given these observations, it was suggested that B cells take up antigen by way of the 
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BCR, which is then processed and presented as peptides in the context of MHC 
molecules to T cells (Howard 1985).  
This model accounted for most observations, regarding the B cell-T cell 
interaction, made up until this point, and resolved the long-standing issue of how MHC-
restriction played into the generation of antibody responses. However, even though it was 
clear that B cells could present antigen to T cells, it remained unclear whether this 
presentation was solely involved in the activation of B cells or whether there was a 
reciprocal effect on T cell activation. To address this question, very many studies were 
undertaken, and many addressed the priming of T cells in B cell deficient mice. These 
studies have yielded a great deal of insight into the role of B cells as APC.  
I will review the literature concerning B cell deficient animals and some evidence 
from therapeutically B cell depleted humans later. First, I will focus on studies where 
positive observations of a role for B cells in the activation of CD4 T cells were made. 
 
1.4.3 Positive Evidence That B Cells Are Involved in CD4 T Cell Priming  
  
The presence of autoreactive B cells in the periphery often leads to autoreactive 
CD4 T cell activation. Lin et al. demonstrated this phenomenon when they employed 
cross-reacting human cytochrome c (hCC) to break B cell tolerance to endogenous mouse 
cytochrome c (mCC) (Lin, Mamula et al. 1991). Despite the production of autoreactive 
anti-mCC antibodies, following immunization with hCC in complete Freund’s adjuvant 
(CFA), mice remain tolerant to mCC at the T cell level. This maintained T cell tolerance 
possibly reflected the scarcity of mCC protein which limited its ability to be presented by 
autoreactive B cells. However, upon immunization with a mixture of hCC and mCC, 
tolerance at both the antibody level and the T cell level was broken. Furthermore, purified 
B cells from mice immunized with hCC alone, when transferred into naive recipients 
allowed efficient priming of mCC specific T cells upon immunization with mCC alone. 
Thus, the presence of autoreactive B cells, and sufficient amounts of antigen, allow for 
priming of autoreactive T cells. These findings were extended by de Vos et al. who 
showed that mice with BCR-transgenic B cells, specific for HEL, that were crossed with 
mice expressing HEL under the !-crystalin promoter, leading to expression in the lens of 
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the eye, supported the accumulation of autoreactive CD4 T cells (de Vos, Fukushima et 
al. 2000). Autoreactive B cells, in this case, remained at least partially ignorant of the 
experimental autoantigen. Thus, autoreactive B cells that are not eliminated by self-
antigens in the periphery, support the survival and activation of autoreactive T cells that 
would normally be eliminated themselves. Taken together, these studies support the idea 
that B cells can play a positive role in antigen presentation, leading to the activation, of 
autoreactive T cells.  
Buhlmann et al. demonstrated that the ability of B cells to prime alloreactive T 
cells in vivo required CD40-CD40L interactions (Buhlmann, Foy et al. 1995). Adoptively 
transferred, MHC disparate B cells elicited potent alloreactive T cell responses. However, 
under conditions where B cells could not receive CD40L signals from T cells, tolerance 
was induced. This finding confirmed, with a description of the signaling molecules 
involved, the work of Ashwell (Ashwell, DeFranco et al. 1984). However, in this system, 
where no peptides from exogenous antigen are presented, the role of activation via the 
BCR could not be addressed. B cells that present antigen without having previously been 
activated by T cells via CD40-CD40L interactions are tolerogenic, whereas antigens 
presented by B cells that have interacted with T cells in this way are potently 
immunogenic.  
It appears that activation of B cells via the BCR is tied to their ability to activate 
CD4 T cells. Employing HEL-specific antigen-receptor transgenic B and T cells, Ho et 
al. re examined the role of BCR ligation in B cell antigen presentation (Ho, Cooke et al. 
1994). In cultures containing only purified B cells and T cells from these transgenic mice, 
HEL protein could elicit substantial T cell activation whereas the MHCII-binding HEL 
peptide did not. This was not due to a defect in presentation alone, but rather a deficiency 
in the co-stimulatory activity of resting and anergic B cells, as agonist antibodies to 
CD28 restored T cell activation in peptide-containing cultures. Croft et al. subsequently 
demonstrated that, although resting B cells do present antigen to naive CD4 T cells, 
leading to initial proliferation, this activation is not sustained, and the T cells eventually 
become anergic (Croft, Joseph et al. 1997; Jaiswal and Croft 1997). A difference, in these 
cultures, between T cells, primed by resting B cells, and those primed by activated B 
cells, is their expression of CD40L. CD4 T cells stimulated by resting B cells, that do not 
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express high levels of B7 co-stimulatory molecules, fail to express CD40L, which in turn 
leads to their inability to reciprocally activate the antigen-presenting B cell. B cells that 
have been activated by binding antigen efficiently prime CD4 T cells.   
It became accepted that while B cells can, and do under some circumstances, 
prime T cells, this priming is likely secondary to initial activation of the T cell by another 
APC (likely a DC). This line of reasoning depended on two main points. Firstly, resting B 
cells are tolerogenic when presenting peptide to naive T cells in the absence of CD40L 
stimulation. Secondly, T cells cannot provide CD40L if not previously activated. Thus a 
chicken-and-egg problem about the initial priming steps of T cell activation made it 
unlikely that a naive B cell could ever activate a naive T cell. If another cell, not 
dependent on CD40L stimulation for its activation, could initiate T cell priming, the 
problem is avoided. The large amount of accumulating evidence that DCs are extremely 
potent APC for CD4 T cells reinforced this notion. This viewpoint became pervasive and 
is widely held to this day. However, it would appear that at least under some 
circumstances resting B cells can be activated sufficiently to initiate the cascade of B 
cell-T cell interactions mediated by peptide-MHC-TCR and CD40-CD40L interactions 
(Kakiuchi, Chesnut et al. 1983; Ashwell, DeFranco et al. 1984), (Ho, Cooke et al. 1994).   
According to Constant (Constant 1999), initial priming by B cells is possible in 
vivo under some circumstances. Transfer of TCR transgenic CD4 T cells specific for a 
peptide of moth cytochrome c (MCC) into either WT or MD4 HEL-specific BCR 
transgenic mice provided an opportunity to examine the presentation of peptide by 
antigen-specific B cells. MCC-specific T cell activation was not observed when limiting 
amounts of MCC alone was injected into WT or MD4 mice, nor was it observed when a 
conjugate of MCC-HEL was given to WT hosts.  Conversely, MD4 mice were able to 
support activation of seeded MCC-specific CD4 T cells when MCC-HEL was given. The 
HEL-specific B cells in these mice became activated to express CD86 and downregulated 
peptide-MHC complexes indicating that they had presented antigen to T cells. Therefore, 
at antigen concentrations below what are required to allow activation by DC, B cells can 
mediate the initial activation of CD4 T cells.  
More recent evidence supports a role for B cells in CD4 T cell responses 
indirectly. In a mouse model where the development of DC is severely impaired, the 
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presence of B cells is sufficient to allow T cell activation (Castiglioni, Lu et al. 2003). In 
addition, by employing two-photon microscopy, Gunzer et al. have observed similar 
patterns of T cell interaction, with activated DC and activated B cells in collagen matrices 
(Gunzer, Weishaupt et al. 2004). Activated B cells and CD4 T cells were visualized 
forming multiple productive immune synapses in an antigen-dependent manner. The B 
cell-T cell interactions have similar characteristics, in terms of duration and functional 
priming, as DC-T cell interactions. Thus, B cells appear to play an active role as APC for 
T cells in certain experimental settings. 
Overall, experimental evidence employing B cells directly as APC supports the 
idea that B cells can directly activate T cells. However, the natural circumstances that 
would lead to exclusive antigen presentation by B cells are unclear. It would seem that 
activation of naive T cells, by B cells would be rare. Most B cell-T cell interactions will 
take place after initial T cell priming by DC. Therefore while B cells are capable of 
priming CD4 T cells directly, it appears that their role as APC is primarily accomplished 
during ongoing immune responses.  
 
1.4.4 Evidence that B cells are involved in T cell priming from studies in B Cell 
Deficient Animal Models 
 
1.4.4.1 Anti-µ  Treatment 
 
 Given the findings discussed above, it is clear that B cells do not normally initiate 
CD4 T cell activation. However, B cell deficient animal models have pointed to a role for 
B cells in the generation of optimal immune responses and in achieving appropriate 
immune responses for clearance of pathogens. 
 In early experiments, in vivo depletion of B cells was employed to confirm their 
role in antibody production. Manning and Jutila undertook such experiments in vivo 
(Manning and Jutila 1972). They employed rabbit anti mouse IgM (anti-µ), given 
continuously to mice from the day of birth, to remove IgM-bearing cells (B cells). Not 
unexpectedly, the results of this study showed greatly decreased antibody production 
when anti-µ treated mice were challenged with sheep erythrocytes (SRBC). However, in 
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a subsequent study, the authors found that anti-µ treated mice were able to reject 
allografts equivalently to their untreated counterparts (Manning and Jutila 1972). Thus, it 
appeared that while B cell functions were removed by anti-µ treatment, the T cell 
functions remained intact.  
 Over the next decade, a number of researchers sought to harness this technique to 
study T cell activation in the absence of B cells. It became clear that in addition to 
removing B cells, anti-µ had an effect on the generation of effector T cells that could not 
be explained simply by the administration of the antibody.  
Janeway et al. demonstrated that T cells from anti-µ treated mice were poor 
helpers for Ig production when co-transferred primed B cells (Janeway, Murgita et al. 
1977). This finding was confirmed by Bottomly (Bottomly, Janeway et al. 1980) 
employing a different hapten-carrier system, and by Rosenberg who showed that SRBC-
primed T cells from anti-µ treated mice were poor helpers for inducing class-switching in 
SRBC primed B cells (Rosenberg and Asofsky 1981). These findings led to the idea that 
in anti-µ treated mice there may also be some defect in T cells.  
Jacov Ron observed that T cells from anti-µ treated and normal mice behaved 
similarly in vitro, indicating that the defect in T cell priming in anti-µ treated mice was 
not T cell intrinsic (Ron, De Baetselier et al. 1981; Ron, De Baetselier et al. 1983). 
Purified T cells from these mice responded equally well to ConA or PHA stimulation. 
However, upon challenge with OVA or KLH in CFA, the proliferative response of T cells 
was poor in anti-µ treated mice. This poor response could not be attributed to innate APC 
as the macrophages and DCs from normal and anti-µ treated mice were found to be very 
similar in their APC function. Infusion of immune serum into anti-µ treated mice did not 
restore T cell priming indicating that a lack of opsonized antigen was also not responsible 
for the T cell priming defect. Hayglass et al. described similar deficiencies in T cell 
priming in anti-µ treated mice which were attributed to a lack of antigen-presentation by 
B cells and not a defect in other APC (Hayglass, Naides et al. 1986). Taken together, 
these findings suggested that the defect in priming of T cells in anti-µ treated mice was 
due to a lack of antigen-presentation by B cells, not a problem with T cells.  
Evidence for a defect in antigen presentation in B cell deficient mice continued to 
accumulate. T cell priming in the lymph-nodes of anti-µ treated mice was severely 
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impaired but could be reconstituted by providing live polyclonal B cells which seeded the 
lymph nodes (Ron and Sprent 1987). Kurt-Jones et al. showed that OVA-specfic T cell 
responses to haptenated OVA could only be reconstituted by the provision of hapten-
specific B cells with compatible MHC (Kurt-Jones, Liano et al. 1988). Thus, antigen-
specific B cells take up the antigen by way of recognition of the hapten, process the OVA 
into peptides and present these peptides to OVA-specific CD4 T cells, leading to mutual 
activation of hapten-specific B cells and optimal generation of OVA-specific T cells. 
 Overwhelmingly, the results of experiments in anti-µ mice seemed to support the 
idea that B cells had a functional role as APC in the generation of optimal T cell 
responses. It was clear that T cell priming in anti-µ mice was not completely absent, and 
in some cases the priming in the spleen to protein antigens was found to be equivalent in 
the presence or absence of B cells (Sunshine, Jimmo et al. 1991). Differences in T cell 
priming by way of route (systemic versus local) suggested that B cells were most critical 
in T cell priming when antigen did not have access to the potent non-B cell APC in the 
spleen.  
 
1.4.4.2 Genetically B cell Deficient Models 
 
Around the mid 1990s, with the advances in genetic manipulation of the mouse, 
the technology for addressing the role of B cells in T cell priming shifted. Two types of 
mouse model, made deficient in B cells by way of genetic mutation, were developed. 
Mice lacking the ability to generate the membrane form of IgM (µMT), and mice that 
could not functionally re-combine the Ig heavy-chain (JHD), came into widespread use. 
Though the technology and systems for assessing T cell activation were much improved 
by this time, many of the results obtain in µMT and JHD mice reflected those obtained in 
anti-µ treated mice.  
Confirming earlier findings that T cell priming in the lymph nodes of B cell 
deficient mice is often impaired, Liu et al. found that upon immunization with OVA or 
KLH in CFA, very little T cell priming occurred in the lymph nodes of JHD mice (Liu, 
Wu et al. 1995). Again, spleen resident DC and macrophages in JHD and WT mice were 
equivalent in ex vivo antigen presentation ability. Similarly, employing the µMT model, 
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Constant et al. reported defects in T cell priming in response to pigeon cytochrome c 
(PCC) proteins, given in CFA, but not when the immunodominant PCC peptide was 
given in CFA (Constant, Sant'Angelo et al. 1995; Constant, Schweitzer et al. 1995). By 
assessing the in vivo loading of antigen to different APC populations, Constant was able 
to suggest that in situations where peptide was given, DC were much more efficient than 
B cells at presentation; conversely, when protein was given, B cells become loaded with 
peptide more efficiently and up-regulate B7 co-stimulatory molecules presumably after 
having taken up antigen by way of the BCR. Macaulay showed that CD4 T cells from 
JHD mice, primed with protein in CFA, did not provide help for B cells to class-switch to 
IgG1. These T cells were deficient in production of IL-4 (Macaulay, DeKruyff et al. 
1998). In a more recent study, Crawford et al. demonstrated that B cells bearing class II 
MHC molecules were critical for the primary expansion, cytokine secretion, and memory 
cell transition of CD4 T cells following immunization with protein on ALUM (Crawford, 
Macleod et al. 2006). B cell deficiency in this system greatly limited the production of 
IL-4 by T cells while leaving IFN! production relatively intact. Thus, the results of the 
majority of experiments undertaken in mice made genetically deficient in B cells 
supported the notion that B cells are critical APC, at least under certain circumstances, 
for optimal CD4 T cell priming.  
At the same time there were a number of reports showing no difference in T cell 
priming between WT and µMT mice. In a comprehensive set of experiments Epstein 
directly addressed this issue. She found no difference in CD4 T cell proliferation, 
cytokine production, or CTL generation, between WT and µMT strains, in various 
experimental systems, such as allograft rejection, protein-in-CFA immunization, and 
immunization with schistosome eggs (Epstein, Di Rosa et al. 1995). The responses in 
control, WT mice in these experiments were somewhat lower than responses normally 
obtained by other groups, employing similar immunizations, which led some to question 
the relevance of Epstein’s findings (Rivera, Chen et al. 2001). 
There appears to be no difference between µMT and WT mice in T cell tolerance 
induction. Baird and Parker backcrossed µMT mice to a HEL-transgenic background and 
found that both strains of mice were tolerant to HEL (Baird and Parker 1996). 
Interestingly, T cells from µMT HEL tolerant mice, challenged with CFA and OVA, 
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produced about 2-fold more IFN! than their WT counterparts. Similarly, Phillips 
demonstrated that both µMT and WT mice could be made tolerant to HGG (Phillips, 
Romball et al. 1996). T cells from CFA HGG challenged µMT mice generated 3-fold 
higher levels of IFN! than T cells from WT C57Bl/6 mice. While these studies seemed to 
demonstrate a bias in the Th1/Th2 nature of immune responses in µMT mice, peripheral 
tolerance for T cells, once thought to proceed through an initial B cell-dependent priming 
step, appeared to be intact in B cell deficient mice.  
Clearly, in different laboratories the level of CD4 T cell activation in B cell 
deficient mice could be variable. This variability was a source of confusion for those 
seeking to describe the role of B cells in CD4 T cell activation. Addressing this issue, 
Rivera et al. pointed out that most reports, in which activation of CD4 T cells was found 
to be similar between WT and B cell deficient animals, employed mice of the C57Bl/6 
genetic background. After backcrossing the µMT mutation to BALB/c and SJL strains, 
the authors were able to offer an explanation for variable results obtained by different 
groups (Rivera, Chen et al. 2001). In µMT C57Bl/6 CD4 T cell priming was found to be 
decreased relative to WT mice, but highly variable from mouse to mouse, and at times, 
reached 30-40% of WT levels. In µMT BALB/c or SJL mice the results were much 
cleaner, i.e. CD4 T cell priming was severely impaired compared to WT controls. The 
demonstration of strain-specific differences in µMT mice has been widely ignored as 
most subsequent studies also employed C57Bl/6 µMT mice. 
The findings of Baird (Baird and Parker 1996) and Phillips (Phillips, Romball et 
al. 1996), where IFN! production was actually higher in response to immunization in 
µMT mice compared to WT mice, together with the findings of Crawford (Crawford, 
Macleod et al. 2006) and Macaulay (Macaulay, DeKruyff et al. 1998), wherein B cell 
deficient mice produced far fewer IL-4-secreting CD4 effector cells upon immunization, 
suggest that B cells are particularly suited to foster Th2 responses. This possibility is in 
line with physiological considerations of the role of B cells as APC, and the interplay 
between Th2 cells and B cell effector function (Harris, Goodrich et al. 2005).  
A pair of interesting studies, undertaken in µMT mice, help reinforce a notion that 
B cell antigen-processing leads to increased Th2 responses. Bradley et al. showed that 
µMT mice, challenged with KLH in CFA, produced effector CD4 T cells that secreted 
! 68 
substantially less of the Th2-associated cytokines IL-4, IL-5 and IL-13 than did their WT 
counterparts (Bradley, Harbertson et al. 2002). Interestingly, the amount of IFN! 
production was virtually identical in both the WT and µMT mice, and this was shown to 
be due primarily to IL-12 production by the remaining APC. Adoptively transferred B 
cells or large numbers of DC could restore Th2 development in µMT mice. Curiously, 
whether excess DC also increased the production of Th1 cytokines was not reported. In a 
follow-up study the specific effector molecules provided by the B cells that can re-
constitute Th2 responses in µMT mice was examined. While reconstitution did not 
require B cell derived IL-4, IL-6, or IL-10, the expression of OX40L by B cells was 
required. These findings suggest that B cells allow for Th2 differentiation by way of APC 
function that depends on the OX40-OX40L interaction.  
 
1.4.5 Confounding Problems in Mice Made Genetically Deficient in B cells 
 
Concurrent with the investigation of the influence of B cells on T cell activation, a 
number of publications emerged that exposed potentially confounding factors in studies 
employing B cell-deficient mice. B cell derived lymphotoxin supports the generation of 
follicular DC clusters (Fu, Huang et al. 1998), the generation of germinal centers and 
overall lymph node organization (Endres, Alimzhanov et al. 1999), and supports the 
survival and expansion of tissue resident DC populations (Kabashima, Banks et al. 2005). 
In addition, µMT and JHD mice are deficient in Peyer’s patch development, M cell 
generation (Golovkina, Shlomchik et al. 1999) and spleen stromal network development 
and have lower numbers of spleen resident DC (Ngo, Cornall et al. 2001). Clearly, the 
overall structure of lymphoid organs and the cell populations within are dramatically 
altered in B cell deficient mice. Therefore, when considering findings that are obtained 
regarding the priming of T cells in B cell deficient animals, one must bear in mind that 
DC presentation to T cells may also be impaired. However, given reports that B cells 
from WT animals, adoptively transferred into B cell deficient mice, largely restore T cell 
responses to WT levels, it is unclear, whether differences in lymphoid architecture truly 
affect the generation of T cell responses in B cell deficient mice.  
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1.4.6 Evidence that B cells are involved in CD4 T cell activation from Models of 
Autoimmunity 
 
It was initially believed that T cell functions remained largely intact in animals 
made B cell deficient. Some of the first evidence that that was not the case came from 
studies in anti-µ treated rats. Willenborg et al. found that while normal Lewis rats were 
highly susceptible to the induction of EAE, their B cell deficient anti-µ treated littermates 
were not (Willenborg and Prowse 1983). None of the rats, in this study, that remained B 
cell deficient following EAE induction, developed symptoms. The very few anti-µ treated 
rats that developed antibody to myelin basic protein, indicating they were not truly B cell 
deficient, developed mild disease. Myers et al. reported that EAE could not be induced in 
anti-µ treated mice (Myers, Sprent et al. 1992). However, it was clear that adoptive 
transfer of encephalitogenic T cells from normal mice experiencing EAE, could not on 
their own, fully induce EAE in B cell deficient mice. The authors describe a role for 
autoantibody in the opsonization of myelin antigens. In parallel with the findings of 
Constant (Constant, Sant'Angelo et al. 1995; Constant, Schweitzer et al. 1995; Constant 
1999) Lyons et al. described an inability to induce EAE, in µMT mice, when myelin 
oligodendrocyte protein was given in CFA. However, when the immunodominant 
peptide, MOG35-55, was injected with CFA, both µMT and WT mice developed disease 
(Lyons, San et al. 1999). Taken together, findings in EAE, a model considered to reflect 
in some respects human multiple sclerosis, are consistent with basic findings in intact and 
B cell deficient mice. B cells are required as APC for the induction of autoreactive T cells 
particularly when protein antigens are given. Presumably this reflects in part the highly 
efficient antigen loading of B cells when protein concentrations are limiting.  
Janeway et al. reported that mice, of the autoimmune prone strain MRLlpr, failed 
to show signs of the fatal lymphoproliferative disease, common in untreated counterparts, 
when treated with anti-µ from birth (Janeway, Ron et al. 1987). Chan, working with 
Shlomchik, bred the MRLlpr mutation into JHD knockouts and confirmed Janeway’s 
findings (Chan, Madaio et al. 1999). Disease in these mice is associated with the 
presence, in lymphoid organs, of high numbers of CD4 and CD8 T cells with an activated 
and memory phenotype. In MRLlpr./lpr JHD mice, no evidence of increased levels of such 
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activated, pathogenic T cells was found. Chan extended these findings by developing a 
novel strain of mice that are capable of generating mature B cells, but whose B cells lack 
the ability to secrete antibody. These membrane IgM (mIgM) mice have become a 
valuable tool for researchers wishing to separate the APC and antibody producing roles 
of B cells, especially in models of autoimmunity. Employing the mIgM strain, crossed 
with MRLlpr mice, it was found that the characteristic T cell activation and 
lymphoproliferation was similar, compared to mice of the MRLlpr parental strain. A 
difference in immunopathology was found only in the kidneys, where Ig-complex 
deposition normally leads to tissue destruction.  Thus, antigen presentation by B cells, 
and not autoantibody production, is key to the development of the characteristic 
autoimmunity found in MRLlpr mice. 
 Although many factors have been found to influence the generation of insulin 
dependent diabetes mellitus (IDDM) in the non-obese diabetic (NOD) strain of mice, B 
cells appear to be absolutely essential for development of this T cell-mediated disease. 
NOD mice develop a form of IDDM that is the result of autoimmune reaction that 
destroys !-islet cell function. Serreze et al. report that after back crossing µMT to NOD 
mice, heterozygotes develop disease at frequencies expected of the parental NOD strain 
(Serreze, Chapman et al. 1996). Conversely, NOD mice homozygous for the µMT 
mutation are completely protected. Thus, B cells likely play a role in the genesis of !-
islet reactive T cells. Whether this role is direct, involving antigen presentation to T cells, 
or indirect, in supporting lymphoid architecture, is not known. 
Another common model of autoimmunity, induced autoimmune arthritis, which 
resembles rheumatoid arthritis in humans, has been found to be B cell dependent. O’Neill 
et al., in two recent studies have found that B cells are essential for priming the T cells 
that lead to severe disease in this model. Comparing JHD mice to mIgM mice, they were 
able to determine that antigen-specific B cell APCs supported the activation of 
autoreactive T cells which in turn lead to further B cell activation (O'Neill, Shlomchik et 
al. 2005). Because these studies were done in mIgM mice, the effects were found to be 
antibody independent. Extending these findings, the authors report that the presence of 
CD80 and CD86 on B cells is required for severe arthritis. While the level of 
autoantibody produced is similar between induced WT and mice where CD80/86 have 
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been removed specifically on B cells, the level of autoreactive T cell activation is 
severely limited (O'Neill, Cao et al. 2007).  
Taken together, the majority of reports regarding B cell deficient mice and their 
susceptibility to experimental autoimmunity support the notion that B cells are essential 
APC for the induction of many autoreactive T cell responses. Because the pathology in 
the models described above is mainly due to tissue infiltrating effector T cells, it is clear 
that B cells, at least in these cases, do present autoantigen leading to the activation of 
autoreactive T cells. 
 
1.4.7 Evidence that B cells are involved in CD4 T cell priming from models of 
infection 
 
 Infection models have led to great insights into how immunity is generated and 
maintained. Researchers have found that B cells play a role, independent of their 
production of antibody, in models of autoimmunity. However, it is more difficult to 
dissect the contributions of different cell types in infection models where effective 
immunity often involves multifaceted attack. Certain pathogens are susceptible to 
clearance by antibody, while others are cleared by CTL most efficiently, or by other 
effector mechanisms. Therefore, in some infection models, it appears that B cells play 
little role in immunity, whereas in others, B cells have been found to be critical.  
Findings from basic work suggest that B cells are more critical for the generation 
of Th2 cells (Macaulay, DeKruyff et al. 1998; Bradley, Harbertson et al. 2002; Linton, 
Bautista et al. 2003; Crawford, Macleod et al. 2006), and thus lead to polarized antibody-
mediated responses whereas a number of reports indicate that Th1-like IFN! responses 
are similar in WT and µMT mice (Baird and Parker 1996; Phillips, Romball et al. 1996). 
Therefore, one may expect that B cell deficient mice infected with pathogens that are 
susceptible to Th1-mediated attack or CTL would not show deficiencies in clearance. 
Conversely, when antibody or Th2 cells were required for pathogen clearance, these B 
cell deficient mice may show enhanced susceptibility. 
 Viruses are most often susceptible to clearance by effector mechanisms of the Th1 
axis. Although antibody can prevent infection of cells, most viral infections are 
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associated with development of CTL that destroy infected cells. Topham et al. found that 
after infection with a mouse adapted influenza virus, both WT and µMT mice cleared the 
pathogen and recovered in a similar fashion (Topham, Tripp et al. 1996). Mice of both 
strains contained similar numbers of IL-2-producing CD4 T cells, and µMT mice actually 
contained more IFN! producing cells, at the height of immunity, than did WT mice. 
Similarly, Mozdzanowska and Gerhard reported that, after infection of µMT and WT 
mice with the PR8 strain of influenza, CD4 T cells were equivalently activated 
(Mozdzanowska, Furchner et al. 1997). However, CD4 T cells alone were insufficient for 
viral clearance, which required either B cells or CD8 T cells. Homann et al. reported 
similar results in µMT and WT mice infected with LCMV (Homann, Tishon et al. 1998). 
During primary acute or chronic infection of mice with different strains of LCMV, the 
number of effector CTLs generated were the same in µMT and WT mice. Upon transfer 
of CD4 T cells from acutely infected WT mice to chronically infected WT mice, the 
infection is resolved. Interestingly, when CD4 T cells from acutely infected µMT mice 
were transferred into chronically infected WT mice, the infection was not resolved. This 
finding seems to indicate that while primary CTL responses to virus are generated in 
µMT mice as well as WT mice, there is a defect in the helper function of CD4 T cells in 
these mice. 
 Not all viral infections are cleared equally well in µMT mice. Bergmann reported 
that µMT mice fail to clear CNS infection of the neurotropic mouse hepatitis virus, 
JMHV, while WT mice clear this infection (Bergmann, Ramakrishna et al. 2001). In this 
case, both virus specific CD8 and CD4 T cell responses were reduced in µMT mice. 
Iijima et al. employing a unique system where B cells and DC could be separately 
removed by administration of diphtheria toxin, showed that in infection with herpes 
simplex virus, both B cells and DC play critical roles in generation of sufficient Th1 
responses to clear the virus (Iijima, Linehan et al. 2008). Thus, in some cases, it appears 
that optimal Th1 responses require B cells. 
 Some pathogens other than viruses are particularly susceptible to attack by Th1-
associated effector mechanisms. Two commonly employed models are infections with 
intracellular parasites, the gram-positive bacterium Listeria monocytogenes, and flagellar 
protozoans of the genus Leishmania. Experimental infection of B cell deficient mice has 
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been reported, by many groups, employing these two pathogens. Matsuzaki et al. 
demonstrated that both µMT and WT mice clear Listeria infections well, but that µMT 
mice generate many fewer Th1 and CTL cells during clearance (Matsuzaki, Vordermeier 
et al. 1999). Similarly Shen et al. show efficient clearance of Listeria during primary 
infection of µMT and WT mice (Shen, Whitmire et al. 2003). However, in the absence of 
B cells post-contraction survival, or memory cell survival, was severely impaired. This 
finding is reminiscent of similar experimental infections in CD4 T cell deficient mice 
(Shedlock and Shen 2003) and supports the conclusion that CD4 T cell helper function is 
impaired in B cell deficient mice. 
 Leishmania major infection in mice results in either effective Th1 immunity and 
pathogen clearance or in ineffective Th2-associated immunity leading to progressive 
disease. While C57Bl/6 mice normally resist challenge with 106 parasites, BALB/c mice 
succumb due to Th2 immune deviation. BALB/c mice can be made resistant by 
immunization with low doses of parasite (Bretscher, Wei et al. 1992) or by blocking IL-4 
(Uzonna and Bretscher 2001). David Sacks reported that partial depletion of mice with 
anti-µ resulted in Th1 development in BALB/c mice (Sacks, Scott et al. 1984). More 
recently, Ronet et al. showed that µMT BALB/c mice were relatively resistant to a 
particular strain of L. major (Ronet, Voigt et al. 2008). Susceptibility could be restored by 
transfer of polyclonal WT B cells but not by MD4 (anti-HEL BCR transgenic) B cells. 
These polyclonal B cells presented an immunodominant peptide of the pathogen. The 
authors conclude that B cells, as APCs, are essential for Th2 development in BALB/c 
mice infected with L. major.  
 The above-cited studies strongly support the hypothesis that B cell APCs are 
associated with Th2 development, whereas Th1 development is often independent of B 
cells. However, some infections, normally cleared or controlled by Th1-associated 
effector mechanisms, become progressive in B cell deficient mice. B cell deficient mice 
have been found to be more susceptible to infection with Salmonella enterica (Mastroeni, 
Simmons et al. 2000; Ugrinovic, Menager et al. 2003) Chlamydia trachomatis (Yang and 
Brunham 1998), and Mycobacterium tuberculosis (Vordermeier, Venkataprasad et al. 
1996; Maglione, Xu et al. 2007). Taking these, and the above findings into consideration, 
it would appear likely that, while B cells are not generally required to generate Th1 
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responses, in certain cases, optimal and protective Th1 responses require B cells. This 
requirement may depend primarily on the antigen presenting function of B cells, leading 
to expansion of Th1 cells in cases where Th1 is predominant. 
 Infections that generally require Th2-associated effector mechanisms for 
clearance also appear to require B cells. For example, malaria parasites are cleared 
primarily by antibody. Comparing T cell responses in Plasmodium infected µMT and WT 
mice, Langhorne et al. showed that while µMT mice failed to clear infection, both strains 
generated large numbers of Plasmodium-specific CD4 T cells (Langhorne, Cross et al. 
1998). The CD4 T cells from µMT mice failed to differentiate into Th2 cells, and were 
poor helpers for antibody production upon adoptive transfer. Significantly, adding back B 
cells to infected mice restored their ability to clear the infection and allowed the evolution 
of Th2 from “stalled” Th1 cells. Similarly, B cells have been shown to influence the 
number of Th1 and Th2 cells generated in murine infections of Trypanasoma cruzi 
(Cardillo, Postol et al. 2007). Thus, B cells are essential for the acquisition of the Th2 
phenotype of CD4 T cells in some cases.  
 Nippostogulis braziliensis and Heligmosomoides polygyrus infections in mice 
result in potent Th2 immunity. Recently, two studies were undertaken to elucidate the 
role of B cells in immunity to these parasitic worms in murine models.  
Again, antigen presentation by B cells appears to be critical in the development of 
appropriate immunity to parasitic worms. Liu et al. infected JHD mice with N. 
braziliensis. The mice were not able to resist this infection (Liu, Liu et al. 2007). A major 
deficit in Th2 generation was observed without a corresponding increase in Th1 cells. 
Imaging of the immune cells from draining lymph nodes of WT infected mice showed 
that production of IL-4 by T cells occurs as early as day 2 post-infection and is produced 
by T cells at the B cell-T cell border in draining lymph nodes. Moreover, JHD mice could 
be reconstituted in their Th2 responses by giving back WT or IL-4 knockout B cells, but 
not B7 knockout B cells, indicating that antigen presentation is the main role for B cells 
in the development of Th2 immunity in this model.  
 A comprehensive study by Wojciechowski examined the role of B cells in H. 
polygyrus infected mice (Wojciechowski, Harris et al. 2009). It was found that protective 
immunity to this worm depends on B cells; both µMT and JHD mice cannot become 
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immune to this infection. Antibody is necessary but not sufficient for immunity since 
secretory IgM deficient (similar to mIgM) mice are highly susceptible to infection, but 
immune serum alone from WT mice cannot protect B cell deficient animals. B cells that 
can present antigen associated with MHCII molecules are required for optimal generation 
of Th2 effector and memory cells in this model. Moreover, IL-4 secretion by B cells is 
dispensable for Th2 generation while IL-2 and TNF! production by B cells positively 
influenced, but was not absolutely required, for Th2 generation leading to effective 
immunity in parasite infected mice.  
The results from B cell deficient mice, in general, appear to support the 
hypothesis that B cells are involved, and often are critical as APC, during infection. It is 
clear that in some cases B cells can support both Th1 and Th2 development. Following 
infection, some effector B cells differentiate into cytokine secreting cells (Harris, Haynes 
et al. 2000). Under Th1-inducing conditions, B cells by virtue of expression of the IFN" 
receptor differentiate into IFN"-secreting Be1 cells (Harris, Goodrich et al. 2005). 
Conversely, B cells exposed to IL-4, produced by Th2 cells, differentiate into Be2 cells 
that secrete IL-4 (Harris, Goodrich et al. 2005). Both B effector cell types likely 
potentiate their corresponding T cell responses by provision of paracrine lineage-specific 
cytokines. Thus, in some cases, B cells may be involved in the maintenance of specific 
Th phenotype and the propagation of effector T cells. Whether B cells are essential for 
clearance of a given pathogen, would depend heavily on the biology of the pathogenesis 
of infection. Differences here may explain why B cells are found to be essential for the 
clearance of some Th1-inducing pathogens but not all. Presumably, in some cases, Th1 
development and sustenance occurs independently of B cell antigen presentation.  
  
1.4.8 Evidence that B cells Are Involved in Activation of CD4 T cells From 
Therapeutic B cell-Depletion in Humans 
 
 Given the issues, highlighted in section 1.4.5 above, concerning the validity of 
observations employing B cell deficient animal models to assess whether B cells are 
involved in T cell activation, this important question has fallen somewhat out of the 
consciousness of many immunologists. Moreover, the widely held view that B cell 
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activation requires CD40L stimulation by activated T cells suggests the B cell-T cell 
interaction is secondary to the DC-T cell interaction. However, some recently emerging 
evidence from human studies employing B cell depleting monoclonal antibodies as 
therapeutic agents in treating cell-mediated autoimmunity has led some to suggest that B 
cell involvement, particularly in sustaining the activation of T cell responses, should be 
reconsidered.  
 Rituximab is a chimeric mouse/human anti-CD20 antibody that has been used 
clinically to selectively deplete B cells in vivo (Reff, Carner et al. 1994; Pescovitz 2006). 
Immunotherapy of this type has been effective in clinical treatment of B cell 
malignancies (Maloney, Grillo-Lopez et al. 1997) and autoimmune diseases such as lupus 
nephritis (Ramos-Casals, Diaz-Lagares et al. 2011). However, evidence is mounting that 
patients with many autoimmune diseases, where pathology is at least partially associated 
with T cells, also respond to treatment with rituximab. Moreover, studies of the treatment 
of lupus with rituximab has yielded evidence that, even though pathology is primarily 
mediated by antibody, autoreactive T cells are inhibited upon B cell depletion (Sfikakis, 
Boletis et al. 2005; Vallerskog, Gunnarsson et al. 2007). These findings have led to the 
suggestion that B cells, functioning as APC, are primary targets for rituximab in SLE 
(Liossis and Sfikakis 2008).  
Despite the relative ineffectiveness of rituximab therapy in SLE (reviewed in 
(Ramos-Casals, Diaz-Lagares et al. 2011)), a number of clinical trials in patients with 
other autoimmune diseases have recently been undertaken (Dorner, Isenberg et al. 2009; 
Levesque 2009).  
 Rituximab treatment of rheumatoid arthritis patients has led to significant 
improvement of clinical symptoms (Edwards, Szczepanski et al. 2004; Cohen, Emery et 
al. 2006). Rheumatoid arthritis is characterized by destruction of joint tissue through a 
variety of immunopathological mechanisms. Classically it has been known that CD4 T 
cells play a central role in the pathogenesis of this disease, primarily due to joint tissue 
infiltration, and activation, of B cells to produce autoantibody (Harris 1990). While the 
pathogenesis of the disease is not fully understood, recent evidence suggests that CD4 T 
cells that produce IL-17 are particularly potent in the pathogenesis of the widely studied 
animal model induced by priming with collagen in CFA (Nakahama, Kimura et al. ; 
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Hirota, Hashimoto et al. 2007). Though direct effects on populations of autoreactive T 
cells have not been reported, the finding that B cell depletion ameliorates disease 
suggests that B cells play an important role in sustaining autoreactive T cells in 
rheumatoid arthritis. 
 Treatement of multiple sclerosis (MS) patients with rituximab has also been 
shown to be effective. The pathogenesis of multiple sclerosis (MS) involves formation of 
infiltrative central nervous system (CNS) lesions. The infiltrates are made up of both T 
cells and B cells. Therapeutic B cell depletion, after a single course of rituximab therapy, 
improves the clinical outcome of MS patients whose disease is refractory to standard 
therapies (Cross, Stark et al. 2006; Hauser, Waubant et al. 2008). Interestingly, Cross et 
al found that while autoantibody titers to a dominant antigen were not affected of B cell 
depletion, both B cells (presumably due to removal by rituximab) and importantly, T 
cells, were found in lower number in the CNS of treated patients. These findings are in 
line with findings in EAE models, outlined above, and support the hypothesis that antigen 
presentation by B cells is important in the pathology of MS. 
 In addition to MS and rheumatoid arthritis, rituximab therapy has been found to 
be effective in treatment of pemphigus vulgaris (Eming, Nagel et al. 2008), autoimmune 
diabetes (Pescovitz, Greenbaum et al. 2009), and Sjogren’s syndrome (Abdulahad, Meijer 
et al. ; Meijer, Meiners et al. 2010). While the effects on the T cell compartment by B cell 
depletion in patients with autoimmune diabetes and Sjogren’s syndrome can only be 
assumed, given the prominent role of T cells in the pathogenesis of these diseases, it was 
directly addressed in patients with pemphigus vulgaris. Eming et al. reported that while 
overall levels of CD4 and CD8 T cells remained constant, the number of desmoglein-
specific T cells, the T cells primarily responsible for the pathogenesis of the disease, were 
dramatically decreased in patients depleted of B cells following rituximab treatment. 
Again, these findings suggest that B cells play a role in antigen-presentation to T cells in 
the pathogenesis of human autoimmune disease.  
 Taken together, the results of clinical trials where B cells are therapeutically 
depleted by the administration of the anti-CD20 monoclonal antibody, rituximab, support 
the hypothesis that B cells are somehow involved in autoreactive T cell responses in 
humans. This role is likely through APC function. However a subtle difference in these 
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findings, from human trials, and others, from animal models, is that in patients with 
autoimmunity, T cell responses are ongoing. If autoreactive T cells are affected by B cell 
depletion in these models, it is after their initial priming. Therefore the data from these 
trials leads to the hypothesis that, rather than being involved, solely and necessarily, in 
the initial priming of autoreactive T cells, antigen presentation by B cells sustains T cell 
responses. This conclusion is in line with our recent findings, as will become apparent 
later in this thesis. However, data bearing directly on the effect of B cell depletion on the 
generation of autoreactive T cells remains sparse, and thus, further investigation is 
warranted.  
 
1.4.9 Conclusions 
 
The history of the study of B cell involvement in CD4 T cell responses dates back 
almost as far as the identification of the two cell types. Both classical studies, and current 
evidence, suggest that B cells are not simply passive recipients of antigen-specific CD4 T 
cell help. By virtue of their ability to take up, process, and present antigen, in association 
with MHCII molecules, B cells are antigen-specific APC. This specificity makes B cells 
unique. B cells capture antigen through the BCR and, therefore, are not only highly 
efficient, picking up antigen at extremely low concentrations, but are also selective in the 
CD4 T cells with which they can interact. Only those CD4 T cells with affinity for 
peptides derived from the antigen for which the BCR has affinity, or antigens that are 
physically linked to this antigen, can be stimulated. Therefore, theoretically, the B cell is 
the ideal APC type to mediate cooperative interactions between CD4 T cells. As 
reviewed above, B cells appear to be critical in maintaining and enhancing the activation 
of CD4 T cells, under at least some circumstances. Furthermore, B cells are capable of 
directly activating CD4 T cells. B cells are intricately involved in the generation of 
effector CD4 T cells during immune responses. 
Another commonality that emerges, from surveying the literature on experimental 
B cell deficiency, is that B cells may be involved in determining the Th1/Th2 phenotype 
of the activated CD4 T cells. In general B cell deficient mice are not more susceptible to 
pathogens, like viruses, that are normally cleared by Th1 effector mechanisms. However, 
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it is clear that in many cases B cells are required to generate Th2 cells. This role is not 
solely through the production of antibody, but is fulfilled by antigen-presentation to T 
cells. These findings are also consistent with the hypothesis that cooperative interactions 
between CD4 T cells, and mediated by B cells, can determine the Th1/Th2 phenotype of 
a particular immune response.  
Findings, made in humans, therapeutically depleted of B cells to treat 
autoimmunity, add further weight to the idea that B cells mediate cooperation between 
CD4 T cells. As I have discussed in section 1.3, epitope spreading is a common 
mechanism by which autoimmunity progresses. If, as has been hypothesized, spreading in 
the repertoire of autoimmune CD4 T cells is a reflection of CD4 T cell cooperation, then 
one would expect B cell depletion to prevent this spreading. Moreover, if continued 
activation of CD4 T cells via cooperative events, mediated by B cells, sustains their 
activation, one would also expect B cell depletion to disrupt this cycle. It appears that 
current clinical evidence regarding the therapeutic efficacy of B cell depletion in various 
autoimmune diseases supports this view. 
Given the evidence above, and previous findings in our, and other, laboratories, 
we conclude that the B cell-CD4 T cell interaction serves, at least under some 
circumstances, to both enhance the generation and activation of effector CD4 T cells and 
to enable the evolution of Th2 cells. Thus, it appears that the majority of findings, in forty 
years of literature on B cells as APC for the activation of CD4 T cells, are consistent with 
the hypothesis that CD4 T cell cooperation is mediated by B cells.  
 
1.5 OX40 and its ligand 
 
1.5.1 Introduction 
  
According to Lafferty and Cunningham-type two-signal models of T cell 
activation, the interaction of an antigen-specific receptor on the surface of a T cell with 
antigen presented on an APC is insufficient for activation of the T cell. Activation 
requires a second signal, delivered by S+ cells via cell-to-cell contact. When formulating 
this model, the authors were particularly concerned with addressing allogeneic 
stimulation of T cells by other cell types. The second signal that is required is thought to 
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be mediated by further interaction by a species-specific surface molecule that is 
expressed on the APC’s surface (Lafferty and Cunningham 1975). The second signal that 
is normally required for T cell activation became known as the co-stimulation signal.  
The first molecules to be identified as co-stimulators were the B7 molecules, 
which engage CD28 on the surface of T cells as discussed in section 1.2.6 and reviewed 
by Wang and Chen (Wang and Chen 2004). The effect of CD28 binding B7 has been 
thoroughly described and its role in the initiation of T cell activation is quite clear. 
However, in the early 1990’s it became clear that there were other surface molecules, 
found on APC, that have an additional co-stimulatory role in the activation of CD4 T 
cells (Ding and Shevach 1996). One subsequently identified family of co-stimulatory 
molecules was the tumor necrosis factor superfamily (TNFSF) and their corresponding 
receptors (TNFR). These molecules have since become known for their role in T cell 
activation and modulation of effector T cell phenotype. There are a number of receptor 
and ligand pairs in the TNFSF with known effects on CD4 T cells (as reviewed by Croft 
(Croft 2003)). I will omit a comprehensive discussion of these molecules and focus on 
the receptor, OX40, and its ligand, OX40L, which have been shown, by others, and 
myself (see chapters 3, 4, and 5) to be involved in the generation and maintenance of 
CD4 T effector cells.  
 
1.5.2 What are OX40 and OX40L and How Do They Function? 
  
 OX40 was first identified as a 50kDa surface protein on CD4 positive T cell 
blasts, and was highly specific to this cell type. The first paper on the antigen, recognized 
by the Oxford MRC monoclonal antibody -40 (OX-40 Ig), also demonstrated a potential 
functional role for OX40. Cross-linking of, OX-40, by OX-40 antibody, resulted in 
stimulation and enhanced proliferation of the T cell blasts (Paterson, Jefferies et al. 
1987). Mouse OX40 was cloned a few years later and identified as a molecule that could 
potentially mediate T cell-B cell interactions. Calderhead and colleagues expressed the 
cloned sequence of mouse OX40 as a fusion protein with human IgG1. They 
subsequently employed this fusion to identify OX40L-bearing cells (Calderhead, 
Buhlmann et al. 1993). The ligand that bound OX40, OX40L, was identified the next 
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year and was found to have costimulatory activity. Wayne Godfrey and colleagues 
identified OX40L from a cDNA library made from transcripts found in phorbol myristate 
acetate (PMA)/ionomycin-stimulated B cells. Upon sequencing, OX40L was found to 
have homology to TNF. Fibroblasts engineered to express OX40L had potent co-
stimulatory activity on T cells that were stimulated with analogs of signal one in vitro 
(Godfrey, Fagnoni et al. 1994). The year after that, the same group that had originally 
cloned OX40 reported that OX40L aggregation on the surface of B cells enhanced their 
proliferation and their secretion of IgG. They also demonstrated that the expression of 
OX40L was optimally induced by cross-linking the B cell receptor, while engaging CD40 
(Stuber, Neurath et al. 1995). It appears that this ligand and receptor pair is involved in 
co-stimulation of T cell responses, especially CD4 T cell responses. Both the ligand and 
receptor are inducible, following antigen-receptor stimulation, and both enhance 
proliferation following cross-linking.  
It appeared, based on expression patterns, that this pair of molecules is involved 
mainly in B cell-T cell interactions. Subsequently OX40L expression has been shown on 
dendritic cells, and that this expression is important for conventional T cell activation as 
well (Murata, Ishii et al. 2000). However, the notion that OX40L-OX40 interactions are 
quite important in B cell-T cell cooperation was further supported by evidence that 
ligation of CD40 on B cells (CD40L is expressed mainly by activated T cells) enhanced 
OX40L expression.  
 Irene Gramaglia demonstrated that stimulation of OX40 enhances the 
proliferation and survival of CD4 T cells. Employing T cell receptor transgenic CD4 T 
cells in vitro, she showed that the enhancement was downstream of B7 signaling, in that 
it could not replace the B7-CD28 interaction. However, OX40 signals acted potently to 
enhance the survival of activated CD4 T cells after antigen stimulation in culture, with 
the maximal difference being seen at 4-6 days of culture. Enhanced survival 
corresponded with the expression of OX40 on activated T cells, which was absent until 
24-hours, and peaked at 48-96 hours. Taking these observations together, the authors 
suggested that the major role of OX40 was to sustain CD4 T cell responses by enhancing 
their survival (Gramaglia, Weinberg et al. 1998). 
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 Stimulation of OX40 inhibits apoptosis in CD4 T cells. Paul Rogers, working in 
Croft’s lab, demonstrated that OX40 stimulation directly enhanced the expression of the 
anti-apoptotic proteins Bcl-2 and Bcl-Xl. The upregulation of OX40 and OX40L was 
found to depend on CD28, which explained the group’s previous findings that B7-CD28 
interactions were up-stream in effect. Moreover OX40 deficient CD4 T cells had 
substantial defects in their ability to survive after antigen stimulation (Rogers, Song et al. 
2001). The mechanism by which OX40 stimulates survival and proliferation, in T cells, 
was recently further elucidated by Jianxun Song. It was found that OX40 signaling 
mediated by the adaptor protein TNF-receptor associated factor- (TRAF-) 2 enhanced 
nuclear factor kappa-B1 (NF!B; RelA/p65 and p50) translocation to the nucleus and 
enhanced the expression of various pro-survival genes (Song, So et al. 2008). These 
findings explained the findings of Gramaglia at a molecular level; stimulation of OX40 
leads to direct enhancement of activation pathways as well as anti-apoptotic molecular 
mechanisms. 
 
1.5.3 Intracellular signaling by OX40 
 
 The major function of OX40, in CD4 T cells, appears to be to enhance cell 
survival, proliferation, and differentiation. As Croft outlines in comprehensive reviews 
(Croft, So et al. 2009; Croft 2010), OX40 signals through three main pathways. The first 
pathway stems from stimulation of TRAF-2 as described above. Two additional 
intracellular pathways, stimulated by the ligation of OX40, are outlined below. 
It appears that OX40 stimulation enhances TCR-associated signaling 
intermediates. The cytoplasmic domain of OX40 directly associates with 
phosphoinositide 3-kinase (PI3K) which increases the levels of phosphoinositide 
phosphate2/3 (PIP2/3; doubly or triply phosphorylated) in the inner leaflet of the plasma 
membrane. The enhanced levels of PIP2/3 attract proteins with the conserved pleckstrin 
homology domain to the membrane. One protein that is recruited is Akt, also known as 
protein kinase B (PKB), which is phosphorylated and leads to downstream effects such as 
enhanced survival, expansion and differentiation in T cells (Song, Ouyang et al. 2005). 
The precise molecular events, that control this interaction, were recently elucidated by So 
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et al. It appears that OX40 directly enhances Akt phosphorylation initiated by TCR 
signaling (So, Choi et al. 2011). Therefore OX40 functions via this pathway to augment 
TCR signaling.  
The third way that OX40 has been found to signal is through synergy with the 
TCR in augmenting Ca2+ flux from the mitochondria leading to Th2 skewing in activated 
CD4 T cells. Though this mechanism is not completely understood, it appears that 
augmented Ca2+ flux following OX40 stimulation, allows a calcineurin dependent 
transcription factor to translocate from the cytoplasm to the nucleus, thus affecting gene 
transcription. So et al. demonstrated that, without OX40 stimulation, the calcineurin-
dependent nuclear factor of activated T cells (NFATc1) fails to translocate to the nucleus. 
This failure resulted in decreased transcription and translation of the IL-4 gene. This 
finding highlights the role of OX40 in the generation of IL-4 producing CD4 T cells, 
which is consistent with the often-discussed function of OX40 in Th2 skewing of T cell 
responses, and the results reported in Chapters 3 and 4.  
From the above-cited studies it can be seen that OX40-OX40L interactions play a 
major role in the CD4 T cell response. The role of OX40 signaling in CD8 T cells is less 
well defined. It seems that OX40-OX40L interactions are particularly suited to modulate 
CD4 T cells responses. As I will outline below, they have been implicated in many 
models of infection, cancer, and autoimmunity, which serves to underscore their 
importance to CD4 T cell biology. 
 
1.5.4 OX40 and OX40L in the context of CD4 T cell cooperation 
 
 Integrating a role for OX40-OX40L interactions into a cooperative model for the 
activation of CD4 T cells places emphasis on the CD4 T cell-B cell interaction step. It is 
possible that, after the initial T cell-DC priming stage, a second round of activation serves 
to amplify the CD4 T cells numbers and to cause their further differentiation. B cells that 
bear OX40L could mediate this subsequent round of proliferation.  
It is possible that OX40-OX40L interactions could also be involved in CD4 T 
cell-T cell interactions. Soroosh et al. reported that both OX40 and OX40L expression on 
T cells is required for their optimal activation and survival in vitro and in vivo (Soroosh, 
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Ine et al. 2006). It appears that T cell-T cell contact is involved in this activation, 
suggesting that in some cases, APC may act as a “dock” around which T cells interact by 
membrane-membrane contact.  
Another study bears directly on the role of B cells, and their expression of 
OX40L, in the activation of CD4 T cells. By using a simple in-vivo model, Phyllis-Jean 
Linton showed that antigen presentation by B cells was essential for optimal expansion, 
and Th2 cytokine secretion by CD4 T cells. Moreover, the author also demonstrated that 
OX40L is essential for this interaction to occur (Linton, Bautista et al. 2003). The system 
made use of µMT mice (which are essentially devoid of B cells) and adoptively 
transferred ovalbumin (OVA) peptide-specific TCR transgenic CD4 T cells. B cell 
deficient mice seeded with 5 x 106 transgenic T cells were immunized with OVA on 
ALUM and generated poor T cell responses compared to similarly immunized WT mice. 
It was found that the defect in proliferation and differentiation of T cells, that was 
observed in µMT mice, could be overcome by supplementing these mice with in vitro-
stimulated WT B cells. When various cytokine knockout mice were employed as a source 
of B cells, there was no detectable deficiency in their ability to aid CD4 T cell responses. 
However when OX40L-/- mice were employed as a source of B cells, their effect was 
completely lost. Thus, at least in one case, immunization with protein antigen in a 
conventional adjuvant preparation, B cells that express OX40L are necessary to allow full 
priming of CD4 T cells 
Taken together, these studies suggest possible roles for OX40-OX40L interaction 
in CD4 T cell cooperation. It is possible that this cooperation occurs via both CD4 T cell-
B cell interaction and through T cell-T cell interaction. Though the details remain 
unclear, both evidence from our work, demonstrated in Chapters 3, 4 and 5, and the 
findings outlined above, support the hypothesis that the OX40-OX40L interaction is 
involve in cooperation between CD4 T cells.  
 
 
 
1.5.5 OX40 and OX40L in infection and cancer models 
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The role of OX40 in infection immunity is still controversial, however, it is likely 
that OX40 is not absolutely required for immunity, but rather it aids in the survival of 
effector cells and the transition to memory. Gramaglia et al. demonstrated that mice, 
immunized with KLH, mounted increased CD4 T cell responses when given an agonist 
antibody to OX40 at the same time. WT mice and OX40-/- T cells could secrete similar 
levels of cytokine during priming phases. However, OX40 deficiency resulted in 
impaired memory cell generation (Gramaglia, Jember et al. 2000). OX40 has also been 
implicated in the generation of Th2 immunity in Leishmania major infections in mice. 
Thus, OX40 signaling aids in survival and memory cell transition in CD4 T cells.  
Much emphasis has been placed on determining whether OX40 stimulation can 
increase the generation of anti-cancer immune responses, which are notoriously weak. As 
Croft reviews (Croft, So et al. 2009), employing OX40 agonistic antibodies, as an 
adjuvant for increasing cancer immunity, has been extensively explored. Agonistic 
antibodies to OX40 have been shown to be effective at increasing anti-tumor CD4 and 
CD8 T cells, and in reducing the suppression of anti-tumor immunity by Tregs. Weinberg 
and colleagues demonstrated that either an agonistic antibody to OX40 or OX40L-Ig, 
administered to mice given a lethal dose of tumor, increased anti-tumor immunity and 
drastically increased survival in mice (Weinberg, Rivera et al. 2000). Interestingly the 
tumors employed in this study were MHCII and OX40 deficient suggesting that the 
agonist did not affect the tumor directly, but increased the generation of CTL by 
promoting CD4 T cell responses.  
Silvia Piconese demonstrated a role for OX40 signaling in reducing the negative 
regulation, by Tregs, of tumor immunity in mice bearing a variety of aggressive 
syngeneic tumors (Piconese, Valzasina et al. 2008). She showed that intraperitoneal or 
intratumor injection of an OX40 agonistic antibody resulted in tumor rejection in at least 
70% of mice. OX40 stimulation appears to antagonize the suppression of immunity by 
Tregs by directly inhibiting them. 
OX40L and OX40 knockout mice have been infected with a variety of agents in 
order to directly test the relevance of these molecules to immunity. The results of these 
studies have been variable and so making general claims about the critical role of OX40 
signaling is difficult. It is possible that in some cases OX40 normally plays a role in 
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immune class regulation (i.e. toward the Th2 pole) in which case knocking out either the 
receptor or the ligand would result in skewed immune class regulation. This would be 
beneficial in some cases and detrimental in others. Alternatively, in situations where 
OX40 would normally mediate effects, compensatory interactions between other 
molecules (maybe other TNFSF or TNFR family members) could take over, masking the 
effect of the OX40 or OX40L deficiency.  
 
1.5.6 OX40 and autoimmunity 
 
Because OX40 ligation is a very potent means of inducing effector function in T 
cells it is easy to imagine how aberrant stimulation of this receptor, particularly in 
autoreactive T cells, might lead to activation of autoimmunity. 
OX40 and OX40L expression is regulated in immune cells and other tissues. As I 
have outlined above, both the ligand and receptor typically require activation via antigen 
stimulation to be expressed on immune cells. It can be intuitively understood that the 
regulation of the expression of these potent molecules should be tightly controlled to 
avoid inappropriate activation of immune cells, particularly T cells, because this could 
lead to immunopathology. Thus, aberrant expression of OX40 or OX40L may lead to 
inappropriate stimulation of autoreactive T cells. 
 How might inappropriate expression of these molecules occur? Though the 
specific endogenous transcriptional activators of ox40 and ox40L genes are unknown, it 
appears that at least two factors are involved. Rudiger Pankow, and colleagues, showed 
that the 5 prime flanking sequences of both ox40 and ox40L contain binding sites for the 
p65/P50 isoform of NF-!B (Pankow, Durkop et al. 2000). This finding built on previous 
work from another group that indicated the Tax protein of human T-cell leukemia virus 
(HTLV-1) induced expression of both OX40 and OX40L on murine T cells 
(Higashimura, Takasawa et al. 1996). Pankow demonstrated that the binding of Tax to 
the flanking sequences required NF-!B. Thus, it appears that both factors act in concert 
to drive expression of OX40 and OX40L. This also leads to an explanation of why cells 
often express both OX40 and OX40L. Because the upstream effectors of NF-!B 
activation may be varied, it is difficult to predict what specific types of abnormal events 
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might lead to the inappropriate expression of OX40 on immune cells, that could affect the 
development of autoimmunity. However, OX40 ligation is known to prevent inactivation 
of CD4 T cells. In this case, chronic inflammation or polymorphisms may lead to 
inappropriate expression of OX40L which could lead to inappropriate activation of 
autoreactive T cells by preventing normal T cell tolerance mechanisms. Whole genome 
association studies have shown a link between OX40L polymorphism and SLE (Manku, 
Graham et al. 2009). 
 It has been reported that ligation, usually by exogenous agonists, of OX40 can 
break T cell tolerance in at least two main ways. Firstly, employing a similar model to 
Elizabeth Kearney (Kearney, Pape et al. 1994), Pratima Bansal-Pakala et al. 
demonstrated that an agonist antibody to OX40 could reverse the tolerogenic effect of 
administration of high-doses of peptide to mice. It was shown that this agonist could 
prevent the induction of T cell anergy if given at the appropriate time (Bansal-Pakala, 
Jember et al. 2001). Another group extended this finding. Lathrop et al. demonstrated that 
stimulation through OX40 can break the unresponsiveness of already anergic T cells and 
allow them to acquire effector function (Lathrop, Huddleston et al. 2004). A second way 
that OX40 signals can break T cell tolerance is by interfering with the function of Tregs. 
Many groups have reported defects in Treg function upon OX40 ligation. In another 
groundbreaking paper, Takanori So and Michael Croft demonstrated that OX40 signals 
actively suppress the generation of Tregs from naive cells in vitro. This effect was due to 
antagonism of foxp3 induction (So and Croft 2007). Thus aberrant OX40 stimulation 
could lead to breakage of CD4 T cell tolerance. 
 Taken together these findings support the notion that OX40 signals mediate 
induction, to effector stage, of T cells, even in the presence of normally tolerogenic 
stimulation. Likely as a consequence of their potent activating effects, deficiencies in 
OX40 and OX40L have been tied to amelioration in inflammatory disorder models in 
rodents such as asthma and colitis and atherosclerosis. Moreover, deficiency in either the 
receptor or the ligand results in inability to generate experimental autoimmune 
encephalomyelitis and completely prevents diabetes in NOD mice, as reviewed in (Croft, 
So et al. 2009). By broad consensus, OX40 and OX40L have a role in autoimmunity and 
aberrant inflammation. However, the question remains as to whether abnormal expression 
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of OX40 and OX40L are at the root of the inappropriate response or whether they are 
simply a result of it. 
 
1.5.7 Summary 
  
 It is clear that these molecules play a major role in the activation and survival of 
CD4 T cells. Functional roles for OX40 ligation, following experimental immunization, 
and in the development of autoimmune diseases, have been described. It appears that the 
patterns of expression of both OX40 and OX40L, combined with compelling evidence 
that expression of OX40L by B cells is necessary for the optimal generation of CD4 T 
effector cells, support the hypothesis that the OX40-OX40L interaction is somehow 
involved in cooperative CD4 T cell responses. The biology of OX40 and OX40L remain 
the topic of current research. 
 
1.6 Trying to Tie it All Together 
  
 In sum, the evidence cited above leads to the belief that CD4 T cells, the cells that 
are centrally involved in orchestrating virtually all immune responses, are susceptible to 
regulation, both positive and negative, by other CD4 T cells. Many different researchers 
have indirectly observed CD4 T cell cooperation. Moreover, it appears that epitope 
spreading, a well-described phenomenon in models of autoimmunity, could be a 
reflection of CD4 T cell cooperation. Cooperative interactions amongst CD4 T cells have 
been shown to be involved in the increased generation of effector cells and Th2 
differentiation; ligation of co-stimulatory molecules, like OX40, on the surface of CD4 T 
cells, leads to similar outcomes. Therefore it is possible that CD4 T cell cooperation 
involves the induction of expression of certain co-stimulatory ligands, by cells stimulated 
by CD4 T cells, which then further stimulate other CD4 T cells.  
 Given that the cellular and molecular mechanisms involved in CD4 T cell 
cooperation remain unclear, the central objective of the research, detailed in the following 
chapters, was to investigate these mechanisms. We hypothesized that cooperation 
between endogenous populations of CD4 T cells could be induced by the provision of 
synthetic peptide antigens to which these cells are known to respond. If such cooperation 
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could be observed, we hoped that by employing such a reductionist approach, we could 
attempt to answer a number of fundamental questions surrounding CD4 cell cooperation: 
1) What APC are involved in mediating cooperative interactions amongst CD4 T cells? 
2) Do these APC mediate cooperation in a “linked” fashion? 3) What types of co-
stimulatory interactions are involved? 4) What are the functional consequences of CD4 T 
cell cooperation? 
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2.0 CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 Mice 
BALB/c mice, aged between 6-10 weeks, were obtained from the College of 
Medicine animal facility at the University of Saskatchewan or from Charles River 
Canada (Sherbrooke, Canada). Parental TCR transgenic DO11.10 mice (H-2d) were 
obtained from The Jackson Laboratory (Bar Harbour, Maine, USA) and were bred and 
housed in the Health Sciences Building Animal Quarters, College of Medicine, 
University of Saskatchewan (Saskatoon, Saskatchewan). In individual experiments, all 
mice were matched for sex and age. All mice were between six and ten weeks of age at 
the beginning of the experiment. All experiments were conducted under a protocol 
approved by the University of Saskatchewan’s Animal Research Ethics Board and that 
adhered to the Canadian Council on Animal Care guidelines for humane animal use.!
 
2.2 Media and Solutions 
 
2.2.1 Carbonate/Bicarbonate Buffer for Coating ELISpot Plates 
Carbonate/bicarbonate buffer (pH 9.5) for coating nitrocellulose-bottom wells in 
96-well ELISPOT trays was prepared by combining 16mL 0.2M Na2CO3 with 34 mL 
0.2M NaHCO3 and 150mL ddH20.  
 
2.2.2 Leibovitz Media 
 Powdered Leibovitz medium (GIBCO Laboratories, Grand Island, NY) was 
prepared according to the manufacturers directions. After adjusting for pH, the prepared 
media was sterilized by filtration through 0.2µm nitrocellulose filter. Sterility of freshly 
prepared media is confirmed by culture at 37O C for 24 hours.  
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2.2.3 NBT/BCIP Developing Solution 
ELISPOT plates were developed by applying a solution of NBT/BCIP substrate 
diluted 1:100 in an alkaline (pH 9.5) substrate buffer consisting of 0.1M Tris-HCl, 0.1M 
NaCl and 0.05M MgCl2 
 
2.2.4 Phosphate Buffered Saline (PBS)  
 Phosphate buffered saline was prepared from a 10x stock solution containing 
80g/L NaCl, 4g/L KCl, 11.5g/L Na2PO4, and 4g/L KH2PO4 in ddH2O adjusted to pH 7.2. 
Working solutions are prepared by diluting the 10x stock with ddH2O. Sterility was 
achieved by autoclaving working solutions.  
 
2.2.5 PBS – Tween 20 (PBST)  
 PBS-Tween was used to wash ELISPOT plates after culture and after addition of 
secondary antibody. PBS-Tween was prepared by adding 0.05% v/v Tween 20 to a 
working solution of PBS.  
 
2.2.5.1 MACS Buffer  
 MACS Buffer consisted of PBS supplemented with 2mM NaEDTA.  
 
2.2.6 RPMI Media 
 Powdered RPMI medium, supplemented with L-glutamine (GIBCO Laboratories, 
Grand Island, NY) was prepared according to the manufacturers directions. After 
adjusting to pH 7.4 the prepared media is sterilized by filtration through 0.2µm 
nitrocellulose filter, resulting in a solution with pH 7.2. Sterility of freshly prepared 
media was confirmed culture at 37O C for 24 hours.  
 
2.2.6.1 RPMI Culture Media 
 For tissue culture and ELISpot blocking, RPMI media was supplemented with 
10% fetal bovine serum (FBS; Hyclone; Canadian Origin), 0.1% 0.5M 2-
mercaptoethanol, 100U/mL penicillin, 100 U/mL streptomycin and 0.8% 100mM sodium 
pyruvate. 
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2.2.6.2 ELISpot and pulsing Media 
 For overnight culture in the ELISPOT assay, and for overnight peptide pulsing 
cultures, RPMI media is supplemented with 0.1% 0.5M 2-mercaptoethanol, 100U/mL 
penicillin, 100 U/mL streptomycin and 0.8% 100mM sodium pyruvate without FBS.  
  
2.3 Antigens 
 
2.3.1 Synthetic Peptides 
The peptides of hen-egg lysozyme, HEL11-25 (AMKRHGLDNYRGYSL), HEL48-63  
(DGSTDYGILQINSRWW), HEL74-96 (NLCNIPCSALLSSDITASVNCAK), and HEL105-
120 (MNAWVAWRNRCKGTDV), as well as chicken ovalbumin peptide, OVA323-339 
(ISQAVHAAHAEINEAGR), and Leishmania analog of activated C kinase peptide, 
LACK156-173 (ICFSPSLEHPIVVSGSWD) were synthesized by the Alberta Peptide 
Institute (Edmonton, Canada) or by GenScript (Piscataway, NJ USA), purified by HPLC, 
to >95% purity, as assessed by mass sprectroscopy. All peptide antigens were dissolved 
in PBS, and stored at -80C until needed.  
 
2.3.2 Protein Antigens  
Hen-egg lysozyme (HEL) (grade VI; Sigma, St. Louis, MO USA) was dissolved 
in PBS and sterilized by filtration through a 0.2µM nitrocellulose filter. In some cases 
heat-aggregated HEL (ha-HEL) was required. This procedure was previously described 
(Peters, Hamilton et al. 2005). 40mg/mL HEL solutions were incubated in a 100oC water 
bath until visible aggregates formed. The aggregated protein was then thoroughly 
disrupted and pulverized using a sterile mortar and pestle. The concentration of ha-HEL 
was determined mathematically taking into account the amount of soluble HEL that 
remained in the supernatant as determined by the absorbance of this solution of light of 
!=280nm. 
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2.4 Eliciting Immune Responses in vivo 
 
2.4.1 ALUM Adjuvant Immunizations  
In order to generate HEL-specific immune responses, mice were injected 
intraperitoneally with 200µL of a 1:1 mixture of heat-aggregated HEL protein in 
phosphate buffered saline with Alhydrogel(R) 2% aluminum hydroxide gel adjuvant 
(ALUM; Superfos Biosector a/s, Vedbaek, Denmark).  
 
2.4.2 CFA and IFA immunizations 
Immunizations with IFA and CFA were prepared by making a 1:1 mixture of the 
appropriate peptide(s) or protein, in phosphate buffered saline, with incomplete Freund’s 
adjuvant (Sigma, Saint Louis, MO USA). Emulsification was achieved by passing the 
mixture rapidly between two syringes joined tip-to-tip. The syringes were kept cold by 
periodically resting them on ice. The emulsification process was continued until a 
consistency was reached where the colloid did not dissociate when dropped in water. In 
some cases, IFA was supplemented with 5µg/mouse of E. Coli serotype O111:B4 LPS 
(Sigma, Saint Louis, MO USA). Mice were immunized with 100µL of the IFA or CFA 
emulsion subcutaneously at the base of the tail or 50µL in the left hind footpad. 
 
2.4.3 Adoptive Transfers of peptide pulsed APC 
  
2.4.3.1 Pulsing 
 Spleens of euthanized naive mice were harvested into 10mL ice-cold Leibovitz 
media and disrupted by pressing through a fine stainless steel mesh. The resulting single-
cell suspension was washed and centrifuged. The cell pellet was suspended to a final 
volume of 3mL. In most cases, LPS from E. Coli serotype O111:B4 LPS (Sigma, Saint 
Louis, MO USA), was added to a final concentration of 1µg/mL. Soluble peptides were 
added to a final concentration of 50µM to ensure loading. These splenocytes were then 
cultured for the indicated time, at 37oC and 5% CO2, in 60mm tissue culture-coated petri 
dishes (BD Falcon). 
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2.4.3.2 Washing and Injection 
 Following culture, peptide pulsed splenocytes were harvested by forceful 
pipetting of cold Leibovitz media. In some cases, certain cell populations were isolated 
by MACS, as described below. If cells were not MACS isolated they were washed, 
centrifuged, and re-suspended three times to remove excess peptide and LPS. The 
remaining viable leukocytes were enumerated by trypan-blue exclusion counting. Cells 
were suspended to an appropriate volume, in Leibovitz media, so that 50µL contained the 
desired number of cells. This 50µL injection was given into the left hind footpad and 
lower leg of Balb/c mice. 
 
2.5 Antibodies  
The CD40 agonist antibody FGK45, the corresponding isotype-matched control 
antibody 2A3, the OX40 (CD134) agonist OX86, and its corresponding isotype-matched 
control antibody HRPN, were obtained from Bio-X-Cell (West Lebanon, NH USA). The 
OX40L (CD252) blocking antibody RM134L, and the corresponding rat IgG2b control 
antibody were obtained, in functional grade, from eBioscience (San Diego, CA USA) or 
from Bio-X-Cell.  
 
2.6 Tolerance induction in vitro 
Activation of DO11.10 T cells was achieved by three-day cultures in 24-well 
culture trays (BD Falcon, Mississauga, ON, Canada). 105 CD4+ DO11.10 splenocytes 
were cultured with 3 x 106 T cell depleted Balb/c in the presence of 0.3µM OVA323-339. 
After this culture some of these activated DO11.10 were subjected to secondary culture. 
Activated CD4+ T cells from primary cultures were isolated by MACS negative 
selection. These were then plated in 96-well V-bottom trays with 3 x 104 fresh T cell 
depleted spleen cells as APC with or without 0.3µM OVA323-339. CTLA4-Ig (BD) at 
10µg/mL was employed to block B7-CD28 interactions 
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2.7 Assessment of Immune Responses by ELISPOT Assay 
 
2.7.1 ELISpot Plate Preparation 
 
 Ninety-six-well nitrocellulose bottom plates (Unifilter 350, Whatman-Unifilter, 
Clifton, NJ, USA) were coated with 100µL 1.25µg/mL purified monoclonal anti- 
interferon gamma (IFN!), interleukin two (IL-2), or interleukin four (IL-4) antibodies 
(BD Pharmingen, San Diego, California, USA) at 37OC for four hours in ELISpot coating 
buffer. The plates are then rinsed with RPMI ELISpot media and blocked with RPMI 
culture media for at least one hour at 37OC.  
 
2.7.2 Spleen and lymph node Cell Preparation 
  
 Spleens of immunized and normal mice were harvested aseptically following 
euthanasia via cervical dislocation. Individual spleens were placed immediately into ice-
cold Leibovitz media and quickly passed though a stainless steel mesh to achieve a rough 
cell suspension. This suspension was mixed thoroughly and rested for two minutes on ice 
to remove remaining cell clumps. The top 5mL of the de-clumped suspension was 
harvested and kept in a separate tube on ice. The number of leukocytes present in this 
suspension was determined by counting non-red blood cells at a 1:5 dilution of on a 
haemocytometer after a further dilution of 1:2 in trypan blue. Only leukocytes that 
exclude the trypan blue stain were counted. The suspension was then centrifuged for ten 
minutes at 250g. The supernatant is removed and the cell pellet is suspended to 107 
leukocytes/mL in RPMI ELISpot media. 
 
2.7.3 Plating of cells and Internal Controls 
  
 The resuspended spleen cells from normal mice were plated at 50µL (5 x 105 
leukocytes)/well. The number of leukocytes per well that reliably generates linear data 
has been determined to be 1.5 x 106 as previously reported (Peters, Hamilton et al. 2005). 
Accordingly, spleen cells from immunized mice were plated in triplicate wells for each 
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condition at 100µL (106 leukocytes)/well. In addition triplicate wells with 1.5 x 106 
leukocytes from unimmunized animals were plated for each assay condition. To elicit 
antigen-dependent cytokine release, peptide antigens were diluted to 140nmol/mL in 
RPMI ELISpot media and 50µL of this solution was added to the appropriate wells. 
Media without antigen was also plated as an antigen-negative control for all spleen 
samples.  
 
2.7.4 Developing and Counting 
 
 ELISpot plates were cultured for 16-20 hours at 37OC and 5% CO2. Following 
culture, the media was removed, and the remaining cells were lysed by washing the plate 
twice with ddH2O. Plates are then further washed with PBS-Tween four times. 
Secondary, biotinylated, anti- IFN!, IL-2, and IL-4 (BD Pharmingen, San Diego, 
California, USA) was diluted to 1.25µg/mL in PBS and 100µL is added to the 
appropriate wells. Plates were then incubated for at least 1.5 hours at room temperture. 
After incubation, excess secondary antibody is removed by washing five times with PBS-
Tween and then two times with ddH2O.  Streptavidin conjugated alkaline phosphatase 
enzyme was then diluted to 0.2µg/mL and 100µL of this solution is added to every well. 
The plates were once again incubated at room temperture for 45 minutes. Plates were 
then washed extensively in dH20 by submersion and 100µL of NBT/BCIP 1:100 
developing solution is added to each well. Plates were incubated at 37OC for about 10 
minutes or until visible spots form. The developing reaction was stopped by washing 
twice in dH2O. Plates were left to dry overnight. Antigen dependent cytokine producing 
(ELISpot forming) cells were enumerated by counting cytokine spots in antigen positive 
wells and subtracting the number of spots in antigen negative wells. Unimmunized 
control samples serve to verify the antigen specificity of the assay; in all reported 
experiments the number of Ag-dependent CSCs in unimmunized samples was less than 
twice the number of spots in antigen negative wells.  
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2.8 Characterization of Cellular Markers by Flow-cytometry 
 
 Flow-cytometry was employed for identification of cells bearing certain surface 
markers. Generally, spleen or lymph node cells were suspended at 107/mL in RPMI 
culture media. To this suspension an appropriate volume (as determined by prior 
experimentation) of fluor-conjugated antibody was added. The samples were incubated 
for 1h on ice and washed twice with ice-cold media. Cells were spun for two minutes at 
850g between washes. For analysis cells are suspended to about 106 mL and analyzed 
immediately on an EPIC XL cytometer (Beckman-Coulter, Mississauga, Ontario).  
 
2.9 Cell Isolations 
 
2.9.1 MACS 
Magnetic labeling and sorting were done according to manufacturer’s 
recommendations except the media (PBS+ 2mM EDTA) contained no FBS. CD4 T cells 
were negatively selected with a T cell selection kit and spleen cells were depleted of T 
cells with CD90 labeled magnetic beads (Miltenyi Biotech, Auburn, CA USA). B cells 
were negatively selected with a B cell negative selection kit. DCs were isolated by 
positive selection with pan-DC microbeads. All samples were passed over magnetically 
charged LS columns (Miltenyi Biotech, Auburn, CA USA).  
 
2.9.2 FACS 
 Fluorescence activated cell sorting was employed to partially purify CFSE-
labeled cells from suspensions of lymph node cells. This was achieved with the assistance 
of Mark Boyd at the Cancer Research Unit of the Saskatchewan Cancer Agency with a 
Coulter EPICS ELITE ESP cell sorter running Expo32 acquisition software. 
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2.10 Determination of mRNA expression 
 
2.10.1 RNA isolation 
 Following isolation by MACS negative selection, B cell mRNA was isolated by 
passage over RNA affinity columns. B cells were first disrupted using the QIAshredder 
spin columns (QIAGEN Canada, Toronto, ON) as per the manufacturer’s instructions. 
The mRNA was isolated from the remaining solution with the RNAeasy kit (QIAGEN) 
as per the manufacturers instructions. The resulting purified mRNA was quantified by 
assessing the final concentration by Nanovue spectrophotometer (GE Healthcare). 
 
 
2.10.2 cDNA preparation 
 Copy DNA was prepared with the iScript kit (BioRad, Mississauga, ON) as per 
the manufacturers instructions. 
 
2.10.3 Q-RT-PCR 
 Quantitative real-time polymerase chain reaction was employed to assess the 
levels of mRNA transcripts from our cultured B cells. This was accomplished employing 
the cDNA prepared as above as a template. 30nM primers (Sequences: OX40L forward 
5!-GGATGCTTCTGTGCTTCATCT; reverse 5!-GTTCTGCACCTCCATAGTTTGA;  
!-actin forward 5!-CCAGCCTTCCTTCCTGGGTA-3!; reverse 5!-CTAGAAGCA-
TTTGCGGTGCA-3) were added to appropriate wells as well as the SsoFast EvaGreen 
supermix (BioRad). Reactions conditions were as per the manufacturer’s instruction. 
Themocycling, data acquisition, and data analysis were accomplished using the CFX96 
QRTPCR system (BioRad) and associated software in the laboratory of Dr. Joyce 
Wilson, department of Microbiology and Immunology, University of Saskatchewan. 
Confirmation that the sequences amplified were specific was accomplished by melt-curve 
analysis and by visualization of the PCR products by ethidium bromide agarose gel 
electrophoresis. 
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3.0 CHAPTER 3 - OBSERVATIONS AND MECHANISMS OF CD4 T 
CELL COOPERATION IN VIVO: I ANALYSIS EMPLOYING 
IMMUNOLOGICALLY INTACT MICE 
 
3.1 Introduction 
 
 Put simply, cooperation between CD4 T cell populations is thought to increase 
CD4 T cell function. When multiple CD4 T cells, with specificity for different peptides in 
association with host MHCII molecules, interact with antigen presenting cells at the same 
time, the overall level of activation of the T cells is increased. Measuring relative 
numbers of cytokine producing cells, particularly those that produce IFN! and IL-4, is a 
surrogate for measuring CD4 T cell function, since activated CD4 T cells mediate their 
effector function primarily by the secretion of cytokines and by providing stimulatory 
ligands through cell-cell contact, The cytokine ELISpot assay is therefore a most 
appropriate tool for measuring relative levels of CD4 T cell activation; it allows for ready 
enumeration of antigen-specific cytokine producing cells in a given population. By 
employing peptides as recall antigen in the ELISpot assay, we are able to detect T cells 
that recognize the most basic immunogenic unit of an antigen that can be recognized by a 
T cell and cytokine secreting cells that lead to the formation of ELISpots upon 
development, ELISpot forming cells, are enumerated. MHCII expressing CD4 T cells can 
be selectively stimulated by using synthetic peptide antigens of a length greater than 
about 10-12 amino acids since, for steric reasons, these peptides bind the groove of 
MHCII but do not bind well to MHCI molecules.  
Given these considerations we sought to develop experimental protocols that 
would allow observation of cooperative interactions between subpopulations of peptide-
specific CD4 T cells. Subsequent to observing CD4 T cell cooperation, we aimed to 
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explore the underlying mechanisms involved. I outline experiments undertaken with 
these aims in mind in this chapter. 
 
3.2 Observations of CD4 T Cell Cooperation During Secondary Immune Responses 
 
 We wished to develop an experimental system, in intact mice, wherein the effects 
of CD4 T cell cooperation could be directly observed. This required establishment of an 
immunization protocol that resulted in sub-optimal generation of CD4 effector cells 
which, under appropriate conditions, could be enhanced. The administration of soluble 
synthetic peptides, known to bind MHCII molecules, in IFA, was found to result in such 
sub-optimal activation of CD4 T cells; the same peptides given in CFA induce much 
more robust effector cell generation (not shown).  
CFA contains the remains of heat-killed Mycobacterium tuberculosis whereas 
IFA consists simply of mineral oil and an emuslifier without dead bacteria. Given the 
plethora of different substances associated with CFA, many of which have known 
immunostimulatory properties (Freund and Bonanto 1946; Freund, Stern et al. 1947; 
Pasare and Medzhitov 2004; O'Neill 2006; Manicassamy and Pulendran 2009), it is 
difficult to dissect their various roles in the enhancement of immunity when this adjuvant 
is employed directly in intact mice. However, we believe that at least some of the effect 
of CFA could be due to cooperative interactions between CD4 T cells that are specific for 
mycobacterial antigens and those CD4 T cells that recognized the incorporated peptide.  
In order to test this possibility directly we developed a simple experimental 
system in which we assessed the involvement of cooperation on the potency of secondary 
immune responses. Secondary immune responses are almost always of a greater 
magnitude and generate increased numbers of effector CD4 T cells than primary 
responses. We hypothesized that enrichment of CD4 T cells specific for mycobacterial 
peptides by prior exposure to CFA would allow for greater cooperative interaction 
between these CD4 T cells and HEL105-120-specific CD4 T cells when CFA containing 
HEL105-120 was given subsequently. As multiple immunizations with CFA are discouraged 
for ethical reasons, we measured secondary immune repsonses naive mice in which we 
had adoptively transferred nylon wool purified (Julius, Simpson et al. 1973) T cells from 
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normal or CFA primed mice. The recipients were then challenged with CFA containing 
10µg of HEL105-120. The results of an experiment of this type are shown in Figure 3.2.1. 
There is a clear increase in the number of HEL105-120-specific cytokine producing cells 
generated in mice that received CFA primed T cells compared to those that received 
normal T cells. Correspondingly, we observed greater numbers of mycobacteria-specific 
cytokine secreting cells in mice that received T cells from CFA-primed mice. This clear 
effect, seen upon transferring T cells, made it plausible that antigen-specific T cells are 
responsible for, by some unknown mechanism, enhancing the activation of CD4 T cells 
specific for HEL105+120. We interpreted this experimental result to mean that cooperative 
interactions may occur between CD4 T cells specific for two antigens incorporated into 
the same adjuvant emulsion. However, because CFA is a general immune stimulator and 
its components are complex and uncharacterized we could not omit the possibility that 
the effects were not directly due to cooperation between CD4 T cell populations.   
Thus, we designed a similar system in which CFA was not used for the second 
immunization. In these experiments the second challenge contained HEL11-25 and HEL105-
120 together in IFA to test whether two peptide-specific populations of CD4 T cells, 
activated by administering two peptides together in IFA, could cooperate to enhance the 
activation of CD4 T cells specific for at least one of two peptides. We undertook the 
experiment, the results of which are shown in Figure 3.2.2. Mice were were primed with 
CFA alone or with CFA with an incorporated MHCII-binding peptide, HEL11-25, and then 
injected with HEL11-25 and HEL105-120 together in IFA  Mice that were primed with CFA 
containing HEL11-25, in comparison to those primed with CFA alone, supported the 
generation of significantly more HEL105-120-specific CD4 T cells upon injection with 
HEL11-25 and HEL105-120 together in IFA. These observations support our hypothesis that 
CD4 T cells can cooperate in-vivo to enhance their own effector function 
The findings made in these systems are complicated by their dependence on 
previous priming by CFA. It was likely that CFA mediated effects that were residual and 
not directly attributable to the activation of CD4 T cells. We therefore sought to eliminate 
this complication in our further experiments.  
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Figure 3.2.1 T cells from CFA-primed mice, upon adoptive transfer to normal mice, 
enhance the generation of HEL105-120-specific cytokine producing CD4 T cells following 
challenge with HEL105-120 in CFA. Normal BALB/c mice were immunized with CFA and 
saline or were left unimmunized. Fourteen days later, splenocytes were isolated from 
both groups of mice and passed over nylon wool. One million of the non-adherent T cells 
were then adoptively transferred into naive BALB/c mice. On the day of transfer, all mice 
were challenged, subcutaneously at the tail base, with CFA containing 10µg of HEL105-120. 
The CFA preparation contains heat-killed mycobacterium tuberculosis. Ten days 
following challenge, the HEL105-120 and the related mycobacterium, BCG-, specific 
cytokine producing cells in the spleen were enumerated by ELISpot assay. Each symbol 
represents the number of antigen-specific ELISpot-forming cells found in the spleen of an 
individual mouse. This is the result of a single experiment with three mice per group (n = 
3).  
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Figure 3.2.2 Mice previously immunized with HEL11-25 in CFA support enhanced 
generation of HEL105-120-specific cytokine producing CD4 T cells following challenge with 
HEL105-120 and HEL11-25 in IFA. Normal BALB/c mice were immunized with CFA alone 
(CFA primed) or with CFA containing 10µg HEL11-25 (CFA/HEL11-25 primed). Fourteen 
days later, all mice were challenged with IFA containing 10µg each of HEL11-25 and 
HEL105-120. Ten days following challenge, the HEL105-120 and HEL11-25-specific cytokine 
producing cells in the spleen were enumerated by ELISpot assay. Each symbol represents 
the number of antigen-specific ELISpot-forming cells found in the spleen of an individual 
mouse. This is the result of a single experiment with three mice per group (n = 3). 
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3.3 Direct Observation of Cooperation between CD4 T cells During Primary 
Immune Responses 
 
 Upon administration of protein antigens, they are endocytosed by APC, processed 
by proteolytic digestion into peptides, and loaded onto MHC molecules for presentation 
to T cells. The repertoire of peptides that are presented depends on the amino acid 
sequence of the protein digested (Weaver, Lazarski et al. 2008), the peptides generated by 
lysosomal proteases (Honey and Rudensky 2003), and the affinity of these peptides for 
host MHC molecules (Buus, Sette et al. 1987). Further on in the generation of T cell 
immunity towards this antigen, the repertoire of CD4 T cells that are generated will 
depend on not only which peptides are available, but also on whether T cells, bearing 
TCRs with affinity for these peptides in the context of MHCII, are present. As the 
repertoire of naive TCRs, due to positive and negative selection in the thymus, depends 
mostly on a combination of host MHC and self-peptides, genetically identical mice likely 
have similar precursor T cell repertoires (Moon, Chu et al. 2007). Similarly, the peptides 
generated and presented in genetically identical mice, immunized with the same protein, 
should be the similar. Therefore, one would predict that the repertoire of CD4 T cells, 
generated upon immunization with a given protein antigen, would be similar between 
individuals of the same mouse strain. This is, in fact, found to be true (Peters, Hamilton et 
al. 2005). 
 Because we were very familiar with the peptides to which an immune response is 
generated in BALB/c mice immunized with hen egg lysozyme (HEL), we saw these as 
ideal peptides to employ in assessing cooperation between CD4 T cell populations. 
Moreover, we had previously published evidence that cooperation between HEL-peptide-
specific CD4 T cell populations facilitated the generation of optimal numbers of effector 
CD4 T cells towards this antigen (Peters, Kroeger et al. 2009). BALB/c mice immunized 
with HEL generate cytokine producing CD4 T cells with specificity for the peptides 
HEL11-25 and HEL105-120 consistently, and effector CD4 T cells specific for HEL48-63 and 
HEL74-96 are often detected, but vary between mice (Figure 3.3.1).  
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Figure 3.3.1 The repertoire of CD4 T cells generated upon immunization with HEL 
protein is predictable and is made up of four main peptide-specific populations. Three 
normal BALB/c mice were immunized, intraperitoneally, with 100µg of heat-aggregated 
HEL on ALUM. Ten days following this immunization, mice were sacrificed and their 
splenocytes were harvested, and either left untreated or were depleted of CD4 T cells by 
MACS. These splenocyte populations were then plated into ELISpot wells to enumerate 
the HEL-specific cytokine producing T cells therein. Individual HEL-peptide-dependent 
ELISpot-forming cells in the spleen of a given mouse are shown in stacked columns. 
Total numbers of HEL-specific ELISpots, produced when HEL protein was added to the 
ELISpot well are shown beside for comparison. This is the result of a single experiment.  
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We hypothesized that if cooperation between HEL derived peptide-specific CD4 T cells 
occurs when the protein antigen is injected into BALB/c mice, then cooperation may also 
occur when the HEL peptides are given together in IFA. We had already observed an 
increased generation of CD4 T cells specific for a target peptide when this target peptide 
and another peptide, against which the mouse had been primed were given together in 
IFA (Figure 3.2.2). Because HEL105-120-specific cytokine producing CD4 T cells are 
generated sub-optimally by the injection of this peptide alone in IFA, we saw these cells 
as ideal targets for assessment of cooperation mediated enhancement of the generation of 
effector function.   
 We tested the possibility that administration of the four MHCII-restricted HEL 
peptides, normally responded to by BALB/c mice, could elicit cooperation between CD4 
T cells specific for these peptides. Mice were given either HEL105-120 alone, or HEL105-120 
plus equal amounts of each of the other three HEL peptides together in IFA. As can be 
seen in Figure 3.3.2, mice immunized with a combination of the four HEL peptides 
generated significantly more HEL105-120-specific effector CD4 T cells than did their 
counterparts immunized with HEL105-120 alone. We also observed that activation of HEL11-
25-specific CD4 T cells occurred when the four HEL peptides were given (Figure 3.3.3). 
This observation is the first, to our knowledge, to show cooperation between endogenous 
populations of CD4 T cells in response to primary immunization. However, we were 
unable to detect cytokine producing CD4 T cells specific for HEL48-63 or HEL74-96 
suggesting that cooperation does not occur for every linked peptide in the mixture.  
Initially, we sought to confirm that the cooperative effect in the generation of HEL105-120-
specific effector CD4 T cells, that we observed upon administration of four HEL 
peptides, compared to when HEL105-120 was given alone in IFA, was not merely a transient 
difference between immune responses developing differently over time. Thus, we 
enumerated the HEL105-120-specific cytokine producing CD4 T cells in the spleen of mice 
treated with these two different immunizations on different days post-immunization. As 
can be seen in Figure 3.3.4, the generation of HEL105-120-specific cytokine producing CD4 
T cells when four peptides are given, roughly parallels what is observed when protein 
antigens are administered; the peak of this response occurs between 7 and 10 days post-
immunization and wanes by fourteen days.  
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Figure 3.3.2 Other HEL peptides co-administered with HEL105-120 increase the generation 
of HEL105-120-specific effector CD4 T cells. BALB/c mice were immunized with either 
10µg of HEL105-120 alone or 10µg of each of HEL11-25, HEL48-63, HEL74-96, and HEL105-120 
(HEL105-120 + 3 HEL peptides), subcutaneously in IFA. HEL105-120-specific cytokine 
producing CD4 T cells in the spleen were enumerated ten days post-immunization. 
Individual HEL105-120-dependent ELISpot-forming cells in the spleen are shown. Each 
symbol represents the number of antigen-specific ELISpot-forming cells found in the 
spleen of an individual mouse. Three independent experiments, and pooled results from 
six independent experiments, with three mice per group (n = 18) are shown. P-values 
indicate the probability that the means of the indicated samples are not significantly 
different as assessed by unpaired, two-tailed, T tests.  
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Figure 3.3.3 Minor HEL peptide-specific CD4 effector T cells are generated upon 
immunization with four HEL peptides in IFA. Mice were immunized with four HEL 
peptides together in IFA as in Figure 4. HEL11-25, HEL48-63, and HEL74-96-specific cytokine 
producing CD4 T cells in the spleen were enumerated ten days post-immunization. Each 
symbol represents the number of antigen-specific ELISpot-forming cells found in the 
spleen of an individual mouse. Pooled results from two to three independent experiments 
with three mice per group are shown. 
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In contrast, mice immunized with HEL105-120 alone in IFA displayed minimal generation 
of HEL105-120-specific cytokine producing cells at all time points investigated. Thus we 
conclude that cooperation between CD4 T cells responding to multiple peptides, 
administered together in IFA, results in genuine increases in levels of effector CD4 T 
cells and not simply increased kinetics of the response to HEL105-120. 
 We subsequently began to inquire as to whether our observations could be 
generalized to other peptide combinations. We reasoned that if we could employ 
combinations of peptides known to activate CD4 T cells this would facilitate further 
analysis of the underlying mechanisms of cooperation between peptides. Much work has 
identified peptides that are consistently responded to, and generate large numbers of CD4 
effector T cells. These so-called “immunodominant” peptides have long off-constants 
when bound to the groove of MHCII molecules (Lazarski, Chaves et al. 2005; Weaver, 
Lazarski et al. 2008) and thus serve to stimulate CD4 T cells particularly well over time. 
Two such peptides that bind well to I-Ad are chicken ovalbumin323-339 (OVA323-339) and 
Leishmania analog of activated C-kinase158-173 (LACK158-173). We hypothesized that 
administration of these peptides with HEL105-120 in IFA would result in activation of CD4 
T cells specific for them and that these activated T cells could affect the generation of 
HEL105-120 specific CD4 T cells. We administered each of these peptides alone, or all three 
together, in IFA, and assessed the generation of CD4 cytokine-producing T cells ten days 
post-immunization. The results of this experiment were somewhat surprising in that it 
appeared that both OVA323-339 and LACK158-173 specific cytokine producing CD4 T cells 
were generated fairly efficiently when the peptides were given alone (Figure 3.3.5). 
Furthermore, it appeared that LACK158-173 might have competed with OVA323-339 for 
binding to I-Ad as the numbers of OVA323-339-specific cytokine producing cells were 
significantly lower in mice given all three peptides together compared with mice given 
OVA323-339 alone. Competition was not observed between HEL105-120 and the other 
peptides; it is known that HEL105-120 binds I-E
d (Weaver, Lazarski et al. 2008). Although 
there was a trend towards increased generation of HEL105-120-specific cytokine producing 
CD4 T cells in mice given these three peptides together, the competition between 
OVA323-339 and LACK158-173 complicated these experiments and thus made them less than 
ideal for further analysis.  
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Figure 3.3.4 Kinetics of the HEL105-120-specific Effector CD4 T cell population following 
immunization with HEL105-120 alone or HEL105-120 together with 3 HEL peptides. BALB/c 
mice were immunized with either 10µg of HEL105-120 alone or 10µg of each of HEL11-25, 
HEL48-63, HEL74-96, and HEL105-120 (HEL105-120 + 3 HEL peptides), subcutaneously in IFA. 
HEL105-120-specific cytokine producing CD4 T cells in the spleen were enumerated before 
injection (day 0) and seven, ten, and fourteen days post-immunization. Pooled responses 
from three individual mice are displayed +/- SEM. This is the result of a single 
representative experiment of three with three mice per group per time point. 
! 116 
! 117 
 
 
 
 
Figure 3.3.5 Inferred Competition between I-Ad-binding peptides, when co-administered 
in IFA in the generation of cytokine-producing CD4 T cells specific for these peptides. 
BALB/c mice were immunized with either HEL105-120 alone, OVA323-339 alone, LACK158-173 
alone, or all three peptides together, subcutaneously in IFA. Peptide-specific ELISpot 
forming cells in the spleen were enumerated on day ten post-immunization. Each symbol 
represents the number of ELISpot forming cell detected in the spleen of an individual 
mouse. Pooled results from two independent experiments with three mice per group are 
shown (n = 3-6). P-values indicate the probability that the means of the indicated samples 
are not significantly different as assessed by unpaired, two-tailed, T tests. 
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However, this experiment caused me to become acutely aware of the possibility of 
competition between peptides for MHCII binding, and thus I sought to avoid it in my 
further experiments.  
 Drawing on our findings from the previous experiment, I reasoned that the 
administration of only two MHCII-binding peptides in IFA would result in the simplest 
situation where endogenous populations of CD4 T cells could facilitate the activation of 
one another when bound to the same APC. If the two peptides were chosen to bind 
separate MHC molecules, competition could be avoided. We therefore undertook an 
experiment to determine whether the I-Ed-binding peptide HEL105-120 and the I-A
d-binding 
peptide OVA323-339, when co-administered in IFA, could elicit cooperative interactions 
between endogenous CD4 T cells. Substantial and significant increases in the generation 
of HEL105-120-specific cytokine producing CD4 T cells were observed when HEL105-120 was 
given with OVA323-339, together in IFA to BALB/c mice, compared to when HEL105-120 was 
given alone (Figure 3.3.6). As previously observed, mice immunized with OVA323-339 
alone in IFA generate many peptide-specific cytokine producing CD4 T cells. We did not 
observe an increase in OVA323-339 specific effector CD4 T cell generation upon co-
administration of HEL105-120 and OVA323-339.  
 In two separate immunization protocols, cooperative effects between co-
administered peptides have been observed. These cooperative effects were manifested 
through increases in the number of HEL105-120-specific cytokine producing CD4 T cells in 
the spleen of mice immunized with multiple peptides compared to the numbers in the 
spleen of mice given HEL105-120 alone. We wished to confirm that similar effects could be 
observed in the population of CD4 T cells that inhabit lymph nodes draining the site of 
IFA injection. We immunized mice with HEL105-120 alone, with HEL105-120 and OVA323-339, 
with HEL105-120 with three HEL peptides, or with the HEL protein itself, subcutaneously 
in IFA in the footpad. Seven or ten days post-immunization HEL105-120-specific cytokine 
producing cells in the popliteal lymph node were enumerated by ELISpot assay. Figure 
3.3.7 displays the results from this experiment. We observed similar patterns of 
enhancement in the generation of HEL105-120-specific effector CD4 T cells as were 
observed in the spleens of mice immunized similarly. 
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Figure 3.3.6 OVA323-339 co-administered with HEL105-120 increases the generation of 
HEL105-120-specific cytokine producing CD4 T cells. BALB/c mice were immunized with 
either 10µg of HEL105-120 alone (H), 10µg of OVA323-339 alone (O), or 10µg of both 
peptides together (H+O), subcutaneously in IFA. Peptide-specific cytokine producing 
CD4 T cells in the spleen were enumerated ten days post-immunization. Each data point 
represents the total number of ELISpot forming cells detected in the spleen of a single 
mouse. These are pooled results from two three independent experiments with two to five 
mice per group (n = 5-12). P-values indicate the probability that the means of the 
indicated samples are not significantly different as assessed by unpaired, two-tailed, T 
tests.  
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Figure 3.3.7 The generation of HEL105-120-specific cytokine producing CD4 T cells in the 
draining popliteal lymph node upon immunization with various IFA preparations 
subcutaneously in the footpad. BALB/c mice were immunized with either 10µg HEL105-
120 alone, 10µg each of HEL105-120 and OVA323-339 (H+O), 10 µg each of HEL11-25, HEL48-63, 
HEL74-96, and HEL105-120, or with HEL protein (molar equivalent to HEL105-120), 
subcutaneously in IFA in the left hind footpad. On days seven and ten post-
immunization, the ELISpot forming HEL105-120-specific CD4 T cell in the popliteal lymph 
node were enumerated. Each data point represents the total number of ELISpot forming 
cells detected in the draining lymph node of a single mouse. This is the result of a single 
experiment with two to three mice per group (n = 2-3).  
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We conclude that our observations made in the spleen of immunized mice probably 
represent well the responses generated in the draining lymph nodes following 
immunization with peptides in IFA. Due to ethical considerations, concerning the 
administration of IFA into the footpad, we avoided experimenting further with this type 
of protocol. 
Three major possibilities exist that may explain the fact that OVA323-339-specific 
CD4 effector T cell generation is not influenced by simultaneous administration of 
HEL105-120 while HEL105-120-specific effector generation is affected by the administration of 
OVA323-339. Our preparation of OVA323-339 may have been contaminated in such a way that 
it contained immunostimulatory molecules that were able to supersede the effects of 
cooperation between CD4 T cells. This possibility could also explain why co-
administration of OVA323-339 with HEL105-120 increases HEL105-120 effector generation. This 
possibility has been addressed in experiments described below, making this possibility 
somewhat unlikely. A second possibility is that the number of OVA323-339-specific 
precursor CD4 T cells in BALB/c mice is greater than those specific for HEL105-120 or 
these CD4 T cells are partially activated in our mice. This possibility would result in 
sufficient cooperation between OVA323-339-specific CD4 T cells to generate optimal 
numbers of effector cells. The third possibility, which we consider to be unlikely, is that 
HEL105-120 specific CD4 T cells are uniquely dependent on additional stimuli that OVA323-
339- and LACK158-173-, and perhaps other peptide-specific CD4 T cells, are not.  
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3.4 Attempts to Mimic Cooperative Effects by Co-administration of 
Immunostimulatory Substances 
 
We had demonstrated that the incorporation of another MHCII-binding peptides 
into IFA when immunizing with HEL105-120 enhanced the activation of CD4 T cells 
specific for this peptide. Our hypothesis that the CD4 T cells specific for the additional 
peptides are activated by, and cooperatively enhance, the generation of HEL105-120 specific 
CD4 T cells by co-presentation on APC was supported by these observations. However, 
despite our monitoring peptide preparations for sterility, it was possible that the effects 
observed were due a contamination of these peptides by bacteria or other stimulatory 
products, thus leading to enhanced activation of APC by their stimulation of TLR or 
other pattern recognition receptors. Finally, because we hypothesized that activation of 
APC by way of CD4 T cell-APC contacts may lead to enhanced peptide-specific effector 
CD4 T cell generation, we reasoned that if the cooperative effects, seen upon 
administration of multiple peptides in IFA, could be mimicked by the administration of a 
given immunostimulatory substance, that this would shed light on the mechanism by 
which CD4 T cells cooperate.  
As mentioned above, CFA contains the remains of heat-killed mycobacteria. We 
knew that peptides or proteins in CFA are generally more immunogenic than when 
administered in IFA. This effect is due to various potent immunostimulation by microbial 
products normally borne by pathogens. These substances, often PAMPS, are detected by 
APC, such as DC and B cells, following their interaction with germline encoded pattern 
recognition receptors. However, the effect could also be partially due to cooperation of 
mycobacteria-specific CD4 T cells with antigen-specific CD4 T cells (see Figure 3.2.1).  
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Figure 3.4.1 The effect of addition of Toll-like receptor ligands to immunizations of HEL 
protein. All BALB/c mice were given 100µg of heat-aggregated HEL in saline 
intraperitoneally. In some cases the protein preparation was supplemented with either 
5µg of E. coli lipopolysaccharide (+LPS), 5µg of c-class CpG ODN (+CpG), or 5µg of 
mycobacterial muramyl dipeptide (+MDP). The HEL-specific cytokine producing CD4 T 
cells in the spleen were enumerated ten days post-immunization. Each data point 
represents the total number of ELISpot-forming cells detected in the spleen of a single 
mouse. This is the result of a single experiment with three mice per group (n = 3). P-
values represent the probability that the means of the two samples indicated are not 
different as assessed by unpaired, two-tailed T tests. 
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Three of the most well-known PAMPS associated with mycobacteria are 
lipopolysaccharide (LPS) and unmethylated cytosine-guanine DNA sequences (CpG), 
and muramyl dipeptide (MDP), a component of the cell wall. The immunostimulatory 
properties of these substances have been well characterized. Activation of APC via TLR 
4, 9, and 2/6, respectively, by these substances leads to enhanced presentation of antigen 
(Pasare and Medzhitov 2004; Moynagh 2005; O'Neill 2006). We sought to determine 
whether PAMPS could mimic the effect of cooperation seen upon administration of 
multiple peptides in IFA. We first determined whether LPS, CpG or MDP could enhance 
minimal responses to a protein antigen. As Figure 3.4.1 shows, 5µg E. coli LPS 
administered with 100µg of heat-aggregated HEL protein, intraperitoneally in saline, 
significantly enhanced the generation of HEL105-120-specific cytokine producing CD4 T 
cells. We found little evidence that CpG or MDP enhanced the generation of protein-
specific immune responses when mice were vaccinated in this way and so the effects of 
these substances were not further investigated.  
Given that LPS substantially enhances protein-specific CD4 effector T cell 
generation, when heat-aggregated HEL was given in saline, we wished to determine 
whether a similar level of LPS could enhance HEL105-120 and HEL protein-specific 
cytokine-producing cell generation when administered in IFA. We found that LPS 
significantly increased the generation of HEL-peptide-specific effector CD4 T cells when 
it was given with protein antigen in IFA, but it did not effect the generation of HEL105-120-
specific CD4 T cells when this peptide was given in IFA (Figure 3.4.2). Based on this 
result, we concluded that activation of innate immune pathways by LPS was not 
sufficient to mimic T cell cooperation and thus, bacterial contamination of our peptide 
stocks was unlikely to have affected the generation of HEL105-120-specific cytokine-
producing cells in our previous experiments.  
. 
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Figure 3.4.2 Addition of LPS to HEL105-120 containing IFA preparations, in contrast to 
HEL protein containing IFA preparations, does not affect the generation of HEL105-120 
cytokine producing CD4 T cells, upon immunization. BALB/c mice were immunized with 
either 10µg of HEL105-120 or 100µg of soluble HEL protein in IFA, subcutaneously at the 
tail base. IFA preparations were either not further supplemented (saline) or were 
supplemented with LPS to achieve a final dose of 5µg per mouse (+LPS). The HEL105-120-
specific and HEL protein-specific cytokine producing CD4 T cells in the spleen were 
enumerated ten days post-immunization. Each data point represents the total number of 
ELISpot-forming cells detected in the spleen of a single mouse. These are pooled data 
from two to three independent experiments with three mice per group (n = 6-9). P-values 
represent the probability that the means of the two samples indicated are not different as 
assessed by unpaired, two-tailed T tests. 
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To rule out the possibility that enhanced HEL105-120-specific effector CD4 T cell 
generation, is solely due to the activation of APC we used an agonist antibody to CD40 to 
artificially activate APC in our assay. The CD40 receptor is a member of the TNF 
receptor superfamily and is constitutively expressed on DC and B cells. Upon the 
administration of this antibody, FGK45, resting APC, that normally inactivate T cells, 
become able to activate CD4 T cells by virtue of the upregulation of co-stimulatory 
molecules (Hawiger, Inaba et al. 2001). Anti-CD40 treated DC can also serve as effective 
initiators of cytotoxic T cell responses (Schoenberger, Toes et al. 1998). Echoing our 
findings with LPS, FGK45 did not significantly increase the numbers of HEL105-120-
specific effector CD4 T cells when HEL105-120 peptide was given in IFA. However, when 
mice immunized with HEL protein in IFA were treated with anti-CD40 the HEL-specific 
cytokine producing cells in the spleen were significantly increased. It thus appears 
activation of APC, in the manner caused by CD40 ligation, cannot mimic T-cell 
cooperation. Interestingly, our results lead us to suggest that the presence of IFA alone 
leads to sufficient activation of the APC, such that single peptides given in IFA are not 
made more immunogenic by the additional presence of LPS, or stimulation by anti-CD40 
agonistic antibody. 
 The finding that LPS and FGK45 served to enhance protein-specific, but not 
peptide-specific immune responses, is interesting. It is possible that these substances play 
a particularly important role in enhancing the presentation of protein derived peptides but 
not antigens that are already processed into peptides. Enhanced generation of protein-
specific cytokine producing cells upon administration of LPS or anti-CD40 may be due to 
more efficient acquisition and processing of proteins, factors that may not be heavily 
involved in the presentation of soluble peptides given in IFA. Alternatively, increased 
APC activation by immunostimulatory substances may serve to enhance CD4 T cell 
responses in down-stream interactions that follow cooperation between CD4 T cells. In a 
preliminary experiment, we found no difference between mice given all four HEL 
peptides in IFA whether the immunization contained LPS or not (not shown). We 
therefore favor the notion that the effect of LPS or FGK45 in enhancing responses to 
HEL protein in IFA is due to more efficient presentation. 
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Figure 3.4.3 Administration of an agonistic antibody to CD40 together with HEL105-120 in 
IFA, in contrast with HEL protein in IFA, does not affect the generation of HEL105-120-
specific cytokine producing CD4 T cells. BALB/c mice were immunized with either 10µg 
of HEL105-120 or 100µg of soluble HEL protein in IFA, subcutaneously at the tail base. 
Mice were injected with 100µg of either an isotype-matched control antibody (2A3) or a 
CD40 agonistic antibody (FGK45) intravenously at the time of immunization. The 
HEL105-120-specific and HEL protein-specific cytokine producing CD4 T cells in the 
spleen were enumerated ten days post-immunization. Each data point represents the total 
number of ELISpot-forming cells detected in the spleen of a single mouse. These are 
pooled data from one to two independent experiments with three mice per group (n = 3-
6). P-values represent the probability that the means of the two samples indicated are not 
different as assessed by unpaired, two-tailed T tests. 
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Having been unsuccessful in enhancing the generation of HEL105-120-specific cytokine 
producing CD4 T cells by immunizing with a single peptide in IFA and additional 
substances aimed at activating APC, we decided to address whether directly stimulating 
CD4 T cells through cell surface receptors, known to augment the activation of the T cell 
itself, could enhance the generation of peptide-specific effector CD4 T cells. CD28, the 
classical co-stimulatory receptor, and OX40 were initially identified as such targets. As 
outlined in the sections 1.2 and 1.5, stimulation through either CD28 or OX40, mediates 
potent enhancement in the generation of CD4 effector T cells and their survival. We 
undertook experiments similar to those outlined above to address the potential role of 
these molecules in our experimental system.  
 Our initial pilot experiments showed that administration of an agonist antibody to 
CD28 did not affect the generation of peptide-specific effector CD4 T cells upon 
administration of HEL105-120 alone in IFA (not shown). This was consistent with our 
previous experiments wherein LPS and FGK45 also did not enhance the generation of 
HEL105-120-specific effector cells; one of the major downstream effects of CD40 
stimulation is the activation of APC to express high-levels of B7 molecules (CD80 and 
CD86). We did not pursue stimulation through CD28 further. However, we observed 
potent and significant increases in the levels of peptide-specific cytokine secreting cells 
generated in mice given an agonistic antibody to OX40, called OX86, whether they were 
immunized with HEL protein in IFA or with HEL105-120 alone in IFA (Figure 3.4.4 A and 
B). We also determined that this effect was dependent on immunization with an 
appropriate peptide at the time of OX86 administration (Figure 3.4.4 C and D). The 
effects of the OX40 agonist were potent and specific. This finding is consistent with the 
finding of others that OX40 is only up-regulated upon TCR ligation and that OX86 can 
be employed to enhance immunity to protein vaccinations and tumor cells (Gramaglia, 
Weinberg et al. 1998; Piconese, Valzasina et al. 2008). 
 Taking the above findings together, we conclude that the cooperative effect, 
observed upon co-administration of multiple MHCII-binding peptides, on the generation 
of HEL105-120-specific effector CD4 T cells, is likely not due to non-specific activation of 
APC presenting the peptide.  
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Figure 3.4.4 Administration of an agonistic antibody to OX40, together with HEL105-120 or 
HEL protein in IFA, positively affects the generation of HEL105-120 cytokine producing 
CD4 T cells. (A and B) BALB/c mice were immunized with either 10µg of HEL105-120 or 
100µg of soluble HEL protein in IFA, at the tail base.  (C and D) BALB/c mice were 
immunized with either 10µg of HEL105-120 or 10µg of HEL11-25 in IFA, at the tail base. 
Mice were treated with 100µg of either an isotype-matched control antibody (HRPN) or 
an OX40 agonistic antibody (OX86) intravenously at the time of immunization. (A and 
B) The HEL105-120-specific and HEL protein-specific cytokine producing CD4 T cells in 
the spleen were enumerated ten days post-immunization. (C and D) Both HEL105-120 and 
HEL11-25-specific cytokine producing CD4 T cells in the spleen were enumerated ten days 
post-immunization. Each data point represents the total number of ELISpot-forming cells 
detected in the spleen of a single mouse. These are pooled data from one to two 
independent experiments with three mice per group (n = 3-6). P-values represent the 
probability that the means of the two samples indicated are not different as assessed by 
unpaired, two-tailed T tests. 
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Furthermore, because peptide-specific responses can be readily increased by the 
administration of OX86, we hypothesized that a critical signal, whether it occurs through 
stimulation of OX86 or another molecule on the surface of CD4 T cells, fails to be 
generated upon administration of HEL105-120 alone but is generated when multiple peptides 
are co-administered. As co-administration of multiple peptides leads to the activation of 
multiple populations of CD4 T cells, we propose that activation of these populations 
leads either directly or indirectly to the expression of certain cell surface ligands on APC 
or on the T cells themselves that serve to enhance mutual activation and effector function 
of other co-activated CD4 T cells.  
 
3.5 Direct Investigation of the Underlying Mechanisms of CD4 T cell Cooperation in 
Intact Mice 
   
Questions about the phenotypes and functions of specific populations of APC and 
peptide-specific CD4 T cells are particularly difficult to address in this experimental 
setting. Because we did not have a way to specifically identify the APC that were 
presenting peptides following immunization, or to track the specific CD4 T cells 
generated or their very scarce precursors, further analysis of these cells was precluded. 
We subsequently developed another experimental system aimed at addressing the cellular 
and molecular mechanisms of CD4 T cell cooperation. The results of experiments 
undertaken in this setting are outlined in Chapter 4 of this thesis. However, there were 
some critical aspects of CD4 T cell cooperation that could be further addressed within the 
context of the system outlined above.  
We hypothesized that multiple antigen-specific CD4 T cells, primed following 
presentation of peptides in our IFA immunizations, cooperated to enhance activation of 
T-cells specific for HEL105-120. If this were true, then CD4 T cells specific for other 
peptides should be present following immunization. To directly address whether CD4 T 
cells specific for other peptides given along with HEL105-120 were required for the 
cooperative effect we selectively removed them by tolerization before immunization. In 
our previous experiments we found that HEL105-120 and OVA323-339-specifc CD4 T cells 
appear to cooperate, in the generation of HEL105-120-specific CD4 effector T cells, when 
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these peptides were given together in IFA. To assess whether OVA323-339-specific CD4 T 
cells were required for this cooperation we removed the OVA323-339-specific CD4 T cells 
from mice by administration of high-doses of soluble OVA323-339, intravenously, two 
weeks prior to immunization. High dose administration of soluble peptide is known to 
result in the functional removal of CD4 T cells specific for a given peptide by forcing 
them into an anergic state or into apoptosis (Kearney, Pape et al. 1994; Peters, Kroeger et 
al. 2009). Figure 3.5.1 shows the results of experiments of this type. It can clearly be seen 
that the cooperative effect between OVA323-339 and HEL105-120 in the generation of HEL105-
120-specific cytokine producing effector CD4 T cells is completely abrogated in OVA323-339 
tolerant mice. This loss of cooperation corresponds with the lack of generation OVA323-
339-specific effector CD4 T cells in these mice, indicating that they were indeed tolerant 
of OVA323-339. We further confirmed that OVA323-339-specific CD4 T cells were required 
for cooperation by replacing the anergic/deleted endogenous OVA323-339-specific cells 
with CD4 T cells from DO11.10 mice. These CD4 T cells express a transgene-encoded 
TCR that recognizes OVA323-339 in the context of I-A
d. Adoptive transfer of DO11.10 CD4 
T cells clearly reconstituted both the generation of OVA323-339-specific cytokine producing 
cells and restored the cooperative effect seen upon administration of HEL105-120 and 
OVA323-339 together in IFA. This result is strong evidence that co-activated CD4 T cells do 
cooperate in vivo with one another in achieving optimal generation of effector CD4 T 
cells.  
Our previous finding that administration of OX86, the OX40 agonistic antibody, 
potently stimulated peptide-specific CD4 T cells when mice were concurrently 
immunized, suggested that OX40 signaling could be involved in CD4 T cell cooperation. 
However, this finding does not address whether OX40-OX40L signaling is involved in 
cooperative interactions between populations of CD4 T cells. To directly determine 
whether OX40-OX40L signaling played a significant role in CD4 T cell cooperative 
responses, we immunized mice with HEL105-120 alone or with HEL105-120 with three HEL 
peptides together in IFA, in the presence or absence of a non-cytolytic blocking antibody 
to OX40L.  
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Figure 3.5.1 Enhancement of HEL105-120-specific CD4 effector generation by co-
administration of HEL105-120 and OVA323-339 requires CD4 T cells specific for OVA323-339. 
BALB/c mice were either treated with saline (N) or made tolerant to OVA323-339 by 
administration of high amounts of OVA323-339 intravenously (Tol) as described in Chapter 
2. Fourteen days later, 105 OVA323-339-specific purified CD4 T cells from DO11.10 mice 
were seeded into some tolerized mice (Tol + DO11.10) intravenously. All mice were then 
immunized with either 10µg of HEL105-120 alone (H), or 10µg of both HEL105-120 and 
OVA323-339 together (H+O), subcutaneously in IFA. Peptide-specific cytokine producing 
CD4 T cells in the spleen were enumerated ten days post-immunization. Each data point 
represents the total number of ELISpot forming cells detected in the spleen of a single 
mouse. These are pooled results from two to four independent experiments with three 
mice per group (n = 6-12). P-values represent the probability that the means of the two 
samples indicated are not different as assessed by unpaired, two-tailed T tests. 
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As can be clearly seen in Figure 3.5.2, blocking OX40L had a potent effect on the 
generation of HEL105-120 specific cytokine-producing CD4 T cells upon immunization 
with all four HEL peptides. However, no effect was observed on the minimal HEL105-120 
responses seen upon immunization with HEL105-120 alone. These results are displayed as 
an index of cooperative effect in panel B. Whereas the number of HEL105-120-specific 
cytokine-producing CD4 T cells is increased between 2.5 and 20-fold in mice given all 
four HEL peptides compared with mice immunized with HEL105-120 alone, the cooperative 
enhancement is severely impaired in the presence of the blocking antibody to OX40L. 
This result strongly supports the hypothesis that OX40-OX40L interactions are involved 
in CD4 T cell cooperation. It appears that they are particularly important in mediating the 
enhanced generation of effector CD4 T cells, seen upon cooperation, and not simply 
critical for the activation of CD4 T cells in a general way.  
The OX40-OX40L interaction had been identified as critical to cooperative 
responses. Our previous work on CD4 T cell cooperation (Peters, Kroeger et al. 2009) led 
us to conclude that, in some cases, CD4 T cell cooperation is required for optimal 
generation of cytokine producing CD4 effector T cells. Evidence for this conclusion 
came from experiments in BALB/c mice made tolerant to HEL105-120. Critically, these 
mice fail to respond to HEL105-120 and all other HEL peptides upon administration with 
HEL protein on ALUM. The generation of CD4 effector T cells specific for the other 
HEL peptides could be rescued by immunizing with HEL coupled to OVA, thus 
replacing the HEL105-120-specific cooperating CD4 T cells with an OVA-specific CD4 T 
cell population. Given our finding that OX40 stimulation mimics, and blocking OX40L 
abrogates, the effects of CD4 T cell cooperation (Figures 3.4.4 and 3.5.2), it was natural 
to address whether OX40 stimulation, on its own, could rescue the generation of HEL-
peptide specific CD4 effector cell generation in HEL105-120 tolerant mice immunized with 
HEL on ALUM. 
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Figure 3.5.2 Blocking OX40L abrogates the effect of cooperation between HEL-peptide-
specific CD4 T cells. (A) BALB/c mice were immunized with HEL105-120 or HEL105-120 + 3 
HEL peptides as in Figure 3-4, and were treated with 100µg of either an isotype-matched 
control (iso. cont.) antibody or an OX40L blocking antibody (OX40L blocker), 
intravenously at the time of immunization. HEL105-120-specific ELISpot forming cells in 
the spleen were enumerated on day 10 post-immunization. (B) The data in panel A is 
displayed as cooperative effect (fold enhancement) of HEL105-120-specific CSCs between 
mice immunized with HEL105-120 alone or with HEL105-120 + 3 HEL peptides together in 
IFA. P-values represent the probability that the means of the two samples indicated are 
not different as assessed by unpaired, two-tailed T tests. These are pooled results from 
three independent experiments with three mice per group (n = 9). 
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Figure 3.5.3 shows the results of an experiment that addresses this question. The 
responses to the HEL11-25, HEL48-63 and HEL74-96 peptides are lost in HEL105-120 tolerant 
animals upon immunization with HEL protein on ALUM. Significantly, these responses 
are rescued upon stimulation with an agonistic antibody to OX40. However, it appears 
that treatment with anti-OX40 antibody rescued the generation of HEL105-120-specific CD4 
T cells as well, a result that is not surprising given that others have published similar 
findings (Bansal-Pakala, Jember et al. 2001). Given that the level of minor peptide-
specific effector T cells generated in HEL105-120 tolerized mice was much greater than in 
normal mice, and our findings that minor-peptide-specific CD4 T effector cells can be 
stimulated directly by anti-OX40 (Figure 3.4.4 C), we suggest that the effect of agonist 
antibody treatment on the generation of CD4 T cells specific for minor HEL peptides, 
was a combination of cooperation resulting from the rescue of the HEL105-120-specific 
CD4 T cells and the direct action of the agonistic antibody on minor peptide-specific 
CD4 T cells.  
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Figure 3.5.3 Stimulation of HEL peptide-specific CD4 T cells through OX40 rescues 
their activation in mice made tolerant to HEL105-120. BALB/c mice were treated with 
saline or were treated with soluble HEL105-120, as described in Chapter 2. Fourteen days 
later all mice were challenged with 100µg of heat-aggregated HEL on ALUM 
intraperitoneally. Some mice were treated with 100µg of an isotype-matched control 
antibody while some tolerant mice were treated with 100µg of an OX40 agonist antibody 
intravenously at the time of immunization. The cytokine producing CD4 T cells in the 
spleen, specific for four different HEL peptides were enumerated by optimized ELISpot 
assay ten days post-immunization. Each data point represents the total number of 
ELISpot forming cells detected in the spleen of a single mouse. These are pooled results 
from three independent experiments with three mice per group (n = 9). P-values represent 
the probability that the means of the two samples indicated are not different as assessed 
by unpaired, two-tailed T tests. 
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3.6 Conclusions 
  
 We had initially hypothesized that CD4 T cells, activated at the same time, could 
cooperate with one another, leading to enhancement of their proliferation and cytokine 
production, i.e. their effector function. We found that CD4 T cells specific for 
mycobacterium-derived peptides, for three peptides of HEL, and for OVA323-339, could 
cooperatively enhance the generation of HEL105-120-specific cytokine producing CD4 T 
cells. This cooperative enhancement could not be mimicked by LPS administration or by 
systemic APC activation by an agonistic antibody to CD40. We therefore conclude that 
CD4 T cell cooperation most likely enhances CD4 T cell activation beyond signals 
delivered by APC activated through LPS or CD40 ligation. We found that CD4 T cells, 
specific for the OVA323-339 peptide, were required to enhance the generation of HEL105-120-
specific effector CD4 T cells when both peptides were given together in IFA. We 
conclude that our observations result from cooperation between CD4 T cells. In two 
separate experimental systems, OX40 stimulation mimics the effects of CD4 T cell 
cooperation. Given these findings, in addition to the ability of OX40L blockade to 
abrogate the effect of CD4 T cell cooperation, we conclude that the OX40-OX40L 
interaction is likely critical in the cooperation between populations of CD4 T cells.  
 As noted above, many questions about the cellular and molecular mechanisms of 
CD4 T cell cooperation remained following the completion of these studies. We therefore 
undertook the development of another experimental system that would allow us to 
address questions such as the nature of the APC that mediates cooperation. This work is 
described in Chapter 4.  
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4.0 CHAPTER 4 - OBSERVATIONS AND MECHANISMS OF CD4 T 
CELL COOPERATION IN VIVO: II ADOPTIVE TRANSFER OF 
PEPTIDE-PULSED APC 
 
4.1 Introduction 
 
 As we have shown in the previous chapter, CD4 T cell populations recognizing 
distinct peptides can cooperate with one another to enhance their own activation 
following immunization with multiple peptides that bind MHCII. The experimental 
protocols outlined in Chapter 3 yielded significant results and allowed us to conclude that 
cooperation between CD4 T cells, differing in TcR specificity, is likely a biologically 
relevant phenomenon, not solely an artifact of our experimental system. We also 
concluded that cooperation between CD4 T cell populations requires signaling through 
OX40-OX40L interactions and that the effects of cooperation cannot be mimicked by co-
administration with LPS or an agonist antibody to CD40. However, a major problem with 
protocols that use IFA to formulate peptides injected into mice is that, upon injection, 
little can be done to identify the cellular and molecular interactions that occur to induce 
CD4 T cell activation and subsequent cooperation. The nature of the APC involved in 
cooperation, whether the same APC must present both peptides simultaneously, and how 
OX40L co-stimulatory signals mediate CD4 T cell cooperation are remaining questions, 
with important implications for understanding the biology of CD4 T cell cooperation. 
Thus we sought to develop a new experimental system that would allow us to address 
these questions.  
 We hypothesized that, upon administration of soluble peptides in IFA, these 
peptides are presented by MHCII-bearing APC following uptake and processing of 
peptide-containing micelles or following exogenous loading of empty MHCII molecules. 
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We reasoned that if a population of APC could be loaded with single or multiple peptides 
in vitro, and then adoptively transferred into mice, they may function to mediate CD4 T 
cell activation and cooperation in a way similar to endogenous APC. The advantage of 
employing this experimental model is that specific APC subpopulations can be isolated 
prior to transfer, loaded with defined peptides, analyzed by flow-cytometry or 
biochemical methods prior to injection, and tracked after injection. The use of this system 
allowed me to investigate the underlying cellular and molecular mechanisms involved in 
cooperative CD4 T cell interactions in vivo. 
 
4.2 Establishing an Experimental System for Adoptive Transfer of APC 
 
 Many reports describe the exogenous loading of APC populations with antigen 
prior to adoptive transfer. This loading is commonly referred to as “antigen pulsing”. 
Typically, APC, such as DC, are pulsed with peptide or protein antigens in culture, 
washed and then injected subcutaneously or intravenously to generate immune responses. 
Given that these protocols have been established and employed to shed light on a variety 
of immunological phenomena, we were confident that such a pulsing system could lead 
to significant results in our own hands.  
 Because CD4 T cell cooperation, in mice immunized with IFA emulsions 
containing peptides, is mediated by endogenous APC, we wished to employ a similar set 
of APC for our pulsing studies. The spleen is a convenient source of APC 
subpopulations, including B cells and various subpopulations of DC. We first used 
unfractionated splenocytes, pulsed with peptides, as APCs in subsequent experiments.  
 Resting APC are often found to be tolerogenic (see section 1.2). We wished to 
avoid inducing tolerance as a complicating factor in our experiments and so attempted to 
activate APC in cultures of splenocytes by supplementing these cultures with LPS. LPS is 
a known ligand for TLR-4 in mice, and upon binding, induces activation of both myeloid 
DC and B cells. These cells rapidly acquire enhanced antigen-presenting capability that 
correlates with the up-regulation of co-stimulatory molecules such as CD86. Figure 4.2.1 
shows the cell surface phenotype, as assessed by flow-cytometry, of splenocytes cultured 
for approximately 24 hours with or without 1µg/mL E. coli LPS in the media.  
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Figure 4.2.1 Overnight culture in the presence of LPS increases CD86 expression by 
splenocytes.  BALB/c splenocytes were prepared as single cell suspension and re-
suspended at a concentration equivalent to two spleens per 3mL of RPMI media without 
FCS supplement. Three mL of this cell suspension was plated in 60mm tissue culture 
dishes with and without 1µg/mL E. coli LPS. Following overnight culture, cells were 
harvested and stained with fluorophore-conjugated monoclonal antibodies to the 
indicated surface protein. Stained cells were analyzed by flow-cytometry. Black 
histograms show the level of fluorescence of cells stained with the appropriate antibody. 
Grey, dotted, histograms show the level of fluorescence of cells stained with a matched 
fluorophore-conjugated isotype-matched control antibody. The percentages of cells 
falling within the gated region within each profile are shown. Data presented are 
representative of results from two independent experiments.  
! 151 
! 152 
 
 The relative proportions of APC populations do not change substantially between 
cultures containing or not containing LPS. The level of CD86 expression increased when 
splenocytes were cultured with LPS. Given the considerations that resting APC are often 
tolerogenic, the finding that CD86 expression increased in splenocytes cultured with 
LPS, and our previous findings that LPS activation of APC in vivo does not affect CD4 T 
cell cooperation, we always employed LPS in our subsequent APC cultures.  
 After analyzing the phenotype of LPS-activated cultured splenocytes, we wanted 
to determine whether LPS stimulated splenocytes could function as APCs in adoptive 
transfer experiments with peptides. We first investigated whether cultured splenocytes, 
injected subcutaneously into the hind footpad, would migrate to the draining lymph node, 
the site of antigen presentation. Overnight-cultured splenocytes were labeled with 
carboxy-fluorocein succinimidyl ester (CFSE), to allow us to detect splenocytes after 
transfer. CFSE-labeled cells were injected subcutaneously into either the footpad or lower 
leg of normal BALB/c mice. We observed that the numbers of CFSE+ cells present in the 
popliteal lymph nodes (LN) peaked at 48h post-injection (data not shown). As can be 
seen in Figure 4.2.2A, the CFSE+ cells that reach the LN constitute a small fraction of the 
total lymph node population that was isolated. We determined that CFSE labeled cells 
expressing CD11c (conventional DC), CD19 (B cells), MHCII, and CD86 reached the 
draining lymph node following adoptive transfer (Figure 4.2.2B). Thus the possibility 
that peptide pulsed, cultured splenocytes could deliver antigen to the draining lymph 
node was confirmed.  
 We next examined whether peptide-pulsed, cultured splenocytes could, in fact, 
present antigen to CD4 T cells in vivo following adoptive transfer. To achieve this, we 
took advantage of a well-described methodology for detecting antigen-induced 
proliferation in CD4 T cells. That is, when CD4 T cells experience antigen presentation 
through ligation of the TCR by peptide-MHCII complexes for which they have affinity, 
they begin to divide. We CFSE labeled splenocytes from DO11.10 mice that contain CD4 
T cells that express a transgene-encoded TCR with affinity for OVA323-339 in the context 
of I-Ad. These labeled splenocytes were then injected intravenously into BALB/c mice. 
One day later, syngeneic splenocytes cultured for 24h in the presence or absence of 
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50µM OVA323-339, were injected into these mice. This high peptide concentration was 
chosen to facilitate rapid loading of empty MHCII molecules. Six days later, the spleens 
and lymph nodes of injected mice were harvested and stained for DO11.10 TCR with a 
clonotype-specific fluorophore-conjugated antibody. Flow cytometry was used to 
monitor DO11.10 TCR+ cells proliferation, by measuring CFSE labeling intensity, and 
clonal expansion by measuring the percentage of DO11.10 TCR+ cells in the lymph nodes 
and spleen. As can be seen in Figure 4.2.3, only when adoptively transferred splenocytes 
were pulsed with OVA323-339 was there division and accumulation of CFSE-labeled 
DO11.10 CD4 T cells. This effect was observed only in the draining lymph nodes at the 
time of analysis. 
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Figure 4.2.2 Cultured splenocytes labeled with CFSE migrate to the popliteal lymph 
node following subcutaneous footpad injection. BALB/c splenocytes were cultured 
overnight as described in Chapter 2 in the presence of 1µg/mL LPS and without 
exogenous peptide. All cells were harvested and labeled with 5µM CFSE. After thorough 
washing, 107 stained splenocytes were re-suspended in 50µL Leibovitz media and 
injected subcutaneously into the footpad and lower leg of BALB/c mice. After 48 hours, 
the popliteal lymph nodes of mice were harvested and stained with fluorophore-
conjugated antibodies to detect the indicated cell surface proteins. Stained cells were 
analyzed by flow-cytometry (A) CFSE positive cells are shown gated from total lymph 
node cells. (B) The expression of individual cell surface proteins is shown for CFSE 
positive cells. Black histograms show the relative frequency of fluorescence of cells 
stained with the indicated antibody. Grey, dotted, histograms show the level of 
fluorescence of cells stained with a matched fluorophore-conjugated isotype-matched 
control antibody. Percentages of cells falling within the gated region of the total number 
of cells within the given plot are shown. These profiles are representative of results from 
three independent experiments.  
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 Taken together, these results indicate that following injection into the footpad the 
peptide pulsed splenocytes migrated to the draining lymph nodes, and presented antigen 
to CD4 T cells. We subsequently investigated whether these splenocytes mediated 
cooperation between CD4 T cell populations. Because we had previously observed that 
simultaneous administration of OVA323-339 and HEL105-120 in IFA resulted in cooperative 
effects on CD4 T cells responses, and because these peptides do not bind to the same 
MHCII molecules, we used these peptides to investigate whether peptide-pulsed APC 
could mediate T cell cooperation.  
 Splenocytes, pulsed with OVA323-339, and injected into mice, presented the peptide 
to CD4 T cells in the draining lymph nodes. However, we did not know whether OVA323-
339 pulsed APCs cells could also present HEL105-120. Furthermore, it was not clear whether 
overnight peptide pulsing was essential for APC loading, or if a shorter time would be 
sufficient. We carried out an experiment to address these questions. Taking advantage of 
the increased generation of effector CD4 T cells upon secondary stimulation, we were 
able to determine that administration of 107 HEL105-120-pulsed splenocytes likely resulted 
in primary stimulation of endogenous CD4 T cells (Figure 4.2.4). Moreover, we found 
significant increases in secondary HEL105-120-specific cytokine producing CD4 T cell 
levels only when splenocytes were cultured in the presence of HEL105-120 for 24 hours.  
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Figure 4.2.3 OVA323-339-pulsed splenocytes present peptide to CD4 T cells following 
subcutaneous injection. Splenocytes from DO11.10 mice, containing CD4 T cells that 
recognize OVA323-339 in the context of I-A
d, were labeled with 5µM CFSE and107 labeled 
splenocytes were injected intravenously into BALB/c mice.  Twenty-four hours later 
these mice were injected subcutaneously in the footpad and lower leg with BALB/c 
splenocytes cultured overnight, in the presence or absence of 50µM OVA323-339 (as 
described in Chapter 2). Six days post-injection, draining popliteal lymph nodes (DLN) 
and spleens from injected mice were harvested and stained with a fluorophore-conjugated 
antibody to the DO11.10 TCR expressed by transgenic CD4 T cells. The level of CFSE 
staining and numbers of DO11.10 positive cells were assessed by flow cytometry. 
Percentages of cells falling within the gate out of the total number of cells within the 
given plot are shown. These results are representative of two independent experiments. 
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Figure 4.2.4 Subcutaneous footpad injection of HEL105-120-pulsed splenocytes results in 
accumulation of HEL105-120-specific cytokine producing CD4 T cells that enhance 
secondary responses to HEL105-120. BALB/c splenocytes were cultured for 24 hours, as 
described in Chapter 2, with 50µM HEL105-120 for the indicated times. After harvesting 
and extensive washing, 107 pulsed splenocytes in 50µL Leibovitz media were injected 
into the footpad and lower leg of normal BALB/c mice. Some mice were injected with 
Leibovitz media alone to serve as controls (N). Fourteen days after injection, mice were 
injected subcuatneously at the tail base with 10µg HEL105-120 in CFA, Ten days post-
injection, the HEL105-120-specific cytokine producing cells in the spleen were enumerated 
by ELISpot. Each data point represents the number of specific ELISpot-forming cells in 
the spleen of a single mouse. P-values indicate the probability that the means of the 
indicated samples are not different as assessed by unpaired, two-tailed T-tests. This is the 
result of a single experiment with three mice per group (n = 3).  
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Having established that antigen presentation to endogenous CD4 T cell populations 
occurs upon injection of HEL105-120 or OVA323-339-pulsed splenocytes, we replicated the 
previous experiments that demonstrated cooperation between two peptide-specific CD4 T 
cell populations. Figure 4.2.5 shows the results of a single experiment in which mice 
were injected with either 107 splenocytes pulsed with HEL105-120 alone, OVA323-339 alone, 
or both peptides together. Ten days after this injection the number of HEL105-120 and 
OVA323-339-specific cytokine producing CD4 cells in the draining popliteal lymph node 
were enumerated. Very low and variable numbers of peptide-specific effector CD4 T 
cells were detected. However, we did not observe statistically significant differences and 
it appeared that the number of HEL105-120-specific cytokine producing CD4 T cells was 
higher, in mice given splenocytes pulsed with both HEL105-120 and OVA323-339, than in mice 
given splenocytes pulsed with HEL105-120 alone.  We hypothesized that the low responses 
observed may be due to the inefficiency inherent in our experimental protocol and 
subsequently attempted to improve the efficiency of CD4 T cell activation.  
 We had shown when HEL105-120 and OVA323-339 are given together in IFA, the 
generation of effector CD4 T cells specific for OVA323-339 is not significantly affected by 
the presence of HEL105-120. Therefore, we thought that we might improve the efficiency of 
CD4 cooperation, in generating HEL105-120-specific cytoking producing cells, without 
compromising the potential to observe converse effects, by seeding mice with exogenous 
OVA323-339-specific CD4 T cells. We therefore seeded normal mice with varying numbers 
of splenocytes from DO11.10 mice, prior to the injection of peptide-pulsed APC. We 
found that increasing the numbers of OVA323-339-specific CD4 T cells had a potentially 
observable effect on the generation of HEL105-120-specific cytokine producing effector 
CD4 T cells, although the differences did not reach statistical significance (Figure 4.2.6). 
We hypothesized that, even in the presence of increased numbers of OVA323-339-specific 
CD4 T cells, the generation of peptide specific effector CD4 T cells was limited. This 
limitation may be due to failure of peptide-pulsed APC to sustain the presentation of 
those peptides over time. When peptides are given in IFA they are likely to be 
continuously presented over the course of the generation of the immune response since 
IFA depots can be found under the skin of immunized mice weeks after injection (data 
not shown).  
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Figure 4.2.5 A single subcutaneous injection of peptide-pulsed splenocytes is insufficient 
to elicit significant primary peptide-specific effector CD4 T cell responses. BALB/c 
splenocytes were cultured overnight, as described in Chapter 2, in the presence of either 
50µM HEL105-120, 50µM OVA323-339, or 50µM of both peptides. Following harvest and 
extensive washing, 107 of pulsed splenocytes in 50µL Leibovitz media were injected into 
the footpad and lower leg of normal BALB/c mice. Ten days post-injection, the HEL105-120 
and OVA323-339-specific cytokine producing cells in the draining popliteal lymph node 
(DLN) were enumerated by ELISpot in mice given only HEL105-120-pulsed splenocytes 
(H), only OVA323-339-pulsed splenocytes (O), and in mice given splenocytes pulsed with 
both HEL105-120 and OVA323-339 (H+O). Each data point represents the number of specific 
ELISpot-forming cells in the popliteal lymph node of a single mouse. P-values indicate 
the probability that the means of the indicated samples are not different as assessed by 
unpaired, two-tailed T-tests. This is the result of a single experiment with three mice per 
group (n = 3). 
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Figure 4.2.6 Mice seeded with DO11.10 splenocytes appear to support enhanced 
generation of OVA323-339 and HEL105-120-specific effector CD4 T cell generation upon 
injection of splenocytes pulsed with both peptides. One day prior to injection of pulsed 
splenocytes, BALB/c mice were injected with DO11.10 splenocytes which contain 
approximately 10% CD4+ DO11.10+ T cells. BALB/c splenocytes were cultured 
overnight, as described in Chapter 2, in the presence of both 50µM HEL105-120 and 50µM 
OVA323-339. Following harvest and extensive washing, 10
7 peptide pulsed splenocytes in 
50µL Leibovitz media were injected into the footpad and lower leg of BALB/c mice 
previously injected with DO11.10 splenocytes. Ten days post-injection, the HEL105-120 and 
OVA323-339-specific cytokine producing cells in the draining popliteal lymph node (DLN) 
were enumerated by ELISpot assay. Each data point represents the number of specific 
ELISpot-forming cells in the popliteal lymph node of a single mouse. This is the result of 
a single experiment with three mice per group (n = 3).  
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We decided to provide more sustained antigen presentation by giving repeated injections 
of peptide-pulsed APC. As can be seen in Figure 4.2.7, three injections of HEL105-120 and 
OVA323-339-pulsed APC, three days apart, resulted in substantial increases in the levels of 
peptide-specific effector CD4 T cells generated nine days after the initial injection. 
Furthermore, there was a clear dose dependent response in the number of OVA323-339-
specific cytokine producing cells generated and, importantly, the level of HEL105-120-
specific effector CD4 T cells was dependent on the number of CD4-positive DO11.10 
cells seeded into mice prior to the first injection. The finding that HEL105-120-specific 
effector cells were more efficiently generated when more OVA323-339 CD4 T cells were 
present, provided direct evidence that cooperation occured between these two CD4 T cell 
populations in the activation of HEL105-120-specific CD4 T cells.  
Since the injection of 105 CD4-positive DO11.10 cells into mice appeared to 
result in optimal generation of HEL105-120-specific responses, we repeated the experiment 
shown in Figure 4.2.7 with that number of DO11.10 CD4 T cells. Figure 4.2.8 shows the 
pooled results of these repeated experiments. A clear cooperative effect in HEL105-120-
specific effector CD4 T cell generation is seen in mice injected with splenocytes pulsed 
with both HEL105-120 and OVA323-339 when compared to mice injected with splenocytes 
pulsed with HEL105-120 alone. Consistent with our earlier observations, only a marginal 
effect on the generation of OVA323-339-specific effector CD4 T cells was observed in mice 
injected with splenocytes pulsed with both peptides. However, interpretation of this 
observation is complicated by the fact that all mice were injected with 105 OVA323-339-
specific CD4 T cells prior to adoptive transfer of peptide-pulsed APC.  
 We therefore established an experimental system, employing adoptively 
transferred peptide-pulsed APC populations to elicit peptide-specific CD4 T cell 
activation, which resulted in cooperative responses between CD4 T cells specific for 
HEL105-120 and OVA323-339, replicating our earlier findings employing peptides 
administered in IFA. We subsequently employed this same basic experimental setup to 
address mechanistic questions surrounding the phenomenon of CD4 T cell cooperation. 
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Figure 4.2.7 Three subcutaneous injections of HEL105-120 and OVA323-339 peptide-pulsed 
splenocytes induce significant peptide-specific effector CD4 T cell responses in 
DO11.10-seeded mice. One day prior to injection of pulsed splenocytes, BALB/c mice 
were injected with the indicated number of MACS purified CD4+ DO11.10 T cells. 
BALB/c slpenocytes were cultured overnight, as described in Chapter 2, in the presence 
of 50µM of both HEL105-120 and OVA323-339. Following harvest and extensive washing, 10
7 
peptide-pulsed splenocytes in 50µL Leibovitz media were injected into the footpad and 
lower leg of normal BALB/c mice on experimental days 0, 3, and 6. Nine days after the 
initial injection of pulsed splenocytes, the HEL105-120 and OVA323-339-specific cytokine 
producing cells in the draining popliteal lymph node (DLN) were enumerated by ELISpot 
assay. Each data point represents the number of specific ELISpot-forming cells in the 
popliteal lymph node of a single mouse. P-values indicate the probability that the means 
of the indicated samples are not different as assessed by unpaired, two-tailed T-tests. This 
is the result of a single experiment with three mice per group (n = 3). 
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Figure 4.2.8 Administration of HEL105-120 and OVA323-339-pulsed splenocytes to DO11.10-
seeded mice results in significant cooperative enhancement of HEL105-120-specific effector 
CD4 T cell generation. One day prior to injection of pulsed splenocytes, BALB/c mice 
were injected with 105 MACS purified CD4+ DO11.10+ T cells. BALB/c splenocytes 
were cultured overnight, as described in Chapter 2, in the presence of either 50µM 
HEL105-120 alone, 50µM OVA323-339 alone, or 50µM of both peptides. Following harvest 
and extensive washing, 107 of peptide-pulsed splenocytes in 50µL Leibovitz media were 
injected subcutaneously into the footpad and lower leg of BALB/c mice on days 0, 3, and 
6. Nine days after the initial injection of pulsed splenocytes, the HEL105-120 and OVA323-
339-specific cytokine producing cells in the spleens and draining popliteal lymph nodes 
(DLN) were enumerated by ELISpot in mice injected with only HEL105-120-pulsed 
splenocytes (H), only OVA323-339-pulsed splenocytes (O), and in mice injected with 
splenocytes  pulsed with both HEL105-120 and OVA323-339 (H+O). Each data point represents 
the number of specific ELISpot-forming cells in the popliteal lymph node of a single 
mouse. P-values indicate the probability that the means of the indicated samples are not 
different as assessed by unpaired, two-tailed T-tests. Results presented are pooled data 
from three to five independent experiments with three mice per group (n = 9-15).  
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4.3 Cellular Mechanisms of CD4 T cell Cooperation 
 
 We confirmed that significant CD4 T cell cooperation can occur between two 
distinct peptide-specific populations when these peptides are presented in association 
with MHCII molecules on adoptively transferred APC. More-specifically, we 
demonstrated that OVA323-339-specific CD4 T cells enhanced the frequency of HEL105-120 
specific CD4 T cells when both peptides are presented by APCs pulsed with peptide at 
the same time. However, the question remained as to whether this cooperation occurred 
between CD4 T cells activated by the same APC or whether antigen presentation by 
different APC within the same lymph node was sufficient to support T cell cooperation. 
The answer to this question has implications for the physiological function of CD4 T cell 
cooperation as outlined in section 1.3. If cooperation generally occurs between CD4 T 
cells activated by the same APC, then the peptides presented will normally be derived 
from antigens that are physically or functionally associated. It is easy to envisage 
situations where linkage between antigens occurs; linkage of peptide epitopes may result 
from their presence within the primary sequence of a single protein, a complex of 
proteins, or indeed an entire microorganism that is taken up and digested within a single 
APC, particularly if the process of antigen uptake is specific. If cooperation between CD4 
T cells generally does not require presentation of two or more peptides on the same APC, 
then there is no requirement for linkage. The implication of finding that CD4 T cells 
cooperate via an unlinked mechanism would be that “bystander” interactions, occurring 
between T cells responding to unlinked interactions, would allow populations of CD4 T 
cells to influence one another, upon their simultaneous interaction within the same lymph 
node, for example. If this type of interaction was common, it would be difficult to 
envisage how the activation and phenotype of CD4 T cells could be exquisitely 
controlled. We therefore undertook experiments designed to determine whether CD4 T 
cell cooperation occurs through linked or bystander interactions between CD4 T cells.  
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Figure 4.3.1. Cooperation between HEL105-120 and OVA323-339-specific CD4 T cells 
requires simultaneous presentation of both peptides by the same APC. BALB/c mice 
were seeded with 105 MACS purified CD4+ DO11.10 T cells one day prior to injecting 
mice three times (as in Figure 4.2.8) with 107 splenocytes pulsed with either HEL105-120 
alone (H), OVA323-339 alone (O), both HEL105-120 and OVA323-339 (H+O), or co-injection of 
107 H and O splenocytes. The peptide-specific cytokine producing cells in the spleen and 
draining lymph nodes of these mice were enumerated by ELISpot on day nine after the 
first injection. Each data point represents the number of specific ELISpot-forming cells in 
the lymphoid organ of a single mouse. P-values indicate the probability that the means of 
the indicated samples are not different as assessed by unpaired, two-tailed T-tests. Data 
were pooled from two to three independent experiments with three mice per group (n = 6-
9).  
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As can be seen from Figure 4.3.1, the cooperative generation of IL-4 producing effector 
CD4 T cells, observed upon administration of dual peptide-pulsed APC, requires 
presentation of HEL105-120 and OVA323-339 on the same APC. The generation of HEL105-120-
specific cytokine producing cells in mice given 107 APC pulsed with both HEL105-120 and 
OVA323-339-pulsed was compared to mice co-injected with 10
7 HEL105-120-pulsed APCs and 
107 OVA323-339-pulsed APCs. The number of total APCs injected was changed to ensure 
that the number of specific peptide-MHCII complexes available was not different 
between groups. No cooperative effect was evident in mice given APC pulsed separately 
with single peptides. The level of HEL105-120-specific cells generated in mice given APC 
loaded with HEL105-120 alone was not different from the number generated in mice given 
APC pulsed with HEL105-120 and OVA323-339 separately. Thus, we can conclude that CD4 T 
cell cooperation normally occurs primarily through linked recognition of peptides.  
We next investigated the nature of the APC that mediates T cell cooperation. 
Because the spleen contains many different potential APC types, a fundamental question 
that arose from our findings was: Is CD4 T cell cooperation mediated by a specific type 
of APC? If so, what APC is it? Differences in the physiological roles for different types 
of APC are a function of their differential uptake of antigen, their presence in different 
physiological niches, and differential expression and timing of processing and 
presentation machinery and co-stimulatory molecules. To put it simply, different APC are 
expected to have different roles in the activation of CD4 T cells because they are 
different. Alternatively, there could be no specific APC requirement for cooperation 
between CD4 T cells, in which case all populations of APC should mediate cooperative 
enhancement of CD4 effector T cells equally well. We therefore attempted to determine 
whether a certain APC type, contained within our pulsed spleen population, preferentially 
mediated cooperation amongst CD4 T cells.  
Dendritic cells, in particular conventional DC and plasmacytoid DC, are seen as 
the most potent activators of naïve T cells. Both of these cell types are found within the 
spleen (Villadangos and Schnorrer 2007). In order to determine whether splenic DCs 
have a role in mediating cooperation between CD4 T cells, we selectively isolated them 
from cultured, pulsed, splenocytes and assessed the generation of HEL105-120-specific CD4 
T cells, following injection, when these DC were pulsed with HEL105-120 alone or with 
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both HEL105-120 and OVA323-339. Figure 4.3.2 displays data pooled from three such 
experiments. While the splenocytes remaining, after DC isolation by MACS, appear to 
have retained the ability to mediate cooperation, DC enriched APC appear unable to 
mediate enhancement of the activation of HEL105-120-specific CD4 T cells when pulsed 
with both peptides. It is clear that the DC enriched APC, given in proportion to the 
numbers isolated by MACS from the total population of splenocytes, elicit substantial 
HEL105-120 and OVA323-339-specific effector CD4 T cell generation. However, even when 
the numbers of DC enriched APC were increased five-fold, enhancement in the 
generation of HEL105-120-specific cytokine producing cells, by cooperative interaction, was 
not observed. 
 Our analysis of the cell surface phenotype of DC-enriched APC was hindered by 
the presence of cell debris in the isolated populations. A large proportion of these cells 
bear CD11c and MHCII (Figure 4.3.3). Cells that expressed MHCII, but not CD11c were 
observed. Our protocol allowed for selection of splenic plasmacytoid DC. We assume 
that at least some of the MHCII expressing, CD11c- cells were plasmacyotid DC as 
virtually none of the cells isolated expressed CD19 indicating that there were few 
contaminating B cells. Given that these cells efficiently activated CD4 T cells even when 
given at levels nearly 100-fold lower than pulsed-splenocyte APC, we believe that the 
majority of these cells were splenic DC. From these findings we conclude that while DC 
potently activate CD4 T cells but appear unable to mediate CD4 T cell cooperation. 
B cells are a major population of APC in the spleen. These cells are at least ten-
fold more prevalent than DC in our pulsed spleen preparations. Their numbers, and their 
well-described ability to present antigen to CD4 T cells, made it likely that B cells were 
activators of T cells in our experimental system. We tested whether purified B cells could 
mediate cooperation between CD4 T cells. After overnight pulsing with HEL105-120 alone 
or with HEL105-120 and OVA323-339 together, B cells were purified from the remaining 
splenocytes by negative selection. The resulting untouched B cells, pulsed with one 
peptide or two, were injected into the footpad of mice seeded with 105 CD4+ DO11.10 
cells, as per our standard protocol. On the ninth day after the initial injection, we 
enumerated the peptide-specific cytokine producing cells in the draining lymph nodes 
and spleens of injected mice.  
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Figure 4.3.2 Enriched splenic DCs do not mediate cooperation between HEL105-120 and 
OVA323-339-specific CD4 T cell populations. BALB/c mice were seeded with 10
5 MACS 
purified CD4+ DO11.10 T cells one day prior to injecting splenocytes cultured as 
described in Chapter two in the presence of 50µM HEL105-120 alone or in the presence of 
both 50µM HEL105-120 and 50µM OVA323-339. After harvesting and washing, splenic DC 
populations were isolated by positive selection using pan-DC-specific MACS beads. 
Selection resulted in the isolation of roughly 2% of the pulsed splenocyte population. 
Both DC depleted and DC enriched (DC+) peptide-pulsed cells were injected in 
proportion to the standard injection of 107 (107 and 2x105 cells respectively). In one 
experiment the number of DC enriched cells was increased five-fold (106 DC+). These 
injections were given on days 0, 3, and 6. On day 9 after the first injection the HEL105-120 
and OVA323-339-specific cytokine-producing cells in the spleens, and draining popliteal 
lymph nodes (DLN), were enumerated by ELISpot, in mice given HEL105-120-pulsed APC 
(H), or HEL105-120 and OVA323-339-pulsed APC (H+O). Each data point represents the 
number of specific ELISpot-forming cells in the lymphoid organ of a single mouse. P-
values indicate the probability that the means of the indicated samples are not different as 
assessed by unpaired, two-tailed T-tests. The data presented are pooled values from one 
to three independent experiments with three mice per group (n = 3-9).  
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Figure 4.3.3 Surface phenotype of the DC-enriched population isolated from cultured 
splenocytes. Splenocytes were cultured and DCs isolated by MACS as in Figure 4.3.2. 
DC enriched cells were then separated from cell debris by centrifugation over a Ficol-
paque gradient. The remaining cells were stained with fluorophore-conjugated antibodies 
specific for the indicated cell surface markers. Assessment of the expression of these 
markers by flow-cytometry on DC-enriched cells is shown. Density plots gated on events 
that had forward and side scatter properties of cells are shown. Percentages of cells 
falling within the quadrant out of the total number of cells within the given plot are 
shown. Data presented are representative of results from two independent experiments.  
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We observed clear cooperative effects in the generation of HEL105-120-specific IFN! and 
IL-4 producing CD4 T cells between mice given B cells pulsed with HEL105-120 alone and 
those given B cells pulsed with HEL105-120 and OVA323-339 (Figure 4.3.4). Subsequently, we 
administered B cells pulsed with OVA323-339 alone to assess whether, when B cells were 
the sole APC presenting peptide, cooperative responses could be observed in the 
generation of OVA323-339-specific effector cells. Consistent with our previous findings, 
cooperation was not observed in the generation of OVA323-339-specific responses. We 
determined that the B cells employed in these studies were at least 95% pure and 
expressed both MHCII and CD86 (Figure 4.3.5). We conclude from these findings that B 
cells are able to mediate cooperation between CD4 T cells.  
Our findings here indicate that CD4 T cell cooperation is mediated primarily by 
APC presenting peptides in a linked fashion and that these APC are normally B cells. 
These findings are consistent with what is known about the antigen-presenting role of B 
cells. Taken as a whole, these findings have important implications for the physiology of 
CD4 T cell cooperation. If our findings reflect are biologically relevant, they suggest that 
cooperative responses generally occur between CD4 T cells that recognize peptides 
bound to MHCII molecule on the same B cell. Since B cells are antigen-specific APC, 
mainly acquiring protein antigen by way of the BCR, CD4 T cell cooperation should 
normally occur between CD4 T cells specific for peptides that are derived from 
physically linked foreign proteins. The implications of this in the generation of normal 
and of abnormal immune responses will be discussed further in Chapters 5 and 6. 
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Figure 4.3.4 Purified B cells mediate cooperation between HEL105-120 and OVA323-339-
specific CD4 T cells. BALB/c mice were injected with 105 MACS purified CD4+ 
DO11.10 T cells one day prior to injection. Splenocytes from BALB/c mice were 
cultured as described in Chapter two in the presence of 50µM HEL105-120 alone or in the 
presence of both 50µM HEL105-120 and 50µM OVA323-339. After harvesting and washing, 
the splenic B cells were isolated by negative selection with the MACS B cell isolation kit. 
Selection resulted in the isolation of roughly 35% of the pulsed splenocytes. B cells were 
injected in proportion to the standard injection of 107, with 3.5 x 106 per mouse. On day 9 
after the first injection the HEL105-120 and OVA323-339-specific cytokine-producing cells in 
the spleens, and draining popliteal lymph nodes (DLN), were enumerated by ELISpot, in 
mice given HEL105-120-pulsed B cells (H), or HEL105-120 and OVA323-339-pulsed B cells 
(H+O). Each data point represents the number of specific ELISpot-forming cells in the 
lymphoid organ of a single mouse. P-values indicate the probability that the means of the 
indicated samples are not different as assessed by unpaired, two-tailed T-tests. Data 
presented were pooled from one to three independent experiments with three mice per 
group (n = 3-9).  
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Figure 4.3.5 Phenotype of MACS purified, peptide pulsed, B cells. Splenocytes were 
cultured and the B cells isolated as in Figure 4.3.4. B cells were then stained with 
fluorophore-conjugated antibodies specific for the indicated cell surface markers. Grey, 
dotted, histograms show the level of fluorescence of cells stained with a matched 
fluorophore-conjugated isotype-matched control antibody. Proportions (% of total) of 
cells falling within the indicated gates are shown. Data presented are representative of 
results from three independent experiments.  
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4.4 Molecular Mechanisms of CD4 T cell Cooperation 
 
 Our data supported the conclusion that B cells are the APC that normally mediate 
cooperation between CD4 T cells in vivo. We decided to investigate the molecular 
interactions involved in this B cell-mediated cooperation. Because cooperation was found 
to occur only when HEL105-120 and OVA323-339 were presented on the same APC we 
hypothesized that the cooperation between CD4 T cells involved antigen-specific 
activation of B cells by CD4 T cells, leading to their enhanced ability to activate other 
CD4 T cells. Classically, CD40L (CD154), borne by activated CD4 T cells is known to 
potently activate B cells (Croft, Bradley et al. 1994; Jaiswal, Dubey et al. 1996; Croft, 
Joseph et al. 1997; Evans, Munks et al. 2000) and increase their ability to present antigen 
to CD4 T cells. Moreover, CD40 stimulation of other APC, such as DC, has been shown 
to license these cells to more potently activate CD8 T cells (Ridge, Di Rosa et al. 1998; 
Schoenberger, Toes et al. 1998). We hypothesized that CD40-CD40L interactions could 
be also be involved in CD4 T cell cooperation.  
 To address whether CD40 expressed by B cells was involved in cooperation 
between CD4 T cell populations, we investigated whether the need for OVA323-339-specific 
CD4 T cell activation, in the generation of optimal HEL105-120-specific effector CD4 T 
cells, could be replaced by treatment of the B cells with an agonistic antibody to CD40 
(FGK45). We therefore pulsed MACS-purified B cells with HEL105-120 in the presence of 
1ng/mL FGK45. The results of a single experiment of this type are shown in Figure 4.4.1. 
We found that while the generation of HEL105-120-specific cytokine producing cells in 
mice given B cells pulsed with HEL105-120 in the presence of FGK45 was not as potent as 
when mice were given B cells pulsed with both HEL105-120 and OVA323-339, there was 
nevertheless a significant increase in the numbers of HEL105-120-specific effector CD4 T 
cells generated when compared with mice given B cells pulsed with HEL105-120 alone. 
These results suggested that CD40 stimulation may play a role in CD4 T cell cooperation, 
and therefore we chose to pursue this further. Curiously, the inclusion of an antibody 
known to aggregate the BCR appeared to reverse the effect of FGK45. Despite the low 
numbers of mice, this finding is interesting and, in retrospect, may be due to inactivation 
of B cells by this antibody. We did not further address this possibility. 
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Figure 4.4.1 Peptide-pulsed B cells, activated in vitro by anti-CD40 antibody, elicit 
increased numbers of HEL105-120-specific effector CD4 T cells than B cells not activated 
with anti-CD40.  MACS purified B cells were cultured overnight in the presence of either 
50µM HEL105-120 alone, 50µM each of HEL105-120 and OVA323-339, 50µM HEL105-120 with 
1ng/mL FGK45 (agonist antibody to CD40), or 50µM HEL105-120 with 1ng/mL FGK45 
and 1µg/mL soluble anti-immunoglobulin antibody. After harvest and extensive washing, 
BALB/c mice, seeded with 105 CD4+ DO11.10 T cells, were injected with 3.5 x 106 
cultured B cells on days 0, 3, and 6, subcutaneously in the footpad and lower leg. On day 
9 after the first injection, the HEL105-120 and OVA323-339-specific cytokine-producing cells 
in the spleens were enumerated by ELISpot assays, in mice injected with either HEL105-
120-pulsed B cells (H), HEL105-120 and OVA323-339-pulsed B cells (H+O), HEL105-120 with 
FGK45 pulsed B cells (H + !CD40), or HEL105-120 with FGK45 and anti-immunoglobulin 
(H+ !CD40+ !Ig). Each data point represents the number of specific ELISpot-forming 
cells in the lymphoid organ of a single mouse. P-values indicate the probability that the 
means of the indicated samples are not different as assessed by unpaired, two-tailed T-
tests. These are the results of a single experiment with three mice per group (n = 3).  
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 To determine whether CD40 stimulation could replace the need for OVA323-339-
specific T cells for the enhanced generation of HEL105-120-specific effector CD4 T cells, 
we decided to undertake the following experiment. APC were cultured overnight in the 
presence of MACS purified CD4 T cells from WT, as a negative control, or DO11.10 
transgenic mice, and in the presence of OVA323-339. We hypothesized that these culture 
conditions would result in the antigen-specific activation of DO11.10 CD4 T cells, 
leading to the corresponding activation of the B cells presenting OVA323-339. In identical 
parallel cultures, we stimulated B cells with 10µg/mL FGK45 (a concentration 
commonly employed to activate B cells in vitro (Godfrey, Fagnoni et al. 1994)). As a 
negative control, APC were cultured in the presence of an isotype-matched control 
antibody. After an initial 24 hours of culture, the splenocytes from these cultures were 
harvested, washed briefly, and re-suspended in fresh media containing 50µM HEL105-120. 
After overnight pulsing, the B cells from these cultures were purified by negative 
selection using MACS and were assessed for their activation status by flow cytometry. 
Figure 4.4.2 shows the activated phenotype of B cells cultured with DO11.10 CD4 T 
cells and OVA323-339 and of B cells cultured with FGK45. These cells express increased 
levels of CD86 and have increased cell size compared to their corresponding isotype 
control mAb-treated B cells. Interestingly, B cells activated by specific CD4 T cells and 
those activated by FGK45 appear very similar in their expression of CD86 and cell size.  
 We next assessed whether HEL105-120-pulsed, purified, B cells, activated in culture 
as above, enhance the generation of HEL105-specific effector cells upon adoptive transfer. 
We observed significant increases in HEL105-120-specific IL-4 producing effector CD4 T 
cell generation in mice that were injected with B cells primed with FGK45 compared to 
mice given B cells treated with control antibody (Figure 4.4.3). We did not observe 
significant increases in IL-4 producing HEL105-120-specific CD4 T cells in mice given B 
cells activated in vitro by DO11.10 T cells. There was, however, a trend in the same 
direction as was observed in mice given FGK45-activated B cells. It appears that CD4 T 
cell cooperation can be partially replaced by CD40 ligation on B cells. We therefore 
concluded that the CD40-CD40L interaction may contribute to cooperation between 
populations of CD4 T cells.  
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Figure 4.4.2 Phenotype of purified B cells isolated from peptide-pulsing cultures under 
activating conditions. MACS-purified B cells were cultured for 24 hours under the 
conditions shown at a final density of 106/well in a 96-well V-bottom plate. These 
cultures contained either 105 MACS purified wild-type CD4 T cells with 1µM OVA323-339 
, 105 DO11.10 CD4 T cells with 1µM OVA323-339, 10µg/mL of the isotype-matched 
control antibody 2A3, or 10µg/mL FGK45. All cells were harvested washed and re-
plated in 3mL fresh media with 50µM HEL and cultured overnight in 60mm tissue 
culture dishes. After this overnight culture B cells were isolated by MACS negative 
selection and stained for the surface markers indicated with fluorophore-conjugated 
antibodies. Assessment, by flow-cytometry, of the proportion of cells that express these 
markers of the total population of isolated cells is shown. Grey, dotted, histograms show 
the level of fluorescence of cells stained with a matched fluorophore-conjugated isotype-
matched control antibody. Data presented are representative of values from two 
independent experiments.  
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Figure 4.4.3 Peptide-pulsed B cells, activated by anti-CD40 antibody in vitro, elicit 
increased numbers of HEL105-120-specific effector CD4 T cells than B cells incubated with 
isotype-control antibody. Total spleen cells were cultured for 24 hours at a final density 
of 106/well in a 96-well V-bottom plate. Splencoytes were co-cultured with either 105 
MACS purified WT CD4 T cells with 1µM OVA323-339 , 10
5 DO11.10 CD4 T cells with 
1µM OVA323-339, 10µg/mL of the isotype-matched control antibody 2A3, or 10µg/mL 
FGK45. All cells were harvested washed and re-plated in 3mL fresh media with 50µM 
HEL and cultured overnight in 60mm tissue culture dishes. After this overnight culture B 
cells were isolated by MACS negative selection and 3.5 x 106 cells were injected 
subcutaneously in the footpad and lower leg of each BALB/c mouse,. This procedure was 
repeated twice more such that injections were given on days 0, 3, and 6. On day 9 after 
the first injection, the HEL105-120-specific cytokine-producing cells in the spleens and 
draining lymph nodes (DLN) were enumerated by ELISpot, in mice given B cells 
cultured with WT CD4 T cells (WT), B cells cultured with DO11.10 CD4 T cells 
(DO11.10). B cells cultured with control antibody (iso. cont.), and B cells cultured with 
FGK45 (FGK45). Each data point represents the number of specific ELISpot-forming 
cells in the lymphoid organ of a single mouse. P-values indicate the probability that the 
means of the indicated samples are not different as assessed by unpaired, two-tailed T-
tests. Data presented are values pooled from two independent experiments with three 
mice per group (n = 6).  
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 In our previous studies we identified the OX40-OX40L interaction as critical in 
cooperative responses between CD4 T cells. Thus it was logical to investigate whether 
this interaction also played a role in CD4 T cell cooperation mediated by pulsed B cells. 
Because we were able to replace the need for OVA323-339-specific CD4 T cell activation 
for the enhanced generation of HEL105-120-specific effector CD4 T cells with FGK45, we 
investigated whether this interaction induced the expression of OX40L in B cells. 
Examination of B cells, activated in culture, for OX40L protein expression was not 
successful. B cell staining with antibodies specific for OX40L was not detectable by 
either flow cytometry or western blots when using the same monoclonal antibody clone. 
However, it was not clear whether these techniques were not sufficiently sensitive to 
detect OX40L on pulsed B cells. We therefore examined the expression of OX40L 
mRNA in activated B cell cultures using quantitative real time polymerase chain reaction 
(qRTPCR). Figure 4.4.4. presents the results of the qRT-PCR experiment. It is clear that 
B cells, when cultured using the experimental conditions examined, expressed equivalent 
amounts of OX40L transcripts. This finding, while somewhat surprising, indicated to us 
that perhaps preferential priming of CD4 T cells, by B cells, which appear to express 
OX40L at similar levels regardless of their state of activation, could be a general 
mechanism of CD4 T cell cooperation. Alternatively, the culture conditions employed in 
our experiment may have influenced the expression of OX40L mRNA in our B cells. 
Moreover, we cannot rule out the possibility that post-transcriptional regulation of 
OX40L message occurred in these B cells. We attempted to determine whether OX40L 
expression is induced on APC presenting OVA323-339 to DO11.10 CD4 T cells in vivo. 
Total splenocytes were pulsed with HEL105-120 alone or with HEL105-120 and OVA323-339 
together, labeled with CFSE, and injected into the footpad of mice seeded with 105 
DO11.10 CD4 T cells. 48 hours after this injection, the DLN of three individual mice per 
group were pooled and the CFSE+ cells from these lymph nodes were sorted with a 
fluorescence activated cell sorter (FACS). Figure 4.4.5A demonstrates that the CFSE+ T 
cells were purified from approximately 0.3% of the total lymph node, to over 40% purity. 
A very small number, 104, of CFSE+ cells were isolated and thus yielded small amounts 
of mRNA. We performed qRTPCR on samples of cDNA derived from 104 CFSE+ cells.  
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Figure 4.4.4 Expression of OX40L mRNA in B cells activated by CD4 T cells or anti 
CD40 agonistic antibody. Total spleen cells were cultured for 24 hours at a final density 
of 106/well in a 96-well V-bottom plate. These cultures contained either 105 MACS 
purified WT CD4 T cells with 1µM OVA323-339 , 10
5 DO11.10 CD4 T cells with 1µM 
OVA323-339, 10µg/mL of the isotype-matched control antibody 2A3, or 10µg/mL FGK45. 
All cells were harvested washed and re-plated in 3mL fresh media with 50µM HEL and 
cultured overnight in 60mm tissue culture dishes. After this overnight culture B cells 
were isolated by MACS negative selection and the mRNA was isolated by passage over 
QIAGEN RNAeasy spin columns. Copy DNA was prepared, employing the BioRad 
iScript kit. Sequences corresponding to roughly 400bp of the primary sequence of mouse 
!-actin, and mouse OX40L were amplified in triplicate in the presence of EvaGreen dye 
to allow detection of amplified DNA. (A) Raw data from qRTPCR run showing observed 
Ct in all wells. !-actin and OX40L cDNA-dependent fluorescence clustered tightly, as 
indicated. (B) Relative gene expression of OX40L, based on ""Ct and normalized to 
control treated B cells is shown. 
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We were able to confirm the expression of !-actin as a positive control, however OX40L 
mRNA expression in these cells was detected at very high Ct values (Figure 4.4.5B). In 
some cases, the signal from template-negative control wells, a result of primer dimer 
formation, was higher than in experimental wells indicating that the levels of OX40L 
cDNA in our samples was exceedingly low. Moreover, the quantity of cDNA generated 
was very small, precluding extensive analysis. Because of the complexity of this type of 
experiment, we did not further pursue these findings. It is possible that at the time point 
investigated OX40L expression had not yet been induced on APC. Though these 
experiments were possibly complicated by the tight regulation of expression of OX40L, 
this type of experiment may be a viable way to analyze the phenotype of adoptively 
transferred APC in the future. In any case, we sought to obtain functional data on the role 
of OX40L in our system when peptides were presented only by pulsed, purified B cells.  
 With some evidence that OX40L was expressed by B cells, and that ligation of 
CD40 on these B cells is sufficient to allow for increased generation of HEL105-120-specific 
effector cells when pulsed B cells are adoptively transferred, we sought functional 
evidence that OX40-OX40L interactions were involved in cooperation between 
populations of CD4 T cells. We first confirmed that stimulation with a monoclonal 
antibody specific for OX40 could enhance the generation of peptide-specific effector 
CD4 generation when peptides were presented by pulsed APC. As shown in Figure 4.4.6, 
administration of the OX40 agonistic antibody OX86 potently and significantly increased 
the generation of peptide-specific cytokine producing cells in mice injected with peptide-
pulsed APC in. It was clear that ligation of OX40 increased the generation of these cells 
substantially above the levels seen in control antibody-treated mice. We observed 
decreases in the numbers of effector cells in the DLN, possibly due to efflux of highly 
activated CD4 T cells. Thus, it appears that signaling through OX40 is not saturated 
during CD4 T cell cooperation.  
 We next performed an experiment to address whether OX40-OX40L interactions 
are critically involved in the generation of cooperative responses between CD4 T cells 
when B cells present antigen. We duplicated our experiments employing HEL105-120-
pulsed or HEL105-120 and OVA323-339-pulsed MACS purified B cells in the presence or 
absence of a blocking antibody for OX40L. 
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Figure 4.4.5. Fluorescence activated cell sorting of peptide-pulsed APC 48 hours after 
injection and assessment of OX40L mRNA expression. Splenocytes were cultured 
overnight in the presence of either 50µM HEL105-120 alone or 50µM OVA323-339 and 
HEL105-120. After washing, the remaining cells from each culture were labeled with CFSE 
and 107 were injected subcutaneously into the hind footpad of three Balb/c mice that were 
seeded, one day before, with 105 DO11.10 CD4 T cells. 48h following this injection, the 
draining popliteal lymph nodes, from mice of each group, were harvested and pooled. 
These lymph node cells were then sorted by a fluorescence activated cell sorter based on 
CFSE. (A) Pre- and post-sort proportions of CFSE+ cells from lymph nodes. (B) After 
cell sorting, mRNA was isolated from CFSE+ enriched populations by passage over 
QIAGEN RNAeasy spin columns. cDNA libraries were prepared, employing the BioRad 
iScript kit. Sequences corresponding to roughly 400bp of the primary sequence of mouse 
!-actin, and mouse OX40L were amplified in triplicate the presence of EvaGreen dye to 
allow detection of amplified DNA. 
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Figure 4.4.6 The generation of HEL105-120-specific effector CD4 T cells by peptide-pulsed 
APC is enhanced by an agonistic antibody to OX40. One day prior to injection of pulsed 
splenocytes, normal BALB/c mice were seeded with 105 MACS purified CD4+ 
DO11.10+ T cells. BALB/c splenocytes were cultured overnight, as described in Chapter 
2, in the presence of 50µM HEL105-120 alone, or 50µM of each of HEL105-120  and OVA323-
339. Following harvest and extensive washing, 10
7 peptide-pulsed splenocytes in 50µL 
Leibovitz media were injected subcutaneously into the footpad and lower leg of normal 
BALB/c mice on days 0, 3, and 6. At the time when pulsed splenocyte were injected the  
mice were also injected intravenously with 50µg of either an isotype-matched control 
antibody (iso. cont.) or with the OX40 agonistic antibody (OX40 agonist). Nine days 
after the initial injection of pulsed splenocytes, the HEL105-120 and OVA323-339-specific 
cytokine producing cells in the spleens and draining popliteal lymph nodes (DLN) were 
enumerated by ELISpot in mice given only HEL105-120-pulsed splenocytes (H), and in 
mice given splenocytes pulsed with both HEL105-120 and OVA323-339 (H+O). Each data 
point represents the number of specific ELISpot-forming cells in the popliteal lymph 
node of individual mice. P-values indicate the probability that the means of the indicated 
samples are not different as assessed by unpaired, two-tailed T-tests. These are the results 
of a single experiment with three mice per group (n = 3).  
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 We observed not only a complete abrogation of cooperative generation of HEL105-120-
specicfic responses mediated by B cells pulsed with both peptides, but also a severe 
limitation in the generation of CD4 T cells specific for either peptide (Figure 4.4.7). We 
conclude that when B cells are the sole APC presenting peptide, that OX40-OX40L 
interactions are critical for the generation of effector CD4 T cells. This finding contrasts 
with our earlier findings that OX40-OX40L interactions only are critical for the 
cooperative enhancement of effector CD4 T cells. When four HEL peptide-specific CD4 
T cell populations cooperate to enhance the generation of HEL105-120-specific CD4 
effector T cells, blocking OX40L blocked only the cooperation dependent component of 
T cell activation and not activation of individual peptide-specific T cell populations.. 
However, when B cells are the sole APC loaded with peptide, OX40L is critically 
important for the generation of all peptide-specific cytokine-producing CD4 T cells. 
Taking these two findings together, we conclude that a major role for B cells as APC, in 
activating CD4 T cells, is to mediate cooperation between them. Whether this 
corresponds with B cell effector function, such as antibody production, has not been 
addressed.  
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Figure 4.4.7. OX40L blockade significantly impairs the generation of peptide-specific 
cytokine producing effector CD4 T cells following injection of peptide-pulsed purified B 
cells. One day prior to injection of pulsed B cells, BALB/c mice were injected with 105 
MACS purified CD4+ DO11.10+ T cells. BALB/c splenocytes were cultured overnight, 
as described in Chapter 2, in the presence of either 50µM HEL105-120 alone or 50µM of 
both HEL105-120 and OVA323-339. Following splenocyte harvest, B cells were isolated by 
MACS negative selection and 3.5 x 106 peptide-pulsed B cells in 50µL Leibovitz media 
were injected subcutaneously into the footpad and lower leg of normal BALB/c mice on 
days 0, 3, and 6. With each B cell injection, mice were injected intravenously with either 
50µg of an isotype-matched control antibody (iso. cont.) or with an OX40 blocking 
antibody (OX40 blocker). Nine days after the initial injection of pulsed splenocytes, the 
HEL105-120 and OVA323-339-specific cytokine producing cells in the spleens and draining 
popliteal lymph nodes (DLN) were enumerated by ELISpot for mice given only HEL105-
120-pulsed B cell (H), and in mice injected with B cells pulsed with both HEL105-120 and 
OVA323-339 (H+O). Each data point represents the number of specific ELISpot-forming 
cells in the spleen and popliteal lymph node of individual mice. P-values indicate the 
probability that the means of the indicated samples are not different as assessed by 
unpaired, two-tailed T-tests. Data presented are values pooled from three independent 
experiments with three mice per group (n = 9). 
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4.5 Functional Consequences of CD4 T cell Cooperation 
 
 Through the findings reported in this and previous chapters, we describe 
observations and give insights into the cellular and molecular mechanisms involved in 
cooperation between CD4 T cell populations that give rise to increased generation of 
effector cells. We have demonstrated that cooperation between OVA323-339 and HEL105-120-
specific populations results in enhanced generation of primary HEL105-120-specific 
responses. We chose to assess whether these enhanced primary immune responses could 
potentially have functional consequences in terms of immune responses.  
A hallmark of the adaptive immune response is the ability to generate 
immunological memory. Upon secondary exposure to the same pathogen, or 
experimental antigen “memory” lymphocytes respond to this antigen again often 
inducing secondary immune responses that are of greater magnitude and the response 
occurs more quickly than the primary response. CD4 effector T cells can transition into 
memory cells and be maintained over time to facilitate these rapid secondary immune 
responses of greater magnitude. The quality of this secondary response is often associated 
with factors that influence effector CD4 T cell generation during the primary phase 
(Pepper and Jenkins). Thus we investigated whether cooperative enhancement of HEL105-
120 specific effector CD4 T cells during the primary response would result in enhanced 
secondary immune responses. 
To address whether cooperation between OVA323-339 and HEL105-120 specific CD4 T 
cells, mediated by dual peptide pulsed B cells, resulted in enhanced memory, we 
undertook the following experiment. BALB/c mice were first injected with CD4 T cells 
from DO11.10 mice and after 24 h were injected with MACS purified B cells pulsed with 
OVA323-339 alone, HEL105-120 alone, or HEL105-120 and OVA323-339 together, as per our 
standard protocol. These mice were left for seven weeks, sufficient time for effector CD4 
transition to memory cells. We then challenged these mice with HEL protein and 
assessed the characteristics of the secondary immune response.  
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Figure 4.5.1 Cooperative enhancement of HEL105-120-specific effector CD4 T cell 
generation results in increased HEL105-120-specific effector cell responses following 
secondary immunization. One day prior to injection of pulsed splenocytes, BALB/c mice 
were seeded with 105 MACS purified CD4+ DO11.10+ T cells. BALB/c slpenocytes 
were cultured overnight, as described in Chapter 2, in the presence of either 50µM 
OVA323-339 alone, 50µM HEL105-120 alone, or 50µM of both HEL105-120  and OVA323-339. 
Following splenocyte harvest, B cells were isolated by MACS negative selection and 3.5 
x 106 peptide-pulsed B cells in 50µL Leibovitz media were injected subcutaneously into 
the footpad and lower leg of BALB/c mice on days 0, 3, and 6. Seven weeks later all 
mice were injected intraperitoneally with 100ug heat-aggregated HEL protein in saline. 
Ten days post-challenge the HEL105-120-specific cytokine producing cells in the spleen of 
mice given OVA323-339-pulsed B cells (O), HEL105-120-pulsed B cells (H), and OVA323-339 
and HEL105-120-pulsed B cells (H+O) were assessed by ELISpot. Each data point 
represents the number of specific ELISpot-forming cells in the spleen of a single mouse. 
P-values indicate the probability that the means of the indicated samples are not different 
as assessed by unpaired, two-tailed T-tests. The data presented are values pooled from 
three independent experiments with two to three mice per group (n = 8). 
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We observed very little HEL105-120-specific cytokine production in mice primed with 
OVA323-339-pulsed B cells. Those mice that had been primed with HEL105-120-pulsed B cells 
generated moderate numbers of IL-2 and IL-4 producing HEL105-120-specific effector cells 
following secondary immunization. Strikingly, mice that were primed with B cells pulsed 
with both HEL105-120 and OVA323-339 produced significantly greater numbers of HEL105-120-
specific IFN! and IL-4 producing effector CD4 T cells following secondary 
immunization with HEL protein (Figure 4.5.1).  
 These observations support the conclusion that CD4 cell cooperation during the 
primary immune response resulted in enhanced memory CD4 T cells and significantly 
increased anamnestic responses. This functional outcome is consistent with our finding 
that OX40-OX40L interactions are critical in CD4 T cell cooperation as others have 
shown that OX40 stimulation of effector CD4 T cells resulted in enhanced T cell survival 
and memory cell commitment (see section 1.5).  
 
4.6 Conclusions 
 
 In summary, I developed an experimental model involving peptide-pulsing of 
APC in vitro and the adoptive transfer of peptide-pulsed APC to investigate functional 
cooperation between CD4 T cell subpopulations. We demonstrated that for cooperation to 
occur between two peptide-specific subpopulations of CD4 T cells, both peptides must be 
presented by the same APC. We observed that this APC could be a B cell and that splenic 
DCs, under the conditions used, did not efficiently mediate cooperation between CD4 T 
cells. We confirmed with this system that OX40-OX40L interactions were critical for 
CD4 T cells cooperation; these interactions were vital for effector CD4 T cell generation 
when B cells alone were loaded with peptide. Finally, we show that enhanced generation 
of primary CD4 T cells through CD4 T cell cooperation can support enhanced secondary 
immune responses.  
 Taking our results together, we conclude that CD4 T cell cooperation, when B 
cells function as the APC, has the potential to influence the magnitude of both primary 
and secondary immune responses. 
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5.0 CHAPTER 5. INVESTIGATIONS OF THE MECHANISMS OF 
TOLERANCE INDUCTION IN CD4 T CELLS 
 
5.1 Introduction 
 
 While the immune system is effective in defending animals from invasion by 
pathogens it also has the potential to cause serious damage to endogenous tissues. Thus, 
maintenance of tolerance to self-components is of central importance for survival in 
animals that possess immune systems. This importance was recognized by early 
immunologists, like Paul Ehrlich, who were aware that antibodies had the capacity to 
cause lysis of host erythrocytes and that in certain pathological situations, antibodies that 
lead to erythrocyte lysis arise endogenously. As discussed in section 1.2, maintenance of 
self-tolerance in T cells occurs by a number of mechanisms. Mature, peripheral, CD4 T 
cells that encounter peptide-MHCII complexes, for which their TCR has affinity, results 
in either activation or inactivation of these cells depending on additional information 
relayed to the CD4 T cell. The additional information required, termed the second signal, 
controls the fate of CD4 T cells that encounter antigen. When the critical second signal is 
relayed to CD4 T cells, they become activated; if this signal is not relayed to the CD4 T 
cell, it is inactivated, undergoing apoptosis or becoming anergic, removing itself from the 
T cell repertoire. Therefore, the circumstances that control the availability of the critical 
second signal determine the fate of CD4 T cells upon antigen encounter. 
 The above-described paradigm for how the activation-inactivation decision is 
made in CD4 T cells is known as the two-signal hypothesis. The most pervasive current 
view, for how the second signal is controlled, stems from the adaptation of the two-signal 
hypothesis by Lafferty and Cunningham (Lafferty and Cunningham 1975). This model 
holds that certain antigen-presenting cell types possess heightened levels of co-
stimulatory molecules on their surface, and that these co-stimulatory molecules are the 
! 210 
necessary and sufficient providers of the critical second signal for T cell activation. 
Numerous observations, made over the past forty years, support this model. However, 
within our laboratory, there have been some who propound a somewhat different model 
for how a critical second signal arises during the generation of immune responses. The 
two-step, two-signal model, put forward by Bretscher in 1999, proposes that the initial 
interaction of CD4 T cells with APC, like DC, activated in such a way that they express 
high-levels of co-stimulatory molecules, is in itself insufficient to result in full activation 
of CD4 T cells. In this model the critical second signal for CD4 T cells, thought to result 
in full activation and acquisition of effector function, is generated uniquely upon the 
interaction of two or more CD4 T cells. Additionally, the interaction of these CD4 T 
cells, as envisaged by Bretscher, is mediated by a B cell to which both T cells bind. 
 As I have demonstrated in the previous two chapters, CD4 T cells having different 
antigen specificities, appear to interact with one another, leading to an enhancement of 
CD4 effector function. I have also shown that B cells play a critical role in mediating this 
cooperative enhancement. However, our data do not indicate that cooperation, amongst 
CD4 T cells, is essential for the generation of effector CD4 T cells as we did not observe 
situations where no effector CD4 T cells were generated upon immunization. Implicit in 
the two-step, two-signal model is that the result of failing to achieve a cooperative 
interaction between CD4 T cells is inactivation of these cells. Again our data, shown in 
the previous chapters, do not appear to support this aspect of the hypothesis. However, it 
is possible that cooperation amongst CD4 T cells, specific for the same peptide, occurs in 
responses to single peptides, thereby leading to cooperation that is not detectible by our 
experimental design. Furthermore, it is possible that the low-level effector CD4 T cell 
generation, seen upon immunization with single peptides is reflective of a state of 
intermediate CD4 T cell activation wherein these cells may produce effector cytokine, 
but are on the pathway towards inactivation.  
  Formal attempts to address the predictions made on the two-step, two-signal 
model led to some interesting observations on the mechanisms of CD4 T cell tolerance 
and a dramatic change in our thinking on the mechanisms controlling CD4 T cell 
tolerance. Below, I present findings that indicate that CD4 T cell cooperation could be 
involved in the activation/inactivation decision of CD4 T cells that bind self-antigens.  
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5.2 Tolerance Induction by Administration of High-Dose Peptide in Naive CD4 T 
cells and Attempts to Prevent it 
 
 Based on the two-step, two-signal model for the primary activation of CD4 T 
cells, one would predict that CD4 T cells that fail to undergo a cooperative interaction, 
following TCR ligation, will be inactivated and eventually undergo cell death. 
Conversely, if, under similar conditions, the CD4 T cell encounters signals mediated 
through CD4 T cell activation of a B cell, then it should become a fully activated effector 
cell. Therefore, it would seem that activation, as a consequence of CD4 T cell 
cooperation, would be dominant over tolerance induction. That is, cooperation should be 
able to rescue CD4 T cells from apoptosis caused by interaction with antigen in a 
tolerogenic fashion. This was our working model at the outset of these studies.   
 In order to address whether CD4 T cell cooperation could rescue CD4 T cells 
from becoming deleted in response to antigen, we developed a protocol that would 
normally induce tolerance of peptide specific CD4 T cells. We found that the 
administration of high doses of HEL105-120 in IFA was tolerogenic, this is in accordance 
with other studies (Murphy, Heimberger et al. 1990; Kearney, Pape et al. 1994; Peters, 
Kroeger et al. 2009). Figure 5.2.1 shows an example of a titration of HEL105-120 given in 
IFA to mice.  Although the tolerance was only seen clearly in the generation of IL-2-
producing cells, we found that inactivation of HEL105-120-specific CD4 T cells was readily 
accomplished by administration of this peptide in IFA. A dose of approximately 200µg 
given intraperitoneally was needed to achieve reliable tolerance.  
 Having established a protocol wherein reliable peptide-specific CD4 T cell 
unresponsiveness could be established, we attempted to rescue the CD4 T cells by 
arranging for cooperative events to occur. Figure 5.2.2 displays the results of such an 
attempt. Mice were given 200µg of HEL105-120 intraperitoneally and were also immunized 
with HEL105-120 together with the three other HEL peptides responded to normally in 
BALB/c mice. This latter immunization normally results in fairly robust activation of 
CD4 T cells specific for HEL105-120 (see Chapter 3 of this thesis). 
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Figure 5.2.1 A Titration of HEL105-120, given intraperitoneally in IFA, with a subsequent 
HEL105-120 in CFA challenge. Normal BALB/c mice were injected intraperitoneally with 
200µL of IFA emulsion containing graduated doses of HEL105-120, or were not injected 
(N). Fourteen days after this initial injection, all mice were challenged with 10µg HEL105-
120 in CFA. Ten days post-challenge, the HEL105-120-specific cytokine-producing cells, in 
the spleen of challenged mice, were enumerated by ELISpot. Each data point represents 
the number of specific ELISpot-forming cells in the spleen of a single mouse. P-values 
indicate the probability that the means of the indicated samples are not different as 
assessed by unpaired, two-tailed T-tests. This is the result of a single representative 
experiment with three mice per group (n = 3) of at least three similar experiments.  
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Control mice, immunized with four HEL peptides in IFA subcutaneously and given only 
IFA intraperitoneally exhibit the expected enhanced generation of HEL105-120 specific 
cytokine-producing T cells, at the time when these were enumerated, during the primary 
response to administered peptides, ten days post-immunization. However, all mice that 
were treated with 200µg of HEL105-120 showed no sign of peptide-specific effectors cells 
on day 10. Following challenge with HEL protein on ALUM, we observed a similar 
pattern on HEL105-120-specific effector CD4 T cells with the exception of mice that 
received four HEL peptides subcutaneously at the same time as a tolerogenic dose of 
HEL105-120 intraperitoneally. These mice had more HEL105-120-specific cytokine-producing 
CD4 T cells, on average, than did mice given HEL105-120 alone subcutaneously with 200µg 
of HEL105-120 intraperitoneally. Thus, while these results did not reach statistical 
significance, it appears that this protocol may have resulted in rescuing of at least some 
CD4 T cells specific for HEL105-120 that would have normally become inactivated.  
However, the above experiment is not without its complications. An alternative 
interpretation of the results shown in Figure 5.2.2, on more conventional theories of CD4 
T cell activation, is that the CD4 T cells that recognize HEL105-120 on APC from lymph 
nodes draining the subcutaneous IFA depot are activated and sequestered within those 
lymph nodes, where they may continually see the antigen in an immunogenic way. If this 
is the case, then these cells are not rescued, per se, but are sheltered from experiencing 
antigen in a tolerogenic context. Because of this difficulty, we decided that in order to 
test whether additional substances, given at the time of tolerance induction, could rescue 
HEL105-120-specific CD4 T cells, they should be directly incorporated into IFA containing 
a high dose of HEL105-120. We undertook numerous experiments attempting to rescue 
HEL105-120-specific CD4 T cells from becoming inactivated by high-doses of the peptide. 
However, we were not able to observe rescuing. For brevity, I will not describe the 
results of these studies, save one.  
 Since we had not been able to rescue or prevent inactivation of HEL105-120-specific 
CD4 T cells in mice injected with IFA containing 200µg of this peptide, we chose to 
investigate whether we could rescue the cells by introducing the peptide in CFA. As we 
have shown, CFA contains mycobacterial antigens that can elicit cooperating CD4 T cells 
(Figure 1.2.1). 
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Figure 5.2.2. Partial prevention of tolerance in mice given four HEL peptides, together 
in IFA, and high-dose HEL105-120 in IFA. All normal BALB/c mice were injected with two 
IFA emulsions, one at the tail base, and the other intraperitoneally. Peptides incorporated 
into these emulsions were 10µg HEL105-120 (H), 10µg each of HEL11-25, HEL48-63, HEL74-96, 
and HEL105-120 (4Hp), or 200µg HEL105-120 (200µg H). Some mice were sacrificed on day 
ten post-injection for enumeration of the HEL105-120-specific cytokine producing cells in 
the spleen. The remaining mice were challenged with 100µg heat-aggregated HEL on 
ALUM on day fourteen post-injection. Ten days post-challenge, the HEL105-120-specific 
cytokine-producing cells, in the spleen of challenged mice, were enumerated by ELISpot. 
Each data point represents the number of specific ELISpot-forming cells in the spleen of 
a single mouse. This is the result of a single experiment with three mice per group (n = 
3). 
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 Moreover, CFA contains many TLR ligands and other inflammatory mediators capable 
of activating APC. We reasoned that, whether one subscribes to conventional theories for 
the activation of CD4 T cells, or to the two-step, two-signal model, both would predict 
that high doses of the peptide, administered in CFA, would cause activation of HEL105-120-
specific CD4 T cells. As can be seen in Figure 5.2.3, administration of 200µg of HEL105-
120 in CFA intraperitoneally to BALB/c mice renders them tolerant of this peptide. We did 
not observe activation of peptide-specific CD4 T cells in primary instances in similarly 
injected mice (not shown). From these results we conclude that one of two possible 
phenomenon occur when high-dose peptide is administered in CFA. Either CD4 T cells, 
never having been activated, are inactivated directly, which seems unlikely given the 
properties of CFA, or CD4 T cells are activated by peptide in CFA and are subsequently 
inactivated. The latter possibility seemed to defy conventional knowledge. T cells were 
once thought to be subject to induction of tolerance only prior to activation. As it turns 
out, a number of studies have demonstrated that inactivation of CD4 T cells in virtually 
any state of activation is readily achievable by administration of antigen in a tolerogenic 
fashion (Critchfield, Racke et al. 1994; Higgins, Mihalyo et al. 2002; Steptoe, Ritchie et 
al. 2007; Kenna, Thomas et al. 2008; Doan, McNally et al. 2009; Kenna, Waldie et al. 
2010; Nasreen, Waldie et al. 2010) (see section 1.2 for a discussion of this).   
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Figure 5.2.3. High dose HEL105-120, given subcutaneously in CFA, is tolerogenic. BALB/c 
mice either with CFA/saline, or with CFA containing 200µg HEL105-120, subcutaneously at 
the tail base. Fourteen days post-injection, all mice were challenged with 100µg heat-
aggregated HEL on ALUM, intraperitoneally. Ten days post-challenge, the HEL105-120-
specific cytokine-producing cells, in the spleen of challenged mice, were enumerated by 
ELISpot. Each data point represents the number of specific ELISpot-forming cells in the 
spleen of a single mouse. P-values indicate the probability that the means of the indicated 
samples are not different as assessed by unpaired, two-tailed T-tests.  This is the result of 
a single representative experiment, of two similar experiments, with six mice per group 
(n = 6). 
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5.3 Tolerance Induction in Activated CD4 T Cells by High-Dose Peptide 
 
 The finding that high doses of peptide, given in IFA or CFA, consistently led to 
inactivation of HEL105-120-specific CD4 T cells in our hands, gave us reason to 
hypothesize that fully activated CD4 effector CD4 T cells could be inactivated by 
administration of high doses of peptide. We think that differential diffusion rates of the 
peptide vs the inflammatory mediators might be responsible for T cell inactivation. CD4 
T cells specific for HEL105-120 would be initially activated at the injection site by APC 
presenting this peptide that had been stimulated by the inflammatory molecules contained 
in CFA. The activated T cells would then circulate to distal sites where peptide is 
presented, having diffused throughout the body, but would be inactivated by “immature, 
or inactive” APC, if the inflammatory mediators had not diffused throughout the body. 
We wished to test the hypothesis as directly as possible. In our primary experiment, we 
attempted in inactivate activated CD4 T by the administration of high dose peptide in 
vivo. We activated CD4 T cells in vivo, by injecting the footpad with low doses of 
HEL105-120, in CFA. From previous work, we knew seen that day ten was the peak of the 
generation of HEL105-120-specific cytokine-producing cells in the spleen following 
immunization in this way. We reasoned that by the peak of effector cell generation, most 
HEL105-120-specific CD4 precursor T cells would have been recruited into the effector 
pool. We therefore chose, first, to attempt to inactivate HEL105-120-specific CD4 T cells at 
the peak of their effector phase. Beginning on day ten post-immunization, mice were 
given either saline or a standard tolerization dose of 300, 100, 100µg HEL105-120, 
intravenously, every five days. On the fourteenth day following the first tolerization 
injection, mice were challenged with heat-aggregated HEL on ALUM. Ten days post-
challenge, we enumerated the HEL105-120 peptide specific cytokine producing cells in 
the spleen of the putatively tolerized mice. We observed that mice that were treated with 
high tolerization doses of HEL105-120 were almost completely unable to generate cytokine 
producing CD4 T cells specific for the peptide (Figure 5.3.1). The number of HEL105-120 
specific cytokine producing cells in the spleens of control-treated mice was significantly 
greater than the number in peptide-treated mice. From this finding, we conclude that 
effector CD4 T cells are sensitive to inactivation by high-dose peptide.  
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Figure 5.3.1. Inactivation of activated HEL105-120-specific CD4 T cells can be induced by 
high-dose peptide given at the peak of the effector phase. All BALB/c mice were injected 
with 10µg HEL105-120 in CFA, subcutaneously in the hind footpad. Ten days later, mice 
were treated intravenously with saline alone (saline) or with 300µg of HEL105-120 in saline 
(Tol). Five and ten days after this first treatment, all mice were treated intravenously with 
either saline (saline) or with 100µg HEL105-120 (Tol). Twenty-five days after the initial 
CFA injection, mice were challenged with 100µg heat-aggregated HEL on ALUM 
intraperitoneally. Ten days post-challenge, the HEL105-120-specific cytokine-producing 
cells, in the spleen of challenged mice, were enumerated by ELISpot. Each data point 
represents the number of specific ELISpot-forming cells in the spleen of a single mouse. 
These are pooled results from three independent experiments with three mice per group 
(n = 9). 
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It was possible that inactivation of effector CD4 T cells at the peak of the primary 
response was facilitated by the normal contraction of effector cells following activation. 
To address whether activated CD4 T cells can be inactivated by peptide during the 
priming phase, we repeated the experiment shown in Figure 5.3.1, giving a single 
injection of 300µg of HEL105-120 on the day of CFA immunization or four days later. 
Figure 5.3.2. shows the results of this experiment. We observed a decrease in the 
numbers of effector cells, as assessed by measuring levels of cytokine producing cells, 
particularly in the draining lymph node of HEL105-120 treated mice, when assessed on day 
seven of the primary response. We interpret these results as evidence that effector cells 
were inactivated following the administration of 300µg HEL105-120. Thus, we conclude 
that effector CD4 T cells are susceptible to inactivation during the priming phase. 
Because we obtained clear results that were largely in line with the observations of 
others, and for ethical reasons concerning the administration of CFA into the footpad of 
mice, we did not pursue further experiments in this system. 
 
5.4 Tolerance Induction in Activated DO11.10 CD4 T Cells: I. In Vitro Cultures 
 
 Although others have published observations detailing the inactivation of 
activated T cells, we believed that our own findings were worth further exploration. 
Given our unique perspectives on the activation of CD4 T cells, and our findings of CD4 
T cell cooperation, we thought it plausible that we would make advances in 
understanding the mechanisms controlling the inactivation of activated CD4 T cells. 
Christopher Rudulier, in our laboratory, had been employing very efficient in vitro 
cultures for assessing how precursor frequency affects the Th1/Th2 phenotype of the 
CD4 T cells activated in culture. We thought that this system could be adapted to study 
the inactivation of CD4 T cells. In his cultures, CD4 T cells from DO11.10 mice, bearing 
transgene-encoded TCRs that recognize OVA323-339 in the context of I-A
d are activated by 
APC presenting OVA323-339. One particular advantage that a culture system of this type 
has over an in vivo system, is the ability to readily analyze the CD4 T cells by flow-
cytometry, due to the availability of the clonotype-specific anti-TCR antibody KJ1-26.  
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Figure 5.3.2. Inactivation of activated HEL105-120-specific CD4 T cells can be induced by 
high-dose peptide given early during the priming phase. All BALB/c mice were injected 
with 10µg HEL105-120 in CFA, subcutaneously in the hind footpad. At the time of 
injection, or four days later, mice were treated intravenously with saline alone or with 
300µg of HEL105-120 in saline (T d0 or T d4). Seven days after the initial injection of CFA, 
the HEL105-120-specific cytokine-producing cells, in the draining lymph nodes (DLN) and 
spleen, were enumerated by ELISpot. This is the result of a single experiment with three 
mice per group (n = 3). 
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The finding that CD4 T cells can be inactivated in vivo suggests that excess signal 
one, in the absence of signal two, or, more TCR signaling than co-stimulation, leads to 
their inactivation. The reasoning behind this conclusion is discussed in section 1.2. 
Briefly, administration of high dose peptide to mice, by systemic routes, is thought to 
enable presentation of this peptide by virtually all MHCII-bearing cells, since the 
majority of these cells are normally in an inactive, resting state, the majority of peptide-
MHCII complexes available for triggering TCR will not be associated with co-
stimulation. This is the basis for the steady-state model for the maintenance of T cell 
tolerance, a point to which we will return at the end of this chapter. The B-7 co-
stimulatory molecules, CD80 and CD86 are well characterized and potentially the most 
important second-signal mediating molecules. These are upregulated on activated DC and 
B cells leading to their ability to potently stimulate T cells. We hypothesized that, due to 
their major role in T cell activation, limiting their signaling may tip the balance in favor 
of excess signal one, leading to inactivation and possibly apoptosis, in culture.  
 To test whether limiting signaling through B-7 molecules could drive inactivation 
of activated T cells when exposed to cognate peptide, we sought to develop a culture 
system wherein we could manipulate the availability of either of these signals to CD4 T 
cells. In order to establish this system, we first needed a way to generate uniformly 
activated CD4 T cells. Since we planned to employ DO11.10 cells, we explored ways to 
activate these cells in culture. As Figure 5.4.1 shows, MACS purified CD4+ DO11.10 
cells from day 3 of culture produced effector cytokines (panel A) and displayed surface 
characteristics (high CD44; low CD62L; high CD86; high GITR) of activated T cells 
(panel B).  
We thus proceeded to culture these purified activated CD4 T cells under three 
different conditions. We included, as a negative control, activated CD4 T cells, with T 
cell depleted splenocytes as APC, in the absence of antigen. The experimental culture 
conditions included activated CD4 T cells with APC and OVA323-339 alone, or APC and 
OVA323-339 with CTLA-4-Ig, to block B-7 molecules. We enumerated the OVA323-339-
specific cytokine producing CD4 T cells in these three cultures on the second and fourth 
day after plating. The pooled results of three of these experiments are displayed in Figure 
5.4.2A.  
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Figure 5.4.1. CD4+ DO11.10 T cells are highly activated following three days of culture 
with 0.3µM OVA323-339 and syngeneic T cell depleted splenocytes. CD4+ DO11.10 T cells 
were isolated from the spleen of transgenic mice by MACS negative selection. 1.5 x 105 
per well of these cells were seeded into 24-well tissue culture trays containing 3 x 106 T 
cell depleted BALB/c splenocytes and 0.3µM OVA323-339 peptide. After three days of 
culture, the CD4+ T cells were re-isolated by MACS negative selection. (A) The OVA323-
339-dependent cytokine secretion of these three day activated DO11.10 cells was assessed 
by ELISpot. This is pooled data from three independent experiments. (B) The cell surface 
phenotypes of day three activated DO11.10 T cells, and freshly isolated naive DO11.10 
CD4 T cells, were assessed by flow cytometry. MACS isolated CD4+ T cells were 
greater than 95% as assessed by staining with an anti-clonotype TCR antibody (not 
shown) and thus histograms shown in B were ungated. Grey, dotted, histograms show the 
level of fluorescence of cells stained with a matched fluorophore-conjugated isotype-
matched control antibody. 
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We observed a sharp increase in the number of cytokine producing cells, in both cultures 
containing peptide, and to a lesser extent in cultures without peptide, until day two. This 
somewhat unexpected finding indicates that many of the DO11.10 CD4 T cells likely 
acquired the ability to produce cytokine after plating into secondary cultures. This is, 
therefore, a caveat to our findings, as all cells were not potently producing cytokine. 
However, given the fairly uniform expression of T cell activation markers, like CD44 and 
GITR, we judge that virtually all of these cells were at least initially stimulated before 
harvest. It is clear, from theses results, that optimal expansion, or acquisition of cytokine 
production, requires both TCR ligation and B-7 co-stimulation in this culture system. 
Cultures containing CTLA-4-Ig with OVA323-339 failed to support optimal expansion of 
cytokine-producing cells, while those cultures without antigen appeared to allow very 
slow expansion, possibly due to residual priming from the initial culture. By day four of 
culture, there was clear evidence that blocking B-7 co-stimulation influenced the cytokine 
secretion of the activated CD4 T cells in culture. We observed consistent declines in the 
numbers of cytokine-producing cells in both cultures containing peptide, possibly due to 
activation induced death of the effector CD4 T cells. However, the drop in numbers of 
OVA323-339-specific effector CD4 T cells in cultures containing CTLA-4-Ig was greater 
proportionally; for all cytokines investigated, the number of cytokine producing cells in 
cultures containing OVA323-339 and CTLA-4-Ig was found to be significantly lower or 
equal to the numbers in cultures containing no peptide. Conversely the numbers of CD4 
T cells that produce cytokine in an OVA323-339-dependent fashion remained significantly 
higher, in cultures supplemented with OVA323-339 alone, compared with the other two 
culture conditions (Figure 5.4.2B).  
Our findings in this in vitro culture system were suggestive of tolerance induction 
of activated CD4 T cells. However, it was possible that the effect of CTLA-4-Ig was 
mainly on the ability of these cells to produce cytokine, and not an influence on cell 
survival. We therefore decided to assess the expression of certain proteins, known to be 
involved in the activation and inactivation of CD4 T cells, in the remaining D011.10 CD4 
T cells, after four days, in each culture condition.  
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Figure 5.4.2 Loss of cytokine production in activated DO11.10 CD4 T cells cultured in 
the presence of OVA323-339 and a CTLA-4-Ig. Day three activated DO11.10 cells were 
isolated as described in Figure 5.4.1. 104 of these cells per well were seeded into 96-well 
V-bottom plates. 3 x 104 T cell depleted splenocytes per well were plated as APC. Wells 
were either cultured without antigen (no peptide), with 0.3µM OVA323-339 alone (OVA323-
339), or with 0.3µM OVA323-339 and 10µg/mL CTLA-4-Ig. (A) On the day of isolation and 
on days two and four of culture, the OVA323-339 specific cytokine producing cells were 
enumerated by ELISpot. (B) The day four data in panel A is redisplayed for statistical 
analysis. P-values indicate the probability that the means of the indicated samples are not 
different as assessed by unpaired, two-tailed T-tests. These are pooled results from three 
independent experiments.  
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We observed evidence of increased apoptosis in cells cultured with peptide and CTLA-4-
Ig. Levels of Annexin V staining were higher, indicating that these cells had a higher 
amount of phosphotidylserine on their surface, a marker that precedes apoptosis (Vermes, 
Haanen et al. 1995). DO11.10 cells that were cultured with peptide and CTLA-4-Ig had 
also down-regulated the anti-apoptotic protein BCL-2. These cells also showed evidence 
of decreased activation, as indicated by lower levels of GITR on the surface and lower 
levels of intracellular BLIMP-1, a transcriptional regulator that is highly expressed in 
effector-phase CD4 T cells (Fazilleau, McHeyzer-Williams et al. 2009), compared with 
DO11.10 cells from cultures without peptide or with peptide alone. Additionally we 
observed similar levels of PD-1 expression, on the surface of DO11.10 cells from 
cultures with peptide alone or with peptide with CTLA-4-Ig, indicating that PD-L-
mediated regulation did not play a major role in this system. Moreover, we did not find 
expression of FoxP3 in any of the DO11.10 cells analyzed, making it unlikely that a 
transition to Treg occurred as a result of any of the culture conditions. Additionally, the 
numbers of DO11.10 CD4 T cells in cultures treated with peptide alone, or with peptide 
with CTLA-4-Ig, did not differ by more than two-fold (not shown), suggesting that 
inactivation, rather than a difference in proliferation, was mainly responsible for the 
difference in numbers of cytokine-producing T cells between these two cultures.   
Taken together, the decreased ability to produce cytokine and the expression of 
cellular markers of inactivation, in previously activated DO11.10 cells cultured with 
OVA323-339 and CTLA-4-Ig, lead us to suggest that these conditions do indeed inactivate 
activated CD4 T cells. Thus both our in vivo evidence, and our evidence from this culture 
system, pointed to a mechanism of tolerance induction, in activated CD4 T cells, that is 
very similar to that of naive CD4 T cells. In order to take our analysis further, we decided 
to combine elements of both of these systems, the obvious relevance of in vivo 
observations, and the ready activation of TCR-transgenic CD4 T cells in vitro, in our 
subsequent studies. 
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Figure 5.4.3 Activated DO11.10 T cells cultured with OVA323-339 and CTLA-4-Ig show 
signs of inactivation. CD4+ DO11.10 T cells were cultured as described in Figure 4.4.2. 
On day four of culture, cells were harvested and analyzed for their expression of the 
indicated surface markers by flow-cytometry. All histograms are gated on cells 
expressing the DO11.10 TCR. Grey histograms show the level of fluorescence of cells 
stained with a matched fluorophore-conjugated isotype-matched control antibody. Dotted 
histograms show the expression of marker on DO11.10 cells cultured without OVA323-339; 
solid black histograms show expression on those cells cultured with 0.3µM OVA323-339 
alone; Dashed histograms are show expression of the indicated markers on DO11.10 T 
cells cultured with 0.3µM OVA323-339 and 10µg/mL CTLA-4-Ig. These are the results of a 
single representative experiment of three.  
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5.5 Tolerance Induction in Activated DO11.10 CD4 T Cells: II. Adoptive Transfer  
 
 Having established that activated CD4 T cells are rapidly inactivated upon 
exposure to antigen in the absence of appropriate second signals, in vivo and in vitro, we 
wished to see whether we could determine the nature of the critical second signal that 
would prevent inactivation of activated CD4 T cells in vivo. We decided to use a system 
in which we inactivate (through high-dose peptide injection), adoptively transferred, in 
vitro activated, DO11.10 CD4 T cells. Figure 5.5.1 displays pooled results from three 
independent experiments demonstrating that day three in vitro activated DO11.10 CD4 T 
cells are readily inactivated following adoptive transfer and administration of high-dose 
(300µg) OVA323-339. As expected from our culture studies, the number of OVA323-339-
specific cytokine-producing CD4 T cells in the spleen of mice given 106 activated 
DO11.10 cells and OVA323-339, intravenously, is decreased dramatically after only four 
days. Having established a protocol wherein activated CD4 T cells could be readily 
inactivated in vivo, we attempted to investigate whether we could rescue these cells from 
inactivation.  
 We hypothesized that systemic activation of APC, by anti-CD40 administration, 
would result in the prevention of inactivation in mice adoptively transferred with 
activated DO11.10 T cells and given high-dose peptide. We make this hypothesis because 
in a previous study administration of an agonistic antibody to CD40 prevented 
inactivation of CD4 T cells (Hawiger, Inaba et al. 2001). In addition, both B cells and DC 
express CD40 constitutively and it is known that stimulation through CD40 results in 
activation of these cells to express high-levels of co-stimulatory molecules such as B-7. 
We hypothesized that following administration of the agonistic antibody virtually all 
MHCII-bearing cells would present OVA323-339 with co-stimulation and thus provide both 
signal one and signal two together and thus rescue CD4 T cell inactivation . Figure 5.5.2 
shows the results of such an experiment.  
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Figure 5.5.1. Adoptively transferred activated CD4+ DO11.10 T cells are inactivated 
upon administration of high-dose OVA323-339. CD4+ DO11.10 T cells were activated and 
isolated as in Figure 5.4.1. 106 of these cells were then adoptively transferred by 
intravenous injection into normal BALB/c mice. Following adoptive transfer, mice were 
either treated with saline or were given a single dose of 300µg OVA323-339 intravenously. 
Four days later the OVA323-339 specific cytokine producing cells in the spleen were 
enumerated by ELISpot. Each data point represents the number of specific ELISpot-
forming cells in the spleen of a single mouse. P-values indicate the probability that the 
means of the indicated samples are not different as assessed by unpaired, two-tailed T-
tests. These are pooled results from three independent experiments with three mice/group 
(n = 9).  
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We found that administration of 100µg FGK45 (a CD40 agonist) to mice given both 
activated DO11.10 cells, and high-dose peptide, completely prevented the inactivation of 
these activated CD4 T cells. We also reasoned that we could restore inactivation when in 
mice given FGK45 by blocking B-7 molecules with 100µg CTLA-4-Ig because CD40 
ligation is known to enhance the expression of B-7 molecules on APC. Surprisingly we 
observed only a partial restoration of tolerance induction in mice treated this way and the  
IL-2 and IFN!-producing OVA323-339-specific cells in the spleen were not affected by 
administration of CTLA-4-Ig. We observed a partial decrease in the numbers of IL-4 
producing cells in the spleen of mice treated with FGK45 and CTLA-4-Ig, suggesting 
that B-7 interactions may be more heavily involved in IL-4 production, a conclusion 
consistent with findings of Rudulier et al. (Rudulier, Kroeger et al. 2012), and others 
(Andres, Howland et al. 2004). We did not attempt to increase the level of CTLA-4-Ig 
given to these mice, however, blocking of B-7 molecules with even 100-fold less CTLA-
4-Ig has been shown to substantially decrease primary CD4 T cell activation in vivo 
(Linsley, Wallace et al. 1992). This finding indicated to us that second signals, other than 
B-7 molecules alone, could be induced on APC, in the mice treated with FGK45.  
Since others (see Chapter 4), have shown that CD40 stimulation of B cells leads 
to their expression of OX40L, we decided to test whether blocking OX40 signaling 
would restore tolerance induction in mice treated with FGK45. Significantly, we 
observed a nearly complete restoration in inactivation of activated CD4 T cells in mice 
treated with both FGK45 and a blocking antibody to OX40L. IL-4 producing cells 
appeared to be the least affected by the administration of this blocking antibody. We also 
addressed whether administration of an agonistic antibody to OX40 could reverse 
tolerance induction. We found that the administration of an OX40 agonistic antibody 
completely inhibited inactivation of activated DO11.10 CD4 T cells, thus confirming the 
plausibility of the interpretation that the major effect of FGK45 is to up-regulate OX40L 
expression. Taken together our results seem to indicate that both B-7 molecules and 
OX40L play a central role in maintaining activation of CD4 T cells exposed to peptide-
MHCII. In other words, it appears that these two molecules are critical in prevention of 
tolerance upon TCR ligation. Moreover, we speculate that IL-4 production depends more 
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heavily on B7-CD28 interactions, while overall persistence of effector function depends 
more heavily on OX40-OX40L interactions. 
Given our findings regarding the role of OX40-OX40L interactions in T cell 
cooperation, the results shown in Figure 5.5.2 are very interesting. The natural means of 
stimulation of APC through CD40 is by provision of CD40L by activated T cells. Thus 
our data lead us to suggest that cooperative interactions, mediated through CD4 T cell 
interaction with antigen-bearing APC, possibly lead to sustained CD4 T cell activation, 
resulting in the prevention of inactivation. However, we have not been able to directly 
test this hypothesis at the time of writing this thesis.  
 
5.6 Conclusions 
 
 Here, we present data detailing the inactivation of CD4 T cells by the 
administration of high doses of soluble peptide. We found that tolerance induction, even 
in the face of stimulation with the potent adjuvant, CFA, results from such 
administration. We further demonstrate that CD4 T cells, deliberately activated, can be 
inactivated by the systemic administration of peptides that stimulate these cells through 
the TCR. We demonstrate that limiting B-7-CD28 interactions in vitro, when activated 
CD4 T cells are exposed to peptide-bearing APC results in their inactivation as assessed 
by cytokine production and by the expression of certain molecular markers of T cell 
inactivation. We demonstrate that activated CD4 T cells can be rescued from inactivation, 
in vivo, by the simultaneous activation of APC by anti-CD40 antibodies. This rescue 
depends on the expression of B-7 and, importantly, of OX40L, presumably by APC. We 
also propose that cooperative interactions, through the induction of OX40L on APC such 
as B cells, might prevent inactivation of CD4 T cells, which could lead to sustained 
activation of these cells. We conclude that effector CD4 T cells can be readily inactivated 
under appropriate circumstances. 
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Figure 5.5.2. Agonist antibodies to CD40 prevent inactivation in adoptively transferred 
activated DO11.10 T cells and this prevention depends on the induction of OX40L and B-
7 molecules. Mice were seeded with day three activated CD4+ DO11.10 cells and treated 
with 300µg of OVA323-339 as in the experiment whose results are recorded in Figure 5.5.1. 
The results from figure 5.5.1 are redrawn as bar graphs proximal to the Y-axis for 
comparative purposes. At the time of injection some OVA323-399-treated mice received 
100µg of the CD40 agonistic antibody, FGK45 (CD40 agonist), or 100µg of the agonistic 
antibody to OX40, OX86 (OX40 agonist). We did not observe any effect of 
administration of 100µg of isotype-matched antibodies with irrelevant specificity so 
responses in these mice were excluded for clarity. Some of the mice treated with FGK45 
were also treated with either saline or 100µg isotype-matched control antibodies (iso. 
cont.), 100µg of the OX40L blocking antibody, RM134L (OX40L blocker), or with a 
non-cytolytic CTLA-4-Ig fusion protein (B7 blocker). On the fourth day after injection 
the OVA323-339 specific cytokine-producing cells in the spleen were enumerated by 
ELISpot. Each data point represents the number of specific ELISpot-forming cells in the 
spleen of a single mouse. These are pooled results from between one and four 
independent experiments with three mice/group (n = 3-12).  
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This conclusion is somewhat inconsistent with our previous working model of CD4 
activation and inactivation. Both the two-step, two-signal model and the conventional 
Lafferty and Cunningham-style models for the initial activation of CD4 T cells into 
effector cells lead to the assumption that once activated, effector CD4 T cells are not 
subject to further regulation by inactivation. This assumption has led to extensive debate, 
as it would seem to also apply to aberrantly activated autoreactive T cells which would 
lead to prevalent autoimmunity. Due to considerations such as these, some have proposed 
that the activation of CD4 T cells requires additional priming steps that involve antigen-
specific cooperation of CD4 T cells (Bretscher 1999). While our results do not support 
this model in its original form, they do suggest that cooperative interactions between CD4 
T cells could be important in sustaining the activation of such cells under conditions that 
would normally result in their inactivation. Explicitly, these conditions would be 
normally met by the presentation of self-peptides by resting APC. 
As will be further discussed in Chapter 6, our findings have important 
implications for the generation of autoimmunity. Since normally the majority of APC that 
present self-peptides will be in a constitutively inactive state, if autoreactive CD4 T cells 
are activated by APC presenting self-peptides in association with appropriate signals, 
then they will be continually inactivated by other APC that present self-peptides without 
the appropriate signals. Though autoimmunity is rare, it does occur, and is associated 
with prolonged inappropriate activation of autoreactive CD4 T cells, and epitope 
spreading (see Chapter 1). We hypothesize that, under certain circumstances, cooperative 
interactions between CD4 T cells may lead to their sustained activation even in situations 
where the autoreactive cells would normally be inactivated. This could occur when a 
sufficient number of APC, presenting self-peptides, are activated by T cells, shifting the 
balance of tolerance/activation towards activation by the expression of B-7 and OX40L.  
 The results obtained through the experiments shown in this chapter led us to a 
dramatic rethinking of our working model for CD4 T cell activation/inactivation. Our 
current view encompasses elements of both conventional models and the two-step two-
signal model. A very brief outline of this model is given here. 
Naive CD4 T cells can be activated by an appropriately activated APC, such as 
DCs, through peptide presentation in association with appropriate co-stimulation. These 
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activated effector CD4 T cells, may then cooperate with one another in antigen-mediated 
interactions with antigen-specific B cells. These cooperative interactions lead to 
enhanced activation, effector function, and survival of CD4 T cells. Autoreactive CD4 T 
cells will normally encounter autopeptides presented by resting APC, leading to the 
inactivation of these autoreactive CD4 T cells. In the event that autoreactive CD4 T cells 
first encounter peptides presented by activated APC, the CD4 T cells are activated. 
However, the majority of autoantigen-presenting cells will be resting, so activated 
autoreactive CD4 T cells will normally be quickly inactivated as they circulate or upon 
removal of inflammatory stimuli. Persistent autoimmunity may occasionally arise when 
sufficient numbers of autoreactive CD4 T cells are activated so that their cooperative 
activation with autoantigen-bearing B cells, and one another, results in sustained effector 
function. The relatively few autoreactive CD4 cells that exist in the periphery, combined 
with the overall tendency to remove autoreactive CD4 T cells and autoreactive B cells 
will mean that these circumstances will rarely be achieved. This model is consistent with 
the vast majority of current literature as well as our own observations. Moreover, it 
makes physiological sense in that it allows rapid responses to foreign antigens, 
particularly infectious agents, and at the same time minimizes the sustained generation of 
autoreactive CD4 T cells. 
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6.0 CHAPTER 6 – DISCUSSION 
 
6.1 General Summary 
 
 The findings presented in this thesis support the hypothesis that CD4 T cells, 
following initial activation, cooperate with one another to enhance their own activation. I 
have detailed the results of experiments that attempt to determine the cellular and some of 
the molecular interactions involved in this cooperation. It appears that, in order for 
cooperative interactions between CD4 T cells to occur, the peptides for which they are 
specific must be presented by the same APC. This requirement for linked recognition 
suggests that specific uptake of antigen by the APC could be involved in influencing CD4 
T cell cooperation. Indeed, I have presented evidence that B cells, which normally 
acquire antigen through the BCR, are efficient mediators of the cooperative interaction 
between CD4 T cells. It appears that DCs, or DC enriched populations, while potent in 
activating effector CD4 T cells, do not mediate cooperation between CD4 T cells. 
Artificial stimulation of B cells, in vitro, through an agonist antibody to CD40, leads to 
enhanced generation of peptide-specific cytokine producing CD4 T cells following 
adoptive transfer of these peptide loaded B cells. Furthermore, blocking OX40L impairs 
cooperative generation of CD4 T effector cells when B cells alone present peptides. The 
interaction between B cells and CD4 T cells appears to depend heavily on OX40-OX40L 
interactions, although we did not find evidence that OX40L was specifically induced on 
B cells following their interaction with CD4 T cells. Taken together, these findings lead 
to a model of CD4 T cell interaction whereby CD4 T cells, interacting via the provision 
of CD40L, enhance the ability of B cells to further stimulate CD4 T cells. This model is 
depicted in Figure 6.1.1.  
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Figure 6.1.1. Model of proposed cellular interactions involved in CD4 T cell 
cooperation. Cooperation between CD4 T cells may involve an initial priming stage (I) 
that is dependent on antigen presentation by DC bearing peptide:MHCII complexes and 
B-7 molecules. A secondary cooperation stage (II) could involve the activation of antigen 
presenting B cells by activated CD4 T cells through CD40-CD40L interactions which 
leads to upregulated OX40L on the surface of the B cells. OX40-OX40L interactions 
between CD4 T cells and B cells and between CD4 T cells may serve to further activate 
the CD4 T cells leading to enhanced proliferation, cytokine production, Th2 
differentiation and survival.  
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Given the roles of the CD40-CD40L and the OX40-OX40L interactions in 
cooperation between CD4 T cells and different APC, it is tempting to consider whether 
the observations detailed in the final experimental chapter can be viewed in the light of 
CD4 T cell cooperation. We show that inactivation of activated, cytokine producing CD4 
T effector cells can be achieved in the periphery, by the administration of high doses of 
the peptide to which they respond. Inactivation can be prevented by simultaneous 
administration of agonist antibodies to CD40, and the prevention of inactivation by CD40 
ligation appears to depend on the induction of B7 and OX40L expression. These findings 
lead us to connect the phenomena of CD4 T cell cooperation and the development of 
autoimmunity. Thus, cooperation between CD4 T cells can potentially lead to sustained 
survival of autoreactive T and B cells. This suggestion has the merit of accounting in a 
natural fashion for the phenomenon of epitope spreading.  
 The results presented here, as a whole, shed light on questions surrounding the 
involvement of CD4 T cells in the determination of their own fate. Whereas conventional 
models for the activation of CD4 T cells place emphasis on the DC-T cell interaction, 
these models cannot account for our findings. We show that CD4 T cells influence one 
another via their interaction with B cells, likely following initial priming by DCs. The 
interaction of primed CD4 T cells with B cells, leading to antibody production, is a well-
described phenomenon. Our data lead us to suggest that the interaction may be more 
heavily involved in the generation of effector CD4 T cells than is currently believed. 
 
6.2 Discussion 
 
6.2.1 Administration of Peptides in IFA 
 
 Over the course of my thesis work, two separate experimental systems were 
developed to observe cooperation between CD4 T cells. In the first system, detailed in 
Chapter 3, we employed synthetic peptides, known to be recognized by BALB/c CD4 T 
cells and co-administered them in IFA. In employing such a methodology, we were 
uncertain about the populations of cells that would present these peptides. Given the 
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properties of water-in-oil emulsion adjuvants, such as IFA, it is not surprising that 
multiple soluble peptides could be delivered to the same APC, if incorporated into the 
same micelle. However, in light of our finding that B cells efficiently mediate 
cooperation between CD4 T cells, peptides, incorporated into our IFA emulsion, should 
have been available in solution as well. It is difficult to envisage that B cells, with affinity 
for components of IFA, preferentially took up micelles containing peptide. Thus, we are 
left to suppose that B cells, present in lymph nodes that receive afferent lymph from the 
site of the IFA depot, acquire peptides from that lymph, that bind directly to the empty 
MHCII molecules on the cell surface. In order for efficient cooperation to occur, both 
peptides should interact with MHCII molecules on the surface of the same B cell. Given 
these requirements, it is remarkable that cooperation was observed under these 
experimental conditions. 
Our observations were not the first to show cooperation between T cells that 
respond to multiple peptides given in IFA. Valmori et al. have reported very similar 
findings, showing a cooperative interaction between CD4 and CD8 T cells, in the 
induction of CTL. This was achieved when MHCII- and MHCI-binding peptides were 
administered together in IFA (Valmori, Romero et al. 1994). However, our findings that 
blocking OX40L inhibits only the cooperation-dependent increase in the generation of 
effector CD4 T cells specific for HEL105-120 when this peptide is given with others in IFA, 
and that this antibody inhibits the generation of all effector CD4 T cells when B cells are 
the sole APC, leads us to suggest that presentation by both non-B APC as well as B cells 
must occur when these peptides are administered in IFA. Moreover, it appears that the 
presentation of peptides by these non-B cell APC, likely DCs, does not depend on the 
OX40-OX40L interaction. That is, upon immunization with peptides in IFA, the peptides 
are presented by both DCs and B cells. DCs may initiate priming of CD4 T cells, while B 
cells mediate cooperation between them, and the latter process depends on OX40L.  
 It can be seen that, for the most part, cooperative interactions between CD4 T 
cells, specific for administered peptides, resulted in the increased generation of only 
HEL105-120-specific cytokine producing cells. To what extent the results reported in this 
thesis can be generalized is therefore unclear. Since the development of OVA323-339-
specific CD4 T effector cells did not benefit from cooperation from HEL105-120-specific 
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CD4 T cells, it is possible that different populations of CD4 T cells differ in their 
susceptibility to cooperative enhancement. Though we have no reason to believe that 
HEL105-120-specific CD4 T cells are unique in their requirements for activation, we have 
no evidence that these cells are not different than the CD4 T cells specific for OVA323-339. 
Conversely, OVA323-339-specific CD4 T cells may not require cooperation from other 
peptide-specific CD4 T cells because they themselves are unique. OVA323-339-specific 
CD4 T cells could be previously activated (potentially due to cross reaction with other 
environmental antigens) in our BALB/c mice. Previous activation may abrogate the need 
for cooperative interactions in the generation of optimal responses. Alternatively, the 
precursor frequency of OVA323-339-specific CD4 T cells may be higher than that of 
HEL105-120 specific CD4 T cells. This increased precursor frequency may lead to 
intraclonal cooperation, which would mask the contribution of CD4 T cell cooperation in 
the generation of OVA323-339-specific effector cells. CD4 T effector cells specific for 
LACK158-173 also appeared to be generated well in the absence of explicit CD4 T cell 
cooperation. It is interesting to note that both OVA323-339 and LACK158-173 are I-A
d binding 
peptides, while HEL105-120 binds I-E
d. Therefore it is possible that the cells specific for 
OVA323-339 and LACK158-173 are more efficiently generated, either by enhanced positive 
selection by I-Ad or preferential TCR rearrangement, leading to enhanced precursor 
frequency. On the other hand, HEL11-25 is an I-A
d-binding peptide which does not appear 
to result in efficient generation of CD4 T effector cells, when given alone in IFA. Though 
we did not formally test whether cooperation can occur between naive HEL105-120 and 
HEL11-25-specific CD4 T cells, our observations (see Figure 3.3.3) suggest that this 
interaction would result in enhanced generation of effector cells specific for both 
peptides. Thus, as we have no reason to suspect that the CD4 T cells specific for HEL105-
120 are in some way unique in their requirement for cooperation, for their optimal 
transition to effector cells, we also have no direct evidence to the contrary. Further work 
will be required to demonstrate that the CD4 T cell cooperation observed here is a 
general phenomenon.  
 Oil emulsion adjuvants are currently in use for human vaccination and have been 
shown to elicit the transcription of a number of inflammation-associated transcripts 
(Mosca, Tritto et al. 2008). Our results, indicating that supplementing IFA with LPS, or 
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giving an agonistic antibody to CD40, does not result in enhanced production of peptide-
specific cytokine producing CD4 T cells, when peptide alone is incorporated into the 
vaccine, are consistent with this finding. In other words, it appears that the IFA 
immunization itself results in sufficient inflammation to enable the activation of innate 
APC. Our findings are direct evidence that the inefficient activation of HEL105-120 specific 
CD4 T cells, when mice are immunized with the peptide alone in IFA, is not due to a lack 
of stimulation of APC by inflammatory mediators. However, the findings that systemic 
administration of FGK45 does not enhance the generation of HEL105-120-specific cytokine 
producing cells, whereas stimulation of B cells in vitro with FGK45 allows more efficient 
activation of HEL105-120-specific CD4 T cells, upon their adoptive transfer, seem to be at 
odds with one another. As I have outlined above, giving peptides in IFA, should lead to 
their presentation by B cells. Therefore, administration of FGK45 to mice immunized 
with HEL105-120 alone in IFA should result in the presence of B cells with increased ability 
to enhance the generation if HEL105-120-specific effector cells. However, we did not 
observe such enhancement. In order to explain this discrepancy, I speculate that, in the 
case of systemic FGK45 administration, a vast excess of APC are activated to express co-
stimulatory molecules, chemokines, and adhesion molecules that increase the frequency 
and duration of APC-T cell interactions. Many of these interactions will be unproductive 
as they will be between either peptide-specific CD4 T cells and APC that are not 
presenting HEL105-120, non-specific CD4 T cells and APC that do present peptide, and 
between non-specific CD4 T cells that interact with APC that are not presenting peptide. 
Normally, the interaction between APC and T cells is made more efficient by the 
expression of molecular mediators and homing receptors that bring activated peptide-
bearing APC in contact with T cells. In situations where many APC are activated but do 
not present the appropriate peptide, i.e. following systemic administration of FGK45, the 
generation of peptide-specific CD4 T cells may actually be inhibited. The generation of 
cytokine producing CD4 T cells was enhanced when only a limited number of pulsed, 
FGK45 stimulated, B cells were given because all the these APC were presenting 
peptide. Thus, the discrepancy between our two seemingly contradictory observations 
made with FGK45 may be resolved. However, FGK45 administration, when HEL protein 
was given in IFA, enhanced the generation of HEL-specific CD4 T effector cells. It is 
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possible that, by virtue of their efficient uptake of protein antigen, by way of the BCR, 
that HEL-specific B cells were able to focus interactions between HEL-peptide-specific 
CD4 T cells, thereby bypassing the inhibition seen when peptide was given in IFA. 
However, these possibilities will remain in the realm of speculation. 
 The most significant finding made in the IFA administration system is that CD4 T 
cells, specific for OVA323-339, had to be present so that co-administration of OVA323-339 
could enhance the generation of HEL105-120-specific cytokine producing CD4 T cells.  
Given the results shown in Figure 3.5.3, that administration of OX86 restored the effector 
function of inactivated HEL105-120-specific CD4 T cells, we assume that high-dose 
administration of OVA323-339 resulted in the induction of anergy of endogenous OVA323-
339-specific CD4 T cells. Therefore, our conclusions can be extended. Functional, non-
anergic, CD4 T cells, specific for OVA323-339 are required for the cooperative 
enhancement of CD4 T cells specific for HEL105-120 when both peptides are given together 
in IFA. This evidence led us to conclude that the observed cooperation, when peptides 
were given together in IFA, was due to genuine interactions between CD4 T cells and not 
simply to non-specific effects of our experimental immunization. In order to further 
explore the mechanisms underlying the cooperation of CD4 T cell populations we 
developed a further experimental system. 
 
6.2.2 The Peptide-Pulsed APC System 
 
 The development of a “pulsing-system” wherein the adoptive transfer of APC, 
loaded with peptide in culture, could be employed to elicit cooperation between CD4 T 
cell populations, was a major advance in our methodology. This system allowed us to 
inquire into the nature of the APC that mediates CD4 T cell cooperation, as well as into 
the molecular signaling that is involved in this interaction. In this system mice were 
seeded with 105 purified CD4+ DO11.10 OVA323-339-specific TCR transgenic T cells. The 
generation of HEL105-120-specific effector cells, in mice given APC pulsed with both 
HEL105-120 and OVA323-339, depends on the number of DO11.10 cells given (Figures 4.2.6 
and 4.2.7). This data in itself is evidence that DO11.10 T cells can cooperate with HEL105-
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120-specific CD4 T cells upon the administration of pulsed APC, enhancing the generation 
of HEL105-120-specific effector cells. 
 Our investigations on the nature of the APC responsible for mediating 
cooperation between populations of CD4 T cells identified the B cell as this mediator. 
Two lines of evidence support this conclusion.  
Firstly, as shown in Figure 4.3.1, cooperative interactions between HEL105-120 and 
OVA323-339-specific CD4 T cells require the peptides to be presented by the same cell. As 
discussed in sections 1.3 and 1.4, presentation by the antigen-specific B cell is viewed as 
the most efficient way that such “linked” interactions can be mediated. Normally, 
antigen-specific B cells endocytose antigen after having encountered it through the BCR. 
Therefore, only antigens that are physically associated with the antigen, recognized by 
the BCR, will be presented by the B cell. In the context of CD4 T cell cooperation and 
infection, this mechanism would ensure that only CD4 T cells specific for peptides 
derived from the same pathogen would cooperate with one another, while CD4 T cells 
specific for peptides derived from other pathogens, self molecules, or allergens etc. 
would not be affected. This type of mechanism for ensuring independence of immune 
responses is potentially important in avoiding the influence of CD4 T cell cooperation on 
the immune phenotype of responses to simultaneous infection with other pathogens or on 
the survival of autoreactive T cells that are present in the periphery. It is difficult to 
envisage how this type of independence could be accomplished by non-specific APC, 
like DCs. 
 The second line of evidence, supporting the role of the B cell in mediating CD4 T 
cell cooperation, is more direct. We isolated B cells from cultures of pulsed spleen APC. 
These B cells, untouched by our depletion protocol, were found to be at least 95% pure. 
B cells, pulsed with both HEL105-120 and OVA323-339 mediated cooperation between CD4 T 
cells that recognize these peptides in the context of MHCII. Thus, positive evidence, in a 
reductionist model, indicates that B cells can directly mediate cooperation between 
DO11.10 T cells and endogenous HEL105-120-specific CD4 T cells.  
We attempted to address whether potent, non-antigen-specific APC, the 
conventional DCs and plasmacytoid DCs from the spleen, could mediate cooperation 
between CD4 T cells. Although our isolation protocol resulted in very poor purity, we, 
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nevertheless, observed substantial activation of CD4 T cells after injection of only 2 x 105 
peptide-pulsed DC-enriched cells. According to our flow-cytometry results this 
corresponds to a number of injected DC on the order of 5-10 x 104. These cells elicited 
robust CD4 effector T cell activation, equivalent to that elicited from the injection of 3.5 
x 106 B cells, but failed to elicit cooperation between HEL105-120 and OVA323-339-specific 
CD4 T cells. The potency of the DCs, in activating CD4 T cells, suggests that these cells 
are functional. However, though we think it unlikely, we cannot rule out the possibility 
that our culture or isolation protocol affected the spleen DCs in a manner that left their 
ability to activate CD4 T cells intact, while disrupting their ability to mediate cooperation 
between CD4 T cells.  
We attempted to investigate the molecular mechanisms involved in this CD4 T 
cell cooperation mediated by B cells. Since CD4 T cells have the capacity to stimulate B 
cells through provision of CD40L, we attempted to mimic the effects of this stimulation 
by administration of the agonistic FGK45 antibody in culture. We found that ligation of 
CD40 in this artificial way enhanced the ability of single-peptide-pulsed B cells to 
activate HEL105-120-specific CD4 T cells. B cells cultured with DO11.10 CD4 T cells in 
the presence of OVA323-339 did not appear to enhance the activation of HEL105-120-specific 
CD4 T cells. However, we observed a similar trend as was observed for FGK4-simulated 
cells.  Given the complexity of this system, it is likely that optimal conditions for B cell 
activation are not achieved by this protocol. Therefore further optimization of this 
protocol may be beneficial in further developing this system.  
Since we had observed a role for OX40L in cooperative CD4 T cell priming, we 
hypothesized that the ligation of CD40, or activation by cognate B cell-T cell interaction, 
would lead to the upregulation of OX40L on B cells. Surprisingly, we observed no 
difference in the level of expression of OX40L-encoding mRNA in B cells cultured either 
in the presence or absence of anti-CD40 or in the presence or absence of appropriate CD4 
T cell “help”. Rather, our data indicated that all B cells, pulsed and cultured under our 
standard conditions, express similar levels of OX40L. We cannot rule out the possibility 
that regulation of OX40L protein expression occurred post-transcriptionally; further 
optimization of the experimental protocol may lead to different results. However, this 
finding is reflected in the results of our functional study. When purified B cells are the 
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only APC presenting peptide antigen, the OX40-OX40L interaction appears to be critical 
for the induction of IFN! and IL-4-producing CD4 T cell responses, in either a 
cooperative or conventional manner. Evidence for this conclusion is seen in Figure 4.4.7. 
Interestingly, blocking OX40L resulted in impaired OVA323-339-specific CD4 effector 
generation, for which a role for CD4 T cell cooperation was not observed. Thus, B cells 
appear to deliver the OX40L as a co-stimulatory molecule during the priming of CD4 T 
cells. Given that others have shown that OX40L expression on B cells is regulated, our 
findings could be, at least in part, artificial; the culture protocol employed may cause 
expression of OX40L on its own. However, it is unclear how this complication could be 
avoided. Functional studies, employing cells from co-stimulatory molecule knockout 
mice as APC, might yield more incisive results regarding the molecular mechanisms of 
CD4 T cell cooperation in the future. 
The expression of co-stimulatory ligands is not restricted to APC. Both B-7.2 and 
OX40L can be expressed by CD4 T cells. Such findings have led to the suggestion that 
CD4 cells may stimulate one another via direct cell-to-cell contact (Soroosh, Ine et al. 
2006; Rudulier, Kroeger et al. 2012). Though our experimental systems were not 
designed to differentiate APC-T cell interactions from T cell-T cell interactions, it 
appears that T cell-T cell interactions do not play a direct role in the cooperativity 
observed. The finding that DC-enriched APC appear not to mediate cooperation between 
CD4 T cells, while B cells do, suggests that cooperation is APC-specific. If the APC 
simply acts as a “dock”, around which antigen-specific CD4 T cells can interact, then no 
APC preference should be observed. B cells could provide critical signals to CD4 T cells 
that then enable them to cooperate via T cell-T cell interaction. However, in the absence 
of direct evidence for this, Occam’s razor would lead us, at least until such evidence is 
found, to disregard this possibility. 
 A potentially important and relevant observation, made during our pulsing 
studies, was that cooperation between CD4 T cells specific for HEL105-120 and DO11.10 
cells specific for OVA323-339 generates enhanced HEL105-120-specific memory. We observed 
greater numbers of HEL105-120-specific cytokine secreting CD4 T cells, following a 
secondary challenge with HEL protein, in mice previously immunized with B cells 
pulsed with HEL105-120 compared to mice that received B cells pulsed with the OVA323-339. 
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However, we observed a significantly greater number of HEL105-120-specific secondary 
effector cells following challenge in mice that received injections of B cells pulsed with 
both HEL105-120 and OVA323-339. Whether this striking result is due to enhanced survival of 
HEL105-120-specific CD4 T cells, or it is due to enhanced potency of the memory cells 
produced, is unknown. However it is remarkable that cooperation between CD4 T cells 
specific for one peptide and CD4 T cells specific for another single peptide can lead to 
such dramatic differences in the secondary immune response. These data indicate that 
CD4 T cell cooperation, leading to enhanced generation of effector CD4 T cells, may also 
lead to enhanced memory T cell formation. This possibility has implications for vaccine 
design. Based on these results, it would appear that immunization with preparations 
containing few immunogenic epitopes would result in poorer memory than immunization 
with more epitopes. However, consideration should also be given to the ability of CD4 T 
cell cooperation to affect the Th1/Th2 nature of immune responses, if CD4 T cell 
cooperation is to be harnessed for vaccination purposes. 
 As outlined in section 1.3, CD4 T cell cooperation has been associated with 
Th1/Th2 immune deviation. Though this phenomenon was not addressed directly in my 
experiments, the results of experiments seem to demonstrate it. In virtually every case, 
the production of IL-4 is effected the most by cooperative interactions. That is, the 
number of IL-4 producing effector CD4 T cells is enhanced more than IL-2 or IFN!-
producing cells upon CD4 T cell cooperation. This finding is very much in line with 
previous investigations on the functional consequences of CD4 T cell cooperation, and 
with more current findings within our laboratory. We intend to investigate this more fully 
in a future study.  
 
6.2.3 The Inactivation of Activated CD4 T cells 
 
 The third experimental chapter of this thesis details my investigations on the 
inactivation of activated CD4 T cells. Much of this work was done in collaboration with 
another member of the lab, Christopher Rudulier. As is shown in Chapter 5, we observed 
that activated CD4 T cells during their initial priming, or at the peak of their proliferation, 
could be inactivated by the intravenous administration of high doses of the peptide, for 
! 256 
which their TCRs have affinity. Three sequential doses of HEL105-120 , given to mice 
primed to HEL105-120 in CFA, resulted in the inability to generate CD4 T cells specific for 
this peptide upon challenge with HEL protein.  
We decided to determine whether this unresponsiveness was the result of 
enhanced activation induced cell death, after the peak of a normal CD4 T cell response, 
or was due to the active tolerogenic effects that directly inactivated HEL105-120-specific 
effector cells. In mice that were immunized with HEL105-120 in CFA, peptide-specific 
effector cells were inactivated within 3 days of a single intravenous injection of 300µg 
HEL105-120. Similar results were obtained in a different experimental system in which 
activated CD4 T cells were adoptively transferred. Inactivation of activated DO11.10 
CD4 T cells occurred within a four-day period. Though we did not attempt to track these 
cells by flow cytometry, this could be easily accomplished. Our functional readout was 
the number of peptide-dependent ELISpot forming cells in the spleen or lymph nodes. 
Therefore, our data that addressed whether the primary effector function of these cells, 
cytokine secretion, remained intact. Our data lead us to believe that activated CD4 T cells 
can be readily inactivated by the administration of high dose peptide. These findings, in 
line with the observations of others, suggest that the provision of excess signal 1 in the 
absence of co-stimulation results in inactivation of T cells at any time in their life cycle. 
However, in this system, we cannot rule out the possibility that “tolerized” effector cells 
migrated out of the spleen (or popliteal lymph nodes) and were therefore not detected. 
This possibility seems unlikely given the findings of Kearney et al. (Kearney, Pape et al. 
1994) and our findings in vitro. 
A culture system was developed to potentially address the mechanism by which 
activated CD4 T cells are inactivated in vivo. We demonstrate that blocking B-7 co-
stimulation, by provision of a high concentration of CTLA-4-Ig effectively limits the 
cytokine production by activated CD4 T cells. Moreover, we show that CD4 T cells, 
cultured with antigen and CTLA-4-Ig express markers of cells undergoing apoptosis. 
This is in contrast to those cultured without antigen or with peptide alone. Given these 
results, we concluded that limiting signal 2, in the presence of excess signal 1, could 
potentially result in inactivation of effector CD4 T cells in vivo. We therefore chose to 
address this possibility, directly, in vivo. 
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Returning to our adoptive transfer system, we showed that the inactivation of 
activated DO11.10 effector CD4 T cells by the administration of high dose peptide can be 
blocked by systemic APC activation via the administration of FGK45. We hypothesized 
that this was due to enhanced expression of co-stimulation on the cells that present 
OVA323-339. We attempted to demonstrate this by blocking co-stimulatory ligands. We 
determined that both B-7 and OX40L co-stimulation were responsible for the prevention 
of inactivation of activated CD4 T cells in our system. Interestingly, blocking B-7 
molecules, following administration of high dose peptide and FGK45, appeared to 
severely limit only the production of IL-4 by activated DO11.10 cells. In contrast, 
blocking OX40L appeared to nearly completely prevent the ability of the DO11.10 cells 
to make IL-2 and IFN! while leaving IL-4 production almost intact. These findings lead 
us to suggest that B-7 co-stimulation may be more important for IL-4 production, while 
OX40L appears to sustain production of IL-2 and IFN!. These findings are consistent 
with some observations (Andres, Howland et al. 2004) and inconsistent with others (So, 
Song et al. 2006). At most, we conclude that B-7 and OX40L have a role in preventing 
the CD40-stimulation-mediated reversal of the inactivation of activated CD4 T cells by 
the administration of high dose peptide.  
As our results are still preliminary, we are hesitant to draw firm conclusions. 
However, the results obtained in this experimental system suggest a mechanism by which 
activated CD4 effector T cells can be sustained in vivo, possibly leading to sustained 
autoimmunity. Stimulation of B cells via CD40 is normally achieved by activated CD4 T 
cells bearing CD40L. We speculate that if a sufficient number of activated autoreactive 
CD4 T cells were generated, then these cells could sustain their own activation though 
CD4 T cell cooperation. As discussed in section 1.3, the few autoreactive CD4 T cells 
that are activated following infection should normally be rapidly inactivated by 
subsequent interactions with self-peptide bearing resting APC. However, if sufficient 
numbers of activated autoreactive CD4 T cells exist in the periphery, or if these cells 
accumulate due to less efficient silencing, then B cells presenting the peptides for which 
they are specific, may be continually activated, leading to sustained levels of autoreactive 
T cells in the periphery. As suggested by Mamula, this initial stage of autoimmunity may 
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lead to a secondary stage wherein autoreactive B cell-T cell interactions may lead to 
epitope spreading and chronic disease (Mamula 1998).  
 As a whole, the data reported in this thesis support the idea that CD4 T cells play 
an active role in self- non-self discrimination. It appears that if sufficient numbers of CD4 
T cells are activated, under appropriate conditions, optimal effector function will be 
achieved. By this mechanism, CD4 T cells require a level of agreement amongst clones, 
on whether to respond to an antigen or not. That is, in order for effective immune 
responses to be initiated, a threshold level of CD4 T cell activation must be crossed. In 
some cases, it appears that this agreement may lead to induction of autoimmunity. 
Therefore, for CD4 T cells, as for those who study them, rule by consensus can be 
dangerous. 
! 259 
 
 
 
 
7.0 CHAPTER 7 - REFERENCES 
 
Abdulahad, W. H., J. M. Meijer, F. G. Kroese, P. M. Meiners, A. Vissink, F. K. 
Spijkervet, C. G. Kallenberg and H. Bootsma "B cell reconstitution and T helper 
cell balance after rituximab treatment of active primary Sjogren's syndrome: a 
double-blind, placebo-controlled study." Arthritis Rheum 63(4): 1116-23. 
Adler, A. J. (2005). "Peripheral Tolerization of Effector and Memory T Cells: 
Implications for Autoimmunity and Tumor-Immunity." Curr Immunol Rev 1(1): 
21-28. 
Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner and H. Pircher (1995). 
"T cell priming versus T cell tolerance induced by synthetic peptides." J Exp Med 
182(1): 261-6. 
Akbari, O., R. H. DeKruyff and D. T. Umetsu (2001). "Pulmonary dendritic cells 
producing IL-10 mediate tolerance induced by respiratory exposure to antigen." 
Nat Immunol 2(8): 725-31. 
Anderson, M. S., E. S. Venanzi, L. Klein, Z. Chen, S. P. Berzins, S. J. Turley, H. von 
Boehmer, R. Bronson, A. Dierich, C. Benoist and D. Mathis (2002). "Projection 
of an immunological self shadow within the thymus by the aire protein." Science 
298(5597): 1395-401. 
Andersson, J., D. Q. Tran, M. Pesu, T. S. Davidson, H. Ramsey, J. J. O'Shea and E. M. 
Shevach (2008). "CD4+ FoxP3+ regulatory T cells confer infectious tolerance in 
a TGF-beta-dependent manner." J Exp Med 205(9): 1975-81. 
Andres, P. G., K. C. Howland, A. Nirula, L. P. Kane, L. Barron, D. Dresnek, A. Sadra, J. 
Imboden, A. Weiss and A. K. Abbas (2004). "Distinct regions in the CD28 
cytoplasmic domain are required for T helper type 2 differentiation." Nat 
Immunol 5(4): 435-42. 
Apostolou, I. and H. von Boehmer (2004). "In vivo instruction of suppressor commitment 
in naive T cells." J Exp Med 199(10): 1401-8. 
Aschenbrenner, K., L. M. D'Cruz, E. H. Vollmann, M. Hinterberger, J. Emmerich, L. K. 
Swee, A. Rolink and L. Klein (2007). "Selection of Foxp3+ regulatory T cells 
specific for self antigen expressed and presented by Aire+ medullary thymic 
epithelial cells." Nat Immunol 8(4): 351-8. 
Ashwell, J. D., A. L. DeFranco, W. E. Paul and R. H. Schwartz (1984). "Antigen 
presentation by resting B cells. Radiosensitivity of the antigen-presentation 
function and two distinct pathways of T cell activation." J Exp Med 159(3): 881-
905. 
Babbitt, B. P., P. M. Allen, G. Matsueda, E. Haber and E. R. Unanue (1985). "Binding of 
immunogenic peptides to Ia histocompatibility molecules." Nature 317(6035): 
359-61. 
! 260 
Bachmann, M. F., L. Hunziker, R. M. Zinkernagel, T. Storni and M. Kopf (2004). 
"Maintenance of memory CTL responses by T helper cells and CD40-CD40 
ligand: antibodies provide the key." Eur J Immunol 34(2): 317-26. 
Baird, A. M. and D. C. Parker (1996). "Analysis of low zone tolerance induction in 
normal and B cell-deficient mice." J Immunol 157(5): 1833-9. 
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of immunity." 
Nature 392(6673): 245-52. 
Bansal-Pakala, P., A. G. Jember and M. Croft (2001). "Signaling through OX40 (CD134) 
breaks peripheral T-cell tolerance." Nat Med 7(8): 907-12. 
Barron, L., B. Knoechel, J. Lohr and A. K. Abbas (2008). "Cutting edge: contributions of 
apoptosis and anergy to systemic T cell tolerance." J Immunol 180(5): 2762-6. 
Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach and D. L. Sacks (2002). 
"CD4+CD25+ regulatory T cells control Leishmania major persistence and 
immunity." Nature 420(6915): 502-7. 
Benacerraf, B., I. Green and W. E. Paul (1967). "The immune response of guinea pigs to 
hapten-poly-L-lysine conjugates as an example of the genetic control of the 
regognition of antigenicity." Cold Spring Harbor Symposiums on Quantatative 
Biology 32: 569. 
Bergmann, C. C., C. Ramakrishna, M. Kornacki and S. A. Stohlman (2001). "Impaired T 
cell immunity in B cell-deficient mice following viral central nervous system 
infection." J Immunol 167(3): 1575-83. 
Bevan, M. J. (1977). "In a radiation chimaera, host H-2 antigens determine immune 
responsiveness of donor cytotoxic cells." Nature 269(5627): 417-8. 
Bingaman, A. W., J. Ha, S. Y. Waitze, M. M. Durham, H. R. Cho, C. Tucker-Burden, R. 
Hendrix, S. R. Cowan, T. C. Pearson and C. P. Larsen (2000). "Vigorous allograft 
rejection in the absence of danger." J Immunol 164(6): 3065-71. 
Blander, J. M. and R. Medzhitov (2006). "Toll-dependent selection of microbial antigens 
for presentation by dendritic cells." Nature 440(7085): 808-12. 
Bluestone, J. A. and A. K. Abbas (2003). "Natural versus adaptive regulatory T cells." 
Nat Rev Immunol 3(3): 253-7. 
Bockenstedt, L. K., R. J. Gee and M. J. Mamula (1995). "Self-peptides in the initiation of 
lupus autoimmunity." J Immunol 154(7): 3516-24. 
Bottomly, K., C. A. Janeway, Jr., B. J. Mathieson and D. E. Mosier (1980). "Absence of 
an antigen-specific helper T cell required for the expression of the T 15 idiotype 
in mice treated with anti-mu antibody." Eur J Immunol 10(2): 159-63. 
Bradley, L. M., J. Harbertson, E. Biederman, Y. Zhang, S. M. Bradley and P. J. Linton 
(2002). "Availability of antigen-presenting cells can determine the extent of CD4 
effector expansion and priming for secretion of Th2 cytokines in vivo." Eur J 
Immunol 32(8): 2338-46. 
Bretscher, P. (1972). "The control of humoral and associative antibody synthesis." 
Transplant Rev 11: 217-67. 
Bretscher, P. and M. Cohn (1970). "A theory of self-nonself discrimination." Science 
169(950): 1042-9. 
Bretscher, P. A. (1974). "On the control between cell-mediated, IgM and IgG immunity." 
Cell Immunol 13(2): 171-95. 
! 261 
Bretscher, P. A. (1983). "In vitro analysis of the cellular interactions between unprimed 
lymphocytes responsible for determining the class of response an antigen induces: 
specific T cells switch a cell-mediated response to a humoral response." J 
Immunol 131(3): 1103-7. 
Bretscher, P. A. (1983). "Regulation of the class of immune response induced by antigen. 
I. Specific T cells switch the in vivo response from a cell-mediated to humoral 
mode." Cell Immunol 81(2): 345-56. 
Bretscher, P. A. (1986). "A cascade of T-T interactions, mediated by the linked 
recognition of antigen, in the induction of T cells able to help delayed-type 
hypersensitivity responses." J Immunol 137(12): 3726-33. 
Bretscher, P. A. (1999). "A two-step, two-signal model for the primary activation of 
precursor helper T cells." Proc Natl Acad Sci U S A 96(1): 185-90. 
Bretscher, P. A. and M. Cohn (1968). "Minimal model for the mechanism of antibody 
induction and paralysis by antigen." Nature 220(5166): 444-8. 
Bretscher, P. A., G. Wei, J. N. Menon and H. Bielefeldt-Ohmann (1992). "Establishment 
of stable, cell-mediated immunity that makes "susceptible" mice resistant to 
Leishmania major." Science 257(5069): 539-42. 
Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. 
Utz, N. Karin, D. Mitchell, T. Veromaa, A. Waisman, A. Gaur, P. Conlon, N. 
Ling, P. J. Fairchild, D. C. Wraith, A. O'Garra, C. G. Fathman and L. Steinman 
(1996). "Treatment of experimental encephalomyelitis with a peptide analogue of 
myelin basic protein." Nature 379(6563): 343-6. 
Brocker, T., M. Riedinger and K. Karjalainen (1997). "Targeted expression of major 
histocompatibility complex (MHC) class II molecules demonstrates that dendritic 
cells can induce negative but not positive selection of thymocytes in vivo." J Exp 
Med 185(3): 541-50. 
Buhlmann, J. E., T. M. Foy, A. Aruffo, K. M. Crassi, J. A. Ledbetter, W. R. Green, J. C. 
Xu, L. D. Shultz, D. Roopesian, R. A. Flavell and et al. (1995). "In the absence of 
a CD40 signal, B cells are tolerogenic." Immunity 2(6): 645-53. 
Burkly, L. C., D. Lo, O. Kanagawa, R. L. Brinster and R. A. Flavell (1989). "T-cell 
tolerance by clonal anergy in transgenic mice with nonlymphoid expression of 
MHC class II I-E." Nature 342(6249): 564-6. 
Burnet, F. M. (1957). "Biology and medicine." Med J Aust 44(13): 406-10. 
Burnet, F. M. and F. Fenner (1949). The Production of Antibodies. New York, NY, 
MacMillan. 
Buus, S., S. Colon, C. Smith, J. H. Freed, C. Miles and H. M. Grey (1986). "Interaction 
between a "processed" ovalbumin peptide and Ia molecules." Proc Natl Acad Sci 
U S A 83(11): 3968-71. 
Buus, S., A. Sette, S. M. Colon, C. Miles and H. M. Grey (1987). "The relation between 
major histocompatibility complex (MHC) restriction and the capacity of Ia to bind 
immunogenic peptides." Science 235(4794): 1353-8. 
Calderhead, D. M., J. E. Buhlmann, A. J. van den Eertwegh, E. Claassen, R. J. Noelle and 
H. P. Fell (1993). "Cloning of mouse Ox40: a T cell activation marker that may 
mediate T-B cell interactions." J Immunol 151(10): 5261-71. 
Campbell, J. D., K. F. Buckland, S. J. McMillan, J. Kearley, W. L. Oldfield, L. J. Stern, 
H. Gronlund, M. van Hage, C. J. Reynolds, R. J. Boyton, S. P. Cobbold, A. B. 
! 262 
Kay, D. M. Altmann, C. M. Lloyd and M. Larche (2009). "Peptide 
immunotherapy in allergic asthma generates IL-10-dependent immunological 
tolerance associated with linked epitope suppression." J Exp Med 206(7): 1535-
47. 
Cardillo, F., E. Postol, J. Nihei, L. S. Aroeira, A. Nomizo and J. Mengel (2007). "B cells 
modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the 
acute phase of Trypanosoma cruzi infection." Immunology 122(4): 584-95. 
Castiglioni, P., C. Lu, D. Lo, M. Croft, P. Langlade-Demoyen, M. Zanetti and M. Gerloni 
(2003). "CD4 T cell priming in dendritic cell-deficient mice." Int Immunol 15(1): 
127-36. 
Chan, O. T., L. G. Hannum, A. M. Haberman, M. P. Madaio and M. J. Shlomchik (1999). 
"A novel mouse with B cells but lacking serum antibody reveals an antibody-
independent role for B cells in murine lupus." J Exp Med 189(10): 1639-48. 
Chan, O. T., M. P. Madaio and M. J. Shlomchik (1999). "B cells are required for lupus 
nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity." J 
Immunol 163(7): 3592-6. 
Chase, M. W. (1946). "The cellular transfer of cutaneous hypersensitivity." J Bacteriol 
51: 643. 
Chatenoud, L. and J. A. Bluestone (2007). "CD3-specific antibodies: a portal to the 
treatment of autoimmunity." Nat Rev Immunol 7(8): 622-32. 
Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady and S. M. 
Wahl (2003). "Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3." J Exp Med 198(12): 1875-86. 
Chen, X., B. Zhou, M. Li, Q. Deng, X. Wu, X. Le, C. Wu, N. Larmonier, W. Zhang, H. 
Zhang, H. Wang and E. Katsanis (2007). "CD4(+)CD25(+)FoxP3(+) regulatory T 
cells suppress Mycobacterium tuberculosis immunity in patients with active 
disease." Clin Immunol 123(1): 50-9. 
Chesnut, R. W., R. O. Endres and H. M. Grey (1980). "Antigen recognition by T cells 
and B cells: recognition of cross-reactivity between native and denatured forms of 
globular antigens." Clin Immunol Immunopathol 15(3): 397-408. 
Chmielowski, B., P. Muranski and L. Ignatowicz (1999). "In the normal repertoire of 
CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs 
with various antigen specificities." J Immunol 162(1): 95-105. 
Claman, H. N., E. A. Chaperon and R. F. Triplett (1966). "Thymus-marrow cell 
combinations. Synergism in antibody production." Proc Soc Exp Biol Med 
122(4): 1167-71. 
Cohen, S. B., P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C. Genovese, 
E. C. Keystone, J. E. Loveless, G. R. Burmester, M. W. Cravets, E. W. Hessey, T. 
Shaw and M. C. Totoritis (2006). "Rituximab for rheumatoid arthritis refractory 
to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, 
double-blind, placebo-controlled, phase III trial evaluating primary efficacy and 
safety at twenty-four weeks." Arthritis Rheum 54(9): 2793-806. 
Constant, S., D. Sant'Angelo, T. Pasqualini, T. Taylor, D. Levin, R. Flavell and K. 
Bottomly (1995). "Peptide and protein antigens require distinct antigen-presenting 
cell subsets for the priming of CD4+ T cells." J Immunol 154(10): 4915-23. 
! 263 
Constant, S., N. Schweitzer, J. West, P. Ranney and K. Bottomly (1995). "B lymphocytes 
can be competent antigen-presenting cells for priming CD4+ T cells to protein 
antigens in vivo." J Immunol 155(8): 3734-41. 
Constant, S. L. (1999). "B lymphocytes as antigen-presenting cells for CD4+ T cell 
priming in vivo." J Immunol 162(10): 5695-703. 
Crawford, A., M. Macleod, T. Schumacher, L. Corlett and D. Gray (2006). "Primary T 
cell expansion and differentiation in vivo requires antigen presentation by B 
cells." J Immunol 176(6): 3498-506. 
Creusot, R. J., L. L. Thomsen, J. P. Tite and B. M. Chain (2003). "Local cooperation 
dominates over competition between CD4+ T cells of different antigen/MHC 
specificity." J Immunol 171(1): 240-6. 
Critchfield, J. M., M. K. Racke, J. C. Zuniga-Pflucker, B. Cannella, C. S. Raine, J. 
Goverman and M. J. Lenardo (1994). "T cell deletion in high antigen dose therapy 
of autoimmune encephalomyelitis." Science 263(5150): 1139-43. 
Croft, M. (2003). "Co-stimulatory members of the TNFR family: keys to effective T-cell 
immunity?" Nat Rev Immunol 3(8): 609-20. 
Croft, M. (2010). "Control of immunity by the TNFR-related molecule OX40 (CD134)." 
Annu Rev Immunol 28: 57-78. 
Croft, M., L. M. Bradley and S. L. Swain (1994). "Naive versus memory CD4 T cell 
response to antigen. Memory cells are less dependent on accessory cell 
costimulation and can respond to many antigen-presenting cell types including 
resting B cells." J Immunol 152(6): 2675-85. 
Croft, M., S. B. Joseph and K. T. Miner (1997). "Partial activation of naive CD4 T cells 
and tolerance induction in response to peptide presented by resting B cells." J 
Immunol 159(7): 3257-65. 
Croft, M., T. So, W. Duan and P. Soroosh (2009). "The significance of OX40 and 
OX40L to T-cell biology and immune disease." Immunol Rev 229(1): 173-91. 
Cross, A. H., J. L. Stark, J. Lauber, M. J. Ramsbottom and J. A. Lyons (2006). 
"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis 
patients." J Neuroimmunol 180(1-2): 63-70. 
Curtsinger, J. M., D. C. Lins and M. F. Mescher (1998). "CD8+ memory T cells 
(CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C-) to 
TCR/CD8 signaling in response to antigen." J Immunol 160(7): 3236-43. 
D'Ambrosio, A., M. Colucci, O. Pugliese, F. Quintieri and M. Boirivant (2008). "Cholera 
toxin B subunit promotes the induction of regulatory T cells by preventing human 
dendritic cell maturation." J Leukoc Biol 84(3): 661-8. 
Dahlberg, P. E., J. M. Schartner, A. Timmel and C. M. Seroogy (2007). "Daily 
subcutaneous injections of peptide induce CD4+ CD25+ T regulatory cells." Clin 
Exp Immunol 149(2): 226-34. 
Dalai, S. K., S. Mirshahidi, A. Morrot, F. Zavala and S. Sadegh-Nasseri (2008). "Anergy 
in memory CD4+ T cells is induced by B cells." J Immunol 181(5): 3221-31. 
de Vos, A. F., A. Fukushima, M. C. Lobanoff, B. P. Vistica, J. C. Lai, J. C. Grivel, E. F. 
Wawrousek, S. M. Whitcup and I. Gery (2000). "Breakdown of tolerance to a 
neo-self antigen in double transgenic mice in which B cells present the antigen." J 
Immunol 164(9): 4594-600. 
! 264 
Ding, L. and E. M. Shevach (1996). "Activated B cells express CD28/B7-independent 
costimulatory activity." J Immunol 157(4): 1389-96. 
Doan, T., A. McNally, R. Thomas and R. J. Steptoe (2009). "Steady-state dendritic cells 
continuously inactivate T cells that escape thymic negative selection." Immunol 
Cell Biol 87(8): 615-22. 
Dorner, T., D. Isenberg, D. Jayne, H. Wiendl, D. Zillikens and G. Burmester (2009). 
"Current status on B-cell depletion therapy in autoimmune diseases other than 
rheumatoid arthritis." Autoimmun Rev 9(2): 82-9. 
Dubey, C., M. Croft and S. L. Swain (1996). "Naive and effector CD4 T cells differ in 
their requirements for T cell receptor versus costimulatory signals." J Immunol 
157(8): 3280-9. 
Edwards, J. C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. 
Close, R. M. Stevens and T. Shaw (2004). "Efficacy of B-cell-targeted therapy 
with rituximab in patients with rheumatoid arthritis." N Engl J Med 350(25): 
2572-81. 
Eming, R., A. Nagel, S. Wolff-Franke, E. Podstawa, D. Debus and M. Hertl (2008). 
"Rituximab exerts a dual effect in pemphigus vulgaris." J Invest Dermatol 
128(12): 2850-8. 
Endres, R., M. B. Alimzhanov, T. Plitz, A. Futterer, M. H. Kosco-Vilbois, S. A. 
Nedospasov, K. Rajewsky and K. Pfeffer (1999). "Mature follicular dendritic cell 
networks depend on expression of lymphotoxin beta receptor by radioresistant 
stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells." J Exp 
Med 189(1): 159-68. 
Epstein, M. M., F. Di Rosa, D. Jankovic, A. Sher and P. Matzinger (1995). "Successful T 
cell priming in B cell-deficient mice." J Exp Med 182(4): 915-22. 
Evans, D. E., M. W. Munks, J. M. Purkerson and D. C. Parker (2000). "Resting B 
lymphocytes as APC for naive T lymphocytes: dependence on CD40 
ligand/CD40." J Immunol 164(2): 688-97. 
Fazilleau, N., L. J. McHeyzer-Williams, H. Rosen and M. G. McHeyzer-Williams 
(2009). "The function of follicular helper T cells is regulated by the strength of T 
cell antigen receptor binding." Nat Immunol 10(4): 375-84. 
Fontenot, J. D., M. A. Gavin and A. Y. Rudensky (2003). "Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells." Nat Immunol 4(4): 
330-6. 
Freund, J. and M. V. Bonanto (1946). "The duration of antibody-formation after injection 
of killed typhoid bacilli in water-in-oil emulsion." J Immunol 52: 231-4. 
Freund, J., E. R. Stern and T. M. Pisani (1947). "Isoallergic encephalomyelitis and 
radiculitis in guinea pigs after one injection of brain and Mycobacteria in water-
in-oil emulsion." J Immunol 57(2): 179-94. 
Fu, Y. X., G. Huang, Y. Wang and D. D. Chaplin (1998). "B lymphocytes induce the 
formation of follicular dendritic cell clusters in a lymphotoxin alpha-dependent 
fashion." J Exp Med 187(7): 1009-18. 
Gabrilovich, D. (2004). "Mechanisms and functional significance of tumour-induced 
dendritic-cell defects." Nat Rev Immunol 4(12): 941-52. 
! 265 
Gallegos, A. M. and M. J. Bevan (2004). "Central tolerance to tissue-specific antigens 
mediated by direct and indirect antigen presentation." J Exp Med 200(8): 1039-
49. 
Gardner, J. M., J. J. Devoss, R. S. Friedman, D. J. Wong, Y. X. Tan, X. Zhou, K. P. 
Johannes, M. A. Su, H. Y. Chang, M. F. Krummel and M. S. Anderson (2008). 
"Deletional tolerance mediated by extrathymic Aire-expressing cells." Science 
321(5890): 843-7. 
Gavin, A. L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler and D. Nemazee (2006). 
"Adjuvant-enhanced antibody responses in the absence of toll-like receptor 
signaling." Science 314(5807): 1936-8. 
Geppert, T. D. and P. E. Lipsky (1987). "Accessory cell independent proliferation of 
human T4 cells stimulated by immobilized monoclonal antibodies to CD3." J 
Immunol 138(6): 1660-6. 
Geppert, T. D. and P. E. Lipsky (1987). "Dissection of defective antigen presentation by 
interferon-gamma-treated fibroblasts." J Immunol 138(2): 385-92. 
Gerloni, M., P. Castiglioni and M. Zanetti (2005). "The cooperation between two CD4 T 
cells induces tumor protective immunity in MUC.1 transgenic mice." J Immunol 
175(10): 6551-9. 
Gerloni, M., S. Xiong, S. Mukerjee, S. P. Schoenberger, M. Croft and M. Zanetti (2000). 
"Functional cooperation between T helper cell determinants." Proc Natl Acad Sci 
U S A 97(24): 13269-74. 
Glimcher, L. H., T. Hamano, R. Asofsky, E. Herber-Katz, S. Hedrick, R. H. Schwartz 
and W. E. Paul (1982). "I region-restricted antigen presentation by B cell-B 
lymphoma hybridomas." Nature 298(5871): 283-4. 
Glimcher, L. H., K. J. Kim, I. Green and W. E. Paul (1982). "Ia antigen-bearing B cell 
tumor lines can present protein antigen and alloantigen in a major 
histocompatibility complex-restricted fashion to antigen-reactive T cells." J Exp 
Med 155(2): 445-59. 
Godfrey, V. L., J. E. Wilkinson and L. B. Russell (1991). "X-linked lymphoreticular 
disease in the scurfy (sf) mutant mouse." Am J Pathol 138(6): 1379-87. 
Godfrey, W. R., F. F. Fagnoni, M. A. Harara, D. Buck and E. G. Engleman (1994). 
"Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with 
homology to tumor necrosis factor." J Exp Med 180(2): 757-62. 
Golovkina, T. V., M. Shlomchik, L. Hannum and A. Chervonsky (1999). "Organogenic 
role of B lymphocytes in mucosal immunity." Science 286(5446): 1965-8. 
Goodnow, C. C., J. Crosbie, S. Adelstein, T. B. Lavoie, S. J. Smith-Gill, R. A. Brink, H. 
Pritchard-Briscoe, J. S. Wotherspoon, R. H. Loblay, K. Raphael and et al. (1988). 
"Altered immunoglobulin expression and functional silencing of self-reactive B 
lymphocytes in transgenic mice." Nature 334(6184): 676-82. 
Graca, L., S. P. Cobbold and H. Waldmann (2002). "Identification of regulatory T cells in 
tolerated allografts." J Exp Med 195(12): 1641-6. 
Gramaglia, I., A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen and M. Croft (2000). 
"The OX40 costimulatory receptor determines the development of CD4 memory 
by regulating primary clonal expansion." J Immunol 165(6): 3043-50. 
! 266 
Gramaglia, I., A. D. Weinberg, M. Lemon and M. Croft (1998). "Ox-40 ligand: a potent 
costimulatory molecule for sustaining primary CD4 T cell responses." J Immunol 
161(12): 6510-7. 
Guerder, S. and P. Matzinger (1992). "A fail-safe mechanism for maintaining self-
tolerance." J Exp Med 176(2): 553-64. 
Guilliams, M., K. Crozat, S. Henri, S. Tamoutounour, P. Grenot, E. Devilard, B. de 
Bovis, L. Alexopoulou, M. Dalod and B. Malissen (2010). "Skin-draining lymph 
nodes contain dermis-derived CD103(-) dendritic cells that constitutively produce 
retinoic acid and induce Foxp3(+) regulatory T cells." Blood 115(10): 1958-68. 
Gunzer, M., C. Weishaupt, A. Hillmer, Y. Basoglu, P. Friedl, K. E. Dittmar, W. Kolanus, 
G. Varga and S. Grabbe (2004). "A spectrum of biophysical interaction modes 
between T cells and different antigen-presenting cells during priming in 3-D 
collagen and in vivo." Blood 104(9): 2801-9. 
Habu, S. and M. C. Raff (1977). "Accessory cell dependence of lectin-induced 
proliferation of mouse T lymphocytes." Eur J Immunol 7(7): 451-7. 
Hanan, R. and J. Oyama (1954). "Inhibition of antibody formation in mature rabbits by 
contact with the antigen at an early age." J Immunol 73(1): 49-53. 
Harris, D. P., S. Goodrich, A. J. Gerth, S. L. Peng and F. E. Lund (2005). "Regulation of 
IFN-gamma production by B effector 1 cells: essential roles for T-bet and the 
IFN-gamma receptor." J Immunol 174(11): 6781-90. 
Harris, D. P., S. Goodrich, K. Mohrs, M. Mohrs and F. E. Lund (2005). "Cutting edge: 
the development of IL-4-producing B cells (B effector 2 cells) is controlled by IL-
4, IL-4 receptor alpha, and Th2 cells." J Immunol 175(11): 7103-7. 
Harris, D. P., L. Haynes, P. C. Sayles, D. K. Duso, S. M. Eaton, N. M. Lepak, L. L. 
Johnson, S. L. Swain and F. E. Lund (2000). "Reciprocal regulation of polarized 
cytokine production by effector B and T cells." Nat Immunol 1(6): 475-82. 
Harris, E. D., Jr. (1990). "Rheumatoid arthritis. Pathophysiology and implications for 
therapy." N Engl J Med 322(18): 1277-89. 
Hartley, S. B., M. P. Cooke, D. A. Fulcher, A. W. Harris, S. Cory, A. Basten and C. C. 
Goodnow (1993). "Elimination of self-reactive B lymphocytes proceeds in two 
stages: arrested development and cell death." Cell 72(3): 325-35. 
Haskins, K., R. Kubo, J. White, M. Pigeon, J. Kappler and P. Marrack (1983). "The 
major histocompatibility complex-restricted antigen receptor on T cells. I. 
Isolation with a monoclonal antibody." J Exp Med 157(4): 1149-69. 
Hauser, S. L., E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. 
Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould and C. H. Smith (2008). "B-cell 
depletion with rituximab in relapsing-remitting multiple sclerosis." N Engl J Med 
358(7): 676-88. 
Hawiger, D., K. Inaba, Y. Dorsett, M. Guo, K. Mahnke, M. Rivera, J. V. Ravetch, R. M. 
Steinman and M. C. Nussenzweig (2001). "Dendritic cells induce peripheral T 
cell unresponsiveness under steady state conditions in vivo." J Exp Med 194(6): 
769-79. 
Hayglass, K. T., S. J. Naides, C. F. Scott, Jr., B. Benacerraf and M. S. Sy (1986). "T cell 
development in B cell-deficient mice. IV. The role of B cells as antigen-
presenting cells in vivo." J Immunol 136(3): 823-9. 
! 267 
Hedrick, S. M., D. I. Cohen, E. A. Nielsen and M. M. Davis (1984). "Isolation of cDNA 
clones encoding T cell-specific membrane-associated proteins." Nature 
308(5955): 149-53. 
Higashimura, N., N. Takasawa, Y. Tanaka, M. Nakamura and K. Sugamura (1996). 
"Induction of OX40, a receptor of gp34, on T cells by trans-acting transcriptional 
activator, Tax, of human T-cell leukemia virus type I." Jpn J Cancer Res 87(3): 
227-31. 
Higgins, A. D., M. A. Mihalyo and A. J. Adler (2002). "Effector CD4 cells are tolerized 
upon exposure to parenchymal self-antigen." J Immunol 169(7): 3622-9. 
Hirota, K., M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. 
Iwakura, N. Sakaguchi and S. Sakaguchi (2007). "T cell self-reactivity forms a 
cytokine milieu for spontaneous development of IL-17+ Th cells that cause 
autoimmune arthritis." J Exp Med 204(1): 41-7. 
Ho, W. Y., M. P. Cooke, C. C. Goodnow and M. M. Davis (1994). "Resting and anergic 
B cells are defective in CD28-dependent costimulation of naive CD4+ T cells." J 
Exp Med 179(5): 1539-49. 
Homann, D., A. Tishon, D. P. Berger, W. O. Weigle, M. G. von Herrath and M. B. 
Oldstone (1998). "Evidence for an underlying CD4 helper and CD8 T-cell defect 
in B-cell-deficient mice: failure to clear persistent virus infection after adoptive 
immunotherapy with virus-specific memory cells from muMT/muMT mice." J 
Virol 72(11): 9208-16. 
Honey, K. and A. Y. Rudensky (2003). "Lysosomal cysteine proteases regulate antigen 
presentation." Nat Rev Immunol 3(6): 472-82. 
Hori, S., T. Nomura and S. Sakaguchi (2003). "Control of regulatory T cell development 
by the transcription factor Foxp3." Science 299(5609): 1057-61. 
Howard, J. C. (1985). "Immunological help at last." Nature 314(6011): 494-5. 
Hsieh, C. S., Y. Liang, A. J. Tyznik, S. G. Self, D. Liggitt and A. Y. Rudensky (2004). 
"Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell 
receptors." Immunity 21(2): 267-77. 
Hsieh, C. S., Y. Zheng, Y. Liang, J. D. Fontenot and A. Y. Rudensky (2006). "An 
intersection between the self-reactive regulatory and nonregulatory T cell receptor 
repertoires." Nat Immunol 7(4): 401-10. 
Hughes, P. D., G. T. Belz, K. A. Fortner, R. C. Budd, A. Strasser and P. Bouillet (2008). 
"Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune 
responses and prevention of autoimmunity." Immunity 28(2): 197-205. 
Humphrey, J. H. (1964). "Immunological Unresponsiveness to Protein Antigens in 
Rabbits. I. The Duration of Unresponsiveness Following a Single Injection at 
Birth." Immunology 7: 449-61. 
Humphrey, J. H. (1964). "Immunological Unresponsiveness to Protein Antigens in 
Rabbits. Ii. The Nature of the Subsequent Antibody Response." Immunology 7: 
462-73. 
Iijima, N., M. M. Linehan, M. Zamora, D. Butkus, R. Dunn, M. R. Kehry, T. M. Laufer 
and A. Iwasaki (2008). "Dendritic cells and B cells maximize mucosal Th1 
memory response to herpes simplex virus." J Exp Med 205(13): 3041-52. 
! 268 
Inaba, K., A. Granelli-Piperno and R. M. Steinman (1983). "Dendritic cells induce T 
lymphocytes to release B cell-stimulating factors by an interleukin 2-dependent 
mechanism." J Exp Med 158(6): 2040-57. 
Inaba, K., S. Turley, T. Iyoda, F. Yamaide, S. Shimoyama, C. Reis e Sousa, R. N. 
Germain, I. Mellman and R. M. Steinman (2000). "The formation of 
immunogenic major histocompatibility complex class II-peptide ligands in 
lysosomal compartments of dendritic cells is regulated by inflammatory stimuli." 
J Exp Med 191(6): 927-36. 
Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, 
K. Okumura, P. S. Linsley, S. Ikehara, S. Muramatsu, R. J. Hodes and R. M. 
Steinman (1994). "The tissue distribution of the B7-2 costimulator in mice: 
abundant expression on dendritic cells in situ and during maturation in vitro." J 
Exp Med 180(5): 1849-60. 
Ingulli, E., A. Mondino, A. Khoruts and M. K. Jenkins (1997). "In vivo detection of 
dendritic cell antigen presentation to CD4(+) T cells." J Exp Med 185(12): 2133-
41. 
Ismail, N., A. Basten, H. Briscoe and P. A. Bretscher (2005). "Increasing the foreignness 
of an antigen, by coupling a second and foreign antigen to it, increases the T 
helper type 2 component of the immune response to the first antigen." 
Immunology 115(1): 34-41. 
Ismail, N. and P. A. Bretscher (1999). "The Th1/Th2 nature of concurrent immune 
responses to unrelated antigens can be independent." J Immunol 163(9): 4842-50. 
Ismail, N. and P. A. Bretscher (2001). "More antigen-dependent CD4(+) T cell / CD4(+) 
T cell interactions are required for the primary generation of Th2 than of Th1 
cells." Eur J Immunol 31(6): 1765-71. 
Jaiswal, A. I. and M. Croft (1997). "CD40 ligand induction on T cell subsets by peptide-
presenting B cells: implications for development of the primary T and B cell 
response." J Immunol 159(5): 2282-91. 
Jaiswal, A. I., C. Dubey, S. L. Swain and M. Croft (1996). "Regulation of CD40 ligand 
expression on naive CD4 T cells: a role for TCR but not co-stimulatory signals." 
Int Immunol 8(2): 275-85. 
Janeway, C. A., Jr. (1992). "The immune system evolved to discriminate infectious 
nonself from noninfectious self." Immunol Today 13(1): 11-6. 
Janeway, C. A., Jr., R. A. Murgita, F. I. Weinbaum, R. Asofsky and H. Wigzell (1977). 
"Evidence for an immunoglobulin-dependent antigen-specific helper T cell." Proc 
Natl Acad Sci U S A 74(10): 4582-6. 
Janeway, C. A., Jr., J. Ron and M. E. Katz (1987). "The B cell is the initiating antigen-
presenting cell in peripheral lymph nodes." J Immunol 138(4): 1051-5. 
Jansson, L., P. Diener, A. Engstrom, T. Olsson and R. Holmdahl (1995). "Spreading of 
the immune response to different myelin basic protein peptides in chronic 
experimental autoimmune encephalomyelitis in B10.RIII mice." Eur J Immunol 
25(8): 2195-200. 
Jenkins, M. K., J. D. Ashwell and R. H. Schwartz (1988). "Allogeneic non-T spleen cells 
restore the responsiveness of normal T cell clones stimulated with antigen and 
chemically modified antigen-presenting cells." J Immunol 140(10): 3324-30. 
! 269 
Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, T. M. Chused and R. H. Schwartz (1987). 
"Molecular events in the induction of a nonresponsive state in interleukin 2-
producing helper T-lymphocyte clones." Proc Natl Acad Sci U S A 84(15): 5409-
13. 
Jenkins, M. K. and R. H. Schwartz (1987). "Antigen presentation by chemically modified 
splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo." 
J Exp Med 165(2): 302-19. 
Jerne, N. K. (1955). "The Natural-Selection Theory of Antibody Formation." Proc Natl 
Acad Sci U S A 41(11): 849-57. 
Jordan, M. S., A. Boesteanu, A. J. Reed, A. L. Petrone, A. E. Holenbeck, M. A. Lerman, 
A. Naji and A. J. Caton (2001). "Thymic selection of CD4+CD25+ regulatory T 
cells induced by an agonist self-peptide." Nat Immunol 2(4): 301-6. 
Julius, M. H., E. Simpson and L. A. Herzenberg (1973). "A rapid method for the isolation 
of functional thymus-derived murine lymphocytes." Eur J Immunol 3(10): 645-9. 
Kabashima, K., T. A. Banks, K. M. Ansel, T. T. Lu, C. F. Ware and J. G. Cyster (2005). 
"Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid 
tissue dendritic cells." Immunity 22(4): 439-50. 
Kakinuma, T., H. Nadiminti, A. S. Lonsdorf, T. Murakami, B. A. Perez, H. Kobayashi, S. 
E. Finkelstein, G. Pothiawala, Y. Belkaid and S. T. Hwang (2007). "Small 
numbers of residual tumor cells at the site of primary inoculation are critical for 
anti-tumor immunity following challenge at a secondary location." Cancer 
Immunol Immunother 56(7): 1119-31. 
Kakiuchi, T., R. W. Chesnut and H. M. Grey (1983). "B cells as antigen-presenting cells: 
the requirement for B cell activation." J Immunol 131(1): 109-14. 
Kappler, J. W., N. Roehm and P. Marrack (1987). "T cell tolerance by clonal elimination 
in the thymus." Cell 49(2): 273-80. 
Kaufman, D. L., M. Clare-Salzler, J. Tian, T. Forsthuber, G. S. Ting, P. Robinson, M. A. 
Atkinson, E. E. Sercarz, A. J. Tobin and P. V. Lehmann (1993). "Spontaneous 
loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-
dependent diabetes." Nature 366(6450): 69-72. 
Kearney, E. R., K. A. Pape, D. Y. Loh and M. K. Jenkins (1994). "Visualization of 
peptide-specific T cell immunity and peripheral tolerance induction in vivo." 
Immunity 1(4): 327-39. 
Keene, J. A. and J. Forman (1982). "Helper activity is required for the in vivo generation 
of cytotoxic T lymphocytes." J Exp Med 155(3): 768-82. 
Kenna, T. J., R. Thomas and R. J. Steptoe (2008). "Steady-state dendritic cells expressing 
cognate antigen terminate memory CD8+ T-cell responses." Blood 111(4): 2091-
100. 
Kenna, T. J., T. Waldie, A. McNally, M. Thomson, H. Yagita, R. Thomas and R. J. 
Steptoe (2010). "Targeting antigen to diverse APCs inactivates memory CD8+ T 
cells without eliciting tissue-destructive effector function." J Immunol 184(2): 
598-606. 
Kindred, B. and D. C. Shreffler (1972). "H-2 dependence of co-operation between T and 
B cells in vivo." J Immunol 109(5): 940-3. 
Kindred, B. and E. Weiler (1972). "The response to SRBC by nude mice injected with 
lymphoid cells other than thymus cells." J Immunol 109(2): 382-7. 
! 270 
Kishimoto, H. and J. Sprent (1999). "Strong TCR ligation without costimulation causes 
rapid onset of Fas-dependent apoptosis of naive murine CD4+ T cells." J 
Immunol 163(4): 1817-26. 
Kisielow, P., H. S. Teh, H. Bluthmann and H. von Boehmer (1988). "Positive selection of 
antigen-specific T cells in thymus by restricting MHC molecules." Nature 
335(6192): 730-3. 
Klein, L., K. Khazaie and H. von Boehmer (2003). "In vivo dynamics of antigen-specific 
regulatory T cells not predicted from behavior in vitro." Proc Natl Acad Sci U S 
A 100(15): 8886-91. 
Koulova, L., E. A. Clark, G. Shu and B. Dupont (1991). "The CD28 ligand B7/BB1 
provides costimulatory signal for alloactivation of CD4+ T cells." J Exp Med 
173(3): 759-62. 
Koyasu, S. (2003). "The role of PI3K in immune cells." Nat Immunol 4(4): 313-9. 
Kreuwel, H. T., S. Aung, C. Silao and L. A. Sherman (2002). "Memory CD8(+) T cells 
undergo peripheral tolerance." Immunity 17(1): 73-81. 
Kursar, M., K. Bonhagen, J. Fensterle, A. Kohler, R. Hurwitz, T. Kamradt, S. H. 
Kaufmann and H. W. Mittrucker (2002). "Regulatory CD4+CD25+ T cells 
restrict memory CD8+ T cell responses." J Exp Med 196(12): 1585-92. 
Kurt-Jones, E. A., D. Liano, K. A. HayGlass, B. Benacerraf, M. S. Sy and A. K. Abbas 
(1988). "The role of antigen-presenting B cells in T cell priming in vivo. Studies 
of B cell-deficient mice." J Immunol 140(11): 3773-8. 
Lafferty, K. J. and A. J. Cunningham (1975). "A new analysis of allogeneic interactions." 
Aust J Exp Biol Med Sci 53(1): 27-42. 
Lamb, J. R. and M. Feldmann (1984). "Essential requirement for major 
histocompatibility complex recognition in T-cell tolerance induction." Nature 
308(5954): 72-4. 
Lamb, J. R., E. D. Zanders, W. Sewell, M. J. Crumpton, M. Feldmann and M. J. Owen 
(1987). "Antigen-specific T cell unresponsiveness in cloned helper T cells 
mediated via the CD2 or CD3/Ti receptor pathways." Eur J Immunol 17(11): 
1641-4. 
Langhorne, J., C. Cross, E. Seixas, C. Li and T. von der Weid (1998). "A role for B cells 
in the development of T cell helper function in a malaria infection in mice." Proc 
Natl Acad Sci U S A 95(4): 1730-4. 
Lanzavecchia, A. (1985). "Antigen-specific interaction between T and B cells." Nature 
314(6011): 537-9. 
Larche, M. and D. C. Wraith (2005). "Peptide-based therapeutic vaccines for allergic and 
autoimmune diseases." Nat Med 11(4 Suppl): S69-76. 
Larsen, C. P., S. C. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. Hodes, R. P. 
Lowry and T. C. Pearson (1994). "Regulation of immunostimulatory function and 
costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells." J 
Immunol 152(11): 5208-19. 
Larsson, E. L. and A. Coutinho (1979). "The role of mitogenic lectins in T-cell 
triggering." Nature 280(5719): 239-41. 
Lathrop, S. K., C. A. Huddleston, P. A. Dullforce, M. J. Montfort, A. D. Weinberg and D. 
C. Parker (2004). "A signal through OX40 (CD134) allows anergic, autoreactive 
T cells to acquire effector cell functions." J Immunol 172(11): 6735-43. 
! 271 
Laufer, T. M., J. DeKoning, J. S. Markowitz, D. Lo and L. H. Glimcher (1996). 
"Unopposed positive selection and autoreactivity in mice expressing class II 
MHC only on thymic cortex." Nature 383(6595): 81-5. 
Lazarski, C. A., F. A. Chaves, S. A. Jenks, S. Wu, K. A. Richards, J. M. Weaver and A. J. 
Sant (2005). "The kinetic stability of MHC class II:peptide complexes is a key 
parameter that dictates immunodominance." Immunity 23(1): 29-40. 
LeClercq, S. A. and P. A. Bretscher (1987). "T cells expressing delayed-type 
hypersensitivity can be derived from a humorally immune lymphocyte 
population." Eur J Immunol 17(7): 949-54. 
Ledbetter, J. A., J. B. Imboden, G. L. Schieven, L. S. Grosmaire, P. S. Rabinovitch, T. 
Lindsten, C. B. Thompson and C. H. June (1990). "CD28 ligation in T-cell 
activation: evidence for two signal transduction pathways." Blood 75(7): 1531-9. 
Lederberg, J. (1959). "Genes and antibodies." Science 129(3364): 1649-53. 
Lehmann, P. V., T. Forsthuber, A. Miller and E. E. Sercarz (1992). "Spreading of T-cell 
autoimmunity to cryptic determinants of an autoantigen." Nature 358(6382): 155-
7. 
Lemaitre, B., E. Nicolas, L. Michaut, J. M. Reichhart and J. A. Hoffmann (1996). "The 
dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent 
antifungal response in Drosophila adults." Cell 86(6): 973-83. 
Levesque, M. C. (2009). "Translational Mini-Review Series on B Cell-Directed 
Therapies: Recent advances in B cell-directed biological therapies for 
autoimmune disorders." Clin Exp Immunol 157(2): 198-208. 
Liblau, R. S., R. Tisch, K. Shokat, X. Yang, N. Dumont, C. C. Goodnow and H. O. 
McDevitt (1996). "Intravenous injection of soluble antigen induces thymic and 
peripheral T-cells apoptosis." Proc Natl Acad Sci U S A 93(7): 3031-6. 
Lin, R. H., M. J. Mamula, J. A. Hardin and C. A. Janeway, Jr. (1991). "Induction of 
autoreactive B cells allows priming of autoreactive T cells." J Exp Med 173(6): 
1433-9. 
Lindstein, T., C. H. June, J. A. Ledbetter, G. Stella and C. B. Thompson (1989). 
"Regulation of lymphokine messenger RNA stability by a surface-mediated T cell 
activation pathway." Science 244(4902): 339-43. 
Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. 
Singh and M. A. Tepper (1992). "Immunosuppression in vivo by a soluble form 
of the CTLA-4 T cell activation molecule." Science 257(5071): 792-5. 
Linton, P. J., B. Bautista, E. Biederman, E. S. Bradley, J. Harbertson, R. M. Kondrack, R. 
C. Padrick and L. M. Bradley (2003). "Costimulation via OX40L expressed by B 
cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 
cytokine secretion in vivo." J Exp Med 197(7): 875-83. 
Liossis, S. N. and P. P. Sfikakis (2008). "Rituximab-induced B cell depletion in 
autoimmune diseases: potential effects on T cells." Clin Immunol 127(3): 280-5. 
Liu, K., T. Iyoda, M. Saternus, Y. Kimura, K. Inaba and R. M. Steinman (2002). 
"Immune tolerance after delivery of dying cells to dendritic cells in situ." J Exp 
Med 196(8): 1091-7. 
Liu, Q., Z. Liu, C. T. Rozo, H. A. Hamed, F. Alem, J. F. Urban, Jr. and W. C. Gause 
(2007). "The role of B cells in the development of CD4 effector T cells during a 
polarized Th2 immune response." J Immunol 179(6): 3821-30. 
! 272 
Liu, S., M. G. Velez, J. Humann, S. Rowland, F. J. Conrad, R. Halverson, R. M. Torres 
and R. Pelanda (2005). "Receptor editing can lead to allelic inclusion and 
development of B cells that retain antibodies reacting with high avidity 
autoantigens." J Immunol 175(8): 5067-76. 
Liu, Y., Y. Wu, L. Ramarathinam, Y. Guo, D. Huszar, M. Trounstine and M. Zhao 
(1995). "Gene-targeted B-deficient mice reveal a critical role for B cells in the 
CD4 T cell response." Int Immunol 7(8): 1353-62. 
Lomonosova, E. and G. Chinnadurai (2008). "BH3-only proteins in apoptosis and 
beyond: an overview." Oncogene 27 Suppl 1: S2-19. 
Lund, F. E. and T. D. Randall (2010). "Effector and regulatory B cells: modulators of 
CD4(+) T cell immunity." Nat Rev Immunol 10(4): 236-47. 
Lyons, J. A., M. San, M. P. Happ and A. H. Cross (1999). "B cells are critical to 
induction of experimental allergic encephalomyelitis by protein but not by a short 
encephalitogenic peptide." Eur J Immunol 29(11): 3432-9. 
Lyubchenko, T., J. M. Dal Porto, V. M. Holers and J. C. Cambier (2007). "Cutting edge: 
Complement (C3d)-linked antigens break B cell anergy." J Immunol 179(5): 
2695-9. 
Macaulay, A. E., R. H. DeKruyff and D. T. Umetsu (1998). "Antigen-primed T cells 
from B cell-deficient JHD mice fail to provide B cell help." J Immunol 160(4): 
1694-700. 
MacDonald, A. J., M. Duffy, M. T. Brady, S. McKiernan, W. Hall, J. Hegarty, M. Curry 
and K. H. Mills (2002). "CD4 T helper type 1 and regulatory T cells induced 
against the same epitopes on the core protein in hepatitis C virus-infected 
persons." J Infect Dis 185(6): 720-7. 
Maglione, P. J., J. Xu and J. Chan (2007). "B cells moderate inflammatory progression 
and enhance bacterial containment upon pulmonary challenge with 
Mycobacterium tuberculosis." J Immunol 178(11): 7222-34. 
Mahnke, K., E. Schmitt, L. Bonifaz, A. H. Enk and H. Jonuleit (2002). "Immature, but 
not inactive: the tolerogenic function of immature dendritic cells." Immunol Cell 
Biol 80(5): 477-83. 
Maloney, D. G., A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. 
Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, K. Wey, I. 
Royston, T. Davis and R. Levy (1997). "IDEC-C2B8 (Rituximab) anti-CD20 
monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's 
lymphoma." Blood 90(6): 2188-95. 
Malynn, B. A. and H. H. Wortis (1984). "Role of antigen-specific B cells in the induction 
of SRBC-specific T cell proliferation." J Immunol 132(5): 2253-8. 
Mamula, M. J. (1998). "Epitope spreading: the role of self peptides and autoantigen 
processing by B lymphocytes." Immunol Rev 164: 231-9. 
Manicassamy, S. and B. Pulendran (2009). "Modulation of adaptive immunity with Toll-
like receptors." Semin Immunol 21(4): 185-93. 
Manku, H., D. S. Graham and T. J. Vyse (2009). "Association of the co-stimulator 
OX40L with systemic lupus erythematosus." J Mol Med 87(3): 229-34. 
Manning, D. D. and J. W. Jutila (1972). "Effect of anti-immunoglobulin antisera on 
homograft rejection in mice." Nat New Biol 237(71): 58-9. 
! 273 
Manning, D. D. and J. W. Jutila (1972). "Immunosuppression in mice injected with 
heterologous anti-immunoglobulin antisera." J Immunol 108(1): 282-5. 
Mastroeni, P., C. Simmons, R. Fowler, C. E. Hormaeche and G. Dougan (2000). "Igh-6(-
/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge 
with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-
cell responses to Salmonella antigens." Infect Immun 68(1): 46-53. 
Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto and T. F. Tedder (2008). 
"Regulatory B cells inhibit EAE initiation in mice while other B cells promote 
disease progression." J Clin Invest 118(10): 3420-30. 
Matsuzaki, G., H. M. Vordermeier, A. Hashimoto, K. Nomoto and J. Ivanyi (1999). "The 
role of B cells in the establishment of T cell response in mice infected with an 
intracellular bacteria, Listeria monocytogenes." Cell Immunol 194(2): 178-85. 
Matzinger, P. (1994). "Tolerance, danger, and the extended family." Annu Rev Immunol 
12: 991-1045. 
Matzinger, P., R. Zamoyska and H. Waldmann (1984). "Self tolerance is H-2-restricted." 
Nature 308(5961): 738-41. 
McDevitt, H. O. and B. Benacerraf (1969). "Genetic control of specific immune 
responses." Adv Immunol 11: 31-74. 
McDevitt, H. O. and A. Chinitz (1969). "Genetic control of the antibody response: 
relationship between immune response and histocompatibility (H-2) type." 
Science 163(3872): 1207-8. 
McDevitt, H. O. and M. Sela (1965). "Genetic control of the antibody response. I. 
Demonstration of determinant-specific differences in response to synthetic 
polypeptide antigens in two strains of inbred mice." J Exp Med 122(3): 517-31. 
McDevitt, H. O. and M. L. Tyan (1968). "Genetic control of the antibody response in 
inbred mice. Transfer of response by spleen cells and linkage to the major 
histocompatibility (H-2) locus." J Exp Med 128(1): 1-11. 
McKean, D. J., A. J. Infante, A. Nilson, M. Kimoto, C. G. Fathman, E. Walker and N. 
Warner (1981). "Major histocompatibility complex-restricted antigen presentation 
to antigen-reactive T cells by B lymphocyte tumor cells." J Exp Med 154(5): 
1419-31. 
Medzhitov, R., P. Preston-Hurlburt and C. A. Janeway, Jr. (1997). "A human homologue 
of the Drosophila Toll protein signals activation of adaptive immunity." Nature 
388(6640): 394-7. 
Meijer, J. M., P. M. Meiners, A. Vissink, F. K. Spijkervet, W. Abdulahad, N. Kamminga, 
E. Brouwer, C. G. Kallenberg and H. Bootsma (2010). "Effectiveness of 
rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, 
placebo-controlled trial." Arthritis Rheum 62(4): 960-8. 
Metcalf, E. S. and N. R. Klinman (1977). "In vitro tolerance induction of bone marrow 
cells: a marker for B cell maturation." J Immunol 118(6): 2111-6. 
Miller, J. F. (1961). "Immunological function of the thymus." Lancet 2: 748-9. 
Miller, J. F. and G. F. Mitchell (1968). "Cell to cell interaction in the immune response. I. 
Hemolysin-forming cells in neonatally thymectomized mice reconstituted with 
thymus or thoracic duct lymphocytes." J Exp Med 128(4): 801-20. 
! 274 
Miller, J. F., M. A. Vadas, A. Whitelaw and J. Gamble (1975). "H-2 gene complex 
restricts transfer of delayed-type hypersensitivity in mice." Proc Natl Acad Sci U 
S A 72(12): 5095-8. 
Miller, M. J., O. Safrina, I. Parker and M. D. Cahalan (2004). "Imaging the single cell 
dynamics of CD4+ T cell activation by dendritic cells in lymph nodes." J Exp 
Med 200(7): 847-56. 
Mims, C., A. Nash and J. Stephen (2001). Mims' Pathogenesis of Infectious Disease. 
London, Elsevier. 
Mitchell, G. F. and J. F. Miller (1968). "Cell to cell interaction in the immune response. 
II. The source of hemolysin-forming cells in irradiated mice given bone marrow 
and thymus or thoracic duct lymphocytes." J Exp Med 128(4): 821-37. 
Mitchell, G. F. and J. F. Miller (1968). "Immunological activity of thymus and thoracic-
duct lymphocytes." Proc Natl Acad Sci U S A 59(1): 296-303. 
Mitchison, N. A. (1969). Cell Populations Involved in Immune Resonses. Immunological 
Tolerance. W. Braun and M. Landy. New York, NY USA, Academic Press: 149. 
Mitchison, N. A. (1971). "The carrier effect in the secondary response to hapten-protein 
conjugates. II. Cellular cooperation." Eur J Immunol 1(1): 18-27. 
Modigliani, Y., P. Pereira, V. Thomas-Vaslin, J. Salaun, O. Burlen-Defranoux, A. 
Coutinho, N. Le Douarin and A. Bandeira (1995). "Regulatory T cells in thymic 
epithelium-induced tolerance. I. Suppression of mature peripheral non-tolerant T 
cells." Eur J Immunol 25(9): 2563-71. 
Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl and M. K. 
Jenkins (2007). "Naive CD4(+) T cell frequency varies for different epitopes and 
predicts repertoire diversity and response magnitude." Immunity 27(2): 203-13. 
Moynagh, P. N. (2005). "TLR signalling and activation of IRFs: revisiting old friends 
from the NF-kappaB pathway." Trends Immunol 26(9): 469-76. 
Mozdzanowska, K., M. Furchner, K. Maiese and W. Gerhard (1997). "CD4+ T cells are 
ineffective in clearing a pulmonary infection with influenza type A virus in the 
absence of B cells." Virology 239(1): 217-25. 
Murata, K., N. Ishii, H. Takano, S. Miura, L. C. Ndhlovu, M. Nose, T. Noda and K. 
Sugamura (2000). "Impairment of antigen-presenting cell function in mice 
lacking expression of OX40 ligand." J Exp Med 191(2): 365-74. 
Murphy, K. M., A. B. Heimberger and D. Y. Loh (1990). "Induction by antigen of 
intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo." Science 
250(4988): 1720-3. 
Myers, K. J., J. Sprent, J. P. Dougherty and Y. Ron (1992). "Synergy between 
encephalitogenic T cells and myelin basic protein-specific antibodies in the 
induction of experimental autoimmune encephalomyelitis." J Neuroimmunol 
41(1): 1-8. 
Nakahama, T., A. Kimura, N. T. Nguyen, I. Chinen, H. Hanieh, K. Nohara, Y. Fujii-
Kuriyama and T. Kishimoto "Aryl hydrocarbon receptor deficiency in T cells 
suppresses the development of collagen-induced arthritis." Proc Natl Acad Sci U 
S A 108(34): 14222-7. 
Nakamura, K., A. Kitani and W. Strober (2001). "Cell contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell 
surface-bound transforming growth factor beta." J Exp Med 194(5): 629-44. 
! 275 
Namba, K., N. Kitaichi, T. Nishida and A. W. Taylor (2002). "Induction of regulatory T 
cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone 
and transforming growth factor-beta2." J Leukoc Biol 72(5): 946-52. 
Nasreen, M., T. M. Waldie, C. M. Dixon and R. J. Steptoe (2010). "Steady-state antigen-
expressing dendritic cells terminate CD4+ memory T-cell responses." Eur J 
Immunol 40(7): 2016-25. 
Nemazee, D. A. (1985). "Immune complexes can trigger specific, T cell-dependent, 
autoanti-IgG antibody production in mice." J Exp Med 161(1): 242-56. 
Nemazee, D. A. and K. Burki (1989). "Clonal deletion of B lymphocytes in a transgenic 
mouse bearing anti-MHC class I antibody genes." Nature 337(6207): 562-6. 
Ngo, V. N., R. J. Cornall and J. G. Cyster (2001). "Splenic T zone development is B cell 
dependent." J Exp Med 194(11): 1649-60. 
Nishizuka, Y. and T. Sakakura (1969). "Thymus and reproduction: sex-linked dysgenesia 
of the gonad after neonatal thymectomy in mice." Science 166(906): 753-5. 
Nossal, G. J., A. Cunningham, G. F. Mitchell and J. F. Miller (1968). "Cell to cell 
interaction in the immune response. 3. Chromosomal marker analysis of single 
antibody-forming cells in reconstituted, irradiated, or thymectomized mice." J 
Exp Med 128(4): 839-53. 
Nossal, G. J. and J. Lederberg (1958). "Antibody production by single cells." Nature 
181(4620): 1419-20. 
Nossal, G. J. and B. L. Pike (1975). "Evidence for the clonal abortion theory of B-
lymphocyte tolerance." J Exp Med 141(4): 904-17. 
Nussenzweig, M. C. and R. M. Steinman (1980). "Contribution of dendritic cells to 
stimulation of the murine syngeneic mixed leukocyte reaction." J Exp Med 
151(5): 1196-212. 
Nussenzweig, M. C., R. M. Steinman, B. Gutchinov and Z. A. Cohn (1980). "Dendritic 
cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T 
lymphocytes." J Exp Med 152(4): 1070-84. 
O'Neill, L. A. (2006). "How Toll-like receptors signal: what we know and what we don't 
know." Curr Opin Immunol 18(1): 3-9. 
O'Neill, S. K., Y. Cao, K. M. Hamel, P. D. Doodes, G. Hutas and A. Finnegan (2007). 
"Expression of CD80/86 on B cells is essential for autoreactive T cell activation 
and the development of arthritis." J Immunol 179(8): 5109-16. 
O'Neill, S. K., M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes and A. Finnegan 
(2005). "Antigen-specific B cells are required as APCs and autoantibody-
producing cells for induction of severe autoimmune arthritis." J Immunol 174(6): 
3781-8. 
Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita and E. Nakayama (1999). 
"Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor 
alpha) monoclonal antibody." Cancer Res 59(13): 3128-33. 
Ota, T., M. Ota, B. H. Duong, A. L. Gavin and D. Nemazee "Liver-expressed Igkappa 
superantigen induces tolerance of polyclonal B cells by clonal deletion not kappa 
to lambda receptor editing." J Exp Med 208(3): 617-29. 
Pacholczyk, R., H. Ignatowicz, P. Kraj and L. Ignatowicz (2006). "Origin and T cell 
receptor diversity of Foxp3+CD4+CD25+ T cells." Immunity 25(2): 249-59. 
! 276 
Pacholczyk, R., J. Kern, N. Singh, M. Iwashima, P. Kraj and L. Ignatowicz (2007). 
"Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells." 
Immunity 27(3): 493-504. 
Paetkau, V., G. Mills, S. Gerhart and V. Monticone (1976). "Proliferation of murine 
thymic lymphocytes in vitro is mediated by the concanavalin A-induced release of 
a lymphokine (costimulator)." J Immunol 117(4): 1320-4. 
Pankow, R., H. Durkop, U. Latza, H. Krause, U. Kunzendorf, T. Pohl and S. Bulfone-
Paus (2000). "The HTLV-I tax protein transcriptionally modulates OX40 antigen 
expression." J Immunol 165(1): 263-70. 
Parish, C. R. (1971). "Immune response to chemically modified flagellin. I. Induction of 
antibody tolerance to flagellin by acetoacetylated derivatives of the protein." J 
Exp Med 134(1): 1-20. 
Parish, C. R. (1971). "Immune response to chemically modified flagellin. II. Evidence for 
a fundamental relationship between humoral and cell-mediated immunity." J Exp 
Med 134(1): 21-47. 
Parish, C. R. and F. Y. Liew (1972). "Immune response to chemically modified flagellin. 
3. Enhanced cell-mediated immunity during high and low zone antibody tolerance 
to flagellin." J Exp Med 135(2): 298-311. 
Pasare, C. and R. Medzhitov (2004). "Toll-dependent control mechanisms of CD4 T cell 
activation." Immunity 21(5): 733-41. 
Paterson, D. J., W. A. Jefferies, J. R. Green, M. R. Brandon, P. Corthesy, M. Puklavec 
and A. F. Williams (1987). "Antigens of activated rat T lymphocytes including a 
molecule of 50,000 Mr detected only on CD4 positive T blasts." Mol Immunol 
24(12): 1281-90. 
Paust, S., L. Lu, N. McCarty and H. Cantor (2004). "Engagement of B7 on effector T 
cells by regulatory T cells prevents autoimmune disease." Proc Natl Acad Sci U S 
A 101(28): 10398-403. 
Pearson, M. N. and S. Raffel (1971). "Macrophage-digested antigen as inducer of delayed 
hypersensitivity." J Exp Med 133(3): 494-505. 
Peggs, K. S. and J. P. Allison (2005). "Co-stimulatory pathways in lymphocyte 
regulation: the immunoglobulin superfamily." Br J Haematol 130(6): 809-24. 
Pepper, M. and M. K. Jenkins "Origins of CD4(+) effector and central memory T cells." 
Nat Immunol 12(6): 467-71. 
Perona-Wright, G., S. M. Anderton, S. E. Howie and D. Gray (2007). "IL-10 permits 
transient activation of dendritic cells to tolerize T cells and protect from central 
nervous system autoimmune disease." Int Immunol 19(9): 1123-34. 
Pescovitz, M. D. (2006). "Rituximab, an anti-cd20 monoclonal antibody: history and 
mechanism of action." Am J Transplant 6(5 Pt 1): 859-66. 
Pescovitz, M. D., C. J. Greenbaum, H. Krause-Steinrauf, D. J. Becker, S. E. Gitelman, R. 
Goland, P. A. Gottlieb, J. B. Marks, P. F. McGee, A. M. Moran, P. Raskin, H. 
Rodriguez, D. A. Schatz, D. Wherrett, D. M. Wilson, J. M. Lachin and J. S. 
Skyler (2009). "Rituximab, B-lymphocyte depletion, and preservation of beta-cell 
function." N Engl J Med 361(22): 2143-52. 
Peters, N. C., D. H. Hamilton and P. A. Bretscher (2005). "Analysis of cytokine-
producing Th cells from hen egg lysozyme-immunized mice reveals large 
! 277 
numbers specific for "cryptic" peptides and different repertoires among different 
Th populations." Eur J Immunol 35(1): 56-65. 
Peters, N. C., D. R. Kroeger, S. Mickelwright and P. A. Bretscher (2009). "CD4 T cell 
cooperation is required for the in vivo activation of CD4 T cells." Int Immunol 
21(11): 1213-24. 
Petrie, H. T. (2002). "Role of thymic organ structure and stromal composition in steady-
state postnatal T-cell production." Immunol Rev 189: 8-19. 
Phillips, J. A., C. G. Romball, M. V. Hobbs, D. N. Ernst, L. Shultz and W. O. Weigle 
(1996). "CD4+ T cell activation and tolerance induction in B cell knockout mice." 
J Exp Med 183(4): 1339-44. 
Piconese, S., B. Valzasina and M. P. Colombo (2008). "OX40 triggering blocks 
suppression by regulatory T cells and facilitates tumor rejection." J Exp Med 
205(4): 825-39. 
Pircher, H., K. Burki, R. Lang, H. Hengartner and R. M. Zinkernagel (1989). "Tolerance 
induction in double specific T-cell receptor transgenic mice varies with antigen." 
Nature 342(6249): 559-61. 
Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. 
Alejos, M. Silva, C. Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton 
and B. Beutler (1998). "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr 
mice: mutations in Tlr4 gene." Science 282(5396): 2085-8. 
Powrie, F. and D. Mason (1990). "OX-22high CD4+ T cells induce wasting disease with 
multiple organ pathology: prevention by the OX-22low subset." J Exp Med 
172(6): 1701-8. 
Quill, H., L. Carlson, B. S. Fox, J. N. Weinstein and R. H. Schwartz (1987). 
"Optimization of antigen presentation to T cell hybridomas by purified Ia 
molecules in planar membranes. Ia molecule polymorphism determines the 
antigenic fine specificity of the response to cytochrome c peptides." J Immunol 
Methods 98(1): 29-41. 
Quill, H. and R. H. Schwartz (1987). "Stimulation of normal inducer T cell clones with 
antigen presented by purified Ia molecules in planar lipid membranes: specific 
induction of a long-lived state of proliferative nonresponsiveness." J Immunol 
138(11): 3704-12. 
Rajewsky, K., E. Rottlander, G. Peltre and B. Muller (1967). "The immune response to a 
hybrid protein molecule; specificity of secondary stimulation and of tolerance 
induction." J Exp Med 126(4): 581-606. 
Rajewsky, K., V. Schirrmacher, S. Nase and N. K. Jerne (1969). "The requirement of 
more than one antigenic determinant for immunogenicity." J Exp Med 129(6): 
1131-43. 
Rammensee, H. G. and M. J. Bevan (1984). "Evidence from in vitro studies that tolerance 
to self antigens is MHC-restricted." Nature 308(5961): 741-4. 
Ramos-Casals, M., C. Diaz-Lagares, M. J. Soto-Cardenas, P. Brito-Zeron, M. J. 
Cuadrado, G. Sanna, L. Bertolaccini and M. A. Khamashta (2011). "Rituximab 
therapy in lupus nephritis: current clinical evidence." Clin Rev Allergy Immunol 
40(3): 159-69. 
! 278 
Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. 
Newman, N. Hanna and D. R. Anderson (1994). "Depletion of B cells in vivo by 
a chimeric mouse human monoclonal antibody to CD20." Blood 83(2): 435-45. 
Reis e Sousa, C. (2006). "Dendritic cells in a mature age." Nat Rev Immunol 6(6): 476-
83. 
Ribatti, D., E. Crivellato and A. Vacca (2006). "The contribution of Bruce Glick to the 
definition of the role played by the bursa of Fabricius in the development of the B 
cell lineage." Clin Exp Immunol 145(1): 1-4. 
Ridge, J. P., F. Di Rosa and P. Matzinger (1998). "A conditioned dendritic cell can be a 
temporal bridge between a CD4+ T-helper and a T-killer cell." Nature 393(6684): 
474-8. 
Rivera, A., C. C. Chen, N. Ron, J. P. Dougherty and Y. Ron (2001). "Role of B cells as 
antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for 
T cell expansion in lymph nodes and for systemic T cell responses to low antigen 
concentrations." Int Immunol 13(12): 1583-93. 
Rogers, P. R., J. Song, I. Gramaglia, N. Killeen and M. Croft (2001). "OX40 promotes 
Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T 
cells." Immunity 15(3): 445-55. 
Ron, Y., P. De Baetselier, J. Gordon, M. Feldman and S. Segal (1981). "Defective 
induction of antigen-reactive proliferating T cells in B cell-deprived mice." Eur J 
Immunol 11(12): 964-8. 
Ron, Y., P. De Baetselier, E. Tzehoval, J. Gordon, M. Feldman and S. Segal (1983). 
"Defective induction of antigen-reactive proliferating T cells in B cell-deprived 
mice. II. Anti-mu treatment affects the initiation and recruitment of T cells." Eur J 
Immunol 13(2): 167-71. 
Ron, Y. and J. Sprent (1987). "T cell priming in vivo: a major role for B cells in 
presenting antigen to T cells in lymph nodes." J Immunol 138(9): 2848-56. 
Ronet, C., H. Voigt, H. Himmelrich, M. A. Doucey, Y. Hauyon-La Torre, M. Revaz-
Breton, F. Tacchini-Cottier, C. Bron, J. Louis and P. Launois (2008). "Leishmania 
major-specific B cells are necessary for Th2 cell development and susceptibility 
to L. major LV39 in BALB/c mice." J Immunol 180(7): 4825-35. 
Rosenberg, Y. J. and R. Asofsky (1981). "T cell regulation of isotype expression. The 
requirement for a second Ig-specific helper T cell population for the induction of 
IgG responses." Eur J Immunol 11(9): 705-10. 
Rosenthal, A. S. and E. M. Shevach (1973). "Function of macrophages in antigen 
recognition by guinea pig T lymphocytes. I. Requirement for histocompatible 
macrophages and lymphocytes." J Exp Med 138(5): 1194-212. 
Rudulier, C., D. Kroeger and P. Bretscher (2012). "Manuscript in Preparation." 
Sacks, D. L., P. A. Scott, R. Asofsky and F. A. Sher (1984). "Cutaneous leishmaniasis in 
anti-IgM-treated mice: enhanced resistance due to functional depletion of a B 
cell-dependent T cell involved in the suppressor pathway." J Immunol 132(4): 
2072-7. 
Sakaguchi, S., K. Fukuma, K. Kuribayashi and T. Masuda (1985). "Organ-specific 
autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence 
for the active participation of T cells in natural self-tolerance; deficit of a T cell 
subset as a possible cause of autoimmune disease." J Exp Med 161(1): 72-87. 
! 279 
Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh and M. Toda (1995). "Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains 
(CD25). Breakdown of a single mechanism of self-tolerance causes various 
autoimmune diseases." J Immunol 155(3): 1151-64. 
Sakaguchi, S., T. Takahashi and Y. Nishizuka (1982). "Study on cellular events in post-
thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in 
normal female mice for the prevention of oophoritis." J Exp Med 156(6): 1577-
86. 
Salmond, R. J., A. Filby, I. Qureshi, S. Caserta and R. Zamoyska (2009). "T-cell receptor 
proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell 
activation, differentiation, and tolerance." Immunol Rev 228(1): 9-22. 
Salvin, S. B. (1958). "Occurrence of delayed hypersensitivity during the development of 
Arthus type hypersensitivity." J Exp Med 107(1): 109-24. 
Scala, G. and J. J. Oppenheim (1983). "Antigen presentation by human monocytes: 
evidence for stimulant processing and requirement for interleukin 1." J Immunol 
131(3): 1160-6. 
Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa and C. J. Melief (1998). 
"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L 
interactions." Nature 393(6684): 480-3. 
Schwartz, R. H. (1992). "Costimulation of T lymphocytes: the role of CD28, CTLA-4, 
and B7/BB1 in interleukin-2 production and immunotherapy." Cell 71(7): 1065-8. 
Seddon, B. and D. Mason (1999). "Peripheral autoantigen induces regulatory T cells that 
prevent autoimmunity." J Exp Med 189(5): 877-82. 
Segura, E. and J. A. Villadangos (2009). "Antigen presentation by dendritic cells in 
vivo." Curr Opin Immunol 21(1): 105-10. 
Serreze, D. V., H. D. Chapman, D. S. Varnum, M. S. Hanson, P. C. Reifsnyder, S. D. 
Richard, S. A. Fleming, E. H. Leiter and L. D. Shultz (1996). "B lymphocytes are 
essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a 
new "speed congenic" stock of NOD.Ig mu null mice." J Exp Med 184(5): 2049-
53. 
Sfikakis, P. P., J. N. Boletis, S. Lionaki, V. Vigklis, K. G. Fragiadaki, A. Iniotaki and H. 
M. Moutsopoulos (2005). "Remission of proliferative lupus nephritis following B 
cell depletion therapy is preceded by down-regulation of the T cell costimulatory 
molecule CD40 ligand: an open-label trial." Arthritis Rheum 52(2): 501-13. 
Shearer, G. M., T. G. Rehn and C. A. Garbarino (1975). "Cell-mediated lympholysis of 
trinitrophenyl-modified autologous lymphocytes. Effector cell specificity to 
modified cell surface components controlled by H-2K and H-2D serological 
regions of the murine major histocompatibility complex." J Exp Med 141(6): 
1348-64. 
Shedlock, D. J. and H. Shen (2003). "Requirement for CD4 T cell help in generating 
functional CD8 T cell memory." Science 300(5617): 337-9. 
Shen, H., J. K. Whitmire, X. Fan, D. J. Shedlock, S. M. Kaech and R. Ahmed (2003). "A 
specific role for B cells in the generation of CD8 T cell memory by recombinant 
Listeria monocytogenes." J Immunol 170(3): 1443-51. 
! 280 
Shevach, E. M., W. E. Paul and I. Green (1972). "Histocompatibility-linked immune 
response gene function in guinea pigs. Specific inhibition of antigen-induced 
lymphocyte proliferation by alloantisera." J Exp Med 136(5): 1207-21. 
Shevach, E. M. and A. S. Rosenthal (1973). "Function of macrophages in antigen 
recognition by guinea pig T lymphocytes. II. Role of the macrophage in the 
regulation of genetic control of the immune response." J Exp Med 138(5): 1213-
29. 
Shimizu, J., S. Yamazaki and S. Sakaguchi (1999). "Induction of tumor immunity by 
removing CD25+CD4+ T cells: a common basis between tumor immunity and 
autoimmunity." J Immunol 163(10): 5211-8. 
Shimonkevitz, R., J. Kappler, P. Marrack and H. Grey (1983). "Antigen recognition by 
H-2-restricted T cells. I. Cell-free antigen processing." J Exp Med 158(2): 303-16. 
Shlomchik, M. J. (2008). "Sites and stages of autoreactive B cell activation and 
regulation." Immunity 28(1): 18-28. 
Shlomchik, M. J., D. Zharhary, T. Saunders, S. A. Camper and M. G. Weigert (1993). "A 
rheumatoid factor transgenic mouse model of autoantibody regulation." Int 
Immunol 5(10): 1329-41. 
Silverstein, A. M. (1989). A History of Immunology. San Diego, CA, Academic Press. 
Silverstein, A. M. (1999). The History of Immunology. Fundamental Immunology. W. E. 
Paul. Philadelphia, PA, Lippencott Williams and Wilkins: 19-35. 
Silverstein, A. M. (2002). "The Clonal Selection Theory: what it really is and why 
modern challenges are misplaced." Nat Immunol 3(9): 793-6. 
Silverstein, A. M. (2005). "Paul Ehrlich, archives and the history of immunology." Nat 
Immunol 6(7): 639. 
So, T., H. Choi and M. Croft (2011). "OX40 complexes with phosphoinositide 3-kinase 
and protein kinase B (PKB) to augment TCR-dependent PKB signaling." J 
Immunol 186(6): 3547-55. 
So, T. and M. Croft (2007). "Cutting edge: OX40 inhibits TGF-beta- and antigen-driven 
conversion of naive CD4 T cells into CD25+Foxp3+ T cells." J Immunol 179(3): 
1427-30. 
Song, G., G. Ouyang and S. Bao (2005). "The activation of Akt/PKB signaling pathway 
and cell survival." J Cell Mol Med 9(1): 59-71. 
Song, J., T. So and M. Croft (2008). "Activation of NF-kappaB1 by OX40 contributes to 
antigen-driven T cell expansion and survival." J Immunol 180(11): 7240-8. 
Soroosh, P., S. Ine, K. Sugamura and N. Ishii (2006). "OX40-OX40 ligand interaction 
through T cell-T cell contact contributes to CD4 T cell longevity." J Immunol 
176(10): 5975-87. 
Steinman, R. M. (2003). "Some interfaces of dendritic cell biology." APMIS 111(7-8): 
675-97. 
Steinman, R. M. and Z. A. Cohn (1973). "Identification of a novel cell type in peripheral 
lymphoid organs of mice. I. Morphology, quantitation, tissue distribution." J Exp 
Med 137(5): 1142-62. 
Steinman, R. M., B. Gutchinov, M. D. Witmer and M. C. Nussenzweig (1983). 
"Dendritic cells are the principal stimulators of the primary mixed leukocyte 
reaction in mice." J Exp Med 157(2): 613-27. 
! 281 
Steinman, R. M., D. Hawiger, K. Liu, L. Bonifaz, D. Bonnyay, K. Mahnke, T. Iyoda, J. 
Ravetch, M. Dhodapkar, K. Inaba and M. Nussenzweig (2003). "Dendritic cell 
function in vivo during the steady state: a role in peripheral tolerance." Ann N Y 
Acad Sci 987: 15-25. 
Steinman, R. M. and M. C. Nussenzweig (1980). "Dendritic cells: features and 
functions." Immunol Rev 53: 127-47. 
Steinman, R. M. and M. D. Witmer (1978). "Lymphoid dendritic cells are potent 
stimulators of the primary mixed leukocyte reaction in mice." Proc Natl Acad Sci 
U S A 75(10): 5132-6. 
Steptoe, R. J., J. M. Ritchie, N. S. Wilson, J. A. Villadangos, A. M. Lew and L. C. 
Harrison (2007). "Cognate CD4+ help elicited by resting dendritic cells does not 
impair the induction of peripheral tolerance in CD8+ T cells." J Immunol 178(4): 
2094-103. 
Stoll, S., J. Delon, T. M. Brotz and R. N. Germain (2002). "Dynamic imaging of T cell-
dendritic cell interactions in lymph nodes." Science 296(5574): 1873-6. 
Stuber, E., M. Neurath, D. Calderhead, H. P. Fell and W. Strober (1995). "Cross-linking 
of OX40 ligand, a member of the TNF/NGF cytokine family, induces 
proliferation and differentiation in murine splenic B cells." Immunity 2(5): 507-
21. 
Suffia, I. J., S. K. Reckling, C. A. Piccirillo, R. S. Goldszmid and Y. Belkaid (2006). 
"Infected site-restricted Foxp3+ natural regulatory T cells are specific for 
microbial antigens." J Exp Med 203(3): 777-88. 
Sun, C. M., J. A. Hall, R. B. Blank, N. Bouladoux, M. Oukka, J. R. Mora and Y. Belkaid 
(2007). "Small intestine lamina propria dendritic cells promote de novo 
generation of Foxp3 T reg cells via retinoic acid." J Exp Med 204(8): 1775-85. 
Sunshine, G. H., B. L. Jimmo, C. Ianelli and L. Jarvis (1991). "Strong priming of T cells 
adoptively transferred into scid mice." J Exp Med 174(6): 1653-6. 
Takahama, Y. (2006). "Journey through the thymus: stromal guides for T-cell 
development and selection." Nat Rev Immunol 6(2): 127-35. 
Takahashi, T., Y. Kuniyasu, M. Toda, N. Sakaguchi, M. Itoh, M. Iwata, J. Shimizu and S. 
Sakaguchi (1998). "Immunologic self-tolerance maintained by CD25+CD4+ 
naturally anergic and suppressive T cells: induction of autoimmune disease by 
breaking their anergic/suppressive state." Int Immunol 10(12): 1969-80. 
Talmage, D. W. (1957). "Allergy and immunology." Annu Rev Med 8: 239-56. 
Talmage, D. W. and D. S. Pearlman (1963). "The antibody response: a model based on 
antagonistic actions of antigen." J Theor Biol 5(2): 321-39. 
Thornton, A. M. and E. M. Shevach (1998). "CD4+CD25+ immunoregulatory T cells 
suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 
production." J Exp Med 188(2): 287-96. 
Thornton, A. M. and E. M. Shevach (2000). "Suppressor effector function of 
CD4+CD25+ immunoregulatory T cells is antigen nonspecific." J Immunol 
164(1): 183-90. 
Tiegs, S. L., D. M. Russell and D. Nemazee (1993). "Receptor editing in self-reactive 
bone marrow B cells." J Exp Med 177(4): 1009-20. 
! 282 
Topham, D. J., R. A. Tripp, A. M. Hamilton-Easton, S. R. Sarawar and P. C. Doherty 
(1996). "Quantitative analysis of the influenza virus-specific CD4+ T cell 
memory in the absence of B cells and Ig." J Immunol 157(7): 2947-52. 
Tucker, M. J. and P. A. Bretscher (1982). "T cells cooperating in the induction of 
delayed-type hypersensitivity act via the linked recognition of antigenic 
determinants." J Exp Med 155(4): 1037-49. 
Ugrinovic, S., N. Menager, N. Goh and P. Mastroeni (2003). "Characterization and 
development of T-Cell immune responses in B-cell-deficient (Igh-6(-/-)) mice 
with Salmonella enterica serovar Typhimurium infection." Infect Immun 71(12): 
6808-19. 
Uzonna, J. E. and P. A. Bretscher (2001). "Anti-IL-4 antibody therapy causes regression 
of chronic lesions caused by medium-dose Leishmania major infection in BALB/c 
mice." Eur J Immunol 31(11): 3175-84. 
Vallerskog, T., I. Gunnarsson, M. Widhe, A. Risselada, L. Klareskog, R. van 
Vollenhoven, V. Malmstrom and C. Trollmo (2007). "Treatment with rituximab 
affects both the cellular and the humoral arm of the immune system in patients 
with SLE." Clin Immunol 122(1): 62-74. 
van der Most, R. G., A. Sette, C. Oseroff, J. Alexander, K. Murali-Krishna, L. L. Lau, S. 
Southwood, J. Sidney, R. W. Chesnut, M. Matloubian and R. Ahmed (1996). 
"Analysis of cytotoxic T cell responses to dominant and subdominant epitopes 
during acute and chronic lymphocytic choriomeningitis virus infection." J 
Immunol 157(12): 5543-54. 
Verbeek, R., K. van der Mark, E. F. Wawrousek, A. C. Plomp and J. M. van Noort 
(2007). "Tolerization of an established alphaB-crystallin-reactive T-cell response 
by intravenous antigen." Immunology 121(3): 416-26. 
Vermes, I., C. Haanen, H. Steffens-Nakken and C. Reutelingsperger (1995). "A novel 
assay for apoptosis. Flow cytometric detection of phosphatidylserine expression 
on early apoptotic cells using fluorescein labelled Annexin V." J Immunol 
Methods 184(1): 39-51. 
Villadangos, J. A. and P. Schnorrer (2007). "Intrinsic and cooperative antigen-presenting 
functions of dendritic-cell subsets in vivo." Nat Rev Immunol 7(7): 543-55. 
von Boehmer, H. (2005). "Mechanisms of suppression by suppressor T cells." Nat 
Immunol 6(4): 338-44. 
Vordermeier, H. M., N. Venkataprasad, D. P. Harris and J. Ivanyi (1996). "Increase of 
tuberculous infection in the organs of B cell-deficient mice." Clin Exp Immunol 
106(2): 312-6. 
Wang, H. G., N. Pathan, I. M. Ethell, S. Krajewski, Y. Yamaguchi, F. Shibasaki, F. 
McKeon, T. Bobo, T. F. Franke and J. C. Reed (1999). "Ca2+-induced apoptosis 
through calcineurin dephosphorylation of BAD." Science 284(5412): 339-43. 
Wang, S. and L. Chen (2004). "T lymphocyte co-signaling pathways of the B7-CD28 
family." Cell Mol Immunol 1(1): 37-42. 
Watts, T. H., A. A. Brian, J. W. Kappler, P. Marrack and H. M. McConnell (1984). 
"Antigen presentation by supported planar membranes containing affinity-purified 
I-Ad." Proc Natl Acad Sci U S A 81(23): 7564-8. 
Weaver, J. M., C. A. Lazarski, K. A. Richards, F. A. Chaves, S. A. Jenks, P. R. Menges 
and A. J. Sant (2008). "Immunodominance of CD4 T cells to foreign antigens is 
! 283 
peptide intrinsic and independent of molecular context: implications for vaccine 
design." J Immunol 181(5): 3039-48. 
Weigle, W. O. (1964). "Studies on the Termination of Acquired Tolerance to Serum 
Protein Antigens Following Injection of Serologically Related Antigens." 
Immunology 7: 239-47. 
Weinberg, A. D., M. M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, 
G. Alvord, C. Bunce and J. Shields (2000). "Engagement of the OX-40 receptor 
in vivo enhances antitumor immunity." J Immunol 164(4): 2160-9. 
Weinberger, O., S. Herrmann, M. F. Mescher, B. Benacerraf and S. J. Burakoff (1981). 
"Antigen-presenting cell function in induction of helper T cells for cytotoxic T-
lymphocyte responses: evidence for antigen processing." Proc Natl Acad Sci U S 
A 78(3): 1796-9. 
Willenborg, D. O. and S. J. Prowse (1983). "Immunoglobulin-deficient rats fail to 
develop experimental allergic encephalomyelitis." J Neuroimmunol 5(2): 99-109. 
Wojciechowski, W., D. P. Harris, F. Sprague, B. Mousseau, M. Makris, K. Kusser, T. 
Honjo, K. Mohrs, M. Mohrs, T. Randall and F. E. Lund (2009). "Cytokine-
producing effector B cells regulate type 2 immunity to H. polygyrus." Immunity 
30(3): 421-33. 
Yamazaki, S., T. Iyoda, K. Tarbell, K. Olson, K. Velinzon, K. Inaba and R. M. Steinman 
(2003). "Direct expansion of functional CD25+ CD4+ regulatory T cells by 
antigen-processing dendritic cells." J Exp Med 198(2): 235-47. 
Yang, X. and R. C. Brunham (1998). "Gene knockout B cell-deficient mice demonstrate 
that B cells play an important role in the initiation of T cell responses to 
Chlamydia trachomatis (mouse pneumonitis) lung infection." J Immunol 161(3): 
1439-46. 
Yano, A., R. H. Schwartz and W. E. Paul (1977). "Antigen presentation in the murine T-
lymphocyte proliferative response. I. Requirement for genetic identity at the 
major histocompatibility complex." J Exp Med 146(3): 828-43. 
Yarovinsky, F., H. Kanzler, S. Hieny, R. L. Coffman and A. Sher (2006). "Toll-like 
receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell 
response." Immunity 25(4): 655-64. 
Yu, M., J. M. Johnson and V. K. Tuohy (1996). "A predictable sequential determinant 
spreading cascade invariably accompanies progression of experimental 
autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of 
clinical disease." J Exp Med 183(4): 1777-88. 
Yu, P., Y. Lee, W. Liu, T. Krausz, A. Chong, H. Schreiber and Y. X. Fu (2005). 
"Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to 
the rejection of late-stage tumors." J Exp Med 201(5): 779-91. 
Zhang, X., D. N. Koldzic, L. Izikson, J. Reddy, R. F. Nazareno, S. Sakaguchi, V. K. 
Kuchroo and H. L. Weiner (2004). "IL-10 is involved in the suppression of 
experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells." 
Int Immunol 16(2): 249-56. 
Zhou, X. M., Y. Liu, G. Payne, R. J. Lutz and T. Chittenden (2000). "Growth factors 
inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on 
Ser155." J Biol Chem 275(32): 25046-51. 
! 284 
Ziegler, H. K. and E. R. Unanue (1982). "Decrease in macrophage antigen catabolism 
caused by ammonia and chloroquine is associated with inhibition of antigen 
presentation to T cells." Proc Natl Acad Sci U S A 79(1): 175-8. 
Zinkernagel, R. M., A. Althage, S. Cooper, G. Callahan and J. Klein (1978). "In 
irradiation chimeras, K or D regions of the chimeric host, not of the donor 
lymphocytes, determine immune responsiveness of antiviral cytotoxic T cells." J 
Exp Med 148(3): 805-10. 
Zinkernagel, R. M. and P. C. Doherty (1974). "Immunological surveillance against 
altered self components by sensitised T lymphocytes in lymphocytic 
choriomeningitis." Nature 251(5475): 547-8. 
Zinkernagel, R. M. and P. C. Doherty (1974). "Restriction of in vitro T cell-mediated 
cytotoxicity in lymphocytic choriomeningitis within a syngeneic or 
semiallogeneic system." Nature 248(450): 701-2. 
 
 
!
